dbid,name,type,uniprot_name,cid,uniprot,poi,ligase,smiles,dc50,dmax,molecular_weight,exact_mass,heavy_atom_count,ring_count,hbond_donor_count,hbond_acceptor_count,molecular_formula,inchi,inchikey
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,39.2/736.2,97.6/68.8,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR L858R,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1218,P00533,EGFR,CRBN,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,872.984,872.396958624,64,7,4,14,C46H52N10O8,"InChI=1S/C46H52N10O8/c1-6-41(57)49-35-24-36(51-46-47-17-16-34(50-46)31-26-55(4)37-13-8-7-10-29(31)37)40(62-5)25-39(35)54(3)19-18-53(2)20-21-63-22-23-64-28-43(59)48-33-12-9-11-30-32(33)27-56(45(30)61)38-14-15-42(58)52-44(38)60/h6-13,16-17,24-26,38H,1,14-15,18-23,27-28H2,2-5H3,(H,48,59)(H,49,57)(H,47,50,51)(H,52,58,60)",WOALWHLORCCRQM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5655,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCN4N=C5[NH]C6=CC=CC=C6N=C5C4=O)=C3C2=O)C(=O)N1,43.4,,587.549,587.17646076,43,6,3,11,C28H25N7O8,"InChI=1S/C28H25N7O8/c36-20-9-8-19(25(38)32-20)35-26(39)15-4-3-7-18(22(15)27(35)40)29-21(37)14-43-13-12-42-11-10-34-28(41)23-24(33-34)31-17-6-2-1-5-16(17)30-23/h1-7,19H,8-14H2,(H,29,37)(H,31,33)(H,32,36,38)",OXSXZSPEDPGYSH-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5655,P00533,EGFR T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCN4N=C5[NH]C6=CC=CC=C6N=C5C4=O)=C3C2=O)C(=O)N1,,,587.549,587.17646076,43,6,3,11,C28H25N7O8,"InChI=1S/C28H25N7O8/c36-20-9-8-19(25(38)32-20)35-26(39)15-4-3-7-18(22(15)27(35)40)29-21(37)14-43-13-12-42-11-10-34-28(41)23-24(33-34)31-17-6-2-1-5-16(17)30-23/h1-7,19H,8-14H2,(H,29,37)(H,31,33)(H,32,36,38)",OXSXZSPEDPGYSH-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5656,P00533,EGFR,CRBN,CN1C(=O)C(C(=O)NNCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=NC2=CC=CC=C21,32.9,,619.591,619.202675508,45,5,4,12,C29H29N7O9,"InChI=1S/C29H29N7O9/c1-35-19-8-3-2-6-17(19)32-24(29(35)43)26(40)34-30-11-12-44-13-14-45-15-22(38)31-18-7-4-5-16-23(18)28(42)36(27(16)41)20-9-10-21(37)33-25(20)39/h2-8,20,30H,9-15H2,1H3,(H,31,38)(H,34,40)(H,33,37,39)",MGPULBDTVXSSAA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5656,P00533,EGFR T790M,CRBN,CN1C(=O)C(C(=O)NNCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=NC2=CC=CC=C21,,,619.591,619.202675508,45,5,4,12,C29H29N7O9,"InChI=1S/C29H29N7O9/c1-35-19-8-3-2-6-17(19)32-24(29(35)43)26(40)34-30-11-12-44-13-14-45-15-22(38)31-18-7-4-5-16-23(18)28(42)36(27(16)41)20-9-10-21(37)33-25(20)39/h2-8,20,30H,9-15H2,1H3,(H,31,38)(H,34,40)(H,33,37,39)",MGPULBDTVXSSAA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5657,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCOCCNC(=O)C4=NC5=CC=CC=C5[NH]C4=O)=C3C2=O)C(=O)N1,,,634.602,634.20234116,46,5,4,11,C30H30N6O10,"InChI=1S/C30H30N6O10/c37-22-9-8-21(26(39)35-22)36-29(42)17-4-3-7-20(24(17)30(36)43)32-23(38)16-46-15-14-45-13-12-44-11-10-31-27(40)25-28(41)34-19-6-2-1-5-18(19)33-25/h1-7,21H,8-16H2,(H,31,40)(H,32,38)(H,34,41)(H,35,37,39)",OZPRDNWEPCURPP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5657,P00533,EGFR T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCOCCNC(=O)C4=NC5=CC=CC=C5[NH]C4=O)=C3C2=O)C(=O)N1,,,634.602,634.20234116,46,5,4,11,C30H30N6O10,"InChI=1S/C30H30N6O10/c37-22-9-8-21(26(39)35-22)36-29(42)17-4-3-7-20(24(17)30(36)43)32-23(38)16-46-15-14-45-13-12-44-11-10-31-27(40)25-28(41)34-19-6-2-1-5-18(19)33-25/h1-7,21H,8-16H2,(H,31,40)(H,32,38)(H,34,41)(H,35,37,39)",OZPRDNWEPCURPP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5658,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCNNC(=O)C4=CC=C(/N=C5\C(=O)NC6=CC=CC=C56)C=C4)=C3C2=O)C(=O)N1,,,681.662,681.218325572,50,6,5,11,C34H31N7O9,"InChI=1S/C34H31N7O9/c42-26-13-12-25(31(45)39-26)41-33(47)22-5-3-7-24(28(22)34(41)48)37-27(43)18-50-17-16-49-15-14-35-40-30(44)19-8-10-20(11-9-19)36-29-21-4-1-2-6-23(21)38-32(29)46/h1-11,25,35H,12-18H2,(H,37,43)(H,40,44)(H,36,38,46)(H,39,42,45)",UUISUTLLNFRLKV-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5658,P00533,EGFR T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCNNC(=O)C4=CC=C(/N=C5\C(=O)NC6=CC=CC=C56)C=C4)=C3C2=O)C(=O)N1,,,681.662,681.218325572,50,6,5,11,C34H31N7O9,"InChI=1S/C34H31N7O9/c42-26-13-12-25(31(45)39-26)41-33(47)22-5-3-7-24(28(22)34(41)48)37-27(43)18-50-17-16-49-15-14-35-40-30(44)19-8-10-20(11-9-19)36-29-21-4-1-2-6-23(21)38-32(29)46/h1-11,25,35H,12-18H2,(H,37,43)(H,40,44)(H,36,38,46)(H,39,42,45)",UUISUTLLNFRLKV-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5659,P00533,EGFR,CRBN,CN1C(=O)/C(=N\C2=CC=C(C(=O)NNCCOCCOCC(=O)NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)C2=CC=CC=C21,,,695.689,695.233975636,51,6,4,11,C35H33N7O9,"InChI=1S/C35H33N7O9/c1-41-25-8-3-2-5-22(25)30(35(41)49)37-21-11-9-20(10-12-21)31(45)40-36-15-16-50-17-18-51-19-28(44)38-24-7-4-6-23-29(24)34(48)42(33(23)47)26-13-14-27(43)39-32(26)46/h2-12,26,36H,13-19H2,1H3,(H,38,44)(H,40,45)(H,39,43,46)/b37-30-",KLLIEGYJHUITHF-ONQIKCEGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5659,P00533,EGFR T790M,CRBN,CN1C(=O)/C(=N\C2=CC=C(C(=O)NNCCOCCOCC(=O)NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)C2=CC=CC=C21,,,695.689,695.233975636,51,6,4,11,C35H33N7O9,"InChI=1S/C35H33N7O9/c1-41-25-8-3-2-5-22(25)30(35(41)49)37-21-11-9-20(10-12-21)31(45)40-36-15-16-50-17-18-51-19-28(44)38-24-7-4-6-23-29(24)34(48)42(33(23)47)26-13-14-27(43)39-32(26)46/h2-12,26,36H,13-19H2,1H3,(H,38,44)(H,40,45)(H,39,43,46)/b37-30-",KLLIEGYJHUITHF-ONQIKCEGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5660,P00533,EGFR,CRBN,O=C(CSC1=NC2=CC=CC=C2O1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,624.632,624.163847476,44,5,4,12,C28H28N6O9S,"InChI=1S/C28H28N6O9S/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-44-28-31-17-5-1-2-7-20(17)43-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",CWWRWDWAERVKAB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5660,P00533,EGFR T790M,CRBN,O=C(CSC1=NC2=CC=CC=C2O1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,624.632,624.163847476,44,5,4,12,C28H28N6O9S,"InChI=1S/C28H28N6O9S/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-44-28-31-17-5-1-2-7-20(17)43-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",CWWRWDWAERVKAB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5661,P00533,EGFR,CRBN,O=C(CSC1=NC2=CC=CC=C2S1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,640.7,640.141003856,44,5,4,12,C28H28N6O8S2,"InChI=1S/C28H28N6O8S2/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-43-28-31-17-5-1-2-7-20(17)44-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",ZYHGWXRBVVVZAU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5661,P00533,EGFR T790M,CRBN,O=C(CSC1=NC2=CC=CC=C2S1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,640.7,640.141003856,44,5,4,12,C28H28N6O8S2,"InChI=1S/C28H28N6O8S2/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-43-28-31-17-5-1-2-7-20(17)44-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",ZYHGWXRBVVVZAU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1220,P00533,EGFR,CRBN,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCOCCOCCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,161,68,961.09,960.44938812,70,7,4,16,C50H60N10O10,"InChI=1S/C50H60N10O10/c1-6-45(61)53-39-28-40(55-50-51-17-16-38(54-50)35-30-59(4)41-13-8-7-10-33(35)41)44(66-5)29-43(39)58(3)19-18-57(2)20-21-67-22-23-68-24-25-69-26-27-70-32-47(63)52-37-12-9-11-34-36(37)31-60(49(34)65)42-14-15-46(62)56-48(42)64/h6-13,16-17,28-30,42H,1,14-15,18-27,31-32H2,2-5H3,(H,52,63)(H,53,61)(H,51,54,55)(H,56,62,64)",MVXHKLZUALKPTB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR L858R,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,570,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1074.342,1073.54332624,77,9,6,18,C56H72FN13O6S,"InChI=1S/C56H72FN13O6S/c1-37-50(77-36-62-37)40-7-5-38(6-8-40)31-61-53(73)47-29-44(72)34-70(47)54(74)51(56(2,3)4)58-17-25-75-27-28-76-26-24-67-20-22-68(23-21-67)43-13-14-48(59-32-43)65-49-30-45-46(33-60-49)64-55(63-42-11-9-41(57)10-12-42)66-52(45)69-18-15-39(35-71)16-19-69/h5-14,30,32-33,36,39,44,47,51,58,71-72H,15-29,31,34-35H2,1-4H3,(H,61,73)(H,59,60,65)(H,63,64,66)/t44-,47+,51-/m1/s1",CQUCWGCCDVGZNK-SRLHMHSXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1549,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,897.027,896.331581496,65,9,3,13,C48H48N8O8S,"InChI=1S/C48H48N8O8S/c57-40-16-15-39(43(58)51-40)56-46(61)36-7-4-8-38(41(36)47(56)62)49-17-24-63-26-27-64-25-23-53-19-21-54(22-20-53)35-13-11-31(12-14-35)33-9-10-34-30-55(45(60)37(34)29-33)42(32-5-2-1-3-6-32)44(59)52-48-50-18-28-65-48/h1-14,18,28-29,39,42,49H,15-17,19-27,30H2,(H,50,52,59)(H,51,57,58)",LCRBAPSWBSEBAG-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1551,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=C(NCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)C=C3C2=O)C(=O)N1,,,898.015,897.326830464,65,9,3,14,C47H47N9O8S,"InChI=1S/C47H47N9O8S/c57-40-13-11-38(42(58)51-40)56-45(61)35-10-9-34(27-37(35)46(56)62)48-14-21-63-23-24-64-22-20-53-16-18-54(19-17-53)39-12-8-32(28-50-39)31-6-7-33-29-55(44(60)36(33)26-31)41(30-4-2-1-3-5-30)43(59)52-47-49-15-25-65-47/h1-10,12,15,25-28,38,41,48H,11,13-14,16-24,29H2,(H,49,52,59)(H,51,57,58)",QHQDVRLNEVZTFS-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1554,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCN3CCN(C4=CC=C(C5=CC=C6CN(C(C(=O)NC7=NC=CS7)C7=CC=CC=C7)C(=O)C6=C5)C=N4)CC3)C(C)(C)C)C=C2)SC=N1,,,1083.351,1082.45065107,77,9,4,15,C57H66N10O8S2,"InChI=1S/C57H66N10O8S2/c1-37-50(77-36-61-37)40-12-10-38(11-13-40)32-60-52(70)46-31-44(68)35-66(46)55(73)51(57(2,3)4)62-48(69)18-25-74-27-28-75-26-24-64-20-22-65(23-21-64)47-17-16-42(33-59-47)41-14-15-43-34-67(54(72)45(43)30-41)49(39-8-6-5-7-9-39)53(71)63-56-58-19-29-76-56/h5-17,19,29-30,33,36,44,46,49,51,68H,18,20-28,31-32,34-35H2,1-4H3,(H,60,70)(H,62,69)(H,58,63,71)/t44-,46+,49?,51-/m1/s1",BJESFCSPXPZXNP-ZSIHQRNSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2000,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,999.3,998.53128434,72,9,5,16,C54H70N12O5S,"InChI=1S/C54H70N12O5S/c1-37-47(72-36-58-37)39-16-14-38(15-17-39)33-56-50(68)46-32-44(67)35-65(46)51(69)48(54(2,3)4)55-22-28-70-30-31-71-29-27-63-23-25-64(26-24-63)42-20-18-41(19-21-42)59-52-57-34-45-49(62-52)66(43-12-8-9-13-43)53(61-45)60-40-10-6-5-7-11-40/h5-7,10-11,14-21,34,36,43-44,46,48,55,67H,8-9,12-13,22-33,35H2,1-4H3,(H,56,68)(H,60,61)(H,57,59,62)/t44-,46+,48-/m1/s1",VKKCYHNIIBYIGZ-IVTDSOLVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2000,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,999.3,998.53128434,72,9,5,16,C54H70N12O5S,"InChI=1S/C54H70N12O5S/c1-37-47(72-36-58-37)39-16-14-38(15-17-39)33-56-50(68)46-32-44(67)35-65(46)51(69)48(54(2,3)4)55-22-28-70-30-31-71-29-27-63-23-25-64(26-24-63)42-20-18-41(19-21-42)59-52-57-34-45-49(62-52)66(43-12-8-9-13-43)53(61-45)60-40-10-6-5-7-11-40/h5-7,10-11,14-21,34,36,43-44,46,48,55,67H,8-9,12-13,22-33,35H2,1-4H3,(H,56,68)(H,60,61)(H,57,59,62)/t44-,46+,48-/m1/s1",VKKCYHNIIBYIGZ-IVTDSOLVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2000,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,999.3,998.53128434,72,9,5,16,C54H70N12O5S,"InChI=1S/C54H70N12O5S/c1-37-47(72-36-58-37)39-16-14-38(15-17-39)33-56-50(68)46-32-44(67)35-65(46)51(69)48(54(2,3)4)55-22-28-70-30-31-71-29-27-63-23-25-64(26-24-63)42-20-18-41(19-21-42)59-52-57-34-45-49(62-52)66(43-12-8-9-13-43)53(61-45)60-40-10-6-5-7-11-40/h5-7,10-11,14-21,34,36,43-44,46,48,55,67H,8-9,12-13,22-33,35H2,1-4H3,(H,56,68)(H,60,61)(H,57,59,62)/t44-,46+,48-/m1/s1",VKKCYHNIIBYIGZ-IVTDSOLVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4278,P00533,EGFR,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,965.187,964.451696628,69,7,4,14,C51H64N8O9S,"InChI=1S/C51H64N8O9S/c1-33-46(69-32-55-33)36-13-11-34(12-14-36)28-52-49(63)41-25-38(60)29-59(41)50(64)47(51(2,3)4)57-44(61)17-21-66-23-24-67-22-18-45(62)58-19-15-35(16-20-58)30-68-43-27-40-39(26-42(43)65-5)48(54-31-53-40)56-37-9-7-6-8-10-37/h6-14,26-27,31-32,35,38,41,47,60H,15-25,28-30H2,1-5H3,(H,52,63)(H,57,61)(H,53,54,56)/t38-,41+,47-/m1/s1",NRZFMGQSOZOFHN-HSKQCWAZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4278,P00533,EGFR L858R,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,965.187,964.451696628,69,7,4,14,C51H64N8O9S,"InChI=1S/C51H64N8O9S/c1-33-46(69-32-55-33)36-13-11-34(12-14-36)28-52-49(63)41-25-38(60)29-59(41)50(64)47(51(2,3)4)57-44(61)17-21-66-23-24-67-22-18-45(62)58-19-15-35(16-20-58)30-68-43-27-40-39(26-42(43)65-5)48(54-31-53-40)56-37-9-7-6-8-10-37/h6-14,26-27,31-32,35,38,41,47,60H,15-25,28-30H2,1-5H3,(H,52,63)(H,57,61)(H,53,54,56)/t38-,41+,47-/m1/s1",NRZFMGQSOZOFHN-HSKQCWAZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4278,P00533,EGFR e19d,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,965.187,964.451696628,69,7,4,14,C51H64N8O9S,"InChI=1S/C51H64N8O9S/c1-33-46(69-32-55-33)36-13-11-34(12-14-36)28-52-49(63)41-25-38(60)29-59(41)50(64)47(51(2,3)4)57-44(61)17-21-66-23-24-67-22-18-45(62)58-19-15-35(16-20-58)30-68-43-27-40-39(26-42(43)65-5)48(54-31-53-40)56-37-9-7-6-8-10-37/h6-14,26-27,31-32,35,38,41,47,60H,15-25,28-30H2,1-5H3,(H,52,63)(H,57,61)(H,53,54,56)/t38-,41+,47-/m1/s1",NRZFMGQSOZOFHN-HSKQCWAZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1475,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,985.133,984.384010992,71,9,3,15,C52H56N8O10S,"InChI=1S/C52H56N8O10S/c61-44-16-15-43(47(62)55-44)60-50(65)40-7-4-8-42(45(40)51(60)66)53-17-24-67-26-28-69-30-31-70-29-27-68-25-23-57-19-21-58(22-20-57)39-13-11-35(12-14-39)37-9-10-38-34-59(49(64)41(38)33-37)46(36-5-2-1-3-6-36)48(63)56-52-54-18-32-71-52/h1-14,18,32-33,43,46,53H,15-17,19-31,34H2,(H,54,56,63)(H,55,61,62)",LWCGWAABACSQFJ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2002,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1087.406,1086.58371384,78,9,5,18,C58H78N12O7S,"InChI=1S/C58H78N12O7S/c1-41-51(78-40-62-41)43-16-14-42(15-17-43)37-60-54(72)50-36-48(71)39-69(50)55(73)52(58(2,3)4)59-22-28-74-30-32-76-34-35-77-33-31-75-29-27-67-23-25-68(26-24-67)46-20-18-45(19-21-46)63-56-61-38-49-53(66-56)70(47-12-8-9-13-47)57(65-49)64-44-10-6-5-7-11-44/h5-7,10-11,14-21,38,40,47-48,50,52,59,71H,8-9,12-13,22-37,39H2,1-4H3,(H,60,72)(H,64,65)(H,61,63,66)/t48-,50+,52-/m1/s1",BPHMNBCRTHSRFO-KPYPFJKESA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2002,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1087.406,1086.58371384,78,9,5,18,C58H78N12O7S,"InChI=1S/C58H78N12O7S/c1-41-51(78-40-62-41)43-16-14-42(15-17-43)37-60-54(72)50-36-48(71)39-69(50)55(73)52(58(2,3)4)59-22-28-74-30-32-76-34-35-77-33-31-75-29-27-67-23-25-68(26-24-67)46-20-18-45(19-21-46)63-56-61-38-49-53(66-56)70(47-12-8-9-13-47)57(65-49)64-44-10-6-5-7-11-44/h5-7,10-11,14-21,38,40,47-48,50,52,59,71H,8-9,12-13,22-37,39H2,1-4H3,(H,60,72)(H,64,65)(H,61,63,66)/t48-,50+,52-/m1/s1",BPHMNBCRTHSRFO-KPYPFJKESA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2002,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1087.406,1086.58371384,78,9,5,18,C58H78N12O7S,"InChI=1S/C58H78N12O7S/c1-41-51(78-40-62-41)43-16-14-42(15-17-43)37-60-54(72)50-36-48(71)39-69(50)55(73)52(58(2,3)4)59-22-28-74-30-32-76-34-35-77-33-31-75-29-27-67-23-25-68(26-24-67)46-20-18-45(19-21-46)63-56-61-38-49-53(66-56)70(47-12-8-9-13-47)57(65-49)64-44-10-6-5-7-11-44/h5-7,10-11,14-21,38,40,47-48,50,52,59,71H,8-9,12-13,22-37,39H2,1-4H3,(H,60,72)(H,64,65)(H,61,63,66)/t48-,50+,52-/m1/s1",BPHMNBCRTHSRFO-KPYPFJKESA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5610,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,856.863,856.326828376,62,7,5,14,C42H43F3N10O7,"InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)",IRLRGBUCUIJYPP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5610,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,856.863,856.326828376,62,7,5,14,C42H43F3N10O7,"InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)",IRLRGBUCUIJYPP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5610,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,856.863,856.326828376,62,7,5,14,C42H43F3N10O7,"InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)",IRLRGBUCUIJYPP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,569,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1118.395,1117.56954099,80,9,6,19,C58H76FN13O7S,"InChI=1S/C58H76FN13O7S/c1-39-52(80-38-64-39)42-7-5-40(6-8-42)33-63-55(75)49-31-46(74)36-72(49)56(76)53(58(2,3)4)60-17-25-77-27-29-79-30-28-78-26-24-69-20-22-70(23-21-69)45-13-14-50(61-34-45)67-51-32-47-48(35-62-51)66-57(65-44-11-9-43(59)10-12-44)68-54(47)71-18-15-41(37-73)16-19-71/h5-14,32,34-35,38,41,46,49,53,60,73-74H,15-31,33,36-37H2,1-4H3,(H,63,75)(H,61,62,67)(H,65,66,68)/t46-,49+,53-/m1/s1",FFHRIJQREBDIFV-XYNMIOBWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1474,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,941.08,940.357796244,68,9,3,14,C50H52N8O9S,"InChI=1S/C50H52N8O9S/c59-42-16-15-41(45(60)53-42)58-48(63)38-7-4-8-40(43(38)49(58)64)51-17-24-65-26-28-67-29-27-66-25-23-55-19-21-56(22-20-55)37-13-11-33(12-14-37)35-9-10-36-32-57(47(62)39(36)31-35)44(34-5-2-1-3-6-34)46(61)54-50-52-18-30-68-50/h1-14,18,30-31,41,44,51H,15-17,19-29,32H2,(H,52,54,61)(H,53,59,60)",DXDCJEWJBVJABL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1476,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-41-14-12-39(44(60)53-41)58-47(63)36-7-4-8-38(42(36)48(58)64)50-15-22-65-24-26-67-27-25-66-23-21-55-17-19-56(20-18-55)40-13-11-34(30-52-40)33-9-10-35-31-57(46(62)37(35)29-33)43(32-5-2-1-3-6-32)45(61)54-49-51-16-28-68-49/h1-11,13,16,28-30,39,43,50H,12,14-15,17-27,31H2,(H,51,54,61)(H,53,59,60)",QVOJDGYNXIRHHU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1476,P00533,EGFR L858R/T790M/C797S,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-41-14-12-39(44(60)53-41)58-47(63)36-7-4-8-38(42(36)48(58)64)50-15-22-65-24-26-67-27-25-66-23-21-55-17-19-56(20-18-55)40-13-11-34(30-52-40)33-9-10-35-31-57(46(62)37(35)29-33)43(32-5-2-1-3-6-32)45(61)54-49-51-16-28-68-49/h1-11,13,16,28-30,39,43,50H,12,14-15,17-27,31H2,(H,51,54,61)(H,53,59,60)",QVOJDGYNXIRHHU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1476,P00533,EGFR L858R/T790M/L718Q,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-41-14-12-39(44(60)53-41)58-47(63)36-7-4-8-38(42(36)48(58)64)50-15-22-65-24-26-67-27-25-66-23-21-55-17-19-56(20-18-55)40-13-11-34(30-52-40)33-9-10-35-31-57(46(62)37(35)29-33)43(32-5-2-1-3-6-32)45(61)54-49-51-16-28-68-49/h1-11,13,16,28-30,39,43,50H,12,14-15,17-27,31H2,(H,51,54,61)(H,53,59,60)",QVOJDGYNXIRHHU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1538,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC(F)=CC=C8O)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,975.069,974.343289052,70,9,4,15,C50H51FN8O10S,"InChI=1S/C50H51FN8O10S/c51-34-8-12-41(60)38(29-34)44(46(63)55-50-53-15-27-70-50)58-30-33-5-4-32(28-37(33)47(58)64)31-6-9-35(10-7-31)57-18-16-56(17-19-57)20-22-68-24-26-69-25-23-67-21-14-52-39-3-1-2-36-43(39)49(66)59(48(36)65)40-11-13-42(61)54-45(40)62/h1-10,12,15,27-29,40,44,52,60H,11,13-14,16-26,30H2,(H,53,55,63)(H,54,61,62)",YJHQLBPJGVDMDW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1540,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC(F)=CC=C8F)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,977.06,976.33895262,70,9,3,14,C50H50F2N8O9S,"InChI=1S/C50H50F2N8O9S/c51-34-8-11-39(52)38(29-34)44(46(63)56-50-54-15-27-70-50)59-30-33-5-4-32(28-37(33)47(59)64)31-6-9-35(10-7-31)58-18-16-57(17-19-58)20-22-68-24-26-69-25-23-67-21-14-53-40-3-1-2-36-43(40)49(66)60(48(36)65)41-12-13-42(61)55-45(41)62/h1-11,15,27-29,41,44,53H,12-14,16-26,30H2,(H,54,56,63)(H,55,61,62)",WHLIZTUDKDTXIF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1550,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8O)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,958.067,957.347959832,69,9,4,16,C49H51N9O10S,"InChI=1S/C49H51N9O10S/c59-39-7-2-1-4-34(39)43(45(62)54-49-51-15-27-69-49)57-30-33-9-8-31(28-36(33)46(57)63)32-10-12-40(52-29-32)56-18-16-55(17-19-56)20-22-67-24-26-68-25-23-66-21-14-50-37-6-3-5-35-42(37)48(65)58(47(35)64)38-11-13-41(60)53-44(38)61/h1-10,12,15,27-29,38,43,50,59H,11,13-14,16-26,30H2,(H,51,54,62)(H,53,60,61)",JTOYENRLVILXMD-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1552,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=C(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)C=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-42-13-11-40(44(60)53-42)58-47(63)37-10-9-36(29-39(37)48(58)64)50-14-21-65-23-25-67-26-24-66-22-20-55-16-18-56(19-17-55)41-12-8-34(30-52-41)33-6-7-35-31-57(46(62)38(35)28-33)43(32-4-2-1-3-5-32)45(61)54-49-51-15-27-68-49/h1-10,12,15,27-30,40,43,50H,11,13-14,16-26,31H2,(H,51,54,61)(H,53,59,60)",SSCWZTSBNMMURN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1555,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOCCN3CCN(C4=CC=C(C5=CC=C6CN(C(C(=O)NC7=NC=CS7)C7=CC=CC=C7)C(=O)C6=C5)C=N4)CC3)C(C)(C)C)C=C2)SC=N1,,,1127.404,1126.47686582,80,9,4,16,C59H70N10O9S2,"InChI=1S/C59H70N10O9S2/c1-39-52(80-38-63-39)42-12-10-40(11-13-42)34-62-54(72)48-33-46(70)37-68(48)57(75)53(59(2,3)4)64-50(71)18-25-76-27-29-78-30-28-77-26-24-66-20-22-67(23-21-66)49-17-16-44(35-61-49)43-14-15-45-36-69(56(74)47(45)32-43)51(41-8-6-5-7-9-41)55(73)65-58-60-19-31-79-58/h5-17,19,31-32,35,38,46,48,51,53,70H,18,20-30,33-34,36-37H2,1-4H3,(H,62,72)(H,64,71)(H,60,65,73)/t46-,48+,51?,53-/m1/s1",KPMNKWKMJWXUGN-RLMRRVSWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2001,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1043.353,1042.55749909,75,9,5,17,C56H74N12O6S,"InChI=1S/C56H74N12O6S/c1-39-49(75-38-60-39)41-16-14-40(15-17-41)35-58-52(70)48-34-46(69)37-67(48)53(71)50(56(2,3)4)57-22-28-72-30-32-74-33-31-73-29-27-65-23-25-66(26-24-65)44-20-18-43(19-21-44)61-54-59-36-47-51(64-54)68(45-12-8-9-13-45)55(63-47)62-42-10-6-5-7-11-42/h5-7,10-11,14-21,36,38,45-46,48,50,57,69H,8-9,12-13,22-35,37H2,1-4H3,(H,58,70)(H,62,63)(H,59,61,64)/t46-,48+,50-/m1/s1",HUPCKZOCINPJII-AJKYVBNFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2001,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1043.353,1042.55749909,75,9,5,17,C56H74N12O6S,"InChI=1S/C56H74N12O6S/c1-39-49(75-38-60-39)41-16-14-40(15-17-41)35-58-52(70)48-34-46(69)37-67(48)53(71)50(56(2,3)4)57-22-28-72-30-32-74-33-31-73-29-27-65-23-25-66(26-24-65)44-20-18-43(19-21-44)61-54-59-36-47-51(64-54)68(45-12-8-9-13-45)55(63-47)62-42-10-6-5-7-11-42/h5-7,10-11,14-21,36,38,45-46,48,50,57,69H,8-9,12-13,22-35,37H2,1-4H3,(H,58,70)(H,62,63)(H,59,61,64)/t46-,48+,50-/m1/s1",HUPCKZOCINPJII-AJKYVBNFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2001,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1043.353,1042.55749909,75,9,5,17,C56H74N12O6S,"InChI=1S/C56H74N12O6S/c1-39-49(75-38-60-39)41-16-14-40(15-17-41)35-58-52(70)48-34-46(69)37-67(48)53(71)50(56(2,3)4)57-22-28-72-30-32-74-33-31-73-29-27-65-23-25-66(26-24-65)44-20-18-43(19-21-44)61-54-59-36-47-51(64-54)68(45-12-8-9-13-45)55(63-47)62-42-10-6-5-7-11-42/h5-7,10-11,14-21,36,38,45-46,48,50,57,69H,8-9,12-13,22-35,37H2,1-4H3,(H,58,70)(H,62,63)(H,59,61,64)/t46-,48+,50-/m1/s1",HUPCKZOCINPJII-AJKYVBNFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,586,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,5.9,,1038.289,1037.49456448,75,8,5,15,C56H67N11O7S,"InChI=1S/C56H67N11O7S/c1-8-47(69)60-39-13-12-14-41(28-39)67-49(71)27-35(2)43-32-58-55(63-52(43)67)61-44-21-20-40(29-46(44)74-7)65-25-23-64(24-26-65)22-11-9-10-15-48(70)62-51(56(4,5)6)54(73)66-33-42(68)30-45(66)53(72)57-31-37-16-18-38(19-17-37)50-36(3)59-34-75-50/h8,12-14,16-21,27-29,32,34,42,45,51,68H,1,9-11,15,22-26,30-31,33H2,2-7H3,(H,57,72)(H,60,69)(H,62,70)(H,58,61,63)/t42-,45+,51-/m1/s1",CBWIPIZLLNOTMZ-PDMHGPQCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,586,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1038.289,1037.49456448,75,8,5,15,C56H67N11O7S,"InChI=1S/C56H67N11O7S/c1-8-47(69)60-39-13-12-14-41(28-39)67-49(71)27-35(2)43-32-58-55(63-52(43)67)61-44-21-20-40(29-46(44)74-7)65-25-23-64(24-26-65)22-11-9-10-15-48(70)62-51(56(4,5)6)54(73)66-33-42(68)30-45(66)53(72)57-31-37-16-18-38(19-17-37)50-36(3)59-34-75-50/h8,12-14,16-21,27-29,32,34,42,45,51,68H,1,9-11,15,22-26,30-31,33H2,2-7H3,(H,57,72)(H,60,69)(H,62,70)(H,58,61,63)/t42-,45+,51-/m1/s1",CBWIPIZLLNOTMZ-PDMHGPQCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2860,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(C2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2NS(C)(=O)=O)=N1,,,1043.758,1042.43241416,72,7,6,14,C52H67ClN10O7S2,"InChI=1S/C52H67ClN10O7S2/c1-32(34-16-18-36(19-17-34)46-33(2)55-31-71-46)56-49(66)43-28-38(64)30-63(43)50(67)47(52(3,4)5)59-45(65)15-9-8-12-24-62-25-22-35(23-26-62)37-20-21-42(44(27-37)70-6)58-51-54-29-39(53)48(60-51)57-40-13-10-11-14-41(40)61-72(7,68)69/h10-11,13-14,16-21,27,29,31-32,35,38,43,47,61,64H,8-9,12,15,22-26,28,30H2,1-7H3,(H,56,66)(H,59,65)(H2,54,57,58,60)/t32-,38+,43-,47+/m0/s1",LWCAXNBXZPQKSD-LOLWDDHHSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2861,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(C2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2N(C)S(C)(=O)=O)=N1,,,1057.785,1056.44806423,73,7,5,14,C53H69ClN10O7S2,"InChI=1S/C53H69ClN10O7S2/c1-33(35-17-19-37(20-18-35)47-34(2)56-32-72-47)57-50(67)44-29-39(65)31-64(44)51(68)48(53(3,4)5)60-46(66)16-10-9-13-25-63-26-23-36(24-27-63)38-21-22-42(45(28-38)71-7)59-52-55-30-40(54)49(61-52)58-41-14-11-12-15-43(41)62(6)73(8,69)70/h11-12,14-15,17-22,28,30,32-33,36,39,44,48,65H,9-10,13,16,23-27,29,31H2,1-8H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t33-,39+,44-,48+/m0/s1",JLWGCLJIWXUANI-WQWWALRQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2862,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1027.674,1026.44701521,71,7,5,14,C52H68ClN10O6PS,"InChI=1S/C52H68ClN10O6PS/c1-33(35-17-19-36(20-18-35)46-34(2)55-32-71-46)56-49(66)42-29-38(64)31-63(42)50(67)47(52(3,4)5)59-45(65)16-10-9-13-23-61-24-26-62(27-25-61)37-21-22-40(43(28-37)69-6)58-51-54-30-39(53)48(60-51)57-41-14-11-12-15-44(41)70(7,8)68/h11-12,14-15,17-22,28,30,32-33,38,42,47,64H,9-10,13,16,23-27,29,31H2,1-8H3,(H,56,66)(H,59,65)(H2,54,57,58,60)/t33-,38+,42-,47+/m0/s1",PGNBEPVWKCSKAS-RZQFPGPRSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2863,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,1057.785,1056.44806423,73,7,5,15,C53H69ClN10O7S2,"InChI=1S/C53H69ClN10O7S2/c1-33(2)73(69,70)45-15-12-11-14-42(45)58-49-40(54)30-55-52(61-49)59-41-22-21-38(28-44(41)71-8)63-26-24-62(25-27-63)23-13-9-10-16-46(66)60-48(53(5,6)7)51(68)64-31-39(65)29-43(64)50(67)57-34(3)36-17-19-37(20-18-36)47-35(4)56-32-72-47/h11-12,14-15,17-22,28,30,32-34,39,43,48,65H,9-10,13,16,23-27,29,31H2,1-8H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t34-,39+,43-,48+/m0/s1",JGZVZHAUKMEBKN-OESUUHGFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5492,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1069.658,1068.40945046,75,8,4,16,C53H62ClFN10O9S,"InChI=1S/C53H62ClFN10O9S/c1-31(2)49(46-21-32(3)62-74-46)53(70)65-27-37(66)23-43(65)52(69)61-41(34-7-9-35(10-8-34)50-33(4)59-30-75-50)26-47(67)56-13-20-72-28-48(68)64-17-15-63(16-18-64)14-6-19-73-45-24-38-42(25-44(45)71-5)57-29-58-51(38)60-36-11-12-40(55)39(54)22-36/h7-12,21-22,24-25,29-31,37,41,43,49,66H,6,13-20,23,26-28H2,1-5H3,(H,56,67)(H,61,69)(H,57,58,60)/t37-,41+,43+,49-/m1/s1",DHBPVPJKBOUIKZ-JYAIWFTJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5500,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1103.691,1102.43132878,77,8,5,15,C54H65ClF2N10O9S,"InChI=1S/C54H65ClF2N10O9S/c1-32-47(77-31-61-32)34-9-7-33(8-10-34)40(63-50(71)42-24-36(68)28-67(42)51(72)48(53(2,3)4)64-52(73)54(57)13-14-54)27-45(69)58-15-22-75-29-46(70)66-19-17-65(18-20-66)16-6-21-76-44-25-37-41(26-43(44)74-5)59-30-60-49(37)62-35-11-12-39(56)38(55)23-35/h7-12,23,25-26,30-31,36,40,42,48,68H,6,13-22,24,27-29H2,1-5H3,(H,58,69)(H,63,71)(H,64,73)(H,59,60,62)/t36-,40+,42+,48-/m1/s1",GLMYWROCCPQEMY-OQQYKNMXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5494,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1113.711,1112.43566521,78,8,4,17,C55H66ClFN10O10S,"InChI=1S/C55H66ClFN10O10S/c1-33(2)51(48-23-34(3)64-77-48)55(72)67-29-39(68)25-45(67)54(71)63-43(36-7-9-37(10-8-36)52-35(4)61-32-78-52)28-49(69)58-13-20-74-21-22-75-30-50(70)66-17-15-65(16-18-66)14-6-19-76-47-26-40-44(27-46(47)73-5)59-31-60-53(40)62-38-11-12-42(57)41(56)24-38/h7-12,23-24,26-27,31-33,39,43,45,51,68H,6,13-22,25,28-30H2,1-5H3,(H,58,69)(H,63,71)(H,59,60,62)/t39-,43+,45+,51-/m1/s1",YXOJREVIFBPBTG-NZMHYKQJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5502,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1147.744,1146.45754353,80,8,5,16,C56H69ClF2N10O10S,"InChI=1S/C56H69ClF2N10O10S/c1-34-49(80-33-63-34)36-9-7-35(8-10-36)42(65-52(73)44-26-38(70)30-69(44)53(74)50(55(2,3)4)66-54(75)56(59)13-14-56)29-47(71)60-15-22-77-23-24-78-31-48(72)68-19-17-67(18-20-68)16-6-21-79-46-27-39-43(28-45(46)76-5)61-32-62-51(39)64-37-11-12-41(58)40(57)25-37/h7-12,25,27-28,32-33,38,42,44,50,70H,6,13-24,26,29-31H2,1-5H3,(H,60,71)(H,65,73)(H,66,75)(H,61,62,64)/t38-,42+,44+,50-/m1/s1",IGYCAMNBZAAFRM-VYRQVLTMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5496,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1157.764,1156.46187996,81,8,4,18,C57H70ClFN10O11S,"InChI=1S/C57H70ClFN10O11S/c1-35(2)53(50-25-36(3)66-80-50)57(74)69-31-41(70)27-47(69)56(73)65-45(38-7-9-39(10-8-38)54-37(4)63-34-81-54)30-51(71)60-13-20-76-21-22-77-23-24-78-32-52(72)68-17-15-67(16-18-68)14-6-19-79-49-28-42-46(29-48(49)75-5)61-33-62-55(42)64-40-11-12-44(59)43(58)26-40/h7-12,25-26,28-29,33-35,41,45,47,53,70H,6,13-24,27,30-32H2,1-5H3,(H,60,71)(H,65,73)(H,61,62,64)/t41-,45+,47+,53-/m1/s1",NFWFKMISKOKRAY-UYZZMYMLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5504,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1191.797,1190.48375828,83,8,5,17,C58H73ClF2N10O11S,"InChI=1S/C58H73ClF2N10O11S/c1-36-51(83-35-65-36)38-9-7-37(8-10-38)44(67-54(75)46-28-40(72)32-71(46)55(76)52(57(2,3)4)68-56(77)58(61)13-14-58)31-49(73)62-15-22-79-23-24-80-25-26-81-33-50(74)70-19-17-69(18-20-70)16-6-21-82-48-29-41-45(30-47(48)78-5)63-34-64-53(41)66-39-11-12-43(60)42(59)27-39/h7-12,27,29-30,34-35,40,44,46,52,72H,6,13-26,28,31-33H2,1-5H3,(H,62,73)(H,67,75)(H,68,77)(H,63,64,66)/t40-,44+,46+,52-/m1/s1",ZXKZWFISZTXLOV-YHXFZPEXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,583,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1052.272,1051.47382904,76,8,5,15,C56H65N11O8S,"InChI=1S/C56H65N11O8S/c1-8-46(69)60-38-12-11-13-40(27-38)67-49(72)26-34(2)42-31-58-55(63-52(42)67)61-43-21-20-39(28-45(43)75-7)64-22-24-65(25-23-64)48(71)15-10-9-14-47(70)62-51(56(4,5)6)54(74)66-32-41(68)29-44(66)53(73)57-30-36-16-18-37(19-17-36)50-35(3)59-33-76-50/h8,11-13,16-21,26-28,31,33,41,44,51,68H,1,9-10,14-15,22-25,29-30,32H2,2-7H3,(H,57,73)(H,60,69)(H,62,70)(H,58,61,63)/t41-,44+,51-/m1/s1",SUWGYDIQBJOKHS-MSYDQUDQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,583,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1052.272,1051.47382904,76,8,5,15,C56H65N11O8S,"InChI=1S/C56H65N11O8S/c1-8-46(69)60-38-12-11-13-40(27-38)67-49(72)26-34(2)42-31-58-55(63-52(42)67)61-43-21-20-39(28-45(43)75-7)64-22-24-65(25-23-64)48(71)15-10-9-14-47(70)62-51(56(4,5)6)54(74)66-32-41(68)29-44(66)53(73)57-30-36-16-18-37(19-17-36)50-35(3)59-33-76-50/h8,11-13,16-21,26-28,31,33,41,44,51,68H,1,9-10,14-15,22-25,29-30,32H2,2-7H3,(H,57,73)(H,60,69)(H,62,70)(H,58,61,63)/t41-,44+,51-/m1/s1",SUWGYDIQBJOKHS-MSYDQUDQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2230,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,840.313,839.295800616,60,7,4,12,C42H43ClFN9O7,"InChI=1S/C42H43ClFN9O7/c1-2-35(54)49-32-22-27-31(46-24-47-39(27)48-25-10-11-29(44)28(43)21-25)23-34(32)60-20-6-15-51-16-18-52(19-17-51)37(56)9-3-4-14-45-30-8-5-7-26-38(30)42(59)53(41(26)58)33-12-13-36(55)50-40(33)57/h2,5,7-8,10-11,21-24,33,45H,1,3-4,6,9,12-20H2,(H,49,54)(H,46,47,48)(H,50,55,57)",DZXXQMUFFJDNFM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2230,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,840.313,839.295800616,60,7,4,12,C42H43ClFN9O7,"InChI=1S/C42H43ClFN9O7/c1-2-35(54)49-32-22-27-31(46-24-47-39(27)48-25-10-11-29(44)28(43)21-25)23-34(32)60-20-6-15-51-16-18-52(19-17-51)37(56)9-3-4-14-45-30-8-5-7-26-38(30)42(59)53(41(26)58)33-12-13-36(55)50-40(33)57/h2,5,7-8,10-11,21-24,33,45H,1,3-4,6,9,12-20H2,(H,49,54)(H,46,47,48)(H,50,55,57)",DZXXQMUFFJDNFM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5472,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1067.686,1066.43018591,75,8,4,15,C54H64ClFN10O8S,"InChI=1S/C54H64ClFN10O8S/c1-32(2)50(47-23-33(3)63-74-47)54(71)66-29-38(67)25-44(66)53(70)62-42(35-10-12-36(13-11-35)51-34(4)60-31-75-51)28-48(68)57-16-7-6-9-49(69)65-20-18-64(19-21-65)17-8-22-73-46-26-39-43(27-45(46)72-5)58-30-59-52(39)61-37-14-15-41(56)40(55)24-37/h10-15,23-24,26-27,30-32,38,42,44,50,67H,6-9,16-22,25,28-29H2,1-5H3,(H,57,68)(H,62,70)(H,58,59,61)/t38-,42+,44+,50-/m1/s1",CLHSOESPINIVIM-VYRQVLTMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5484,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1101.719,1100.45206422,77,8,5,14,C55H67ClF2N10O8S,"InChI=1S/C55H67ClF2N10O8S/c1-33-48(77-32-62-33)35-12-10-34(11-13-35)41(64-51(72)43-26-37(69)30-68(43)52(73)49(54(2,3)4)65-53(74)55(58)16-17-55)29-46(70)59-18-7-6-9-47(71)67-22-20-66(21-23-67)19-8-24-76-45-27-38-42(28-44(45)75-5)60-31-61-50(38)63-36-14-15-40(57)39(56)25-36/h10-15,25,27-28,31-32,37,41,43,49,69H,6-9,16-24,26,29-30H2,1-5H3,(H,59,70)(H,64,72)(H,65,74)(H,60,61,63)/t37-,41+,43+,49-/m1/s1",UHXOCIVWYWWAFP-JYAIWFTJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,568,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1042.3,1041.5171115,75,9,6,16,C55H68FN13O5S,"InChI=1S/C55H68FN13O5S/c1-35-49(75-34-60-35)38-10-8-36(9-11-38)29-59-52(73)45-27-42(71)32-69(45)53(74)50(55(2,3)4)64-48(72)7-5-6-20-66-23-25-67(26-24-66)41-16-17-46(57-30-41)63-47-28-43-44(31-58-47)62-54(61-40-14-12-39(56)13-15-40)65-51(43)68-21-18-37(33-70)19-22-68/h8-17,28,30-31,34,37,42,45,50,70-71H,5-7,18-27,29,32-33H2,1-4H3,(H,59,73)(H,64,72)(H,57,58,63)(H,61,62,65)/t42-,45+,50-/m1/s1",DBOZEYKAOPNYFQ-YPPXMBQWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2865,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1013.647,1012.43136514,70,7,5,14,C51H66ClN10O6PS,"InChI=1S/C51H66ClN10O6PS/c1-32(34-16-18-35(19-17-34)45-33(2)54-31-70-45)55-48(65)41-28-37(63)30-62(41)49(66)46(51(3,4)5)58-44(64)15-11-12-22-60-23-25-61(26-24-60)36-20-21-39(42(27-36)68-6)57-50-53-29-38(52)47(59-50)56-40-13-9-10-14-43(40)69(7,8)67/h9-10,13-14,16-21,27,29,31-32,37,41,46,63H,11-12,15,22-26,28,30H2,1-8H3,(H,55,65)(H,58,64)(H2,53,56,57,59)/t32-,37+,41-,46+/m0/s1",PIVNHCZTKNSYDX-KXGURFEISA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,587,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1010.235,1009.46326436,73,8,5,15,C54H63N11O7S,"InChI=1S/C54H63N11O7S/c1-8-45(67)58-37-11-9-12-39(26-37)65-47(69)25-33(2)41-30-56-53(61-50(41)65)59-42-19-18-38(27-44(42)72-7)63-23-21-62(22-24-63)20-10-13-46(68)60-49(54(4,5)6)52(71)64-31-40(66)28-43(64)51(70)55-29-35-14-16-36(17-15-35)48-34(3)57-32-73-48/h8-9,11-12,14-19,25-27,30,32,40,43,49,66H,1,10,13,20-24,28-29,31H2,2-7H3,(H,55,70)(H,58,67)(H,60,68)(H,56,59,61)/t40-,43+,49-/m1/s1",GHHZCEDRWNWCTG-PCGSYBQZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,587,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1010.235,1009.46326436,73,8,5,15,C54H63N11O7S,"InChI=1S/C54H63N11O7S/c1-8-45(67)58-37-11-9-12-39(26-37)65-47(69)25-33(2)41-30-56-53(61-50(41)65)59-42-19-18-38(27-44(42)72-7)63-23-21-62(22-24-63)20-10-13-46(68)60-49(54(4,5)6)52(71)64-31-40(66)28-43(64)51(70)55-29-35-14-16-36(17-15-35)48-34(3)57-32-73-48/h8-9,11-12,14-19,25-27,30,32,40,43,49,66H,1,10,13,20-24,28-29,31H2,2-7H3,(H,55,70)(H,58,67)(H,60,68)(H,56,59,61)/t40-,43+,49-/m1/s1",GHHZCEDRWNWCTG-PCGSYBQZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2864,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,999.62,998.415715078,69,7,5,14,C50H64ClN10O6PS,"InChI=1S/C50H64ClN10O6PS/c1-31(33-15-17-34(18-16-33)44-32(2)53-30-69-44)54-47(64)40-27-36(62)29-61(40)48(65)45(50(3,4)5)57-43(63)14-11-21-59-22-24-60(25-23-59)35-19-20-38(41(26-35)67-6)56-49-52-28-37(51)46(58-49)55-39-12-9-10-13-42(39)68(7,8)66/h9-10,12-13,15-20,26,28,30-31,36,40,45,62H,11,14,21-25,27,29H2,1-8H3,(H,54,64)(H,57,63)(H2,52,55,56,58)/t31-,36+,40-,45+/m0/s1",CQYHZVXZWVBOLV-DKGDNKRPSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,567,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,34.8,98,1070.354,1069.54841162,77,9,6,16,C57H72FN13O5S,"InChI=1S/C57H72FN13O5S/c1-37-51(77-36-62-37)40-12-10-38(11-13-40)31-61-54(75)47-29-44(73)34-71(47)55(76)52(57(2,3)4)66-50(74)9-7-5-6-8-22-68-25-27-69(28-26-68)43-18-19-48(59-32-43)65-49-30-45-46(33-60-49)64-56(63-42-16-14-41(58)15-17-42)67-53(45)70-23-20-39(35-72)21-24-70/h10-19,30,32-33,36,39,44,47,52,72-73H,5-9,20-29,31,34-35H2,1-4H3,(H,61,75)(H,66,74)(H,59,60,65)(H,63,64,67)/t44-,47+,52-/m1/s1",LCTCXOPSLJEXKE-FEDPBZRBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1543,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCCCCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,865.029,864.341752256,63,9,3,11,C48H48N8O6S,"InChI=1S/C48H48N8O6S/c57-40-20-19-39(43(58)51-40)56-46(61)36-11-8-12-38(41(36)47(56)62)49-21-6-1-2-7-23-53-24-26-54(27-25-53)35-17-15-31(16-18-35)33-13-14-34-30-55(45(60)37(34)29-33)42(32-9-4-3-5-10-32)44(59)52-48-50-22-28-63-48/h3-5,8-18,22,28-29,39,42,49H,1-2,6-7,19-21,23-27,30H2,(H,50,52,59)(H,51,57,58)",PILAFINNPPGQBT-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1995,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,N.D.,995.312,994.53636972,72,9,5,14,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1995,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,126.2,90.3,995.312,994.53636972,72,9,5,14,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1995,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,0.51,80.4,995.312,994.53636972,72,9,5,14,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2610,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1026.322,1025.53094999,74,7,5,14,C56H71N11O6S,"InChI=1S/C56H71N11O6S/c1-10-49(69)60-43-30-44(62-55-57-25-24-42(61-55)41-34-65(8)45-18-15-14-17-40(41)45)48(73-9)31-46(43)66(28-27-64(6)7)26-16-12-11-13-19-50(70)63-52(56(3,4)5)54(72)67-33-39(68)29-47(67)53(71)58-32-37-20-22-38(23-21-37)51-36(2)59-35-74-51/h10,14-15,17-18,20-25,30-31,34-35,39,47,52,68H,1,11-13,16,19,26-29,32-33H2,2-9H3,(H,58,71)(H,60,69)(H,63,70)(H,57,61,62)/t39-,47+,52-/m1/s1",RLLCZBYYTSDTJQ-VHKLOALXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2610,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1026.322,1025.53094999,74,7,5,14,C56H71N11O6S,"InChI=1S/C56H71N11O6S/c1-10-49(69)60-43-30-44(62-55-57-25-24-42(61-55)41-34-65(8)45-18-15-14-17-40(41)45)48(73-9)31-46(43)66(28-27-64(6)7)26-16-12-11-13-19-50(70)63-52(56(3,4)5)54(72)67-33-39(68)29-47(67)53(71)58-32-37-20-22-38(23-21-37)51-36(2)59-35-74-51/h10,14-15,17-18,20-25,30-31,34-35,39,47,52,68H,1,11-13,16,19,26-29,32-33H2,2-9H3,(H,58,71)(H,60,69)(H,63,70)(H,57,61,62)/t39-,47+,52-/m1/s1",RLLCZBYYTSDTJQ-VHKLOALXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2619,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1050.348,1049.54218337,76,9,5,15,C57H71N13O5S,"InChI=1S/C57H71N13O5S/c1-6-49(73)68-27-25-44(35-68)70-52-46(63-56(70)62-41-14-10-9-11-15-41)34-59-55(65-52)61-42-21-23-43(24-22-42)67-30-28-66(29-31-67)26-13-8-7-12-16-48(72)64-51(57(3,4)5)54(75)69-36-45(71)32-47(69)53(74)58-33-39-17-19-40(20-18-39)50-38(2)60-37-76-50/h6,9-11,14-15,17-24,34,37,44-45,47,51,71H,1,7-8,12-13,16,25-33,35-36H2,2-5H3,(H,58,74)(H,62,63)(H,64,72)(H,59,61,65)/t44-,45+,47-,51+/m0/s1",FXWJQZDZCXGXTI-XSCJKQSPSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2619,P00533,EGFR e19d,VHL,C=CC(=O)N1CC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1050.348,1049.54218337,76,9,5,15,C57H71N13O5S,"InChI=1S/C57H71N13O5S/c1-6-49(73)68-27-25-44(35-68)70-52-46(63-56(70)62-41-14-10-9-11-15-41)34-59-55(65-52)61-42-21-23-43(24-22-42)67-30-28-66(29-31-67)26-13-8-7-12-16-48(72)64-51(57(3,4)5)54(75)69-36-45(71)32-47(69)53(74)58-33-39-17-19-40(20-18-39)50-38(2)60-37-76-50/h6,9-11,14-15,17-24,34,37,44-45,47,51,71H,1,7-8,12-13,16,25-33,35-36H2,2-5H3,(H,58,74)(H,62,63)(H,64,72)(H,59,61,65)/t44-,45+,47-,51+/m0/s1",FXWJQZDZCXGXTI-XSCJKQSPSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2620,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1064.375,1063.55783344,77,9,5,15,C58H73N13O5S,"InChI=1S/C58H73N13O5S/c1-6-50(74)69-28-14-17-45(36-69)71-53-47(64-57(71)63-42-15-10-9-11-16-42)35-60-56(66-53)62-43-23-25-44(26-24-43)68-31-29-67(30-32-68)27-13-8-7-12-18-49(73)65-52(58(3,4)5)55(76)70-37-46(72)33-48(70)54(75)59-34-40-19-21-41(22-20-40)51-39(2)61-38-77-51/h6,9-11,15-16,19-26,35,38,45-46,48,52,72H,1,7-8,12-14,17-18,27-34,36-37H2,2-5H3,(H,59,75)(H,63,64)(H,65,73)(H,60,62,66)/t45-,46+,48-,52+/m0/s1",CSQRGDCIFDELOJ-XBQJXWJCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2620,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1064.375,1063.55783344,77,9,5,15,C58H73N13O5S,"InChI=1S/C58H73N13O5S/c1-6-50(74)69-28-14-17-45(36-69)71-53-47(64-57(71)63-42-15-10-9-11-16-42)35-60-56(66-53)62-43-23-25-44(26-24-43)68-31-29-67(30-32-68)27-13-8-7-12-18-49(73)65-52(58(3,4)5)55(76)70-37-46(72)33-48(70)54(75)59-34-40-19-21-41(22-20-40)51-39(2)61-38-77-51/h6,9-11,15-16,19-26,35,38,45-46,48,52,72H,1,7-8,12-14,17-18,27-34,36-37H2,2-5H3,(H,59,75)(H,63,64)(H,65,73)(H,60,62,66)/t45-,46+,48-,52+/m0/s1",CSQRGDCIFDELOJ-XBQJXWJCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2866,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1041.701,1040.46266527,72,7,5,14,C53H70ClN10O6PS,"InChI=1S/C53H70ClN10O6PS/c1-34(36-18-20-37(21-19-36)47-35(2)56-33-72-47)57-50(67)43-30-39(65)32-64(43)51(68)48(53(3,4)5)60-46(66)17-11-9-10-14-24-62-25-27-63(28-26-62)38-22-23-41(44(29-38)70-6)59-52-55-31-40(54)49(61-52)58-42-15-12-13-16-45(42)71(7,8)69/h12-13,15-16,18-23,29,31,33-34,39,43,48,65H,9-11,14,17,24-28,30,32H2,1-8H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t34-,39+,43-,48+/m0/s1",VTNGOAUXHNQCSE-OESUUHGFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,585,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,466,,1066.343,1065.52586461,77,8,5,15,C58H71N11O7S,"InChI=1S/C58H71N11O7S/c1-8-49(71)62-41-15-14-16-43(30-41)69-51(73)29-37(2)45-34-60-57(65-54(45)69)63-46-23-22-42(31-48(46)76-7)67-27-25-66(26-28-67)24-13-11-9-10-12-17-50(72)64-53(58(4,5)6)56(75)68-35-44(70)32-47(68)55(74)59-33-39-18-20-40(21-19-39)52-38(3)61-36-77-52/h8,14-16,18-23,29-31,34,36,44,47,53,70H,1,9-13,17,24-28,32-33,35H2,2-7H3,(H,59,74)(H,62,71)(H,64,72)(H,60,63,65)/t44-,47+,53-/m1/s1",UKICTJWYEJNYHR-JSYKSQSDSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,585,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1066.343,1065.52586461,77,8,5,15,C58H71N11O7S,"InChI=1S/C58H71N11O7S/c1-8-49(71)62-41-15-14-16-43(30-41)69-51(73)29-37(2)45-34-60-57(65-54(45)69)63-46-23-22-42(31-48(46)76-7)67-27-25-66(26-28-67)24-13-11-9-10-12-17-50(72)64-53(58(4,5)6)56(75)68-35-44(70)32-47(68)55(74)59-33-39-18-20-40(21-19-39)52-38(3)61-36-77-52/h8,14-16,18-23,29-31,34,36,44,47,53,70H,1,9-13,17,24-28,32-33,35H2,2-7H3,(H,59,74)(H,62,71)(H,64,72)(H,60,63,65)/t44-,47+,53-/m1/s1",UKICTJWYEJNYHR-JSYKSQSDSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1996,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1009.339,1008.55201978,73,9,5,14,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1996,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,151.2,80.3,1009.339,1008.55201978,73,9,5,14,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1996,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,3.54,74.8,1009.339,1008.55201978,73,9,5,14,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2613,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1040.349,1039.54660006,75,7,5,14,C57H73N11O6S,"InChI=1S/C57H73N11O6S/c1-10-50(70)61-44-31-45(63-56-58-26-25-43(62-56)42-35-67(8)46-19-16-15-18-41(42)46)49(74-9)32-47(44)66(7)29-28-65(6)27-17-13-11-12-14-20-51(71)64-53(57(3,4)5)55(73)68-34-40(69)30-48(68)54(72)59-33-38-21-23-39(24-22-38)52-37(2)60-36-75-52/h10,15-16,18-19,21-26,31-32,35-36,40,48,53,69H,1,11-14,17,20,27-30,33-34H2,2-9H3,(H,59,72)(H,61,70)(H,64,71)(H,58,62,63)/t40-,48+,53-/m1/s1",ZSAWNDDMNMQIIJ-KEQUNFJLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2613,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1040.349,1039.54660006,75,7,5,14,C57H73N11O6S,"InChI=1S/C57H73N11O6S/c1-10-50(70)61-44-31-45(63-56-58-26-25-43(62-56)42-35-67(8)46-19-16-15-18-41(42)46)49(74-9)32-47(44)66(7)29-28-65(6)27-17-13-11-12-14-20-51(71)64-53(57(3,4)5)55(73)68-34-40(69)30-48(68)54(72)59-33-38-21-23-39(24-22-38)52-37(2)60-36-75-52/h10,15-16,18-19,21-26,31-32,35-36,40,48,53,69H,1,11-14,17,20,27-30,33-34H2,2-9H3,(H,59,72)(H,61,70)(H,64,71)(H,58,62,63)/t40-,48+,53-/m1/s1",ZSAWNDDMNMQIIJ-KEQUNFJLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2621,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1078.402,1077.5734835,78,9,5,15,C59H75N13O5S,"InChI=1S/C59H75N13O5S/c1-6-51(75)70-29-15-18-46(37-70)72-54-48(65-58(72)64-43-16-11-10-12-17-43)36-61-57(67-54)63-44-24-26-45(27-25-44)69-32-30-68(31-33-69)28-14-9-7-8-13-19-50(74)66-53(59(3,4)5)56(77)71-38-47(73)34-49(71)55(76)60-35-41-20-22-42(23-21-41)52-40(2)62-39-78-52/h6,10-12,16-17,20-27,36,39,46-47,49,53,73H,1,7-9,13-15,18-19,28-35,37-38H2,2-5H3,(H,60,76)(H,64,65)(H,66,74)(H,61,63,67)/t46-,47+,49-,53+/m0/s1",WSSNDQVXHFXMID-APOZONLHSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2621,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1078.402,1077.5734835,78,9,5,15,C59H75N13O5S,"InChI=1S/C59H75N13O5S/c1-6-51(75)70-29-15-18-46(37-70)72-54-48(65-58(72)64-43-16-11-10-12-17-43)36-61-57(67-54)63-44-24-26-45(27-25-44)69-32-30-68(31-33-69)28-14-9-7-8-13-19-50(74)66-53(59(3,4)5)56(77)71-38-47(73)34-49(71)55(76)60-35-41-20-22-42(23-21-41)52-40(2)62-39-78-52/h6,10-12,16-17,20-27,36,39,46-47,49,53,73H,1,7-9,13-15,18-19,28-35,37-38H2,2-5H3,(H,60,76)(H,64,65)(H,66,74)(H,61,63,67)/t46-,47+,49-,53+/m0/s1",WSSNDQVXHFXMID-APOZONLHSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2625,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,1.56,86,1092.429,1091.58913356,79,9,5,15,C60H77N13O5S,"InChI=1S/C60H77N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h7,11-13,17-18,21-28,36,39-40,47-48,50,54,74H,1,8-10,14-16,19-20,29-35,37-38H2,2-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",RYXQXEGTLNBKEC-DKQRTKIFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2625,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,0.49,82,1092.429,1091.58913356,79,9,5,15,C60H77N13O5S,"InChI=1S/C60H77N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h7,11-13,17-18,21-28,36,39-40,47-48,50,54,74H,1,8-10,14-16,19-20,29-35,37-38H2,2-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",RYXQXEGTLNBKEC-DKQRTKIFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2626,P00533,EGFR L858R/T790M,VHL,CCC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1094.445,1093.60478363,79,9,5,15,C60H79N13O5S,"InChI=1S/C60H79N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h11-13,17-18,21-28,36,39-40,47-48,50,54,74H,7-10,14-16,19-20,29-35,37-38H2,1-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",NEBQLCJXQCQWAT-DKQRTKIFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2626,P00533,EGFR e19d,VHL,CCC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1094.445,1093.60478363,79,9,5,15,C60H79N13O5S,"InChI=1S/C60H79N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h11-13,17-18,21-28,36,39-40,47-48,50,54,74H,7-10,14-16,19-20,29-35,37-38H2,1-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",NEBQLCJXQCQWAT-DKQRTKIFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2867,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,8,,1055.728,1054.47831533,73,7,5,14,C54H72ClN10O6PS,"InChI=1S/C54H72ClN10O6PS/c1-35(37-19-21-38(22-20-37)48-36(2)57-34-73-48)58-51(68)44-31-40(66)33-65(44)52(69)49(54(3,4)5)61-47(67)18-12-10-9-11-15-25-63-26-28-64(29-27-63)39-23-24-42(45(30-39)71-6)60-53-56-32-41(55)50(62-53)59-43-16-13-14-17-46(43)72(7,8)70/h13-14,16-17,19-24,30,32,34-35,40,44,49,66H,9-12,15,18,25-29,31,33H2,1-8H3,(H,58,68)(H,61,67)(H2,56,59,60,62)/t35-,40+,44-,49+/m0/s1",KSHZFKVXGRVRTM-XJLLBULKSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2867,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(CCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1055.728,1054.47831533,73,7,5,14,C54H72ClN10O6PS,"InChI=1S/C54H72ClN10O6PS/c1-35(37-19-21-38(22-20-37)48-36(2)57-34-73-48)58-51(68)44-31-40(66)33-65(44)52(69)49(54(3,4)5)61-47(67)18-12-10-9-11-15-25-63-26-28-64(29-27-63)39-23-24-42(45(30-39)71-6)60-53-56-32-41(55)50(62-53)59-43-16-13-14-17-46(43)72(7,8)70/h13-14,16-17,19-24,30,32,34-35,40,44,49,66H,9-12,15,18,25-29,31,33H2,1-8H3,(H,58,68)(H,61,67)(H2,56,59,60,62)/t35-,40+,44-,49+/m0/s1",KSHZFKVXGRVRTM-XJLLBULKSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2867,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(CCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1055.728,1054.47831533,73,7,5,14,C54H72ClN10O6PS,"InChI=1S/C54H72ClN10O6PS/c1-35(37-19-21-38(22-20-37)48-36(2)57-34-73-48)58-51(68)44-31-40(66)33-65(44)52(69)49(54(3,4)5)61-47(67)18-12-10-9-11-15-25-63-26-28-64(29-27-63)39-23-24-42(45(30-39)71-6)60-53-56-32-41(55)50(62-53)59-43-16-13-14-17-46(43)72(7,8)70/h13-14,16-17,19-24,30,32,34-35,40,44,49,66H,9-12,15,18,25-29,31,33H2,1-8H3,(H,58,68)(H,61,67)(H2,56,59,60,62)/t35-,40+,44-,49+/m0/s1",KSHZFKVXGRVRTM-XJLLBULKSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1544,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCCCCCCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,893.083,892.373052384,65,9,3,11,C50H52N8O6S,"InChI=1S/C50H52N8O6S/c59-42-22-21-41(45(60)53-42)58-48(63)38-13-10-14-40(43(38)49(58)64)51-23-8-3-1-2-4-9-25-55-26-28-56(29-27-55)37-19-17-33(18-20-37)35-15-16-36-32-57(47(62)39(36)31-35)44(34-11-6-5-7-12-34)46(61)54-50-52-24-30-65-50/h5-7,10-20,24,30-31,41,44,51H,1-4,8-9,21-23,25-29,32H2,(H,52,54,61)(H,53,59,60)",OARWNJPFFUUHMW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2868,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1069.755,1068.4939654,74,7,5,14,C55H74ClN10O6PS,"InChI=1S/C55H74ClN10O6PS/c1-36(38-20-22-39(23-21-38)49-37(2)58-35-74-49)59-52(69)45-32-41(67)34-66(45)53(70)50(55(3,4)5)62-48(68)19-13-11-9-10-12-16-26-64-27-29-65(30-28-64)40-24-25-43(46(31-40)72-6)61-54-57-33-42(56)51(63-54)60-44-17-14-15-18-47(44)73(7,8)71/h14-15,17-18,20-25,31,33,35-36,41,45,50,67H,9-13,16,19,26-30,32,34H2,1-8H3,(H,59,69)(H,62,68)(H2,57,60,61,63)/t36-,41+,45-,50+/m0/s1",AAANIVVODIZQAG-NYJWCRJYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,584,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,132,,1094.397,1093.55716474,79,8,5,15,C60H75N11O7S,"InChI=1S/C60H75N11O7S/c1-8-51(73)64-43-17-16-18-45(32-43)71-53(75)31-39(2)47-36-62-59(67-56(47)71)65-48-25-24-44(33-50(48)78-7)69-29-27-68(28-30-69)26-15-13-11-9-10-12-14-19-52(74)66-55(60(4,5)6)58(77)70-37-46(72)34-49(70)57(76)61-35-41-20-22-42(23-21-41)54-40(3)63-38-79-54/h8,16-18,20-25,31-33,36,38,46,49,55,72H,1,9-15,19,26-30,34-35,37H2,2-7H3,(H,61,76)(H,64,73)(H,66,74)(H,62,65,67)/t46-,49+,55-/m1/s1",WWVCWKWNVMYOAL-CKCQHBCRSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,584,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1094.397,1093.55716474,79,8,5,15,C60H75N11O7S,"InChI=1S/C60H75N11O7S/c1-8-51(73)64-43-17-16-18-45(32-43)71-53(75)31-39(2)47-36-62-59(67-56(47)71)65-48-25-24-44(33-50(48)78-7)69-29-27-68(28-30-69)26-15-13-11-9-10-12-14-19-52(74)66-55(60(4,5)6)58(77)70-37-46(72)34-49(70)57(76)61-35-41-20-22-42(23-21-41)54-40(3)63-38-79-54/h8,16-18,20-25,31-33,36,38,46,49,55,72H,1,9-15,19,26-30,34-35,37H2,2-7H3,(H,61,76)(H,64,73)(H,66,74)(H,62,65,67)/t46-,49+,55-/m1/s1",WWVCWKWNVMYOAL-CKCQHBCRSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,577,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,25.3,,1122.451,1121.58846487,81,8,5,15,C62H79N11O7S,"InChI=1S/C62H79N11O7S/c1-8-53(75)66-45-19-18-20-47(34-45)73-55(77)33-41(2)49-38-64-61(69-58(49)73)67-50-27-26-46(35-52(50)80-7)71-31-29-70(30-32-71)28-17-15-13-11-9-10-12-14-16-21-54(76)68-57(62(4,5)6)60(79)72-39-48(74)36-51(72)59(78)63-37-43-22-24-44(25-23-43)56-42(3)65-40-81-56/h8,18-20,22-27,33-35,38,40,48,51,57,74H,1,9-17,21,28-32,36-37,39H2,2-7H3,(H,63,78)(H,66,75)(H,68,76)(H,64,67,69)/t48-,51+,57-/m1/s1",HQGHIKHHXKBFOJ-OIQPADLRSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,577,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,50.3,,1122.451,1121.58846487,81,8,5,15,C62H79N11O7S,"InChI=1S/C62H79N11O7S/c1-8-53(75)66-45-19-18-20-47(34-45)73-55(77)33-41(2)49-38-64-61(69-58(49)73)67-50-27-26-46(35-52(50)80-7)71-31-29-70(30-32-71)28-17-15-13-11-9-10-12-14-16-21-54(76)68-57(62(4,5)6)60(79)72-39-48(74)36-51(72)59(78)63-37-43-22-24-44(25-23-43)56-42(3)65-40-81-56/h8,18-20,22-27,33-35,38,40,48,51,57,74H,1,9-17,21,28-32,36-37,39H2,2-7H3,(H,63,78)(H,66,75)(H,68,76)(H,64,67,69)/t48-,51+,57-/m1/s1",HQGHIKHHXKBFOJ-OIQPADLRSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4281,P00533,EGFR,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1003.324,1002.54011771,72,7,4,12,C56H74N8O7S,"InChI=1S/C56H74N8O7S/c1-38-51(72-37-60-38)41-24-22-39(23-25-41)33-57-54(68)46-30-43(65)34-64(46)55(69)52(56(2,3)4)62-49(66)20-16-11-9-7-6-8-10-12-17-21-50(67)63-28-26-40(27-29-63)35-71-48-32-45-44(31-47(48)70-5)53(59-36-58-45)61-42-18-14-13-15-19-42/h13-15,18-19,22-25,31-32,36-37,40,43,46,52,65H,6-12,16-17,20-21,26-30,33-35H2,1-5H3,(H,57,68)(H,62,66)(H,58,59,61)/t43-,46+,52-/m1/s1",MMPNZJCRKQTTJP-YFNYOHRESA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4281,P00533,EGFR L858R,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1003.324,1002.54011771,72,7,4,12,C56H74N8O7S,"InChI=1S/C56H74N8O7S/c1-38-51(72-37-60-38)41-24-22-39(23-25-41)33-57-54(68)46-30-43(65)34-64(46)55(69)52(56(2,3)4)62-49(66)20-16-11-9-7-6-8-10-12-17-21-50(67)63-28-26-40(27-29-63)35-71-48-32-45-44(31-47(48)70-5)53(59-36-58-45)61-42-18-14-13-15-19-42/h13-15,18-19,22-25,31-32,36-37,40,43,46,52,65H,6-12,16-17,20-21,26-30,33-35H2,1-5H3,(H,57,68)(H,62,66)(H,58,59,61)/t43-,46+,52-/m1/s1",MMPNZJCRKQTTJP-YFNYOHRESA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4281,P00533,EGFR e19d,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1003.324,1002.54011771,72,7,4,12,C56H74N8O7S,"InChI=1S/C56H74N8O7S/c1-38-51(72-37-60-38)41-24-22-39(23-25-41)33-57-54(68)46-30-43(65)34-64(46)55(69)52(56(2,3)4)62-49(66)20-16-11-9-7-6-8-10-12-17-21-50(67)63-28-26-40(27-29-63)35-71-48-32-45-44(31-47(48)70-5)53(59-36-58-45)61-42-18-14-13-15-19-42/h13-15,18-19,22-25,31-32,36-37,40,43,46,52,65H,6-12,16-17,20-21,26-30,33-35H2,1-5H3,(H,57,68)(H,62,66)(H,58,59,61)/t43-,46+,52-/m1/s1",MMPNZJCRKQTTJP-YFNYOHRESA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5613,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,897.916,897.353377472,65,7,6,14,C44H46F3N11O7,"InChI=1S/C44H46F3N11O7/c1-3-35(59)51-26-8-6-9-27(22-26)52-39-30(44(45,46)47)24-50-43(55-39)53-31-13-12-28(23-34(31)65-2)57-20-18-56(19-21-57)25-37(61)49-17-5-4-16-48-32-11-7-10-29-38(32)42(64)58(41(29)63)33-14-15-36(60)54-40(33)62/h3,6-13,22-24,33,48H,1,4-5,14-21,25H2,2H3,(H,49,61)(H,51,59)(H,54,60,62)(H2,50,52,53,55)",DBCOQEBSRVLNQM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5613,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,897.916,897.353377472,65,7,6,14,C44H46F3N11O7,"InChI=1S/C44H46F3N11O7/c1-3-35(59)51-26-8-6-9-27(22-26)52-39-30(44(45,46)47)24-50-43(55-39)53-31-13-12-28(23-34(31)65-2)57-20-18-56(19-21-57)25-37(61)49-17-5-4-16-48-32-11-7-10-29-38(32)42(64)58(41(29)63)33-14-15-36(60)54-40(33)62/h3,6-13,22-24,33,48H,1,4-5,14-21,25H2,2H3,(H,49,61)(H,51,59)(H,54,60,62)(H2,50,52,53,55)",DBCOQEBSRVLNQM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5613,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,897.916,897.353377472,65,7,6,14,C44H46F3N11O7,"InChI=1S/C44H46F3N11O7/c1-3-35(59)51-26-8-6-9-27(22-26)52-39-30(44(45,46)47)24-50-43(55-39)53-31-13-12-28(23-34(31)65-2)57-20-18-56(19-21-57)25-37(61)49-17-5-4-16-48-32-11-7-10-29-38(32)42(64)58(41(29)63)33-14-15-36(60)54-40(33)62/h3,6-13,22-24,33,48H,1,4-5,14-21,25H2,2H3,(H,49,61)(H,51,59)(H,54,60,62)(H2,50,52,53,55)",DBCOQEBSRVLNQM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,561,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,885.018,884.424591016,65,9,5,14,C47H53FN12O5,"InChI=1S/C47H53FN12O5/c48-31-8-10-32(11-9-31)51-47-53-38-27-50-41(25-35(38)44(56-47)59-19-16-30(29-61)17-20-59)54-40-14-12-33(26-49-40)58-23-21-57(22-24-58)18-3-1-2-7-42(62)52-37-6-4-5-34-36(37)28-60(46(34)65)39-13-15-43(63)55-45(39)64/h4-6,8-12,14,25-27,30,39,61H,1-3,7,13,15-24,28-29H2,(H,52,62)(H,49,50,54)(H,51,53,56)(H,55,63,64)",ODJQZPLMAOELRA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5463,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,865.008,864.407129384,64,7,4,12,C48H52N10O6,"InChI=1S/C48H52N10O6/c1-6-23-57(24-12-8-9-18-44(60)50-35-16-13-15-32-34(35)30-58(47(32)63)40-19-20-45(61)54-46(40)62)26-25-55(3)41-28-42(64-5)38(27-37(41)51-43(59)7-2)53-48-49-22-21-36(52-48)33-29-56(4)39-17-11-10-14-31(33)39/h1,7,10-11,13-17,21-22,27-29,40H,2,8-9,12,18-20,23-26,30H2,3-5H3,(H,50,60)(H,51,59)(H,49,52,53)(H,54,61,62)",LZLZXSSMSNOMPK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5611,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-33(57)49-24-6-4-7-25(20-24)50-37-28(42(43,44)45)22-48-41(53-37)51-29-11-10-26(21-32(29)63-2)55-18-16-54(17-19-55)23-35(59)47-15-14-46-30-9-5-8-27-36(30)40(62)56(39(27)61)31-12-13-34(58)52-38(31)60/h3-11,20-22,31,46H,1,12-19,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",FVYDZXSZKLYSRY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5611,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,355.9,83,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-33(57)49-24-6-4-7-25(20-24)50-37-28(42(43,44)45)22-48-41(53-37)51-29-11-10-26(21-32(29)63-2)55-18-16-54(17-19-55)23-35(59)47-15-14-46-30-9-5-8-27-36(30)40(62)56(39(27)61)31-12-13-34(58)52-38(31)60/h3-11,20-22,31,46H,1,12-19,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",FVYDZXSZKLYSRY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5611,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-33(57)49-24-6-4-7-25(20-24)50-37-28(42(43,44)45)22-48-41(53-37)51-29-11-10-26(21-32(29)63-2)55-18-16-54(17-19-55)23-35(59)47-15-14-46-30-9-5-8-27-36(30)40(62)56(39(27)61)31-12-13-34(58)52-38(31)60/h3-11,20-22,31,46H,1,12-19,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",FVYDZXSZKLYSRY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5618,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,855.879,855.342812788,62,7,6,13,C42H44F3N11O6,"InChI=1S/C42H44F3N11O6/c1-3-35(57)49-25-6-4-7-26(20-25)50-38-30(42(43,44)45)22-48-41(53-38)51-32-11-10-27(21-34(32)62-2)55-18-16-54(17-19-55)24-37(59)47-15-14-46-31-9-5-8-28-29(31)23-56(40(28)61)33-12-13-36(58)52-39(33)60/h3-11,20-22,33,46H,1,12-19,23-24H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",ZZEWLUKGFOHQPN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5618,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,855.879,855.342812788,62,7,6,13,C42H44F3N11O6,"InChI=1S/C42H44F3N11O6/c1-3-35(57)49-25-6-4-7-26(20-25)50-38-30(42(43,44)45)22-48-41(53-38)51-32-11-10-27(21-34(32)62-2)55-18-16-54(17-19-55)24-37(59)47-15-14-46-31-9-5-8-28-29(31)23-56(40(28)61)33-12-13-36(58)52-39(33)60/h3-11,20-22,33,46H,1,12-19,23-24H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",ZZEWLUKGFOHQPN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5618,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,855.879,855.342812788,62,7,6,13,C42H44F3N11O6,"InChI=1S/C42H44F3N11O6/c1-3-35(57)49-25-6-4-7-26(20-25)50-38-30(42(43,44)45)22-48-41(53-38)51-32-11-10-27(21-34(32)62-2)55-18-16-54(17-19-55)24-37(59)47-15-14-46-31-9-5-8-28-29(31)23-56(40(28)61)33-12-13-36(58)52-39(33)60/h3-11,20-22,33,46H,1,12-19,23-24H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",ZZEWLUKGFOHQPN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5475,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1109.767,1108.4771361,78,8,4,15,C57H70ClFN10O8S,"InChI=1S/C57H70ClFN10O8S/c1-35(2)53(50-26-36(3)66-77-50)57(74)69-32-41(70)28-47(69)56(73)65-45(38-13-15-39(16-14-38)54-37(4)63-34-78-54)31-51(71)60-19-10-8-6-7-9-12-52(72)68-23-21-67(22-24-68)20-11-25-76-49-29-42-46(30-48(49)75-5)61-33-62-55(42)64-40-17-18-44(59)43(58)27-40/h13-18,26-27,29-30,33-35,41,45,47,53,70H,6-12,19-25,28,31-32H2,1-5H3,(H,60,71)(H,65,73)(H,61,62,64)/t41-,45+,47+,53-/m1/s1",KTBJMRVBXCURAL-UYZZMYMLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5487,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1143.8,1142.49901442,80,8,5,14,C58H73ClF2N10O8S,"InChI=1S/C58H73ClF2N10O8S/c1-36-51(80-35-65-36)38-15-13-37(14-16-38)44(67-54(75)46-29-40(72)33-71(46)55(76)52(57(2,3)4)68-56(77)58(61)19-20-58)32-49(73)62-21-10-8-6-7-9-12-50(74)70-25-23-69(24-26-70)22-11-27-79-48-30-41-45(31-47(48)78-5)63-34-64-53(41)66-39-17-18-43(60)42(59)28-39/h13-18,28,30-31,34-35,40,44,46,52,72H,6-12,19-27,29,32-33H2,1-5H3,(H,62,73)(H,67,75)(H,68,77)(H,63,64,66)/t40-,44+,46+,52-/m1/s1",BDAXJHVAQPPZDC-YHXFZPEXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2229,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,826.286,825.280150552,59,7,4,12,C41H41ClFN9O7,"InChI=1S/C41H41ClFN9O7/c1-2-34(53)48-31-21-26-30(45-23-46-38(26)47-24-9-10-28(43)27(42)20-24)22-33(31)59-19-5-14-50-15-17-51(18-16-50)36(55)8-4-13-44-29-7-3-6-25-37(29)41(58)52(40(25)57)32-11-12-35(54)49-39(32)56/h2-3,6-7,9-10,20-23,32,44H,1,4-5,8,11-19H2,(H,48,53)(H,45,46,47)(H,49,54,56)",PTYUVGHJRRBMOG-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2229,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,826.286,825.280150552,59,7,4,12,C41H41ClFN9O7,"InChI=1S/C41H41ClFN9O7/c1-2-34(53)48-31-21-26-30(45-23-46-38(26)47-24-9-10-28(43)27(42)20-24)22-33(31)59-19-5-14-50-15-17-51(18-16-50)36(55)8-4-13-44-29-7-3-6-25-37(29)41(58)52(40(25)57)32-11-12-35(54)49-39(32)56/h2-3,6-7,9-10,20-23,32,44H,1,4-5,8,11-19H2,(H,48,53)(H,45,46,47)(H,49,54,56)",PTYUVGHJRRBMOG-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5471,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1053.659,1052.41453584,74,8,4,15,C53H62ClFN10O8S,"InChI=1S/C53H62ClFN10O8S/c1-31(2)49(46-22-32(3)62-73-46)53(70)65-28-37(66)24-43(65)52(69)61-41(34-9-11-35(12-10-34)50-33(4)59-30-74-50)27-47(67)56-15-6-8-48(68)64-19-17-63(18-20-64)16-7-21-72-45-25-38-42(26-44(45)71-5)57-29-58-51(38)60-36-13-14-40(55)39(54)23-36/h9-14,22-23,25-26,29-31,37,41,43,49,66H,6-8,15-21,24,27-28H2,1-5H3,(H,56,67)(H,61,69)(H,57,58,60)/t37-,41+,43+,49-/m1/s1",VTEHNUQLGGNRDD-JYAIWFTJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5483,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1087.692,1086.43641416,76,8,5,14,C54H65ClF2N10O8S,"InChI=1S/C54H65ClF2N10O8S/c1-32-47(76-31-61-32)34-11-9-33(10-12-34)40(63-50(71)42-25-36(68)29-67(42)51(72)48(53(2,3)4)64-52(73)54(57)15-16-54)28-45(69)58-17-6-8-46(70)66-21-19-65(20-22-66)18-7-23-75-44-26-37-41(27-43(44)74-5)59-30-60-49(37)62-35-13-14-39(56)38(55)24-35/h9-14,24,26-27,30-31,36,40,42,48,68H,6-8,15-23,25,28-29H2,1-5H3,(H,58,69)(H,63,71)(H,64,73)(H,59,60,62)/t36-,40+,42+,48-/m1/s1",MLPWVFYXPJNYIP-OQQYKNMXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,592,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1000.639,999.424372256,70,7,4,13,C51H63ClFN9O7S,"InChI=1S/C51H63ClFN9O7S/c1-32-46(70-31-57-32)34-14-12-33(13-15-34)28-54-49(66)41-25-36(63)29-62(41)50(67)47(51(2,3)4)59-44(64)10-7-6-8-11-45(65)61-21-19-60(20-22-61)18-9-23-69-43-26-37-40(27-42(43)68-5)55-30-56-48(37)58-35-16-17-39(53)38(52)24-35/h12-17,24,26-27,30-31,36,41,47,63H,6-11,18-23,25,28-29H2,1-5H3,(H,54,66)(H,59,64)(H,55,56,58)/t36-,41+,47-/m1/s1",ISBWTTKCXBFWJM-FGUOTCRGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,592,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1000.639,999.424372256,70,7,4,13,C51H63ClFN9O7S,"InChI=1S/C51H63ClFN9O7S/c1-32-46(70-31-57-32)34-14-12-33(13-15-34)28-54-49(66)41-25-36(63)29-62(41)50(67)47(51(2,3)4)59-44(64)10-7-6-8-11-45(65)61-21-19-60(20-22-61)18-9-23-69-43-26-37-40(27-42(43)68-5)55-30-56-48(37)58-35-16-17-39(53)38(52)24-35/h12-17,24,26-27,30-31,36,41,47,63H,6-11,18-23,25,28-29H2,1-5H3,(H,54,66)(H,59,64)(H,55,56,58)/t36-,41+,47-/m1/s1",ISBWTTKCXBFWJM-FGUOTCRGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2231,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,30-50/100,,854.34,853.31145068,61,7,4,12,C43H45ClFN9O7,"InChI=1S/C43H45ClFN9O7/c1-2-36(55)50-33-23-28-32(47-25-48-40(28)49-26-11-12-30(45)29(44)22-26)24-35(33)61-21-7-16-52-17-19-53(20-18-52)38(57)10-4-3-5-15-46-31-9-6-8-27-39(31)43(60)54(42(27)59)34-13-14-37(56)51-41(34)58/h2,6,8-9,11-12,22-25,34,46H,1,3-5,7,10,13-21H2,(H,50,55)(H,47,48,49)(H,51,56,58)",UFVWZVUFBJDPFK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2231,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,100,40,854.34,853.31145068,61,7,4,12,C43H45ClFN9O7,"InChI=1S/C43H45ClFN9O7/c1-2-36(55)50-33-23-28-32(47-25-48-40(28)49-26-11-12-30(45)29(44)22-26)24-35(33)61-21-7-16-52-17-19-53(20-18-52)38(57)10-4-3-5-15-46-31-9-6-8-27-39(31)43(60)54(42(27)59)34-13-14-37(56)51-41(34)58/h2,6,8-9,11-12,22-25,34,46H,1,3-5,7,10,13-21H2,(H,50,55)(H,47,48,49)(H,51,56,58)",UFVWZVUFBJDPFK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5473,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1081.713,1080.44583597,76,8,4,15,C55H66ClFN10O8S,"InChI=1S/C55H66ClFN10O8S/c1-33(2)51(48-24-34(3)64-75-48)55(72)67-30-39(68)26-45(67)54(71)63-43(36-11-13-37(14-12-36)52-35(4)61-32-76-52)29-49(69)58-17-8-6-7-10-50(70)66-21-19-65(20-22-66)18-9-23-74-47-27-40-44(28-46(47)73-5)59-31-60-53(40)62-38-15-16-42(57)41(56)25-38/h11-16,24-25,27-28,31-33,39,43,45,51,68H,6-10,17-23,26,29-30H2,1-5H3,(H,58,69)(H,63,71)(H,59,60,62)/t39-,43+,45+,51-/m1/s1",GNNZZAAWTZBPGM-NZMHYKQJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5485,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1115.746,1114.46771429,78,8,5,14,C56H69ClF2N10O8S,"InChI=1S/C56H69ClF2N10O8S/c1-34-49(78-33-63-34)36-13-11-35(12-14-36)42(65-52(73)44-27-38(70)31-69(44)53(74)50(55(2,3)4)66-54(75)56(59)17-18-56)30-47(71)60-19-8-6-7-10-48(72)68-23-21-67(22-24-68)20-9-25-77-46-28-39-43(29-45(46)76-5)61-32-62-51(39)64-37-15-16-41(58)40(57)26-37/h11-16,26,28-29,32-33,38,42,44,50,70H,6-10,17-25,27,30-31H2,1-5H3,(H,60,71)(H,65,73)(H,66,75)(H,61,62,64)/t38-,42+,44+,50-/m1/s1",XEFGFUQIJSNZHH-VYRQVLTMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,276,P00533,EGFR,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,11.7/22.3,98.9/96.6,934.532,933.366188684,65,6,4,13,C47H57ClFN7O8S,"InChI=1S/C47H57ClFN7O8S/c1-29-42(65-28-53-29)31-11-9-30(10-12-31)25-50-45(59)38-22-33(57)26-56(38)46(60)43(47(2,3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14,21,23-24,27-28,33,38,43,57H,6-8,15-20,22,25-26H2,1-5H3,(H,50,59)(H,55,58)(H,51,52,54)/t33-,38+,43-/m1/s1",NICKHWYZMNLEPJ-TZSMONEZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,277,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCOCCCCOCCCCOC3=CC4=NC=NC(NC5=CC=C(F)C(Cl)=C5)=C4C=C3NC(=O)/C=C/CN(C)C)C(C)(C)C)C=C2)SC=N1,215.8,79.1,1086.773,1085.4975372,76,6,5,14,C56H73ClFN9O8S,"InChI=1S/C56H73ClFN9O8S/c1-37-51(76-36-62-37)39-19-17-38(18-20-39)33-59-54(71)47-30-41(68)34-67(47)55(72)52(56(2,3)4)65-50(70)15-8-7-9-24-73-25-10-11-26-74-27-12-13-28-75-48-32-45-42(31-46(48)64-49(69)16-14-23-66(5)6)53(61-35-60-45)63-40-21-22-44(58)43(57)29-40/h14,16-22,29,31-32,35-36,41,47,52,68H,7-13,15,23-28,30,33-34H2,1-6H3,(H,59,71)(H,64,69)(H,65,70)(H,60,61,63)/b16-14+/t41-,47+,52-/m1/s1",BXHBYEPLXDQKAT-JYCNGAFSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,560,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,899.045,898.44024108,66,9,5,14,C48H55FN12O5,"InChI=1S/C48H55FN12O5/c49-32-9-11-33(12-10-32)52-48-54-39-28-51-42(26-36(39)45(57-48)60-20-17-31(30-62)18-21-60)55-41-15-13-34(27-50-41)59-24-22-58(23-25-59)19-4-2-1-3-8-43(63)53-38-7-5-6-35-37(38)29-61(47(35)66)40-14-16-44(64)56-46(40)65/h5-7,9-13,15,26-28,31,40,62H,1-4,8,14,16-25,29-30H2,(H,53,63)(H,50,51,55)(H,52,54,57)(H,56,64,65)",FFVKASNNDQLIDU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1993,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,824.003,823.428199176,61,9,4,12,C46H53N11O4,"InChI=1S/C46H53N11O4/c58-40(50-37-16-10-15-35-36(37)30-56(44(35)61)39-22-23-41(59)52-43(39)60)17-6-1-2-9-24-54-25-27-55(28-26-54)33-20-18-32(19-21-33)48-45-47-29-38-42(53-45)57(34-13-7-8-14-34)46(51-38)49-31-11-4-3-5-12-31/h3-5,10-12,15-16,18-21,29,34,39H,1-2,6-9,13-14,17,22-28,30H2,(H,49,51)(H,50,58)(H,47,48,53)(H,52,59,60)",WHKCGHLFWIJUOU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1993,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,824.003,823.428199176,61,9,4,12,C46H53N11O4,"InChI=1S/C46H53N11O4/c58-40(50-37-16-10-15-35-36(37)30-56(44(35)61)39-22-23-41(59)52-43(39)60)17-6-1-2-9-24-54-25-27-55(28-26-54)33-20-18-32(19-21-33)48-45-47-29-38-42(53-45)57(34-13-7-8-14-34)46(51-38)49-31-11-4-3-5-12-31/h3-5,10-12,15-16,18-21,29,34,39H,1-2,6-9,13-14,17,22-28,30H2,(H,49,51)(H,50,58)(H,47,48,53)(H,52,59,60)",WHKCGHLFWIJUOU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1993,P00533,EGFR e19d,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,824.003,823.428199176,61,9,4,12,C46H53N11O4,"InChI=1S/C46H53N11O4/c58-40(50-37-16-10-15-35-36(37)30-56(44(35)61)39-22-23-41(59)52-43(39)60)17-6-1-2-9-24-54-25-27-55(28-26-54)33-20-18-32(19-21-33)48-45-47-29-38-42(53-45)57(34-13-7-8-14-34)46(51-38)49-31-11-4-3-5-12-31/h3-5,10-12,15-16,18-21,29,34,39H,1-2,6-9,13-14,17,22-28,30H2,(H,49,51)(H,50,58)(H,47,48,53)(H,52,59,60)",WHKCGHLFWIJUOU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5464,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,879.035,878.422779448,65,7,4,12,C49H54N10O6,"InChI=1S/C49H54N10O6/c1-6-24-58(25-13-9-8-10-19-45(61)51-36-17-14-16-33-35(36)31-59(48(33)64)41-20-21-46(62)55-47(41)63)27-26-56(3)42-29-43(65-5)39(28-38(42)52-44(60)7-2)54-49-50-23-22-37(53-49)34-30-57(4)40-18-12-11-15-32(34)40/h1,7,11-12,14-18,22-23,28-30,41H,2,8-10,13,19-21,24-27,31H2,3-5H3,(H,51,61)(H,52,60)(H,50,53,54)(H,55,62,63)",ZVJMBUCONGNNOE-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,559,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,45.2,87,913.072,912.455891144,67,9,5,14,C49H57FN12O5,"InChI=1S/C49H57FN12O5/c50-33-10-12-34(13-11-33)53-49-55-40-29-52-43(27-37(40)46(58-49)61-21-18-32(31-63)19-22-61)56-42-16-14-35(28-51-42)60-25-23-59(24-26-60)20-5-3-1-2-4-9-44(64)54-39-8-6-7-36-38(39)30-62(48(36)67)41-15-17-45(65)57-47(41)66/h6-8,10-14,16,27-29,32,41,63H,1-5,9,15,17-26,30-31H2,(H,54,64)(H,51,52,56)(H,53,55,58)(H,57,65,66)",ZWLPWTDAYPOQGR-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,565,P00533,EGFR,CRBN,CN(C)C1CCN(C2=CC=C(NC3=CC4=C(N5CCN(CCCCCCCC(=O)NC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1,,,926.115,925.48752562,68,9,4,14,C50H60FN13O4,"InChI=1S/C50H60FN13O4/c1-60(2)35-20-23-62(24-21-35)36-16-18-43(52-30-36)57-44-29-38-41(31-53-44)56-50(54-34-14-12-33(51)13-15-34)59-47(38)63-27-25-61(26-28-63)22-7-5-3-4-6-11-45(65)55-40-10-8-9-37-39(40)32-64(49(37)68)42-17-19-46(66)58-48(42)67/h8-10,12-16,18,29-31,35,42H,3-7,11,17,19-28,32H2,1-2H3,(H,55,65)(H,52,53,57)(H,54,56,59)(H,58,66,67)",JWIJDEAEELQGIY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1994,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,838.03,837.44384924,62,9,4,12,C47H55N11O4,"InChI=1S/C47H55N11O4/c59-41(51-38-17-11-16-36-37(38)31-57(45(36)62)40-23-24-42(60)53-44(40)61)18-7-2-1-3-10-25-55-26-28-56(29-27-55)34-21-19-33(20-22-34)49-46-48-30-39-43(54-46)58(35-14-8-9-15-35)47(52-39)50-32-12-5-4-6-13-32/h4-6,11-13,16-17,19-22,30,35,40H,1-3,7-10,14-15,18,23-29,31H2,(H,50,52)(H,51,59)(H,48,49,54)(H,53,60,61)",TWTFDTRUNNZWOY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1994,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,838.03,837.44384924,62,9,4,12,C47H55N11O4,"InChI=1S/C47H55N11O4/c59-41(51-38-17-11-16-36-37(38)31-57(45(36)62)40-23-24-42(60)53-44(40)61)18-7-2-1-3-10-25-55-26-28-56(29-27-55)34-21-19-33(20-22-34)49-46-48-30-39-43(54-46)58(35-14-8-9-15-35)47(52-39)50-32-12-5-4-6-13-32/h4-6,11-13,16-17,19-22,30,35,40H,1-3,7-10,14-15,18,23-29,31H2,(H,50,52)(H,51,59)(H,48,49,54)(H,53,60,61)",TWTFDTRUNNZWOY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1994,P00533,EGFR e19d,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,838.03,837.44384924,62,9,4,12,C47H55N11O4,"InChI=1S/C47H55N11O4/c59-41(51-38-17-11-16-36-37(38)31-57(45(36)62)40-23-24-42(60)53-44(40)61)18-7-2-1-3-10-25-55-26-28-56(29-27-55)34-21-19-33(20-22-34)49-46-48-30-39-43(54-46)58(35-14-8-9-15-35)47(52-39)50-32-12-5-4-6-13-32/h4-6,11-13,16-17,19-22,30,35,40H,1-3,7-10,14-15,18,23-29,31H2,(H,50,52)(H,51,59)(H,48,49,54)(H,53,60,61)",TWTFDTRUNNZWOY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5465,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,893.062,892.438429512,66,7,4,12,C50H56N10O6,"InChI=1S/C50H56N10O6/c1-6-25-59(26-14-10-8-9-11-20-46(62)52-37-18-15-17-34-36(37)32-60(49(34)65)42-21-22-47(63)56-48(42)64)28-27-57(3)43-30-44(66-5)40(29-39(43)53-45(61)7-2)55-50-51-24-23-38(54-50)35-31-58(4)41-19-13-12-16-33(35)41/h1,7,12-13,15-19,23-24,29-31,42H,2,8-11,14,20-22,25-28,32H2,3-5H3,(H,52,62)(H,53,61)(H,51,54,55)(H,56,63,64)",NEPHIFUOEBQFEW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5467,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,921.116,920.46972964,68,7,4,12,C52H60N10O6,"InChI=1S/C52H60N10O6/c1-6-27-61(28-16-12-10-8-9-11-13-22-48(64)54-39-20-17-19-36-38(39)34-62(51(36)67)44-23-24-49(65)58-50(44)66)30-29-59(3)45-32-46(68-5)42(31-41(45)55-47(63)7-2)57-52-53-26-25-40(56-52)37-33-60(4)43-21-15-14-18-35(37)43/h1,7,14-15,17-21,25-26,31-33,44H,2,8-13,16,22-24,27-30,34H2,3-5H3,(H,54,64)(H,55,63)(H,53,56,57)(H,58,65,66)",CHDLLVONGFYTLZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,563,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4C=C(CN5CCN(C6=CC=C(NC7=CC8=C(N9CCC(CO)CC9)N=C(NC9=CC=C(F)C=C9)N=C8C=N7)N=C6)CC5)N=N4)C=CC=C3C2=O)C(=O)N1,,,994.15,993.48858824,73,10,5,17,C52H60FN15O5,"InChI=1S/C52H60FN15O5/c53-35-10-12-36(13-11-35)56-52-58-43-29-55-46(27-40(43)49(61-52)66-21-18-34(33-69)19-22-66)59-45-16-14-38(28-54-45)65-25-23-64(24-26-65)30-37-31-67(63-62-37)20-5-3-1-2-4-9-47(70)57-42-8-6-7-39-41(42)32-68(51(39)73)44-15-17-48(71)60-50(44)72/h6-8,10-14,16,27-29,31,34,44,69H,1-5,9,15,17-26,30,32-33H2,(H,57,70)(H,54,55,59)(H,56,58,61)(H,60,71,72)",YGIUVVAIJWPSDA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2403,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,934.43,933.348898808,67,8,4,14,C47H49ClFN11O7,"InChI=1S/C47H49ClFN11O7/c48-33-23-29(15-16-34(33)49)52-44-32-24-37(54-41(62)14-10-21-58-19-6-4-7-20-58)39(25-36(32)50-28-51-44)67-27-30-26-59(57-56-30)22-8-3-1-2-5-13-40(61)53-35-12-9-11-31-43(35)47(66)60(46(31)65)38-17-18-42(63)55-45(38)64/h9-12,14-16,23-26,28,38H,1-8,13,17-22,27H2,(H,53,61)(H,54,62)(H,50,51,52)(H,55,63,64)/b14-10+",IKDWVMHENZHDMZ-GXDHUFHOSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2405,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,962.484,961.380198936,69,8,4,14,C49H53ClFN11O7,"InChI=1S/C49H53ClFN11O7/c50-35-25-31(17-18-36(35)51)54-46-34-26-39(56-43(64)16-12-23-60-21-8-6-9-22-60)41(27-38(34)52-30-53-46)69-29-32-28-61(59-58-32)24-10-5-3-1-2-4-7-15-42(63)55-37-14-11-13-33-45(37)49(68)62(48(33)67)40-19-20-44(65)57-47(40)66/h11-14,16-18,25-28,30,40H,1-10,15,19-24,29H2,(H,55,63)(H,56,64)(H,52,53,54)(H,57,65,66)/b16-12+",WAIDPWGKISVORF-FOWTUZBSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5612,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,883.889,883.337727408,64,7,6,14,C43H44F3N11O7,"InChI=1S/C43H44F3N11O7/c1-3-34(58)50-25-7-4-8-26(21-25)51-38-29(43(44,45)46)23-49-42(54-38)52-30-12-11-27(22-33(30)64-2)56-19-17-55(18-20-56)24-36(60)48-16-6-15-47-31-10-5-9-28-37(31)41(63)57(40(28)62)32-13-14-35(59)53-39(32)61/h3-5,7-12,21-23,32,47H,1,6,13-20,24H2,2H3,(H,48,60)(H,50,58)(H,53,59,61)(H2,49,51,52,54)",YIUFSCFMBJSOOL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5612,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,883.889,883.337727408,64,7,6,14,C43H44F3N11O7,"InChI=1S/C43H44F3N11O7/c1-3-34(58)50-25-7-4-8-26(21-25)51-38-29(43(44,45)46)23-49-42(54-38)52-30-12-11-27(22-33(30)64-2)56-19-17-55(18-20-56)24-36(60)48-16-6-15-47-31-10-5-9-28-37(31)41(63)57(40(28)62)32-13-14-35(59)53-39(32)61/h3-5,7-12,21-23,32,47H,1,6,13-20,24H2,2H3,(H,48,60)(H,50,58)(H,53,59,61)(H2,49,51,52,54)",YIUFSCFMBJSOOL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5612,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,883.889,883.337727408,64,7,6,14,C43H44F3N11O7,"InChI=1S/C43H44F3N11O7/c1-3-34(58)50-25-7-4-8-26(21-25)51-38-29(43(44,45)46)23-49-42(54-38)52-30-12-11-27(22-33(30)64-2)56-19-17-55(18-20-56)24-36(60)48-16-6-15-47-31-10-5-9-28-37(31)41(63)57(40(28)62)32-13-14-35(59)53-39(32)61/h3-5,7-12,21-23,32,47H,1,6,13-20,24H2,2H3,(H,48,60)(H,50,58)(H,53,59,61)(H2,49,51,52,54)",YIUFSCFMBJSOOL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,571,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3C=C(CN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1155.42,1154.57602334,83,10,6,21,C59H75FN16O6S,"InChI=1S/C59H75FN16O6S/c1-39-53(83-38-65-39)42-7-5-40(6-8-42)31-64-56(79)50-29-47(78)36-76(50)57(80)54(59(2,3)4)61-17-25-81-27-28-82-26-24-75-35-45(70-71-75)34-72-20-22-73(23-21-72)46-13-14-51(62-32-46)68-52-30-48-49(33-63-52)67-58(66-44-11-9-43(60)10-12-44)69-55(48)74-18-15-41(37-77)16-19-74/h5-14,30,32-33,35,38,41,47,50,54,61,77-78H,15-29,31,34,36-37H2,1-4H3,(H,64,79)(H,62,63,68)(H,66,67,69)/t47-,50+,54-/m1/s1",SCALGKKEKZAYQL-PZUTWEFSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2622,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1107.4,1106.56364709,80,9,6,16,C59H74N14O6S,"InChI=1S/C59H74N14O6S/c1-6-51(77)71-27-13-16-45(35-71)73-54-47(66-58(73)65-42-14-9-7-10-15-42)34-62-57(68-54)64-43-22-24-44(25-23-43)70-30-28-69(29-31-70)37-50(76)60-26-12-8-11-17-49(75)67-53(59(3,4)5)56(79)72-36-46(74)32-48(72)55(78)61-33-40-18-20-41(21-19-40)52-39(2)63-38-80-52/h6-7,9-10,14-15,18-25,34,38,45-46,48,53,74H,1,8,11-13,16-17,26-33,35-37H2,2-5H3,(H,60,76)(H,61,78)(H,65,66)(H,67,75)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",GKMLWAGLQFDOKQ-BCWDIVJWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2622,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1107.4,1106.56364709,80,9,6,16,C59H74N14O6S,"InChI=1S/C59H74N14O6S/c1-6-51(77)71-27-13-16-45(35-71)73-54-47(66-58(73)65-42-14-9-7-10-15-42)34-62-57(68-54)64-43-22-24-44(25-23-43)70-30-28-69(29-31-70)37-50(76)60-26-12-8-11-17-49(75)67-53(59(3,4)5)56(79)72-36-46(74)32-48(72)55(78)61-33-40-18-20-41(21-19-40)52-39(2)63-38-80-52/h6-7,9-10,14-15,18-25,34,38,45-46,48,53,74H,1,8,11-13,16-17,26-33,35-37H2,2-5H3,(H,60,76)(H,61,78)(H,65,66)(H,67,75)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",GKMLWAGLQFDOKQ-BCWDIVJWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5614,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,911.943,911.369027536,66,7,6,14,C45H48F3N11O7,"InChI=1S/C45H48F3N11O7/c1-3-36(60)52-27-9-7-10-28(23-27)53-40-31(45(46,47)48)25-51-44(56-40)54-32-14-13-29(24-35(32)66-2)58-21-19-57(20-22-58)26-38(62)50-18-6-4-5-17-49-33-12-8-11-30-39(33)43(65)59(42(30)64)34-15-16-37(61)55-41(34)63/h3,7-14,23-25,34,49H,1,4-6,15-22,26H2,2H3,(H,50,62)(H,52,60)(H,55,61,63)(H2,51,53,54,56)",XMLUWHZDWMZRLS-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5614,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,911.943,911.369027536,66,7,6,14,C45H48F3N11O7,"InChI=1S/C45H48F3N11O7/c1-3-36(60)52-27-9-7-10-28(23-27)53-40-31(45(46,47)48)25-51-44(56-40)54-32-14-13-29(24-35(32)66-2)58-21-19-57(20-22-58)26-38(62)50-18-6-4-5-17-49-33-12-8-11-30-39(33)43(65)59(42(30)64)34-15-16-37(61)55-41(34)63/h3,7-14,23-25,34,49H,1,4-6,15-22,26H2,2H3,(H,50,62)(H,52,60)(H,55,61,63)(H2,51,53,54,56)",XMLUWHZDWMZRLS-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5614,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,911.943,911.369027536,66,7,6,14,C45H48F3N11O7,"InChI=1S/C45H48F3N11O7/c1-3-36(60)52-27-9-7-10-28(23-27)53-40-31(45(46,47)48)25-51-44(56-40)54-32-14-13-29(24-35(32)66-2)58-21-19-57(20-22-58)26-38(62)50-18-6-4-5-17-49-33-12-8-11-30-39(33)43(65)59(42(30)64)34-15-16-37(61)55-41(34)63/h3,7-14,23-25,34,49H,1,4-6,15-22,26H2,2H3,(H,50,62)(H,52,60)(H,55,61,63)(H2,51,53,54,56)",XMLUWHZDWMZRLS-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,590,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1178.823,1177.5084958,82,7,4,18,C58H77ClFN9O12S,"InChI=1S/C58H77ClFN9O12S/c1-39-53(82-38-64-39)41-9-7-40(8-10-41)35-61-56(73)48-32-43(70)36-69(48)57(74)54(58(2,3)4)66-51(71)13-21-76-23-25-78-27-29-80-30-28-79-26-24-77-22-14-52(72)68-18-16-67(17-19-68)15-6-20-81-50-33-44-47(34-49(50)75-5)62-37-63-55(44)65-42-11-12-46(60)45(59)31-42/h7-12,31,33-34,37-38,43,48,54,70H,6,13-30,32,35-36H2,1-5H3,(H,61,73)(H,66,71)(H,62,63,65)/t43-,48+,54-/m1/s1",PQNOXKXLYLTRFY-WBGXEMRLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,590,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1178.823,1177.5084958,82,7,4,18,C58H77ClFN9O12S,"InChI=1S/C58H77ClFN9O12S/c1-39-53(82-38-64-39)41-9-7-40(8-10-41)35-61-56(73)48-32-43(70)36-69(48)57(74)54(58(2,3)4)66-51(71)13-21-76-23-25-78-27-29-80-30-28-79-26-24-77-22-14-52(72)68-18-16-67(17-19-68)15-6-20-81-50-33-44-47(34-49(50)75-5)62-37-63-55(44)65-42-11-12-46(60)45(59)31-42/h7-12,31,33-34,37-38,43,48,54,70H,6,13-30,32,35-36H2,1-5H3,(H,61,73)(H,66,71)(H,62,63,65)/t43-,48+,54-/m1/s1",PQNOXKXLYLTRFY-WBGXEMRLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1548,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,1057.196,1056.40514036,76,9,3,16,C55H60N8O12S,"InChI=1S/C55H60N8O12S/c64-46-16-15-45(50(66)58-46)63-53(69)42-7-4-8-44(48(42)54(63)70)56-18-25-72-27-29-74-31-33-75-32-30-73-28-26-71-24-17-47(65)61-22-20-60(21-23-61)41-13-11-37(12-14-41)39-9-10-40-36-62(52(68)43(40)35-39)49(38-5-2-1-3-6-38)51(67)59-55-57-19-34-76-55/h1-14,19,34-35,45,49,56H,15-18,20-33,36H2,(H,57,59,67)(H,58,64,66)",NQLZSRAQWCFGSA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5499,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1259.897,1258.52995952,88,8,4,20,C62H80ClFN10O13S,"InChI=1S/C62H80ClFN10O13S/c1-40(2)58(55-31-41(3)71-87-55)62(79)74-37-46(75)33-52(74)61(78)70-50(43-7-9-44(10-8-43)59-42(4)68-39-88-59)36-56(76)65-14-22-82-24-26-84-28-30-85-29-27-83-25-23-81-21-13-57(77)73-18-16-72(17-19-73)15-6-20-86-54-34-47-51(35-53(54)80-5)66-38-67-60(47)69-45-11-12-49(64)48(63)32-45/h7-12,31-32,34-35,38-40,46,50,52,58,75H,6,13-30,33,36-37H2,1-5H3,(H,65,76)(H,70,78)(H,66,67,69)/t46-,50+,52+,58-/m1/s1",PQAZOTYGULGKJL-FAVMTTGLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5507,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1293.93,1292.55183784,90,8,5,19,C63H83ClF2N10O13S,"InChI=1S/C63H83ClF2N10O13S/c1-41-56(90-40-70-41)43-9-7-42(8-10-43)49(72-59(80)51-34-45(77)38-76(51)60(81)57(62(2,3)4)73-61(82)63(66)14-15-63)37-54(78)67-16-24-85-26-28-87-30-32-88-31-29-86-27-25-84-23-13-55(79)75-20-18-74(19-21-75)17-6-22-89-53-35-46-50(36-52(53)83-5)68-39-69-58(46)71-44-11-12-48(65)47(64)33-44/h7-12,33,35-36,39-40,45,49,51,57,77H,6,13-32,34,37-38H2,1-5H3,(H,67,78)(H,72,80)(H,73,82)(H,68,69,71)/t45-,49+,51+,57-/m1/s1",LRJQWBDAUMUYAQ-HCQLXHEYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1547,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,1013.143,1012.37892561,73,9,3,15,C53H56N8O11S,"InChI=1S/C53H56N8O11S/c62-44-16-15-43(48(64)56-44)61-51(67)40-7-4-8-42(46(40)52(61)68)54-18-25-70-27-29-72-31-30-71-28-26-69-24-17-45(63)59-22-20-58(21-23-59)39-13-11-35(12-14-39)37-9-10-38-34-60(50(66)41(38)33-37)47(36-5-2-1-3-6-36)49(65)57-53-55-19-32-73-53/h1-14,19,32-33,43,47,54H,15-18,20-31,34H2,(H,55,57,65)(H,56,62,64)",RQWUUMNUWMTZQD-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5498,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1215.844,1214.50374477,85,8,4,19,C60H76ClFN10O12S,"InChI=1S/C60H76ClFN10O12S/c1-38(2)56(53-29-39(3)69-84-53)60(77)72-35-44(73)31-50(72)59(76)68-48(41-7-9-42(10-8-41)57-40(4)66-37-85-57)34-54(74)63-14-22-80-24-26-82-28-27-81-25-23-79-21-13-55(75)71-18-16-70(17-19-71)15-6-20-83-52-32-45-49(33-51(52)78-5)64-36-65-58(45)67-43-11-12-47(62)46(61)30-43/h7-12,29-30,32-33,36-38,44,48,50,56,73H,6,13-28,31,34-35H2,1-5H3,(H,63,74)(H,68,76)(H,64,65,67)/t44-,48+,50+,56-/m1/s1",WXGPZJDYSLRMDS-HHHFUCLFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5506,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1249.877,1248.52562309,87,8,5,18,C61H79ClF2N10O12S,"InChI=1S/C61H79ClF2N10O12S/c1-39-54(87-38-68-39)41-9-7-40(8-10-41)47(70-57(78)49-32-43(75)36-74(49)58(79)55(60(2,3)4)71-59(80)61(64)14-15-61)35-52(76)65-16-24-83-26-28-85-30-29-84-27-25-82-23-13-53(77)73-20-18-72(19-21-73)17-6-22-86-51-33-44-48(34-50(51)81-5)66-37-67-56(44)69-42-11-12-46(63)45(62)31-42/h7-12,31,33-34,37-38,43,47,49,55,75H,6,13-30,32,35-36H2,1-5H3,(H,65,76)(H,70,78)(H,71,80)(H,66,67,69)/t43-,47+,49+,55-/m1/s1",VOWRMQVEPOIRPR-BUCBQYKQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,589,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1090.717,1089.45606631,76,7,4,16,C54H69ClFN9O10S,"InChI=1S/C54H69ClFN9O10S/c1-35-49(76-34-60-35)37-9-7-36(8-10-37)31-57-52(69)44-28-39(66)32-65(44)53(70)50(54(2,3)4)62-47(67)13-21-72-23-25-74-26-24-73-22-14-48(68)64-18-16-63(17-19-64)15-6-20-75-46-29-40-43(30-45(46)71-5)58-33-59-51(40)61-38-11-12-42(56)41(55)27-38/h7-12,27,29-30,33-34,39,44,50,66H,6,13-26,28,31-32H2,1-5H3,(H,57,69)(H,62,67)(H,58,59,61)/t39-,44+,50-/m1/s1",DUHAIXHBBDGIBP-MLENZQCQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,589,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1090.717,1089.45606631,76,7,4,16,C54H69ClFN9O10S,"InChI=1S/C54H69ClFN9O10S/c1-35-49(76-34-60-35)37-9-7-36(8-10-37)31-57-52(69)44-28-39(66)32-65(44)53(70)50(54(2,3)4)62-47(67)13-21-72-23-25-74-26-24-73-22-14-48(68)64-18-16-63(17-19-64)15-6-20-75-46-29-40-43(30-45(46)71-5)58-33-59-51(40)61-38-11-12-42(56)41(55)27-38/h7-12,27,29-30,33-34,39,44,50,66H,6,13-26,28,31-32H2,1-5H3,(H,57,69)(H,62,67)(H,58,59,61)/t39-,44+,50-/m1/s1",DUHAIXHBBDGIBP-MLENZQCQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1473,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,969.09,968.352710864,70,9,3,14,C51H52N8O10S,"InChI=1S/C51H52N8O10S/c60-42-16-15-41(46(62)54-42)59-49(65)38-7-4-8-40(44(38)50(59)66)52-18-25-68-27-29-69-28-26-67-24-17-43(61)57-22-20-56(21-23-57)37-13-11-33(12-14-37)35-9-10-36-32-58(48(64)39(36)31-35)45(34-5-2-1-3-6-34)47(63)55-51-53-19-30-70-51/h1-14,19,30-31,41,45,52H,15-18,20-29,32H2,(H,53,55,63)(H,54,60,62)",YQIWOKJOFFNGOJ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1473,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,969.09,968.352710864,70,9,3,14,C51H52N8O10S,"InChI=1S/C51H52N8O10S/c60-42-16-15-41(46(62)54-42)59-49(65)38-7-4-8-40(44(38)50(59)66)52-18-25-68-27-29-69-28-26-67-24-17-43(61)57-22-20-56(21-23-57)37-13-11-33(12-14-37)35-9-10-36-32-58(48(64)39(36)31-35)45(34-5-2-1-3-6-34)47(63)55-51-53-19-30-70-51/h1-14,19,30-31,41,45,52H,15-18,20-29,32H2,(H,53,55,63)(H,54,60,62)",YQIWOKJOFFNGOJ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5497,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1171.791,1170.47753002,82,8,4,18,C58H72ClFN10O11S,"InChI=1S/C58H72ClFN10O11S/c1-36(2)54(51-27-37(3)67-81-51)58(75)70-33-42(71)29-48(70)57(74)66-46(39-7-9-40(10-8-39)55-38(4)64-35-82-55)32-52(72)61-14-22-78-24-26-79-25-23-77-21-13-53(73)69-18-16-68(17-19-69)15-6-20-80-50-30-43-47(31-49(50)76-5)62-34-63-56(43)65-41-11-12-45(60)44(59)28-41/h7-12,27-28,30-31,34-36,42,46,48,54,71H,6,13-26,29,32-33H2,1-5H3,(H,61,72)(H,66,74)(H,62,63,65)/t42-,46+,48+,54-/m1/s1",SQUJSQSJQZXAKH-FOCFZSKWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5505,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1205.824,1204.49940834,84,8,5,17,C59H75ClF2N10O11S,"InChI=1S/C59H75ClF2N10O11S/c1-37-52(84-36-66-37)39-9-7-38(8-10-39)45(68-55(76)47-30-41(73)34-72(47)56(77)53(58(2,3)4)69-57(78)59(62)14-15-59)33-50(74)63-16-24-81-26-28-82-27-25-80-23-13-51(75)71-20-18-70(19-21-71)17-6-22-83-49-31-42-46(32-48(49)79-5)64-35-65-54(42)67-40-11-12-44(61)43(60)29-40/h7-12,29,31-32,35-36,41,45,47,53,73H,6,13-28,30,33-34H2,1-5H3,(H,63,74)(H,68,76)(H,69,78)(H,64,65,67)/t41-,45+,47+,53-/m1/s1",OESWSLAPUVIPCV-UYZZMYMLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1546,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,925.037,924.326496116,67,9,3,13,C49H48N8O9S,"InChI=1S/C49H48N8O9S/c58-40-16-15-39(44(60)52-40)57-47(63)36-7-4-8-38(42(36)48(57)64)50-18-25-66-27-26-65-24-17-41(59)55-22-20-54(21-23-55)35-13-11-31(12-14-35)33-9-10-34-30-56(46(62)37(34)29-33)43(32-5-2-1-3-6-32)45(61)53-49-51-19-28-67-49/h1-14,19,28-29,39,43,50H,15-18,20-27,30H2,(H,51,53,61)(H,52,58,60)",BHOFOVKVHRLVFH-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5495,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1127.738,1126.45131528,79,8,4,17,C56H68ClFN10O10S,"InChI=1S/C56H68ClFN10O10S/c1-34(2)52(49-25-35(3)65-78-49)56(73)68-31-40(69)27-46(68)55(72)64-44(37-7-9-38(10-8-37)53-36(4)62-33-79-53)30-50(70)59-14-22-76-24-23-75-21-13-51(71)67-18-16-66(17-19-67)15-6-20-77-48-28-41-45(29-47(48)74-5)60-32-61-54(41)63-39-11-12-43(58)42(57)26-39/h7-12,25-26,28-29,32-34,40,44,46,52,69H,6,13-24,27,30-31H2,1-5H3,(H,59,70)(H,64,72)(H,60,61,63)/t40-,44+,46+,52-/m1/s1",HSYGBRJEVWUWJH-YHXFZPEXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5503,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1161.771,1160.47319359,81,8,5,16,C57H71ClF2N10O10S,"InChI=1S/C57H71ClF2N10O10S/c1-35-50(81-34-64-35)37-9-7-36(8-10-37)43(66-53(74)45-28-39(71)32-70(45)54(75)51(56(2,3)4)67-55(76)57(60)14-15-57)31-48(72)61-16-24-79-26-25-78-23-13-49(73)69-20-18-68(19-21-69)17-6-22-80-47-29-40-44(30-46(47)77-5)62-33-63-52(40)65-38-11-12-42(59)41(58)27-38/h7-12,27,29-30,33-34,39,43,45,51,71H,6,13-26,28,31-32H2,1-5H3,(H,61,72)(H,66,74)(H,67,76)(H,62,63,65)/t39-,43+,45+,51-/m1/s1",HZSHXUUDFTUBHJ-NZMHYKQJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,581,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,69,,1108.38,1107.5364293,80,8,5,15,C60H73N11O8S,"InChI=1S/C60H73N11O8S/c1-8-50(73)64-42-16-15-17-44(31-42)71-53(76)30-38(2)46-35-62-59(67-56(46)71)65-47-25-24-43(32-49(47)79-7)68-26-28-69(29-27-68)52(75)19-14-12-10-9-11-13-18-51(74)66-55(60(4,5)6)58(78)70-36-45(72)33-48(70)57(77)61-34-40-20-22-41(23-21-40)54-39(3)63-37-80-54/h8,15-17,20-25,30-32,35,37,45,48,55,72H,1,9-14,18-19,26-29,33-34,36H2,2-7H3,(H,61,77)(H,64,73)(H,66,74)(H,62,65,67)/t45-,48+,55-/m1/s1",NXHJICMMHCOKPI-ZRJZPVMUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,581,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1108.38,1107.5364293,80,8,5,15,C60H73N11O8S,"InChI=1S/C60H73N11O8S/c1-8-50(73)64-42-16-15-17-44(31-42)71-53(76)30-38(2)46-35-62-59(67-56(46)71)65-47-25-24-43(32-49(47)79-7)68-26-28-69(29-27-68)52(75)19-14-12-10-9-11-13-18-51(74)66-55(60(4,5)6)58(78)70-36-45(72)33-48(70)57(77)61-34-40-20-22-41(23-21-40)54-39(3)63-37-80-54/h8,15-17,20-25,30-32,35,37,45,48,55,72H,1,9-14,18-19,26-29,33-34,36H2,2-7H3,(H,61,77)(H,64,73)(H,66,74)(H,62,65,67)/t45-,48+,55-/m1/s1",NXHJICMMHCOKPI-ZRJZPVMUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5476,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1123.794,1122.49278616,79,8,4,15,C58H72ClFN10O8S,"InChI=1S/C58H72ClFN10O8S/c1-36(2)54(51-27-37(3)67-78-51)58(75)70-33-42(71)29-48(70)57(74)66-46(39-14-16-40(17-15-39)55-38(4)64-35-79-55)32-52(72)61-20-11-9-7-6-8-10-13-53(73)69-24-22-68(23-25-69)21-12-26-77-50-30-43-47(31-49(50)76-5)62-34-63-56(43)65-41-18-19-45(60)44(59)28-41/h14-19,27-28,30-31,34-36,42,46,48,54,71H,6-13,20-26,29,32-33H2,1-5H3,(H,61,72)(H,66,74)(H,62,63,65)/t42-,46+,48+,54-/m1/s1",VZEWWNCXKUBTMG-FOCFZSKWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5488,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1157.827,1156.51466448,81,8,5,14,C59H75ClF2N10O8S,"InChI=1S/C59H75ClF2N10O8S/c1-37-52(81-36-66-37)39-16-14-38(15-17-39)45(68-55(76)47-30-41(73)34-72(47)56(77)53(58(2,3)4)69-57(78)59(62)20-21-59)33-50(74)63-22-11-9-7-6-8-10-13-51(75)71-26-24-70(25-27-71)23-12-28-80-49-31-42-46(32-48(49)79-5)64-35-65-54(42)67-40-18-19-44(61)43(60)29-40/h14-19,29,31-32,35-36,41,45,47,53,73H,6-13,20-28,30,33-34H2,1-5H3,(H,63,74)(H,68,76)(H,69,78)(H,64,65,67)/t41-,45+,47+,53-/m1/s1",FXPAXWXTFWZCFT-UYZZMYMLSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,582,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,235,,1080.326,1079.50512917,78,8,5,15,C58H69N11O8S,"InChI=1S/C58H69N11O8S/c1-8-48(71)62-40-14-13-15-42(29-40)69-51(74)28-36(2)44-33-60-57(65-54(44)69)63-45-23-22-41(30-47(45)77-7)66-24-26-67(27-25-66)50(73)17-12-10-9-11-16-49(72)64-53(58(4,5)6)56(76)68-34-43(70)31-46(68)55(75)59-32-38-18-20-39(21-19-38)52-37(3)61-35-78-52/h8,13-15,18-23,28-30,33,35,43,46,53,70H,1,9-12,16-17,24-27,31-32,34H2,2-7H3,(H,59,75)(H,62,71)(H,64,72)(H,60,63,65)/t43-,46+,53-/m1/s1",HQDMTJMOYXRLMD-BSDSDUADSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,582,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1080.326,1079.50512917,78,8,5,15,C58H69N11O8S,"InChI=1S/C58H69N11O8S/c1-8-48(71)62-40-14-13-15-42(29-40)69-51(74)28-36(2)44-33-60-57(65-54(44)69)63-45-23-22-41(30-47(45)77-7)66-24-26-67(27-25-66)50(73)17-12-10-9-11-16-49(72)64-53(58(4,5)6)56(76)68-34-43(70)31-46(68)55(75)59-32-38-18-20-39(21-19-38)52-37(3)61-35-78-52/h8,13-15,18-23,28-30,33,35,43,46,53,70H,1,9-12,16-17,24-27,31-32,34H2,2-7H3,(H,59,75)(H,62,71)(H,64,72)(H,60,63,65)/t43-,46+,53-/m1/s1",HQDMTJMOYXRLMD-BSDSDUADSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2232,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,<30/100,,868.367,867.327100744,62,7,4,12,C44H47ClFN9O7,"InChI=1S/C44H47ClFN9O7/c1-2-37(56)51-34-24-29-33(48-26-49-41(29)50-27-12-13-31(46)30(45)23-27)25-36(34)62-22-8-17-53-18-20-54(21-19-53)39(58)11-5-3-4-6-16-47-32-10-7-9-28-40(32)44(61)55(43(28)60)35-14-15-38(57)52-42(35)59/h2,7,9-10,12-13,23-26,35,47H,1,3-6,8,11,14-22H2,(H,51,56)(H,48,49,50)(H,52,57,59)",YTNYTUGBAXJPBN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2232,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,30-100,,868.367,867.327100744,62,7,4,12,C44H47ClFN9O7,"InChI=1S/C44H47ClFN9O7/c1-2-37(56)51-34-24-29-33(48-26-49-41(29)50-27-12-13-31(46)30(45)23-27)25-36(34)62-22-8-17-53-18-20-54(21-19-53)39(58)11-5-3-4-6-16-47-32-10-7-9-28-40(32)44(61)55(43(28)60)35-14-15-38(57)52-42(35)59/h2,7,9-10,12-13,23-26,35,47H,1,3-6,8,11,14-22H2,(H,51,56)(H,48,49,50)(H,52,57,59)",YTNYTUGBAXJPBN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5474,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1095.74,1094.46148604,77,8,4,15,C56H68ClFN10O8S,"InChI=1S/C56H68ClFN10O8S/c1-34(2)52(49-25-35(3)65-76-49)56(73)68-31-40(69)27-46(68)55(72)64-44(37-12-14-38(15-13-37)53-36(4)62-33-77-53)30-50(70)59-18-9-7-6-8-11-51(71)67-22-20-66(21-23-67)19-10-24-75-48-28-41-45(29-47(48)74-5)60-32-61-54(41)63-39-16-17-43(58)42(57)26-39/h12-17,25-26,28-29,32-34,40,44,46,52,69H,6-11,18-24,27,30-31H2,1-5H3,(H,59,70)(H,64,72)(H,60,61,63)/t40-,44+,46+,52-/m1/s1",UPGPYGVCAVJCCR-YHXFZPEXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5486,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1129.773,1128.48336435,79,8,5,14,C57H71ClF2N10O8S,"InChI=1S/C57H71ClF2N10O8S/c1-35-50(79-34-64-35)37-14-12-36(13-15-37)43(66-53(74)45-28-39(71)32-70(45)54(75)51(56(2,3)4)67-55(76)57(60)18-19-57)31-48(72)61-20-9-7-6-8-11-49(73)69-24-22-68(23-25-69)21-10-26-78-47-29-40-44(30-46(47)77-5)62-33-63-52(40)65-38-16-17-42(59)41(58)27-38/h12-17,27,29-30,33-34,39,43,45,51,71H,6-11,18-26,28,31-32H2,1-5H3,(H,61,72)(H,66,74)(H,67,76)(H,62,63,65)/t39-,43+,45+,51-/m1/s1",GWVORCNYVKAQRY-NZMHYKQJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,591,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,958.558,957.377422064,67,7,4,13,C48H57ClFN9O7S,"InChI=1S/C48H57ClFN9O7S/c1-29-43(67-28-54-29)31-9-7-30(8-10-31)25-51-46(63)38-22-33(60)26-59(38)47(64)44(48(2,3)4)56-41(61)13-14-42(62)58-18-16-57(17-19-58)15-6-20-66-40-23-34-37(24-39(40)65-5)52-27-53-45(34)55-32-11-12-36(50)35(49)21-32/h7-12,21,23-24,27-28,33,38,44,60H,6,13-20,22,25-26H2,1-5H3,(H,51,63)(H,56,61)(H,52,53,55)/t33-,38+,44-/m1/s1",DUGBSNFGNATMEE-VSPJSQPSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,591,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,958.558,957.377422064,67,7,4,13,C48H57ClFN9O7S,"InChI=1S/C48H57ClFN9O7S/c1-29-43(67-28-54-29)31-9-7-30(8-10-31)25-51-46(63)38-22-33(60)26-59(38)47(64)44(48(2,3)4)56-41(61)13-14-42(62)58-18-16-57(17-19-58)15-6-20-66-40-23-34-37(24-39(40)65-5)52-27-53-45(34)55-32-11-12-36(50)35(49)21-32/h7-12,21,23-24,27-28,33,38,44,60H,6,13-20,22,25-26H2,1-5H3,(H,51,63)(H,56,61)(H,52,53,55)/t33-,38+,44-/m1/s1",DUGBSNFGNATMEE-VSPJSQPSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2228,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,812.259,811.264500488,58,7,4,12,C40H39ClFN9O7,"InChI=1S/C40H39ClFN9O7/c1-2-33(52)47-30-20-25-29(44-22-45-37(25)46-23-7-8-27(42)26(41)19-23)21-32(30)58-18-4-13-49-14-16-50(17-15-49)35(54)11-12-43-28-6-3-5-24-36(28)40(57)51(39(24)56)31-9-10-34(53)48-38(31)55/h2-3,5-8,19-22,31,43H,1,4,9-18H2,(H,47,52)(H,44,45,46)(H,48,53,55)",CYRZHTYQRKEAID-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2228,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,812.259,811.264500488,58,7,4,12,C40H39ClFN9O7,"InChI=1S/C40H39ClFN9O7/c1-2-33(52)47-30-20-25-29(44-22-45-37(25)46-23-7-8-27(42)26(41)19-23)21-32(30)58-18-4-13-49-14-16-50(17-15-49)35(54)11-12-43-28-6-3-5-24-36(28)40(57)51(39(24)56)31-9-10-34(53)48-38(31)55/h2-3,5-8,19-22,31,43H,1,4,9-18H2,(H,47,52)(H,44,45,46)(H,48,53,55)",CYRZHTYQRKEAID-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5470,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1039.632,1038.39888578,73,8,4,15,C52H60ClFN10O8S,"InChI=1S/C52H60ClFN10O8S/c1-30(2)48(45-21-31(3)61-72-45)52(69)64-27-36(65)23-42(64)51(68)60-40(33-7-9-34(10-8-33)49-32(4)58-29-73-49)26-46(66)55-14-13-47(67)63-18-16-62(17-19-63)15-6-20-71-44-24-37-41(25-43(44)70-5)56-28-57-50(37)59-35-11-12-39(54)38(53)22-35/h7-12,21-22,24-25,28-30,36,40,42,48,65H,6,13-20,23,26-27H2,1-5H3,(H,55,66)(H,60,68)(H,56,57,59)/t36-,40+,42+,48-/m1/s1",CJLNAUKEMYLBRN-OQQYKNMXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5482,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1073.665,1072.4207641,75,8,5,14,C53H63ClF2N10O8S,"InChI=1S/C53H63ClF2N10O8S/c1-31-46(75-30-60-31)33-9-7-32(8-10-33)39(62-49(70)41-24-35(67)28-66(41)50(71)47(52(2,3)4)63-51(72)53(56)14-15-53)27-44(68)57-16-13-45(69)65-20-18-64(19-21-65)17-6-22-74-43-25-36-40(26-42(43)73-5)58-29-59-48(36)61-34-11-12-38(55)37(54)23-34/h7-12,23,25-26,29-30,35,39,41,47,67H,6,13-22,24,27-28H2,1-5H3,(H,57,68)(H,62,70)(H,63,72)(H,58,59,61)/t35-,39+,41+,47-/m1/s1",WMQKYBZMAJVTOD-GVXQOCCOSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,593,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,3.3,,1056.747,1055.48697251,74,7,4,13,C55H71ClFN9O7S,"InChI=1S/C55H71ClFN9O7S/c1-36-50(74-35-61-36)38-18-16-37(17-19-38)32-58-53(70)45-29-40(67)33-66(45)54(71)51(55(2,3)4)63-48(68)14-11-9-7-6-8-10-12-15-49(69)65-25-23-64(24-26-65)22-13-27-73-47-30-41-44(31-46(47)72-5)59-34-60-52(41)62-39-20-21-43(57)42(56)28-39/h16-21,28,30-31,34-35,40,45,51,67H,6-15,22-27,29,32-33H2,1-5H3,(H,58,70)(H,63,68)(H,59,60,62)/t40-,45+,51-/m1/s1",HLFLODKZIGYHNR-LTEFSYCBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,593,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,5,,1056.747,1055.48697251,74,7,4,13,C55H71ClFN9O7S,"InChI=1S/C55H71ClFN9O7S/c1-36-50(74-35-61-36)38-18-16-37(17-19-38)32-58-53(70)45-29-40(67)33-66(45)54(71)51(55(2,3)4)63-48(68)14-11-9-7-6-8-10-12-15-49(69)65-25-23-64(24-26-65)22-13-27-73-47-30-41-44(31-46(47)72-5)59-34-60-52(41)62-39-20-21-43(57)42(56)28-39/h16-21,28,30-31,34-35,40,45,51,67H,6-15,22-27,29,32-33H2,1-5H3,(H,58,70)(H,63,68)(H,59,60,62)/t40-,45+,51-/m1/s1",HLFLODKZIGYHNR-LTEFSYCBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5477,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1137.821,1136.50843623,80,8,4,15,C59H74ClFN10O8S,"InChI=1S/C59H74ClFN10O8S/c1-37(2)55(52-28-38(3)68-79-52)59(76)71-34-43(72)30-49(71)58(75)67-47(40-15-17-41(18-16-40)56-39(4)65-36-80-56)33-53(73)62-21-12-10-8-6-7-9-11-14-54(74)70-25-23-69(24-26-70)22-13-27-78-51-31-44-48(32-50(51)77-5)63-35-64-57(44)66-42-19-20-46(61)45(60)29-42/h15-20,28-29,31-32,35-37,43,47,49,55,72H,6-14,21-27,30,33-34H2,1-5H3,(H,62,73)(H,67,75)(H,63,64,66)/t43-,47+,49+,55-/m1/s1",VALYMTQFIVLATQ-BUCBQYKQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5489,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1171.854,1170.53031454,82,8,5,14,C60H77ClF2N10O8S,"InChI=1S/C60H77ClF2N10O8S/c1-38-53(82-37-67-38)40-17-15-39(16-18-40)46(69-56(77)48-31-42(74)35-73(48)57(78)54(59(2,3)4)70-58(79)60(63)21-22-60)34-51(75)64-23-12-10-8-6-7-9-11-14-52(76)72-27-25-71(26-28-72)24-13-29-81-50-32-43-47(33-49(50)80-5)65-36-66-55(43)68-41-19-20-45(62)44(61)30-41/h15-20,30,32-33,36-37,42,46,48,54,74H,6-14,21-29,31,34-35H2,1-5H3,(H,64,75)(H,69,77)(H,70,79)(H,65,66,68)/t42-,46+,48+,54-/m1/s1",UNUYMASCZFRMQY-FOCFZSKWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2227,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,798.232,797.248850424,57,7,4,12,C39H37ClFN9O7,"InChI=1S/C39H37ClFN9O7/c1-2-32(51)46-29-18-24-28(43-21-44-36(24)45-22-7-8-26(41)25(40)17-22)19-31(29)57-16-4-11-48-12-14-49(15-13-48)34(53)20-42-27-6-3-5-23-35(27)39(56)50(38(23)55)30-9-10-33(52)47-37(30)54/h2-3,5-8,17-19,21,30,42H,1,4,9-16,20H2,(H,46,51)(H,43,44,45)(H,47,52,54)",CNJATHSQDNDLIM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2227,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,798.232,797.248850424,57,7,4,12,C39H37ClFN9O7,"InChI=1S/C39H37ClFN9O7/c1-2-32(51)46-29-18-24-28(43-21-44-36(24)45-22-7-8-26(41)25(40)17-22)19-31(29)57-16-4-11-48-12-14-49(15-13-48)34(53)20-42-27-6-3-5-23-35(27)39(56)50(38(23)55)30-9-10-33(52)47-37(30)54/h2-3,5-8,17-19,21,30,42H,1,4,9-16,20H2,(H,46,51)(H,43,44,45)(H,47,52,54)",CNJATHSQDNDLIM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2396,P00533,EGFR L858R/T790M,CRBN,COC1=CC(N2CCC(N3CCN(C(=O)CNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,<100,,883.347,882.313358186,62,8,4,14,C43H48ClN10O7P,"InChI=1S/C43H48ClN10O7P/c1-61-34-23-27(11-12-30(34)48-43-46-24-29(44)39(50-43)47-31-8-4-5-10-35(31)62(2,3)60)51-17-15-26(16-18-51)52-19-21-53(22-20-52)37(56)25-45-32-9-6-7-28-38(32)42(59)54(41(28)58)33-13-14-36(55)49-40(33)57/h4-12,23-24,26,33,45H,13-22,25H2,1-3H3,(H,49,55,57)(H2,46,47,48,50)",AQGLXXCBEXDRNS-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5469,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1025.605,1024.38323572,72,8,4,15,C51H58ClFN10O8S,"InChI=1S/C51H58ClFN10O8S/c1-29(2)47(44-19-30(3)60-71-44)51(68)63-26-35(64)21-41(63)50(67)59-39(32-7-9-33(10-8-32)48-31(4)57-28-72-48)24-45(65)54-25-46(66)62-16-14-61(15-17-62)13-6-18-70-43-22-36-40(23-42(43)69-5)55-27-56-49(36)58-34-11-12-38(53)37(52)20-34/h7-12,19-20,22-23,27-29,35,39,41,47,64H,6,13-18,21,24-26H2,1-5H3,(H,54,65)(H,59,67)(H,55,56,58)/t35-,39+,41+,47-/m1/s1",FOLVRBMWEYRSAE-GVXQOCCOSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5481,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1059.638,1058.40511403,74,8,5,14,C52H61ClF2N10O8S,"InChI=1S/C52H61ClF2N10O8S/c1-30-45(74-29-59-30)32-9-7-31(8-10-32)38(61-48(69)40-22-34(66)27-65(40)49(70)46(51(2,3)4)62-50(71)52(55)13-14-52)25-43(67)56-26-44(68)64-18-16-63(17-19-64)15-6-20-73-42-23-35-39(24-41(42)72-5)57-28-58-47(35)60-33-11-12-37(54)36(53)21-33/h7-12,21,23-24,28-29,34,38,40,46,66H,6,13-20,22,25-27H2,1-5H3,(H,56,67)(H,61,69)(H,62,71)(H,57,58,60)/t34-,38+,40+,46-/m1/s1",CGOTUNNDPPEANJ-PEFPNBTRSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,562,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,870.991,870.408940952,64,9,5,14,C46H51FN12O5,"InChI=1S/C46H51FN12O5/c47-30-7-9-31(10-8-30)50-46-52-37-26-49-40(24-34(37)43(55-46)58-18-15-29(28-60)16-19-58)53-39-13-11-32(25-48-39)57-22-20-56(21-23-57)17-2-1-6-41(61)51-36-5-3-4-33-35(36)27-59(45(33)64)38-12-14-42(62)54-44(38)63/h3-5,7-11,13,24-26,29,38,60H,1-2,6,12,14-23,27-28H2,(H,51,61)(H,48,49,53)(H,50,52,55)(H,54,62,63)",ZLQKFKXUGYUHGE-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5462,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,850.981,850.39147932,63,7,4,12,C47H50N10O6,"InChI=1S/C47H50N10O6/c1-6-22-56(23-11-10-17-43(59)49-34-15-12-14-31-33(34)29-57(46(31)62)39-18-19-44(60)53-45(39)61)25-24-54(3)40-27-41(63-5)37(26-36(40)50-42(58)7-2)52-47-48-21-20-35(51-47)32-28-55(4)38-16-9-8-13-30(32)38/h1,7-9,12-16,20-21,26-28,39H,2,10-11,17-19,22-25,29H2,3-5H3,(H,49,59)(H,50,58)(H,48,51,52)(H,53,60,61)",BFSUALZSNVHREQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,564,P00533,EGFR,CRBN,O=C(CN1CCN(C2=CC=C(NC3=CC4=C(N5CCC(CO)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1)NCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.989,899.39910454,66,9,6,15,C46H50FN13O6,"InChI=1S/C46H50FN13O6/c47-29-4-6-30(7-5-29)51-46-53-36-24-50-39(22-33(36)43(56-46)59-16-13-28(27-61)14-17-59)54-38-10-8-31(23-49-38)58-20-18-57(19-21-58)26-42(64)48-15-12-41(63)52-35-3-1-2-32-34(35)25-60(45(32)66)37-9-11-40(62)55-44(37)65/h1-8,10,22-24,28,37,61H,9,11-21,25-27H2,(H,48,64)(H,52,63)(H,49,50,54)(H,51,53,56)(H,55,62,65)",BJYUZUZKGOOWHB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,566,P00533,EGFR,CRBN,CN(C)C1CCN(C2=CC=C(NC3=CC4=C(N5CCN(CC(=O)NCCC(=O)NC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1,,,913.032,912.430739016,67,9,5,15,C47H53FN14O5,"InChI=1S/C47H53FN14O5/c1-58(2)31-15-18-60(19-16-31)32-10-12-39(50-25-32)55-40-24-34-37(26-51-40)54-47(52-30-8-6-29(48)7-9-30)57-44(34)61-22-20-59(21-23-61)28-43(65)49-17-14-42(64)53-36-5-3-4-33-35(36)27-62(46(33)67)38-11-13-41(63)56-45(38)66/h3-10,12,24-26,31,38H,11,13-23,27-28H2,1-2H3,(H,49,65)(H,53,64)(H,50,51,55)(H,52,54,57)(H,56,63,66)",GUZCGEKRDGMCQI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,572,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)NC6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)=C1,>2000,,979.108,978.438823436,72,8,4,14,C53H58N10O9,"InChI=1S/C53H58N10O9/c1-4-43(64)55-34-15-13-16-36(30-34)62-47(68)29-33(2)38-32-54-53(59-49(38)62)57-39-22-21-35(31-42(39)72-3)60-25-27-61(28-26-60)46(67)20-12-10-8-6-5-7-9-11-19-44(65)56-40-18-14-17-37-48(40)52(71)63(51(37)70)41-23-24-45(66)58-50(41)69/h4,13-18,21-22,29-32,41H,1,5-12,19-20,23-28H2,2-3H3,(H,55,64)(H,56,65)(H,54,57,59)(H,58,66,69)",JYBLMIXCGVMISV-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,572,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)NC6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)=C1,>2000,,979.108,978.438823436,72,8,4,14,C53H58N10O9,"InChI=1S/C53H58N10O9/c1-4-43(64)55-34-15-13-16-36(30-34)62-47(68)29-33(2)38-32-54-53(59-49(38)62)57-39-22-21-35(31-42(39)72-3)60-25-27-61(28-26-60)46(67)20-12-10-8-6-5-7-9-11-19-44(65)56-40-18-14-17-37-48(40)52(71)63(51(37)70)41-23-24-45(66)58-50(41)69/h4,13-18,21-22,29-32,41H,1,5-12,19-20,23-28H2,2-3H3,(H,55,64)(H,56,65)(H,54,57,59)(H,58,66,69)",JYBLMIXCGVMISV-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5602,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,981.046,980.41564338,71,7,5,13,C50H55F3N10O8,"InChI=1S/C50H55F3N10O8/c1-3-40(64)55-31-14-12-15-32(28-31)56-45-35(50(51,52)53)30-54-49(60-45)58-36-21-20-33(29-39(36)71-2)61-24-26-62(27-25-61)43(67)19-11-9-7-5-4-6-8-10-18-41(65)57-37-17-13-16-34-44(37)48(70)63(47(34)69)38-22-23-42(66)59-46(38)68/h3,12-17,20-21,28-30,38H,1,4-11,18-19,22-27H2,2H3,(H,55,64)(H,57,65)(H,59,66,68)(H2,54,56,58,60)",CSKMUJOYDMXURU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5602,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,981.046,980.41564338,71,7,5,13,C50H55F3N10O8,"InChI=1S/C50H55F3N10O8/c1-3-40(64)55-31-14-12-15-32(28-31)56-45-35(50(51,52)53)30-54-49(60-45)58-36-21-20-33(29-39(36)71-2)61-24-26-62(27-25-61)43(67)19-11-9-7-5-4-6-8-10-18-41(65)57-37-17-13-16-34-44(37)48(70)63(47(34)69)38-22-23-42(66)59-46(38)68/h3,12-17,20-21,28-30,38H,1,4-11,18-19,22-27H2,2H3,(H,55,64)(H,57,65)(H,59,66,68)(H2,54,56,58,60)",CSKMUJOYDMXURU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5602,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,981.046,980.41564338,71,7,5,13,C50H55F3N10O8,"InChI=1S/C50H55F3N10O8/c1-3-40(64)55-31-14-12-15-32(28-31)56-45-35(50(51,52)53)30-54-49(60-45)58-36-21-20-33(29-39(36)71-2)61-24-26-62(27-25-61)43(67)19-11-9-7-5-4-6-8-10-18-41(65)57-37-17-13-16-34-44(37)48(70)63(47(34)69)38-22-23-42(66)59-46(38)68/h3,12-17,20-21,28-30,38H,1,4-11,18-19,22-27H2,2H3,(H,55,64)(H,57,65)(H,59,66,68)(H2,54,56,58,60)",CSKMUJOYDMXURU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,573,P00533,EGFR L858R/T790M,cIAP1,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)CC6=CC=CC=C6)CC5)C=C4OC)N=C32)=C1,>2000,,999.271,998.574194708,73,6,6,13,C56H74N10O7,"InChI=1S/C56H74N10O7/c1-6-49(67)60-41-22-19-23-43(35-41)66-51(69)33-39(4)44-37-59-56(63-53(44)66)62-46-26-25-42(36-48(46)73-5)64-28-30-65(31-29-64)50(68)24-17-12-10-8-7-9-11-13-18-27-58-54(71)47(32-38(2)3)61-55(72)52(70)45(57)34-40-20-15-14-16-21-40/h6,14-16,19-23,25-26,33,35-38,45,47,52,70H,1,7-13,17-18,24,27-32,34,57H2,2-5H3,(H,58,71)(H,60,67)(H,61,72)(H,59,62,63)/t45-,47+,52+/m1/s1",DOEISPNISSZUOZ-KTBSTWIUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,573,P00533,EGFR,cIAP1,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)CC6=CC=CC=C6)CC5)C=C4OC)N=C32)=C1,>2000,,999.271,998.574194708,73,6,6,13,C56H74N10O7,"InChI=1S/C56H74N10O7/c1-6-49(67)60-41-22-19-23-43(35-41)66-51(69)33-39(4)44-37-59-56(63-53(44)66)62-46-26-25-42(36-48(46)73-5)64-28-30-65(31-29-64)50(68)24-17-12-10-8-7-9-11-13-18-27-58-54(71)47(32-38(2)3)61-55(72)52(70)45(57)34-40-20-15-14-16-21-40/h6,14-16,19-23,25-26,33,35-38,45,47,52,70H,1,7-13,17-18,24,27-32,34,57H2,2-5H3,(H,58,71)(H,60,67)(H,61,72)(H,59,62,63)/t45-,47+,52+/m1/s1",DOEISPNISSZUOZ-KTBSTWIUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,574,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,263.8,,1307.385,1305.55090567,93,9,5,14,C71H79Cl2F2N11O7,"InChI=1S/C71H79Cl2F2N11O7/c1-8-60(87)79-47-20-18-21-49(39-47)86-62(89)36-44(2)51-42-78-69(83-66(51)86)81-56-30-27-48(40-58(56)93-7)84-32-34-85(35-33-84)61(88)24-16-14-12-10-9-11-13-15-17-31-77-67(90)45-25-29-55(57(37-45)92-6)80-68(91)65-63(50-22-19-23-53(73)64(50)75)71(43-76,59(82-65)41-70(3,4)5)52-28-26-46(72)38-54(52)74/h8,18-23,25-30,36-40,42,59,63,65,82H,1,9-17,24,31-35,41H2,2-7H3,(H,77,90)(H,79,87)(H,80,91)(H,78,81,83)/t59-,63-,65+,71-/m0/s1",DCPNWQZQYCVVJX-UYDHSDFFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,574,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1307.385,1305.55090567,93,9,5,14,C71H79Cl2F2N11O7,"InChI=1S/C71H79Cl2F2N11O7/c1-8-60(87)79-47-20-18-21-49(39-47)86-62(89)36-44(2)51-42-78-69(83-66(51)86)81-56-30-27-48(40-58(56)93-7)84-32-34-85(35-33-84)61(88)24-16-14-12-10-9-11-13-15-17-31-77-67(90)45-25-29-55(57(37-45)92-6)80-68(91)65-63(50-22-19-23-53(73)64(50)75)71(43-76,59(82-65)41-70(3,4)5)52-28-26-46(72)38-54(52)74/h8,18-23,25-30,36-40,42,59,63,65,82H,1,9-17,24,31-35,41H2,2-7H3,(H,77,90)(H,79,87)(H,80,91)(H,78,81,83)/t59-,63-,65+,71-/m0/s1",DCPNWQZQYCVVJX-UYDHSDFFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,575,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1293.402,1291.57164111,92,9,5,14,C71H81Cl2F2N11O6,"InChI=1S/C71H81Cl2F2N11O6/c1-8-61(87)79-48-21-19-22-50(40-48)86-62(88)37-45(2)52-43-78-69(83-66(52)86)81-57-30-27-49(41-59(57)92-7)85-35-33-84(34-36-85)32-18-16-14-12-10-9-11-13-15-17-31-77-67(89)46-25-29-56(58(38-46)91-6)80-68(90)65-63(51-23-20-24-54(73)64(51)75)71(44-76,60(82-65)42-70(3,4)5)53-28-26-47(72)39-55(53)74/h8,19-30,37-41,43,60,63,65,82H,1,9-18,31-36,42H2,2-7H3,(H,77,89)(H,79,87)(H,80,90)(H,78,81,83)/t60-,63-,65+,71-/m0/s1",UPZKEHBNYUDGOC-AFJHDGOUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,575,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1293.402,1291.57164111,92,9,5,14,C71H81Cl2F2N11O6,"InChI=1S/C71H81Cl2F2N11O6/c1-8-61(87)79-48-21-19-22-50(40-48)86-62(88)37-45(2)52-43-78-69(83-66(52)86)81-57-30-27-49(41-59(57)92-7)85-35-33-84(34-36-85)32-18-16-14-12-10-9-11-13-15-17-31-77-67(89)46-25-29-56(58(38-46)91-6)80-68(90)65-63(51-23-20-24-54(73)64(51)75)71(44-76,60(82-65)42-70(3,4)5)53-28-26-47(72)39-55(53)74/h8,19-30,37-41,43,60,63,65,82H,1,9-18,31-36,42H2,2-7H3,(H,77,89)(H,79,87)(H,80,90)(H,78,81,83)/t60-,63-,65+,71-/m0/s1",UPZKEHBNYUDGOC-AFJHDGOUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,576,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,312.9,,1136.434,1135.56772942,82,8,5,15,C62H77N11O8S,"InChI=1S/C62H77N11O8S/c1-8-52(75)66-44-18-17-19-46(33-44)73-55(78)32-40(2)48-37-64-61(69-58(48)73)67-49-27-26-45(34-51(49)81-7)70-28-30-71(31-29-70)54(77)21-16-14-12-10-9-11-13-15-20-53(76)68-57(62(4,5)6)60(80)72-38-47(74)35-50(72)59(79)63-36-42-22-24-43(25-23-42)56-41(3)65-39-82-56/h8,17-19,22-27,32-34,37,39,47,50,57,74H,1,9-16,20-21,28-31,35-36,38H2,2-7H3,(H,63,79)(H,66,75)(H,68,76)(H,64,67,69)/t47-,50+,57-/m1/s1",GSUQPNOGNRJJQO-YTFMVYPUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,576,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1136.434,1135.56772942,82,8,5,15,C62H77N11O8S,"InChI=1S/C62H77N11O8S/c1-8-52(75)66-44-18-17-19-46(33-44)73-55(78)32-40(2)48-37-64-61(69-58(48)73)67-49-27-26-45(34-51(49)81-7)70-28-30-71(31-29-70)54(77)21-16-14-12-10-9-11-13-15-20-53(76)68-57(62(4,5)6)60(80)72-38-47(74)35-50(72)59(79)63-36-42-22-24-43(25-23-42)56-41(3)65-39-82-56/h8,17-19,22-27,32-34,37,39,47,50,57,74H,1,9-16,20-21,28-31,35-36,38H2,2-7H3,(H,63,79)(H,66,75)(H,68,76)(H,64,67,69)/t47-,50+,57-/m1/s1",GSUQPNOGNRJJQO-YTFMVYPUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5478,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,7.1,,1151.848,1150.52408629,81,8,4,15,C60H76ClFN10O8S,"InChI=1S/C60H76ClFN10O8S/c1-38(2)56(53-29-39(3)69-80-53)60(77)72-35-44(73)31-50(72)59(76)68-48(41-16-18-42(19-17-41)57-40(4)66-37-81-57)34-54(74)63-22-13-11-9-7-6-8-10-12-15-55(75)71-26-24-70(25-27-71)23-14-28-79-52-32-45-49(33-51(52)78-5)64-36-65-58(45)67-43-20-21-47(62)46(61)30-43/h16-21,29-30,32-33,36-38,44,48,50,56,73H,6-15,22-28,31,34-35H2,1-5H3,(H,63,74)(H,68,76)(H,64,65,67)/t44-,48+,50+,56-/m1/s1",VDUPETHSNLCFNB-HHHFUCLFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5490,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1185.881,1184.54596461,83,8,5,14,C61H79ClF2N10O8S,"InChI=1S/C61H79ClF2N10O8S/c1-39-54(83-38-68-39)41-18-16-40(17-19-41)47(70-57(78)49-32-43(75)36-74(49)58(79)55(60(2,3)4)71-59(80)61(64)22-23-61)35-52(76)65-24-13-11-9-7-6-8-10-12-15-53(77)73-28-26-72(27-29-73)25-14-30-82-51-33-44-48(34-50(51)81-5)66-37-67-56(44)69-42-20-21-46(63)45(62)31-42/h16-21,31,33-34,37-38,43,47,49,55,75H,6-15,22-30,32,35-36H2,1-5H3,(H,65,76)(H,70,78)(H,71,80)(H,66,67,69)/t43-,47+,49+,55-/m1/s1",JGPDJHWVBWWLDS-BUCBQYKQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,578,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,77,,1279.331,1277.51960554,91,9,5,14,C69H75Cl2F2N11O7,"InChI=1S/C69H75Cl2F2N11O7/c1-8-58(85)77-45-18-16-19-47(37-45)84-60(87)34-42(2)49-40-76-67(81-64(49)84)79-54-28-25-46(38-56(54)91-7)82-30-32-83(33-31-82)59(86)22-14-12-10-9-11-13-15-29-75-65(88)43-23-27-53(55(35-43)90-6)78-66(89)63-61(48-20-17-21-51(71)62(48)73)69(41-74,57(80-63)39-68(3,4)5)50-26-24-44(70)36-52(50)72/h8,16-21,23-28,34-38,40,57,61,63,80H,1,9-15,22,29-33,39H2,2-7H3,(H,75,88)(H,77,85)(H,78,89)(H,76,79,81)/t57-,61-,63+,69-/m0/s1",GDBFIWQFEZVSAL-RBRUZKMXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,578,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1279.331,1277.51960554,91,9,5,14,C69H75Cl2F2N11O7,"InChI=1S/C69H75Cl2F2N11O7/c1-8-58(85)77-45-18-16-19-47(37-45)84-60(87)34-42(2)49-40-76-67(81-64(49)84)79-54-28-25-46(38-56(54)91-7)82-30-32-83(33-31-82)59(86)22-14-12-10-9-11-13-15-29-75-65(88)43-23-27-53(55(35-43)90-6)78-66(89)63-61(48-20-17-21-51(71)62(48)73)69(41-74,57(80-63)39-68(3,4)5)50-26-24-44(70)36-52(50)72/h8,16-21,23-28,34-38,40,57,61,63,80H,1,9-15,22,29-33,39H2,2-7H3,(H,75,88)(H,77,85)(H,78,89)(H,76,79,81)/t57-,61-,63+,69-/m0/s1",GDBFIWQFEZVSAL-RBRUZKMXSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,579,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1251.277,1249.48830541,89,9,5,14,C67H71Cl2F2N11O7,"InChI=1S/C67H71Cl2F2N11O7/c1-8-56(83)75-43-16-14-17-45(35-43)82-58(85)32-40(2)47-38-74-65(79-62(47)82)77-52-26-23-44(36-54(52)89-7)80-28-30-81(31-29-80)57(84)20-12-10-9-11-13-27-73-63(86)41-21-25-51(53(33-41)88-6)76-64(87)61-59(46-18-15-19-49(69)60(46)71)67(39-72,55(78-61)37-66(3,4)5)48-24-22-42(68)34-50(48)70/h8,14-19,21-26,32-36,38,55,59,61,78H,1,9-13,20,27-31,37H2,2-7H3,(H,73,86)(H,75,83)(H,76,87)(H,74,77,79)/t55-,59-,61+,67-/m0/s1",GGZIIUYEYTZDCD-ASJDMNHUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,579,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1251.277,1249.48830541,89,9,5,14,C67H71Cl2F2N11O7,"InChI=1S/C67H71Cl2F2N11O7/c1-8-56(83)75-43-16-14-17-45(35-43)82-58(85)32-40(2)47-38-74-65(79-62(47)82)77-52-26-23-44(36-54(52)89-7)80-28-30-81(31-29-80)57(84)20-12-10-9-11-13-27-73-63(86)41-21-25-51(53(33-41)88-6)76-64(87)61-59(46-18-15-19-49(69)60(46)71)67(39-72,55(78-61)37-66(3,4)5)48-24-22-42(68)34-50(48)70/h8,14-19,21-26,32-36,38,55,59,61,78H,1,9-13,20,27-31,37H2,2-7H3,(H,73,86)(H,75,83)(H,76,87)(H,74,77,79)/t55-,59-,61+,67-/m0/s1",GGZIIUYEYTZDCD-ASJDMNHUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5514,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,843.357,842.331851776,60,7,3,12,C43H48ClFN8O7,"InChI=1S/C43H48ClFN8O7/c1-59-36-25-34-31(40(48-26-47-34)49-28-10-12-33(45)32(44)23-28)24-37(36)60-21-7-16-51-17-19-52(20-18-51)39(55)8-5-3-2-4-6-15-46-27-9-11-29-30(22-27)43(58)53(42(29)57)35-13-14-38(54)50-41(35)56/h9-12,22-26,35,46H,2-8,13-21H2,1H3,(H,47,48,49)(H,50,54,56)",SFHMCPHJVQETCU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,580,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1223.223,1221.45700528,87,9,5,14,C65H67Cl2F2N11O7,"InChI=1S/C65H67Cl2F2N11O7/c1-8-54(81)73-41-14-12-15-43(33-41)80-56(83)30-38(2)45-36-72-63(77-60(45)80)75-50-24-21-42(34-52(50)87-7)78-26-28-79(29-27-78)55(82)18-10-9-11-25-71-61(84)39-19-23-49(51(31-39)86-6)74-62(85)59-57(44-16-13-17-47(67)58(44)69)65(37-70,53(76-59)35-64(3,4)5)46-22-20-40(66)32-48(46)68/h8,12-17,19-24,30-34,36,53,57,59,76H,1,9-11,18,25-29,35H2,2-7H3,(H,71,84)(H,73,81)(H,74,85)(H,72,75,77)/t53-,57-,59+,65-/m0/s1",KFRDCTCOKBRAAL-OIUJZHHCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,580,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1223.223,1221.45700528,87,9,5,14,C65H67Cl2F2N11O7,"InChI=1S/C65H67Cl2F2N11O7/c1-8-54(81)73-41-14-12-15-43(33-41)80-56(83)30-38(2)45-36-72-63(77-60(45)80)75-50-24-21-42(34-52(50)87-7)78-26-28-79(29-27-78)55(82)18-10-9-11-25-71-61(84)39-19-23-49(51(31-39)86-6)74-62(85)59-57(44-16-13-17-47(67)58(44)69)65(37-70,53(76-59)35-64(3,4)5)46-22-20-40(66)32-48(46)68/h8,12-17,19-24,30-34,36,53,57,59,76H,1,9-11,18,25-29,35H2,2-7H3,(H,71,84)(H,73,81)(H,74,85)(H,72,75,77)/t53-,57-,59+,65-/m0/s1",KFRDCTCOKBRAAL-OIUJZHHCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5512,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,815.303,814.300551648,58,7,3,12,C41H44ClFN8O7,"InChI=1S/C41H44ClFN8O7/c1-57-34-23-32-29(38(46-24-45-32)47-26-8-10-31(43)30(42)21-26)22-35(34)58-19-5-14-49-15-17-50(18-16-49)37(53)6-3-2-4-13-44-25-7-9-27-28(20-25)41(56)51(40(27)55)33-11-12-36(52)48-39(33)54/h7-10,20-24,33,44H,2-6,11-19H2,1H3,(H,45,46,47)(H,48,52,54)",VLEREXHCBCVHGO-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,588,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1002.611,1001.40363681,70,7,4,14,C50H61ClFN9O8S,"InChI=1S/C50H61ClFN9O8S/c1-31-45(70-30-56-31)33-9-7-32(8-10-33)27-53-48(65)40-24-35(62)28-61(40)49(66)46(50(2,3)4)58-43(63)13-21-68-22-14-44(64)60-18-16-59(17-19-60)15-6-20-69-42-25-36-39(26-41(42)67-5)54-29-55-47(36)57-34-11-12-38(52)37(51)23-34/h7-12,23,25-26,29-30,35,40,46,62H,6,13-22,24,27-28H2,1-5H3,(H,53,65)(H,58,63)(H,54,55,57)/t35-,40+,46-/m1/s1",HZVDJJAXDIAOHI-QRYWEXOJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,588,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1002.611,1001.40363681,70,7,4,14,C50H61ClFN9O8S,"InChI=1S/C50H61ClFN9O8S/c1-31-45(70-30-56-31)33-9-7-32(8-10-33)27-53-48(65)40-24-35(62)28-61(40)49(66)46(50(2,3)4)58-43(63)13-21-68-22-14-44(64)60-18-16-59(17-19-60)15-6-20-69-42-25-36-39(26-41(42)67-5)54-29-55-47(36)57-34-11-12-38(52)37(51)23-34/h7-12,23,25-26,29-30,35,40,46,62H,6,13-22,24,27-28H2,1-5H3,(H,53,65)(H,58,63)(H,54,55,57)/t35-,40+,46-/m1/s1",HZVDJJAXDIAOHI-QRYWEXOJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1545,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,880.984,880.300281368,64,9,3,12,C47H44N8O8S,"InChI=1S/C47H44N8O8S/c56-38-16-15-37(42(58)50-38)55-45(61)34-7-4-8-36(40(34)46(55)62)48-18-25-63-24-17-39(57)53-22-20-52(21-23-53)33-13-11-29(12-14-33)31-9-10-32-28-54(44(60)35(32)27-31)41(30-5-2-1-3-6-30)43(59)51-47-49-19-26-64-47/h1-14,19,26-27,37,41,48H,15-18,20-25,28H2,(H,49,51,59)(H,50,56,58)",MPSFLLYYUBBAEB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5493,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1083.685,1082.42510053,76,8,4,16,C54H64ClFN10O9S,"InChI=1S/C54H64ClFN10O9S/c1-32(2)50(47-23-33(3)63-75-47)54(71)66-29-38(67)25-44(66)53(70)62-42(35-7-9-36(10-8-35)51-34(4)60-31-76-51)28-48(68)57-14-22-73-21-13-49(69)65-18-16-64(17-19-65)15-6-20-74-46-26-39-43(27-45(46)72-5)58-30-59-52(39)61-37-11-12-41(56)40(55)24-37/h7-12,23-24,26-27,30-32,38,42,44,50,67H,6,13-22,25,28-29H2,1-5H3,(H,57,68)(H,62,70)(H,58,59,61)/t38-,42+,44+,50-/m1/s1",GBUREHDGQZLEIU-VYRQVLTMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5501,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1117.718,1116.44697884,78,8,5,15,C55H67ClF2N10O9S,"InChI=1S/C55H67ClF2N10O9S/c1-33-48(78-32-62-33)35-9-7-34(8-10-35)41(64-51(72)43-26-37(69)30-68(43)52(73)49(54(2,3)4)65-53(74)55(58)14-15-55)29-46(70)59-16-24-76-23-13-47(71)67-20-18-66(19-21-67)17-6-22-77-45-27-38-42(28-44(45)75-5)60-31-61-50(38)63-36-11-12-40(57)39(56)25-36/h7-12,25,27-28,31-32,37,41,43,49,69H,6,13-24,26,29-30H2,1-5H3,(H,59,70)(H,64,72)(H,65,74)(H,60,61,63)/t37-,41+,43+,49-/m1/s1",VEWVNHVHVUTJSR-JYAIWFTJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,594,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,860.344,859.322015364,61,7,4,14,C42H47ClFN9O8,"InChI=1S/C42H47ClFN9O8/c1-59-34-24-32-28(39(48-25-47-32)49-26-6-7-30(44)29(43)22-26)23-35(34)61-19-3-13-51-15-17-52(18-16-51)14-10-36(54)46-12-21-60-20-11-45-31-5-2-4-27-38(31)42(58)53(41(27)57)33-8-9-37(55)50-40(33)56/h2,4-7,22-25,33,45H,3,8-21H2,1H3,(H,46,54)(H,47,48,49)(H,50,55,56)",PDCRYPGMVLBRTP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,594,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,860.344,859.322015364,61,7,4,14,C42H47ClFN9O8,"InChI=1S/C42H47ClFN9O8/c1-59-34-24-32-28(39(48-25-47-32)49-26-6-7-30(44)29(43)22-26)23-35(34)61-19-3-13-51-15-17-52(18-16-51)14-10-36(54)46-12-21-60-20-11-45-31-5-2-4-27-38(31)42(58)53(41(27)57)33-8-9-37(55)50-40(33)56/h2,4-7,22-25,33,45H,3,8-21H2,1H3,(H,46,54)(H,47,48,49)(H,50,55,56)",PDCRYPGMVLBRTP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,595,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,1036.556,1035.42687436,73,7,4,18,C50H63ClFN9O12,"InChI=1S/C50H63ClFN9O12/c1-67-42-32-40-36(47(56-33-55-40)57-34-6-7-38(52)37(51)30-34)31-43(42)73-19-3-13-59-15-17-60(18-16-59)14-10-44(62)54-12-21-69-23-25-71-27-29-72-28-26-70-24-22-68-20-11-53-39-5-2-4-35-46(39)50(66)61(49(35)65)41-8-9-45(63)58-48(41)64/h2,4-7,30-33,41,53H,3,8-29H2,1H3,(H,54,62)(H,55,56,57)(H,58,63,64)",NKTVFYFQSABEHM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,595,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,1036.556,1035.42687436,73,7,4,18,C50H63ClFN9O12,"InChI=1S/C50H63ClFN9O12/c1-67-42-32-40-36(47(56-33-55-40)57-34-6-7-38(52)37(51)30-34)31-43(42)73-19-3-13-59-15-17-60(18-16-59)14-10-44(62)54-12-21-69-23-25-71-27-29-72-28-26-70-24-22-68-20-11-53-39-5-2-4-35-46(39)50(66)61(49(35)65)41-8-9-45(63)58-48(41)64/h2,4-7,30-33,41,53H,3,8-29H2,1H3,(H,54,62)(H,55,56,57)(H,58,63,64)",NKTVFYFQSABEHM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,596,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,872.399,871.358400872,62,7,4,13,C44H51ClFN9O7,"InChI=1S/C44H51ClFN9O7/c1-61-36-26-34-30(41(50-27-49-34)51-28-10-11-32(46)31(45)24-28)25-37(36)62-23-7-17-53-19-21-54(22-20-53)18-14-38(56)48-16-5-3-2-4-15-47-33-9-6-8-29-40(33)44(60)55(43(29)59)35-12-13-39(57)52-42(35)58/h6,8-11,24-27,35,47H,2-5,7,12-23H2,1H3,(H,48,56)(H,49,50,51)(H,52,57,58)",MPXZGDAUSAQINZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,596,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,872.399,871.358400872,62,7,4,13,C44H51ClFN9O7,"InChI=1S/C44H51ClFN9O7/c1-61-36-26-34-30(41(50-27-49-34)51-28-10-11-32(46)31(45)24-28)25-37(36)62-23-7-17-53-19-21-54(22-20-53)18-14-38(56)48-16-5-3-2-4-15-47-33-9-6-8-29-40(33)44(60)55(43(29)59)35-12-13-39(57)52-42(35)58/h6,8-11,24-27,35,47H,2-5,7,12-23H2,1H3,(H,48,56)(H,49,50,51)(H,52,57,58)",MPXZGDAUSAQINZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,597,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,25,,901.437,900.373716588,64,7,3,13,C46H54ClFN8O8,"InChI=1S/C46H54ClFN8O8/c1-62-38-28-35-32(43(51-29-50-35)52-30-12-13-34(48)33(47)26-30)27-39(38)64-25-9-18-54-20-22-55(23-21-54)19-16-40(57)49-17-6-4-2-3-5-7-24-63-37-11-8-10-31-42(37)46(61)56(45(31)60)36-14-15-41(58)53-44(36)59/h8,10-13,26-29,36H,2-7,9,14-25H2,1H3,(H,49,57)(H,50,51,52)(H,53,58,59)",ALKKWBPMCDDKKA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,597,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,11,,901.437,900.373716588,64,7,3,13,C46H54ClFN8O8,"InChI=1S/C46H54ClFN8O8/c1-62-38-28-35-32(43(51-29-50-35)52-30-12-13-34(48)33(47)26-30)27-39(38)64-25-9-18-54-20-22-55(23-21-54)19-16-40(57)49-17-6-4-2-3-5-7-24-63-37-11-8-10-31-42(37)46(61)56(45(31)60)36-14-15-41(58)53-44(36)59/h8,10-13,26-29,36H,2-7,9,14-25H2,1H3,(H,49,57)(H,50,51,52)(H,53,58,59)",ALKKWBPMCDDKKA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2615,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2CC2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1146.433,1145.56331274,83,9,6,16,C62H75N13O7S,"InChI=1S/C62H75N13O7S/c1-39-56(83-38-67-39)42-20-18-41(19-21-42)34-66-59(80)52-30-44(76)35-75(52)60(81)57(62(2,3)4)71-54(77)15-9-7-8-12-23-64-55(78)37-73-25-27-74(28-26-73)51-32-53(82-6)49(31-48(51)68-58(79)43(33-63)29-40-16-17-40)70-61-65-24-22-47(69-61)46-36-72(5)50-14-11-10-13-45(46)50/h10-11,13-14,18-22,24,29,31-32,36,38,40,44,52,57,76H,7-9,12,15-17,23,25-28,30,34-35,37H2,1-6H3,(H,64,78)(H,66,80)(H,68,79)(H,71,77)(H,65,69,70)/b43-29+/t44-,52+,57-/m1/s1",IYEGDDXKUGKHBL-YIBIMTPWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2615,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2CC2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1146.433,1145.56331274,83,9,6,16,C62H75N13O7S,"InChI=1S/C62H75N13O7S/c1-39-56(83-38-67-39)42-20-18-41(19-21-42)34-66-59(80)52-30-44(76)35-75(52)60(81)57(62(2,3)4)71-54(77)15-9-7-8-12-23-64-55(78)37-73-25-27-74(28-26-73)51-32-53(82-6)49(31-48(51)68-58(79)43(33-63)29-40-16-17-40)70-61-65-24-22-47(69-61)46-36-72(5)50-14-11-10-13-45(46)50/h10-11,13-14,18-22,24,29,31-32,36,38,40,44,52,57,76H,7-9,12,15-17,23,25-28,30,34-35,37H2,1-6H3,(H,64,78)(H,66,80)(H,68,79)(H,71,77)(H,65,69,70)/b43-29+/t44-,52+,57-/m1/s1",IYEGDDXKUGKHBL-YIBIMTPWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2616,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2=CC=NC=C2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1183.454,1182.55856171,86,9,6,17,C64H74N14O7S,"InChI=1S/C64H74N14O7S/c1-41-58(86-40-70-41)44-18-16-43(17-19-44)36-69-61(83)54-32-46(79)37-78(54)62(84)59(64(2,3)4)74-56(80)15-9-7-8-12-23-67-57(81)39-76-27-29-77(30-28-76)53-34-55(85-6)51(33-50(53)71-60(82)45(35-65)31-42-20-24-66-25-21-42)73-63-68-26-22-49(72-63)48-38-75(5)52-14-11-10-13-47(48)52/h10-11,13-14,16-22,24-26,31,33-34,38,40,46,54,59,79H,7-9,12,15,23,27-30,32,36-37,39H2,1-6H3,(H,67,81)(H,69,83)(H,71,82)(H,74,80)(H,68,72,73)/b45-31+/t46-,54+,59-/m1/s1",NIJQPCPIFFRGOF-XYOSPYPGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2616,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2=CC=NC=C2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1183.454,1182.55856171,86,9,6,17,C64H74N14O7S,"InChI=1S/C64H74N14O7S/c1-41-58(86-40-70-41)44-18-16-43(17-19-44)36-69-61(83)54-32-46(79)37-78(54)62(84)59(64(2,3)4)74-56(80)15-9-7-8-12-23-67-57(81)39-76-27-29-77(30-28-76)53-34-55(85-6)51(33-50(53)71-60(82)45(35-65)31-42-20-24-66-25-21-42)73-63-68-26-22-49(72-63)48-38-75(5)52-14-11-10-13-47(48)52/h10-11,13-14,16-22,24-26,31,33-34,38,40,46,54,59,79H,7-9,12,15,23,27-30,32,36-37,39H2,1-6H3,(H,67,81)(H,69,83)(H,71,82)(H,74,80)(H,68,72,73)/b45-31+/t46-,54+,59-/m1/s1",NIJQPCPIFFRGOF-XYOSPYPGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2623,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1121.427,1120.57929715,81,9,6,16,C60H76N14O6S,"InChI=1S/C60H76N14O6S/c1-6-52(78)72-28-14-17-46(36-72)74-55-48(67-59(74)66-43-15-10-9-11-16-43)35-63-58(69-55)65-44-23-25-45(26-24-44)71-31-29-70(30-32-71)38-51(77)61-27-13-8-7-12-18-50(76)68-54(60(3,4)5)57(80)73-37-47(75)33-49(73)56(79)62-34-41-19-21-42(22-20-41)53-40(2)64-39-81-53/h6,9-11,15-16,19-26,35,39,46-47,49,54,75H,1,7-8,12-14,17-18,27-34,36-38H2,2-5H3,(H,61,77)(H,62,79)(H,66,67)(H,68,76)(H,63,65,69)/t46-,47+,49-,54+/m0/s1",IROOQIWNFFCZLN-VEJFJKOFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2623,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1121.427,1120.57929715,81,9,6,16,C60H76N14O6S,"InChI=1S/C60H76N14O6S/c1-6-52(78)72-28-14-17-46(36-72)74-55-48(67-59(74)66-43-15-10-9-11-16-43)35-63-58(69-55)65-44-23-25-45(26-24-44)71-31-29-70(30-32-71)38-51(77)61-27-13-8-7-12-18-50(76)68-54(60(3,4)5)57(80)73-37-47(75)33-49(73)56(79)62-34-41-19-21-42(22-20-41)53-40(2)64-39-81-53/h6,9-11,15-16,19-26,35,39,46-47,49,54,75H,1,7-8,12-14,17-18,27-34,36-38H2,2-5H3,(H,61,77)(H,62,79)(H,66,67)(H,68,76)(H,63,65,69)/t46-,47+,49-,54+/m0/s1",IROOQIWNFFCZLN-VEJFJKOFSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5615,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,925.97,925.3846776,67,7,6,14,C46H50F3N11O7,"InChI=1S/C46H50F3N11O7/c1-3-37(61)53-28-10-8-11-29(24-28)54-41-32(46(47,48)49)26-52-45(57-41)55-33-15-14-30(25-36(33)67-2)59-22-20-58(21-23-59)27-39(63)51-19-7-5-4-6-18-50-34-13-9-12-31-40(34)44(66)60(43(31)65)35-16-17-38(62)56-42(35)64/h3,8-15,24-26,35,50H,1,4-7,16-23,27H2,2H3,(H,51,63)(H,53,61)(H,56,62,64)(H2,52,54,55,57)",HLDZFDOEIBZQRP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5615,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,925.97,925.3846776,67,7,6,14,C46H50F3N11O7,"InChI=1S/C46H50F3N11O7/c1-3-37(61)53-28-10-8-11-29(24-28)54-41-32(46(47,48)49)26-52-45(57-41)55-33-15-14-30(25-36(33)67-2)59-22-20-58(21-23-59)27-39(63)51-19-7-5-4-6-18-50-34-13-9-12-31-40(34)44(66)60(43(31)65)35-16-17-38(62)56-42(35)64/h3,8-15,24-26,35,50H,1,4-7,16-23,27H2,2H3,(H,51,63)(H,53,61)(H,56,62,64)(H2,52,54,55,57)",HLDZFDOEIBZQRP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5615,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,925.97,925.3846776,67,7,6,14,C46H50F3N11O7,"InChI=1S/C46H50F3N11O7/c1-3-37(61)53-28-10-8-11-29(24-28)54-41-32(46(47,48)49)26-52-45(57-41)55-33-15-14-30(25-36(33)67-2)59-22-20-58(21-23-59)27-39(63)51-19-7-5-4-6-18-50-34-13-9-12-31-40(34)44(66)60(43(31)65)35-16-17-38(62)56-42(35)64/h3,8-15,24-26,35,50H,1,4-7,16-23,27H2,2H3,(H,51,63)(H,53,61)(H,56,62,64)(H2,52,54,55,57)",HLDZFDOEIBZQRP-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2402,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,892.349,891.301948616,64,8,4,14,C44H43ClFN11O7,"InChI=1S/C44H43ClFN11O7/c45-30-20-26(12-13-31(30)46)49-41-29-21-34(51-38(59)11-7-18-55-16-3-1-4-17-55)36(22-33(29)47-25-48-41)64-24-27-23-56(54-53-27)19-5-2-10-37(58)50-32-9-6-8-28-40(32)44(63)57(43(28)62)35-14-15-39(60)52-42(35)61/h6-9,11-13,20-23,25,35H,1-5,10,14-19,24H2,(H,50,58)(H,51,59)(H,47,48,49)(H,52,60,61)/b11-7+",NUPNAAWSDJSHQQ-YRNVUSSQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1219,P00533,EGFR,CRBN,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCOCCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,917.037,916.423173372,67,7,4,15,C48H56N10O9,"InChI=1S/C48H56N10O9/c1-6-43(59)51-37-26-38(53-48-49-17-16-36(52-48)33-28-57(4)39-13-8-7-10-31(33)39)42(64-5)27-41(37)56(3)19-18-55(2)20-21-65-22-23-66-24-25-67-30-45(61)50-35-12-9-11-32-34(35)29-58(47(32)63)40-14-15-44(60)54-46(40)62/h6-13,16-17,26-28,40H,1,14-15,18-25,29-30H2,2-5H3,(H,50,61)(H,51,59)(H,49,52,53)(H,54,60,62)",SLRLENALOHTBGF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5511,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,801.276,800.284901584,57,7,3,12,C40H42ClFN8O7,"InChI=1S/C40H42ClFN8O7/c1-56-33-22-31-28(37(45-23-44-31)46-25-7-9-30(42)29(41)20-25)21-34(33)57-18-4-13-48-14-16-49(17-15-48)36(52)5-2-3-12-43-24-6-8-26-27(19-24)40(55)50(39(26)54)32-10-11-35(51)47-38(32)53/h6-9,19-23,32,43H,2-5,10-18H2,1H3,(H,44,45,46)(H,47,51,53)",LLPZVMLJFWXNSU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5513,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,829.33,828.316201712,59,7,3,12,C42H46ClFN8O7,"InChI=1S/C42H46ClFN8O7/c1-58-35-24-33-30(39(47-25-46-33)48-27-9-11-32(44)31(43)22-27)23-36(35)59-20-6-15-50-16-18-51(19-17-50)38(54)7-4-2-3-5-14-45-26-8-10-28-29(21-26)42(57)52(41(28)56)34-12-13-37(53)49-40(34)55/h8-11,21-25,34,45H,2-7,12-20H2,1H3,(H,46,47,48)(H,49,53,55)",OOOBRWIBWJRNLX-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2407,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,938.374,937.30742792,67,8,4,16,C45H45ClFN11O9,"InChI=1S/C45H45ClFN11O9/c46-31-20-27(9-10-32(31)47)50-42-30-21-35(52-38(59)8-5-15-56-13-2-1-3-14-56)37(22-34(30)48-26-49-42)67-24-28-23-57(55-54-28)16-17-65-18-19-66-25-40(61)51-33-7-4-6-29-41(33)45(64)58(44(29)63)36-11-12-39(60)53-43(36)62/h4-10,20-23,26,36H,1-3,11-19,24-25H2,(H,51,61)(H,52,59)(H,48,49,50)(H,53,60,62)/b8-5+",CZGGKPSGPDNZOD-VMPITWQZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2408,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCOCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,982.427,981.333642668,70,8,4,17,C47H49ClFN11O10,"InChI=1S/C47H49ClFN11O10/c48-33-22-29(9-10-34(33)49)52-44-32-23-37(54-40(61)8-5-15-58-13-2-1-3-14-58)39(24-36(32)50-28-51-44)70-26-30-25-59(57-56-30)16-17-67-18-19-68-20-21-69-27-42(63)53-35-7-4-6-31-43(35)47(66)60(46(31)65)38-11-12-41(62)55-45(38)64/h4-10,22-25,28,38H,1-3,11-21,26-27H2,(H,53,63)(H,54,61)(H,50,51,52)(H,55,62,64)/b8-5+",MDHFKGKNXKSKPN-VMPITWQZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1553,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(OCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,943.052,942.3370608,68,9,2,15,C49H50N8O10S,"InChI=1S/C49H50N8O10S/c58-41-14-12-38(44(59)52-41)57-47(62)36-7-4-8-39(42(36)48(57)63)67-27-26-66-25-24-65-23-22-64-21-20-54-16-18-55(19-17-54)40-13-11-34(30-51-40)33-9-10-35-31-56(46(61)37(35)29-33)43(32-5-2-1-3-6-32)45(60)53-49-50-15-28-68-49/h1-11,13,15,28-30,38,43H,12,14,16-27,31H2,(H,50,53,60)(H,52,58,59)",WWOKCOMOIMLOBV-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5509,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,773.222,772.253601456,55,7,3,12,C38H38ClFN8O7,"InChI=1S/C38H38ClFN8O7/c1-54-31-20-29-26(35(43-21-42-29)44-23-4-6-28(40)27(39)18-23)19-32(31)55-16-2-11-46-12-14-47(15-13-46)34(50)9-10-41-22-3-5-24-25(17-22)38(53)48(37(24)52)30-7-8-33(49)45-36(30)51/h3-6,17-21,30,41H,2,7-16H2,1H3,(H,42,43,44)(H,45,49,51)",UOSCSJYBYLMABE-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1542,P00533,EGFR L858R/T790M,CRBN,O=C(COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCCCNC(=O)CN1CCN(C2=CC=C(C3=CC=C4CN(C(C(=O)NC5=NC=CS5)C5=CC=CC=C5)C(=O)C4=C3)C=C2)CC1,,,952.063,951.337395148,69,9,4,13,C50H49N9O9S,"InChI=1S/C50H49N9O9S/c60-40-18-17-38(45(63)54-40)59-48(66)36-9-6-10-39(43(36)49(59)67)68-30-42(62)52-20-5-4-19-51-41(61)29-56-22-24-57(25-23-56)35-15-13-31(14-16-35)33-11-12-34-28-58(47(65)37(34)27-33)44(32-7-2-1-3-8-32)46(64)55-50-53-21-26-69-50/h1-3,6-16,21,26-27,38,44H,4-5,17-20,22-25,28-30H2,(H,51,61)(H,52,62)(H,53,55,64)(H,54,60,63)",DRFUYHRFDSPHBM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2614,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1101.345,1100.52659288,79,7,6,17,C57H72N12O9S,"InChI=1S/C57H72N12O9S/c1-10-49(71)62-43-28-44(64-56-59-20-19-42(63-56)41-32-68(8)45-14-12-11-13-40(41)45)48(76-9)29-46(43)67(7)23-22-66(6)33-50(72)58-21-24-77-25-26-78-34-51(73)65-53(57(3,4)5)55(75)69-31-39(70)27-47(69)54(74)60-30-37-15-17-38(18-16-37)52-36(2)61-35-79-52/h10-20,28-29,32,35,39,47,53,70H,1,21-27,30-31,33-34H2,2-9H3,(H,58,72)(H,60,74)(H,62,71)(H,65,73)(H,59,63,64)/t39-,47+,53-/m1/s1",VJOYYKYPRAJJHC-BRBZWKBWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2614,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1101.345,1100.52659288,79,7,6,17,C57H72N12O9S,"InChI=1S/C57H72N12O9S/c1-10-49(71)62-43-28-44(64-56-59-20-19-42(63-56)41-32-68(8)45-14-12-11-13-40(41)45)48(76-9)29-46(43)67(7)23-22-66(6)33-50(72)58-21-24-77-25-26-78-34-51(73)65-53(57(3,4)5)55(75)69-31-39(70)27-47(69)54(74)60-30-37-15-17-38(18-16-37)52-36(2)61-35-79-52/h10-20,28-29,32,35,39,47,53,70H,1,21-27,30-31,33-34H2,2-9H3,(H,58,72)(H,60,74)(H,62,71)(H,65,73)(H,59,63,64)/t39-,47+,53-/m1/s1",VJOYYKYPRAJJHC-BRBZWKBWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2624,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1139.398,1138.55347633,82,9,6,18,C59H74N14O8S,"InChI=1S/C59H74N14O8S/c1-6-51(77)71-23-10-13-45(34-71)73-54-47(66-58(73)65-42-11-8-7-9-12-42)33-62-57(68-54)64-43-18-20-44(21-19-43)70-26-24-69(25-27-70)36-49(75)60-22-28-80-29-30-81-37-50(76)67-53(59(3,4)5)56(79)72-35-46(74)31-48(72)55(78)61-32-40-14-16-41(17-15-40)52-39(2)63-38-82-52/h6-9,11-12,14-21,33,38,45-46,48,53,74H,1,10,13,22-32,34-37H2,2-5H3,(H,60,75)(H,61,78)(H,65,66)(H,67,76)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",HTDTVBXASZKIHM-BCWDIVJWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2624,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1139.398,1138.55347633,82,9,6,18,C59H74N14O8S,"InChI=1S/C59H74N14O8S/c1-6-51(77)71-23-10-13-45(34-71)73-54-47(66-58(73)65-42-11-8-7-9-12-42)33-62-57(68-54)64-43-18-20-44(21-19-43)70-26-24-69(25-27-70)36-49(75)60-22-28-80-29-30-81-37-50(76)67-53(59(3,4)5)56(79)72-35-46(74)31-48(72)55(78)61-32-40-14-16-41(17-15-40)52-39(2)63-38-82-52/h6-9,11-12,14-21,33,38,45-46,48,53,74H,1,10,13,22-32,34-37H2,2-5H3,(H,60,75)(H,61,78)(H,65,66)(H,67,76)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",HTDTVBXASZKIHM-BCWDIVJWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1541,P00533,EGFR L858R/T790M,CRBN,O=C(COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCOCCOCCOCCNC(=O)CN1CCN(C2=CC=C(C3=CC=C4CN(C(C(=O)NC5=NC=CS5)C5=CC=CC=C5)C(=O)C4=C3)C=C2)CC1,,,1056.168,1055.38473926,76,9,4,16,C54H57N9O12S,"InChI=1S/C54H57N9O12S/c64-44-16-15-42(49(67)58-44)63-52(70)40-7-4-8-43(47(40)53(63)71)75-34-46(66)56-18-25-73-27-29-74-28-26-72-24-17-55-45(65)33-60-20-22-61(23-21-60)39-13-11-35(12-14-39)37-9-10-38-32-62(51(69)41(38)31-37)48(36-5-2-1-3-6-36)50(68)59-54-57-19-30-76-54/h1-14,19,30-31,42,48H,15-18,20-29,32-34H2,(H,55,65)(H,56,66)(H,57,59,68)(H,58,64,67)",SGYWRAOXWISULN-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,3189,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCOCCOCCOCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,765.195,764.237282696,54,6,3,12,C37H38ClFN6O9,"InChI=1S/C37H38ClFN6O9/c1-50-31-19-29-24(35(41-21-40-29)42-22-5-6-27(39)26(38)17-22)18-32(31)54-16-15-53-14-13-52-12-11-51-10-9-34(47)43-28-4-2-3-23-25(28)20-45(37(23)49)30-7-8-33(46)44-36(30)48/h2-6,17-19,21,30H,7-16,20H2,1H3,(H,43,47)(H,40,41,42)(H,44,46,48)",MDAGJVVQTFPEOF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1997,P00533,EGFR,CRBN,CN(CCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.07,898.460227576,66,9,4,15,C48H58N12O6,"InChI=1S/C48H58N12O6/c1-56(32-43(62)52-39-13-7-12-37-38(39)31-59(46(37)64)41-18-19-42(61)54-45(41)63)24-26-65-28-29-66-27-25-57-20-22-58(23-21-57)35-16-14-34(15-17-35)50-47-49-30-40-44(55-47)60(36-10-5-6-11-36)48(53-40)51-33-8-3-2-4-9-33/h2-4,7-9,12-17,30,36,41H,5-6,10-11,18-29,31-32H2,1H3,(H,51,53)(H,52,62)(H,49,50,55)(H,54,61,63)",WHRASSDAJIPBAF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1997,P00533,EGFR L858R/T790M,CRBN,CN(CCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.07,898.460227576,66,9,4,15,C48H58N12O6,"InChI=1S/C48H58N12O6/c1-56(32-43(62)52-39-13-7-12-37-38(39)31-59(46(37)64)41-18-19-42(61)54-45(41)63)24-26-65-28-29-66-27-25-57-20-22-58(23-21-57)35-16-14-34(15-17-35)50-47-49-30-40-44(55-47)60(36-10-5-6-11-36)48(53-40)51-33-8-3-2-4-9-33/h2-4,7-9,12-17,30,36,41H,5-6,10-11,18-29,31-32H2,1H3,(H,51,53)(H,52,62)(H,49,50,55)(H,54,61,63)",WHRASSDAJIPBAF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1997,P00533,EGFR e19d,CRBN,CN(CCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.07,898.460227576,66,9,4,15,C48H58N12O6,"InChI=1S/C48H58N12O6/c1-56(32-43(62)52-39-13-7-12-37-38(39)31-59(46(37)64)41-18-19-42(61)54-45(41)63)24-26-65-28-29-66-27-25-57-20-22-58(23-21-57)35-16-14-34(15-17-35)50-47-49-30-40-44(55-47)60(36-10-5-6-11-36)48(53-40)51-33-8-3-2-4-9-33/h2-4,7-9,12-17,30,36,41H,5-6,10-11,18-29,31-32H2,1H3,(H,51,53)(H,52,62)(H,49,50,55)(H,54,61,63)",WHRASSDAJIPBAF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1998,P00533,EGFR e19d,CRBN,CN(CCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,1.91,82,943.123,942.486442324,69,9,4,16,C50H62N12O7,"InChI=1S/C50H62N12O7/c1-58(34-45(64)54-41-13-7-12-39-40(41)33-61(48(39)66)43-18-19-44(63)56-47(43)65)24-26-67-28-30-69-31-29-68-27-25-59-20-22-60(23-21-59)37-16-14-36(15-17-37)52-49-51-32-42-46(57-49)62(38-10-5-6-11-38)50(55-42)53-35-8-3-2-4-9-35/h2-4,7-9,12-17,32,38,43H,5-6,10-11,18-31,33-34H2,1H3,(H,53,55)(H,54,64)(H,51,52,57)(H,56,63,65)",YTBOHZLAPNSENZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1998,P00533,EGFR,CRBN,CN(CCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,N.D.,943.123,942.486442324,69,9,4,16,C50H62N12O7,"InChI=1S/C50H62N12O7/c1-58(34-45(64)54-41-13-7-12-39-40(41)33-61(48(39)66)43-18-19-44(63)56-47(43)65)24-26-67-28-30-69-31-29-68-27-25-59-20-22-60(23-21-59)37-16-14-36(15-17-37)52-49-51-32-42-46(57-49)62(38-10-5-6-11-38)50(55-42)53-35-8-3-2-4-9-35/h2-4,7-9,12-17,32,38,43H,5-6,10-11,18-31,33-34H2,1H3,(H,53,55)(H,54,64)(H,51,52,57)(H,56,63,65)",YTBOHZLAPNSENZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1998,P00533,EGFR L858R/T790M,CRBN,CN(CCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,943.123,942.486442324,69,9,4,16,C50H62N12O7,"InChI=1S/C50H62N12O7/c1-58(34-45(64)54-41-13-7-12-39-40(41)33-61(48(39)66)43-18-19-44(63)56-47(43)65)24-26-67-28-30-69-31-29-68-27-25-59-20-22-60(23-21-59)37-16-14-36(15-17-37)52-49-51-32-42-46(57-49)62(38-10-5-6-11-38)50(55-42)53-35-8-3-2-4-9-35/h2-4,7-9,12-17,32,38,43H,5-6,10-11,18-31,33-34H2,1H3,(H,53,55)(H,54,64)(H,51,52,57)(H,56,63,65)",YTBOHZLAPNSENZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1999,P00533,EGFR,CRBN,CN(CCOCCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,987.176,986.512657072,72,9,4,17,C52H66N12O8,"InChI=1S/C52H66N12O8/c1-60(36-47(66)56-43-13-7-12-41-42(43)35-63(50(41)68)45-18-19-46(65)58-49(45)67)24-26-69-28-30-71-32-33-72-31-29-70-27-25-61-20-22-62(23-21-61)39-16-14-38(15-17-39)54-51-53-34-44-48(59-51)64(40-10-5-6-11-40)52(57-44)55-37-8-3-2-4-9-37/h2-4,7-9,12-17,34,40,45H,5-6,10-11,18-33,35-36H2,1H3,(H,55,57)(H,56,66)(H,53,54,59)(H,58,65,67)",YHKWJWJTXQMPOK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1999,P00533,EGFR L858R/T790M,CRBN,CN(CCOCCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,987.176,986.512657072,72,9,4,17,C52H66N12O8,"InChI=1S/C52H66N12O8/c1-60(36-47(66)56-43-13-7-12-41-42(43)35-63(50(41)68)45-18-19-46(65)58-49(45)67)24-26-69-28-30-71-32-33-72-31-29-70-27-25-61-20-22-62(23-21-61)39-16-14-38(15-17-39)54-51-53-34-44-48(59-51)64(40-10-5-6-11-40)52(57-44)55-37-8-3-2-4-9-37/h2-4,7-9,12-17,34,40,45H,5-6,10-11,18-33,35-36H2,1H3,(H,55,57)(H,56,66)(H,53,54,59)(H,58,65,67)",YHKWJWJTXQMPOK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,1999,P00533,EGFR e19d,CRBN,CN(CCOCCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,987.176,986.512657072,72,9,4,17,C52H66N12O8,"InChI=1S/C52H66N12O8/c1-60(36-47(66)56-43-13-7-12-41-42(43)35-63(50(41)68)45-18-19-46(65)58-49(45)67)24-26-69-28-30-71-32-33-72-31-29-70-27-25-61-20-22-62(23-21-61)39-16-14-38(15-17-39)54-51-53-34-44-48(59-51)64(40-10-5-6-11-40)52(57-44)55-37-8-3-2-4-9-37/h2-4,7-9,12-17,34,40,45H,5-6,10-11,18-33,35-36H2,1H3,(H,55,57)(H,56,66)(H,53,54,59)(H,58,65,67)",YHKWJWJTXQMPOK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5518,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,949.434,948.358460448,67,7,3,16,C46H54ClFN8O11,"InChI=1S/C46H54ClFN8O11/c1-62-39-28-37-34(43(51-29-50-37)52-31-4-6-36(48)35(47)26-31)27-40(39)67-16-2-11-54-12-14-55(15-13-54)42(58)9-17-63-19-21-65-23-24-66-22-20-64-18-10-49-30-3-5-32-33(25-30)46(61)56(45(32)60)38-7-8-41(57)53-44(38)59/h3-6,25-29,38,49H,2,7-24H2,1H3,(H,50,51,52)(H,53,57,59)",ZGONVRUBNDGAQY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5595,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,882.857,882.306092932,64,7,5,13,C43H41F3N10O8,"InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)",OBHMXNAEXVRWTQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5595,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,882.857,882.306092932,64,7,5,13,C43H41F3N10O8,"InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)",OBHMXNAEXVRWTQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5595,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,882.857,882.306092932,64,7,5,13,C43H41F3N10O8,"InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)",OBHMXNAEXVRWTQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5460,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,35.5,,822.927,822.360179192,61,7,4,12,C45H46N10O6,"InChI=1S/C45H46N10O6/c1-6-20-54(21-18-42(58)47-32-13-10-12-29-31(32)27-55(44(29)60)37-15-16-41(57)51-43(37)59)23-22-52(3)38-25-39(61-5)35(24-34(38)48-40(56)7-2)50-45-46-19-17-33(49-45)30-26-53(4)36-14-9-8-11-28(30)36/h1,7-14,17,19,24-26,37H,2,15-16,18,20-23,27H2,3-5H3,(H,47,58)(H,48,56)(H,46,49,50)(H,51,57,59)",XCZMVDGRCQBGPQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5461,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,13.2,,836.954,836.375829256,62,7,4,12,C46H48N10O6,"InChI=1S/C46H48N10O6/c1-6-21-55(22-11-16-42(58)48-33-14-10-13-30-32(33)28-56(45(30)61)38-17-18-43(59)52-44(38)60)24-23-53(3)39-26-40(62-5)36(25-35(39)49-41(57)7-2)51-46-47-20-19-34(50-46)31-27-54(4)37-15-9-8-12-29(31)37/h1,7-10,12-15,19-20,25-27,38H,2,11,16-18,21-24,28H2,3-5H3,(H,48,58)(H,49,57)(H,47,50,51)(H,52,59,60)",MTMBWVDGSVDKJC-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2404,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,948.457,947.364548872,68,8,4,14,C48H51ClFN11O7,"InChI=1S/C48H51ClFN11O7/c49-34-24-30(16-17-35(34)50)53-45-33-25-38(55-42(63)15-11-22-59-20-7-5-8-21-59)40(26-37(33)51-29-52-45)68-28-31-27-60(58-57-31)23-9-4-2-1-3-6-14-41(62)54-36-13-10-12-32-44(36)48(67)61(47(32)66)39-18-19-43(64)56-46(39)65/h10-13,15-17,24-27,29,39H,1-9,14,18-23,28H2,(H,54,62)(H,55,63)(H,51,52,53)(H,56,64,65)/b15-11+",PULWYZNNFMFWCK-RVDMUPIBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2406,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,976.511,975.395849,70,8,4,14,C50H55ClFN11O7,"InChI=1S/C50H55ClFN11O7/c51-36-26-32(18-19-37(36)52)55-47-35-27-40(57-44(65)17-13-24-61-22-9-7-10-23-61)42(28-39(35)53-31-54-47)70-30-33-29-62(60-59-33)25-11-6-4-2-1-3-5-8-16-43(64)56-38-15-12-14-34-46(38)50(69)63(49(34)68)41-20-21-45(66)58-48(41)67/h12-15,17-19,26-29,31,41H,1-11,16,20-25,30H2,(H,56,64)(H,57,65)(H,53,54,55)(H,58,66,67)/b17-13+",QSSBLKJKHHKWHN-GHRIWEEISA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2409,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCOCCOCCOCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,1070.533,1069.38607216,76,8,4,19,C51H57ClFN11O12,"InChI=1S/C51H57ClFN11O12/c52-37-26-33(9-10-38(37)53)56-48-36-27-41(58-44(65)8-5-15-62-13-2-1-3-14-62)43(28-40(36)54-32-55-48)76-30-34-29-63(61-60-34)16-17-71-18-19-72-20-21-73-22-23-74-24-25-75-31-46(67)57-39-7-4-6-35-47(39)51(70)64(50(35)69)42-11-12-45(66)59-49(42)68/h4-10,26-29,32,42H,1-3,11-25,30-31H2,(H,57,67)(H,58,65)(H,54,55,56)(H,59,66,68)/b8-5+",BPDICUFDYMBUFW-VMPITWQZSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2410,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1049.675,1048.4308546,74,8,5,15,C53H62ClFN12O6S,"InChI=1S/C53H62ClFN12O6S/c1-33-48(74-32-59-33)35-15-13-34(14-16-35)27-56-51(71)44-24-38(68)29-67(44)52(72)49(53(2,3)4)62-47(70)11-6-9-22-66-28-37(63-64-66)30-73-45-26-42-39(50(58-31-57-42)60-36-17-18-41(55)40(54)23-36)25-43(45)61-46(69)12-10-21-65-19-7-5-8-20-65/h10,12-18,23,25-26,28,31-32,38,44,49,68H,5-9,11,19-22,24,27,29-30H2,1-4H3,(H,56,71)(H,61,69)(H,62,70)(H,57,58,60)/b12-10+/t38-,44+,49-/m1/s1",GVYSMKFEIYRGRE-QFYOULDSSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2411,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,7.95,98,1091.756,1090.4778048,77,8,5,15,C56H68ClFN12O6S,"InChI=1S/C56H68ClFN12O6S/c1-36-51(77-35-62-36)38-18-16-37(17-19-38)30-59-54(74)47-27-41(71)32-70(47)55(75)52(56(2,3)4)65-50(73)14-9-6-5-7-12-25-69-31-40(66-67-69)33-76-48-29-45-42(53(61-34-60-45)63-39-20-21-44(58)43(57)26-39)28-46(48)64-49(72)15-13-24-68-22-10-8-11-23-68/h13,15-21,26,28-29,31,34-35,41,47,52,71H,5-12,14,22-25,27,30,32-33H2,1-4H3,(H,59,74)(H,64,72)(H,65,73)(H,60,61,63)/b15-13+/t41-,47+,52-/m1/s1",BUDQKNIUFHYJQZ-ABSCMPNGSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2412,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1105.783,1104.49345486,78,8,5,15,C57H70ClFN12O6S,"InChI=1S/C57H70ClFN12O6S/c1-37-52(78-36-63-37)39-19-17-38(18-20-39)31-60-55(75)48-28-42(72)33-71(48)56(76)53(57(2,3)4)66-51(74)15-10-7-5-6-8-13-26-70-32-41(67-68-70)34-77-49-30-46-43(54(62-35-61-46)64-40-21-22-45(59)44(58)27-40)29-47(49)65-50(73)16-14-25-69-23-11-9-12-24-69/h14,16-22,27,29-30,32,35-36,42,48,53,72H,5-13,15,23-26,28,31,33-34H2,1-4H3,(H,60,75)(H,65,73)(H,66,74)(H,61,62,64)/b16-14+/t42-,48+,53-/m1/s1",PFGSMDXDMXYRTC-SBVKIVAMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2413,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1119.81,1118.50910492,79,8,5,15,C58H72ClFN12O6S,"InChI=1S/C58H72ClFN12O6S/c1-38-53(79-37-64-38)40-20-18-39(19-21-40)32-61-56(76)49-29-43(73)34-72(49)57(77)54(58(2,3)4)67-52(75)16-11-8-6-5-7-9-14-27-71-33-42(68-69-71)35-78-50-31-47-44(55(63-36-62-47)65-41-22-23-46(60)45(59)28-41)30-48(50)66-51(74)17-15-26-70-24-12-10-13-25-70/h15,17-23,28,30-31,33,36-37,43,49,54,73H,5-14,16,24-27,29,32,34-35H2,1-4H3,(H,61,76)(H,66,74)(H,67,75)(H,62,63,65)/b17-15+/t43-,49+,54-/m1/s1",CCYWJYVSARIZBI-QRLVMSRCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2414,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,3.57,91,1133.837,1132.52475499,80,8,5,15,C59H74ClFN12O6S,"InChI=1S/C59H74ClFN12O6S/c1-39-54(80-38-65-39)41-21-19-40(20-22-41)33-62-57(77)50-30-44(74)35-73(50)58(78)55(59(2,3)4)68-53(76)17-12-9-7-5-6-8-10-15-28-72-34-43(69-70-72)36-79-51-32-48-45(56(64-37-63-48)66-42-23-24-47(61)46(60)29-42)31-49(51)67-52(75)18-16-27-71-25-13-11-14-26-71/h16,18-24,29,31-32,34,37-38,44,50,55,74H,5-15,17,25-28,30,33,35-36H2,1-4H3,(H,62,77)(H,67,75)(H,68,76)(H,63,64,66)/b18-16+/t44-,50+,55-/m1/s1",RBUUUIFZYMVDPT-DLMBMICPSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2415,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1095.7,1094.43633391,77,8,5,17,C54H64ClFN12O8S,"InChI=1S/C54H64ClFN12O8S/c1-34-49(77-33-60-34)36-12-10-35(11-13-36)27-57-52(72)45-24-39(69)29-68(45)53(73)50(54(2,3)4)63-48(71)31-75-22-21-74-20-19-67-28-38(64-65-67)30-76-46-26-43-40(51(59-32-58-43)61-37-14-15-42(56)41(55)23-37)25-44(46)62-47(70)9-8-18-66-16-6-5-7-17-66/h8-15,23,25-26,28,32-33,39,45,50,69H,5-7,16-22,24,27,29-31H2,1-4H3,(H,57,72)(H,62,70)(H,63,71)(H,58,59,61)/b9-8+/t39-,45+,50-/m1/s1",ZBDSGNZFIXZXPY-BAKNNEFNSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2416,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1227.859,1226.51497815,86,8,5,20,C60H76ClFN12O11S,"InChI=1S/C60H76ClFN12O11S/c1-40-55(86-39-66-40)42-12-10-41(11-13-42)33-63-58(78)51-30-45(75)35-74(51)59(79)56(60(2,3)4)69-54(77)37-84-28-27-83-26-25-82-24-23-81-22-21-80-20-19-73-34-44(70-71-73)36-85-52-32-49-46(57(65-38-64-49)67-43-14-15-48(62)47(61)29-43)31-50(52)68-53(76)9-8-18-72-16-6-5-7-17-72/h8-15,29,31-32,34,38-39,45,51,56,75H,5-7,16-28,30,33,35-37H2,1-4H3,(H,63,78)(H,68,76)(H,69,77)(H,64,65,67)/b9-8+/t45-,51+,56-/m1/s1",XPPPWNIOTVFKQS-ONKWTBNWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2417,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,N.D.,1139.753,1138.46254866,80,8,5,18,C56H68ClFN12O9S,"InChI=1S/C56H68ClFN12O9S/c1-36-51(80-35-62-36)38-12-10-37(11-13-38)29-59-54(74)47-26-41(71)31-70(47)55(75)52(56(2,3)4)65-50(73)33-78-24-23-77-22-21-76-20-19-69-30-40(66-67-69)32-79-48-28-45-42(53(61-34-60-45)63-39-14-15-44(58)43(57)25-39)27-46(48)64-49(72)9-8-18-68-16-6-5-7-17-68/h8-15,25,27-28,30,34-35,41,47,52,71H,5-7,16-24,26,29,31-33H2,1-4H3,(H,59,74)(H,64,72)(H,65,73)(H,60,61,63)/b9-8+/t41-,47+,52-/m1/s1",VQDITZKUBYFBHD-MUHNYSBJSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2418,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCN3C=C(CCCCCOC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,36.51,,1151.808,1150.49893416,81,8,5,17,C58H72ClFN12O8S,"InChI=1S/C58H72ClFN12O8S/c1-38-53(81-37-64-38)40-16-14-39(15-17-40)32-61-56(76)49-29-43(73)34-72(49)57(77)54(58(2,3)4)67-52(75)35-79-27-26-78-25-23-71-33-42(68-69-71)12-7-5-10-24-80-50-31-47-44(55(63-36-62-47)65-41-18-19-46(60)45(59)28-41)30-48(50)66-51(74)13-11-22-70-20-8-6-9-21-70/h11,13-19,28,30-31,33,36-37,43,49,54,73H,5-10,12,20-27,29,32,34-35H2,1-4H3,(H,61,76)(H,66,74)(H,67,75)(H,62,63,65)/b13-11+/t43-,49+,54-/m1/s1",PXQHEFZTJMGFAP-QLJGRUAOSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2605,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1126.443,1125.59461287,81,7,5,16,C60H79N13O7S,"InChI=1S/C60H79N13O7S/c1-39-55(81-38-63-39)41-23-21-40(22-24-41)35-62-57(78)50-32-42(74)36-73(50)58(79)56(60(2,3)4)67-53(76)18-14-20-54(77)71(9)31-29-69(7)27-15-19-52(75)64-46-33-47(51(80-11)34-49(46)70(8)30-28-68(5)6)66-59-61-26-25-45(65-59)44-37-72(10)48-17-13-12-16-43(44)48/h12-13,15-17,19,21-26,33-34,37-38,42,50,56,74H,14,18,20,27-32,35-36H2,1-11H3,(H,62,78)(H,64,75)(H,67,76)(H,61,65,66)/b19-15+/t42-,50+,56-/m1/s1",NLHHAISQIXLYLK-GYTYBLAQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2605,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1126.443,1125.59461287,81,7,5,16,C60H79N13O7S,"InChI=1S/C60H79N13O7S/c1-39-55(81-38-63-39)41-23-21-40(22-24-41)35-62-57(78)50-32-42(74)36-73(50)58(79)56(60(2,3)4)67-53(76)18-14-20-54(77)71(9)31-29-69(7)27-15-19-52(75)64-46-33-47(51(80-11)34-49(46)70(8)30-28-68(5)6)66-59-61-26-25-45(65-59)44-37-72(10)48-17-13-12-16-43(44)48/h12-13,15-17,19,21-26,33-34,37-38,42,50,56,74H,14,18,20,27-32,35-36H2,1-11H3,(H,62,78)(H,64,75)(H,67,76)(H,61,65,66)/b19-15+/t42-,50+,56-/m1/s1",NLHHAISQIXLYLK-GYTYBLAQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2606,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1154.497,1153.625913,83,7,5,16,C62H83N13O7S,"InChI=1S/C62H83N13O7S/c1-41-57(83-40-65-41)43-25-23-42(24-26-43)37-64-59(80)52-34-44(76)38-75(52)60(81)58(62(2,3)4)69-55(78)20-13-12-14-22-56(79)73(9)33-31-71(7)29-17-21-54(77)66-48-35-49(53(82-11)36-51(48)72(8)32-30-70(5)6)68-61-63-28-27-47(67-61)46-39-74(10)50-19-16-15-18-45(46)50/h15-19,21,23-28,35-36,39-40,44,52,58,76H,12-14,20,22,29-34,37-38H2,1-11H3,(H,64,80)(H,66,77)(H,69,78)(H,63,67,68)/b21-17+/t44-,52+,58-/m1/s1",AUDHLQVDQXAEMW-FUPPDTOQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2606,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1154.497,1153.625913,83,7,5,16,C62H83N13O7S,"InChI=1S/C62H83N13O7S/c1-41-57(83-40-65-41)43-25-23-42(24-26-43)37-64-59(80)52-34-44(76)38-75(52)60(81)58(62(2,3)4)69-55(78)20-13-12-14-22-56(79)73(9)33-31-71(7)29-17-21-54(77)66-48-35-49(53(82-11)36-51(48)72(8)32-30-70(5)6)68-61-63-28-27-47(67-61)46-39-74(10)50-19-16-15-18-45(46)50/h15-19,21,23-28,35-36,39-40,44,52,58,76H,12-14,20,22,29-34,37-38H2,1-11H3,(H,64,80)(H,66,77)(H,69,78)(H,63,67,68)/b21-17+/t44-,52+,58-/m1/s1",AUDHLQVDQXAEMW-FUPPDTOQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2607,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1168.524,1167.64156306,84,7,5,16,C63H85N13O7S,"InChI=1S/C63H85N13O7S/c1-42-58(84-41-66-42)44-26-24-43(25-27-44)38-65-60(81)53-35-45(77)39-76(53)61(82)59(63(2,3)4)70-56(79)21-14-12-13-15-23-57(80)74(9)34-32-72(7)30-18-22-55(78)67-49-36-50(54(83-11)37-52(49)73(8)33-31-71(5)6)69-62-64-29-28-48(68-62)47-40-75(10)51-20-17-16-19-46(47)51/h16-20,22,24-29,36-37,40-41,45,53,59,77H,12-15,21,23,30-35,38-39H2,1-11H3,(H,65,81)(H,67,78)(H,70,79)(H,64,68,69)/b22-18+/t45-,53+,59-/m1/s1",BHWDRQOZBAXOIL-YABATYFBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2607,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1168.524,1167.64156306,84,7,5,16,C63H85N13O7S,"InChI=1S/C63H85N13O7S/c1-42-58(84-41-66-42)44-26-24-43(25-27-44)38-65-60(81)53-35-45(77)39-76(53)61(82)59(63(2,3)4)70-56(79)21-14-12-13-15-23-57(80)74(9)34-32-72(7)30-18-22-55(78)67-49-36-50(54(83-11)37-52(49)73(8)33-31-71(5)6)69-62-64-29-28-48(68-62)47-40-75(10)51-20-17-16-19-46(47)51/h16-20,22,24-29,36-37,40-41,45,53,59,77H,12-15,21,23,30-35,38-39H2,1-11H3,(H,65,81)(H,67,78)(H,70,79)(H,64,68,69)/b22-18+/t45-,53+,59-/m1/s1",BHWDRQOZBAXOIL-YABATYFBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2608,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1097.445,1096.60444928,79,7,5,15,C60H80N12O6S,"InChI=1S/C60H80N12O6S/c1-40-55(79-39-63-40)42-25-23-41(24-26-42)36-62-57(76)51-33-43(73)37-72(51)58(77)56(60(2,3)4)67-54(75)21-14-12-11-13-17-29-69(7)30-18-22-53(74)64-47-34-48(52(78-10)35-50(47)70(8)32-31-68(5)6)66-59-61-28-27-46(65-59)45-38-71(9)49-20-16-15-19-44(45)49/h15-16,18-20,22-28,34-35,38-39,43,51,56,73H,11-14,17,21,29-33,36-37H2,1-10H3,(H,62,76)(H,64,74)(H,67,75)(H,61,65,66)/b22-18+/t43-,51+,56-/m1/s1",UOILNJUDFXJYIX-NQQHQXCWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2608,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1097.445,1096.60444928,79,7,5,15,C60H80N12O6S,"InChI=1S/C60H80N12O6S/c1-40-55(79-39-63-40)42-25-23-41(24-26-42)36-62-57(76)51-33-43(73)37-72(51)58(77)56(60(2,3)4)67-54(75)21-14-12-11-13-17-29-69(7)30-18-22-53(74)64-47-34-48(52(78-10)35-50(47)70(8)32-31-68(5)6)66-59-61-28-27-46(65-59)45-38-71(9)49-20-16-15-19-44(45)49/h15-16,18-20,22-28,34-35,38-39,43,51,56,73H,11-14,17,21,29-33,36-37H2,1-10H3,(H,62,76)(H,64,74)(H,67,75)(H,61,65,66)/b22-18+/t43-,51+,56-/m1/s1",UOILNJUDFXJYIX-NQQHQXCWSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2609,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1125.499,1124.63574941,81,7,5,15,C62H84N12O6S,"InChI=1S/C62H84N12O6S/c1-42-57(81-41-65-42)44-27-25-43(26-28-44)38-64-59(78)53-35-45(75)39-74(53)60(79)58(62(2,3)4)69-56(77)23-16-14-12-11-13-15-19-31-71(7)32-20-24-55(76)66-49-36-50(54(80-10)37-52(49)72(8)34-33-70(5)6)68-61-63-30-29-48(67-61)47-40-73(9)51-22-18-17-21-46(47)51/h17-18,20-22,24-30,36-37,40-41,45,53,58,75H,11-16,19,23,31-35,38-39H2,1-10H3,(H,64,78)(H,66,76)(H,69,77)(H,63,67,68)/b24-20+/t45-,53+,58-/m1/s1",BDPJWTWTFREFOU-HAZLKTSUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2609,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1125.499,1124.63574941,81,7,5,15,C62H84N12O6S,"InChI=1S/C62H84N12O6S/c1-42-57(81-41-65-42)44-27-25-43(26-28-44)38-64-59(78)53-35-45(75)39-74(53)60(79)58(62(2,3)4)69-56(77)23-16-14-12-11-13-15-19-31-71(7)32-20-24-55(76)66-49-36-50(54(80-10)37-52(49)72(8)34-33-70(5)6)68-61-63-30-29-48(67-61)47-40-73(9)51-22-18-17-21-46(47)51/h17-18,20-22,24-30,36-37,40-41,45,53,58,75H,11-16,19,23,31-35,38-39H2,1-10H3,(H,64,78)(H,66,76)(H,69,77)(H,63,67,68)/b24-20+/t45-,53+,58-/m1/s1",BDPJWTWTFREFOU-HAZLKTSUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2611,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1171.48,1170.6048432,84,7,6,17,C62H82N12O9S,"InChI=1S/C62H82N12O9S/c1-10-54(76)67-48-34-49(69-61-64-25-24-47(68-61)46-38-72(8)50-18-15-14-17-45(46)50)53(81-9)35-51(48)73(29-28-71(6)7)27-16-12-11-13-19-55(77)63-26-30-82-31-32-83-39-56(78)70-58(62(3,4)5)60(80)74-37-44(75)33-52(74)59(79)65-36-42-20-22-43(23-21-42)57-41(2)66-40-84-57/h10,14-15,17-18,20-25,34-35,38,40,44,52,58,75H,1,11-13,16,19,26-33,36-37,39H2,2-9H3,(H,63,77)(H,65,79)(H,67,76)(H,70,78)(H,64,68,69)/t44-,52+,58-/m1/s1",ALUNGNVSILUROK-WZWSVSESSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2611,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1171.48,1170.6048432,84,7,6,17,C62H82N12O9S,"InChI=1S/C62H82N12O9S/c1-10-54(76)67-48-34-49(69-61-64-25-24-47(68-61)46-38-72(8)50-18-15-14-17-45(46)50)53(81-9)35-51(48)73(29-28-71(6)7)27-16-12-11-13-19-55(77)63-26-30-82-31-32-83-39-56(78)70-58(62(3,4)5)60(80)74-37-44(75)33-52(74)59(79)65-36-42-20-22-43(23-21-42)57-41(2)66-40-84-57/h10,14-15,17-18,20-25,34-35,38,40,44,52,58,75H,1,11-13,16,19,26-33,36-37,39H2,2-9H3,(H,63,77)(H,65,79)(H,67,76)(H,70,78)(H,64,68,69)/t44-,52+,58-/m1/s1",ALUNGNVSILUROK-WZWSVSESSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2612,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1153.509,1152.63066403,83,7,6,15,C63H84N12O7S,"InChI=1S/C63H84N12O7S/c1-10-55(77)68-49-36-50(70-62-65-31-29-48(69-62)47-40-73(8)51-22-18-17-21-46(47)51)54(82-9)37-52(49)74(34-33-72(6)7)32-20-14-12-15-23-56(78)64-30-19-13-11-16-24-57(79)71-59(63(3,4)5)61(81)75-39-45(76)35-53(75)60(80)66-38-43-25-27-44(28-26-43)58-42(2)67-41-83-58/h10,17-18,21-22,25-29,31,36-37,40-41,45,53,59,76H,1,11-16,19-20,23-24,30,32-35,38-39H2,2-9H3,(H,64,78)(H,66,80)(H,68,77)(H,71,79)(H,65,69,70)/t45-,53+,59-/m1/s1",UWPKPQXGEGLODQ-BDMCWMSBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2612,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1153.509,1152.63066403,83,7,6,15,C63H84N12O7S,"InChI=1S/C63H84N12O7S/c1-10-55(77)68-49-36-50(70-62-65-31-29-48(69-62)47-40-73(8)51-22-18-17-21-46(47)51)54(82-9)37-52(49)74(34-33-72(6)7)32-20-14-12-15-23-56(78)64-30-19-13-11-16-24-57(79)71-59(63(3,4)5)61(81)75-39-45(76)35-53(75)60(80)66-38-43-25-27-44(28-26-43)58-42(2)67-41-83-58/h10,17-18,21-22,25-29,31,36-37,40-41,45,53,59,76H,1,11-16,19-20,23-24,30,32-35,38-39H2,2-9H3,(H,64,78)(H,66,80)(H,68,77)(H,71,79)(H,65,69,70)/t45-,53+,59-/m1/s1",UWPKPQXGEGLODQ-BDMCWMSBSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2617,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(C)CC2)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1134.422,1133.56331274,82,8,6,16,C61H75N13O7S,"InChI=1S/C61H75N13O7S/c1-38-54(82-37-65-38)40-21-19-39(20-22-40)34-64-57(79)50-29-42(75)35-74(50)58(80)55(60(2,3)4)69-52(76)17-11-10-12-18-53(77)70-61(5,6)32-41(33-62)56(78)66-46-30-47(51(81-9)31-49(46)73-27-25-71(7)26-28-73)68-59-63-24-23-45(67-59)44-36-72(8)48-16-14-13-15-43(44)48/h13-16,19-24,30-32,36-37,42,50,55,75H,10-12,17-18,25-29,34-35H2,1-9H3,(H,64,79)(H,66,78)(H,69,76)(H,70,77)(H,63,67,68)/b41-32+/t42-,50+,55-/m1/s1",QDRZFVWTDVQLLE-SSYYUHPMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2617,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(C)CC2)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1134.422,1133.56331274,82,8,6,16,C61H75N13O7S,"InChI=1S/C61H75N13O7S/c1-38-54(82-37-65-38)40-21-19-39(20-22-40)34-64-57(79)50-29-42(75)35-74(50)58(80)55(60(2,3)4)69-52(76)17-11-10-12-18-53(77)70-61(5,6)32-41(33-62)56(78)66-46-30-47(51(81-9)31-49(46)73-27-25-71(7)26-28-73)68-59-63-24-23-45(67-59)44-36-72(8)48-16-14-13-15-43(44)48/h13-16,19-24,30-32,36-37,42,50,55,75H,10-12,17-18,25-29,34-35H2,1-9H3,(H,64,79)(H,66,78)(H,69,76)(H,70,77)(H,63,67,68)/b41-32+/t42-,50+,55-/m1/s1",QDRZFVWTDVQLLE-SSYYUHPMSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2618,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1150.465,1149.59461287,83,7,6,16,C62H79N13O7S,"InChI=1S/C62H79N13O7S/c1-39-55(83-38-66-39)41-24-22-40(23-25-41)35-65-58(80)51-30-43(76)36-75(51)59(81)56(61(2,3)4)70-53(77)20-14-12-13-15-21-54(78)71-62(5,6)33-42(34-63)57(79)67-47-31-48(52(82-11)32-50(47)73(9)29-28-72(7)8)69-60-64-27-26-46(68-60)45-37-74(10)49-19-17-16-18-44(45)49/h16-19,22-27,31-33,37-38,43,51,56,76H,12-15,20-21,28-30,35-36H2,1-11H3,(H,65,80)(H,67,79)(H,70,77)(H,71,78)(H,64,68,69)/b42-33+/t43-,51+,56-/m1/s1",PLSIZPKPMOPGBN-MGAZKENVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,2618,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1150.465,1149.59461287,83,7,6,16,C62H79N13O7S,"InChI=1S/C62H79N13O7S/c1-39-55(83-38-66-39)41-24-22-40(23-25-41)35-65-58(80)51-30-43(76)36-75(51)59(81)56(61(2,3)4)70-53(77)20-14-12-13-15-21-54(78)71-62(5,6)33-42(34-63)57(79)67-47-31-48(52(82-11)32-50(47)73(9)29-28-72(7)8)69-60-64-27-26-46(68-60)45-37-74(10)49-19-17-16-18-44(45)49/h16-19,22-27,31-33,37-38,43,51,56,76H,12-15,20-21,28-30,35-36H2,1-11H3,(H,65,80)(H,67,79)(H,70,77)(H,71,78)(H,64,68,69)/b42-33+/t43-,51+,56-/m1/s1",PLSIZPKPMOPGBN-MGAZKENVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5598,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,924.938,924.353043124,67,7,5,13,C46H47F3N10O8,"InChI=1S/C46H47F3N10O8/c1-3-36(60)51-27-10-8-11-28(24-27)52-41-31(46(47,48)49)26-50-45(56-41)54-32-17-16-29(25-35(32)67-2)57-20-22-58(23-21-57)39(63)15-7-5-4-6-14-37(61)53-33-13-9-12-30-40(33)44(66)59(43(30)65)34-18-19-38(62)55-42(34)64/h3,8-13,16-17,24-26,34H,1,4-7,14-15,18-23H2,2H3,(H,51,60)(H,53,61)(H,55,62,64)(H2,50,52,54,56)",OIMOWCZKWKGTPW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5598,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,924.938,924.353043124,67,7,5,13,C46H47F3N10O8,"InChI=1S/C46H47F3N10O8/c1-3-36(60)51-27-10-8-11-28(24-27)52-41-31(46(47,48)49)26-50-45(56-41)54-32-17-16-29(25-35(32)67-2)57-20-22-58(23-21-57)39(63)15-7-5-4-6-14-37(61)53-33-13-9-12-30-40(33)44(66)59(43(30)65)34-18-19-38(62)55-42(34)64/h3,8-13,16-17,24-26,34H,1,4-7,14-15,18-23H2,2H3,(H,51,60)(H,53,61)(H,55,62,64)(H2,50,52,54,56)",OIMOWCZKWKGTPW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5598,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,924.938,924.353043124,67,7,5,13,C46H47F3N10O8,"InChI=1S/C46H47F3N10O8/c1-3-36(60)51-27-10-8-11-28(24-27)52-41-31(46(47,48)49)26-50-45(56-41)54-32-17-16-29(25-35(32)67-2)57-20-22-58(23-21-57)39(63)15-7-5-4-6-14-37(61)53-33-13-9-12-30-40(33)44(66)59(43(30)65)34-18-19-38(62)55-42(34)64/h3,8-13,16-17,24-26,34H,1,4-7,14-15,18-23H2,2H3,(H,51,60)(H,53,61)(H,55,62,64)(H2,50,52,54,56)",OIMOWCZKWKGTPW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5597,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,910.911,910.33739306,66,7,5,13,C45H45F3N10O8,"InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)",KJJWOVIQRJNQJI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5597,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,910.911,910.33739306,66,7,5,13,C45H45F3N10O8,"InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)",KJJWOVIQRJNQJI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5597,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,910.911,910.33739306,66,7,5,13,C45H45F3N10O8,"InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)",KJJWOVIQRJNQJI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5599,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,938.965,938.368693188,68,7,5,13,C47H49F3N10O8,"InChI=1S/C47H49F3N10O8/c1-3-37(61)52-28-11-9-12-29(25-28)53-42-32(47(48,49)50)27-51-46(57-42)55-33-18-17-30(26-36(33)68-2)58-21-23-59(24-22-58)40(64)16-8-6-4-5-7-15-38(62)54-34-14-10-13-31-41(34)45(67)60(44(31)66)35-19-20-39(63)56-43(35)65/h3,9-14,17-18,25-27,35H,1,4-8,15-16,19-24H2,2H3,(H,52,61)(H,54,62)(H,56,63,65)(H2,51,53,55,57)",XOIIYPQWBHJYDK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5599,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,938.965,938.368693188,68,7,5,13,C47H49F3N10O8,"InChI=1S/C47H49F3N10O8/c1-3-37(61)52-28-11-9-12-29(25-28)53-42-32(47(48,49)50)27-51-46(57-42)55-33-18-17-30(26-36(33)68-2)58-21-23-59(24-22-58)40(64)16-8-6-4-5-7-15-38(62)54-34-14-10-13-31-41(34)45(67)60(44(31)66)35-19-20-39(63)56-43(35)65/h3,9-14,17-18,25-27,35H,1,4-8,15-16,19-24H2,2H3,(H,52,61)(H,54,62)(H,56,63,65)(H2,51,53,55,57)",XOIIYPQWBHJYDK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5599,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,938.965,938.368693188,68,7,5,13,C47H49F3N10O8,"InChI=1S/C47H49F3N10O8/c1-3-37(61)52-28-11-9-12-29(25-28)53-42-32(47(48,49)50)27-51-46(57-42)55-33-18-17-30(26-36(33)68-2)58-21-23-59(24-22-58)40(64)16-8-6-4-5-7-15-38(62)54-34-14-10-13-31-41(34)45(67)60(44(31)66)35-19-20-39(63)56-43(35)65/h3,9-14,17-18,25-27,35H,1,4-8,15-16,19-24H2,2H3,(H,52,61)(H,54,62)(H,56,63,65)(H2,51,53,55,57)",XOIIYPQWBHJYDK-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5601,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,967.019,966.399993316,70,7,5,13,C49H53F3N10O8,"InChI=1S/C49H53F3N10O8/c1-3-39(63)54-30-13-11-14-31(27-30)55-44-34(49(50,51)52)29-53-48(59-44)57-35-20-19-32(28-38(35)70-2)60-23-25-61(26-24-60)42(66)18-10-8-6-4-5-7-9-17-40(64)56-36-16-12-15-33-43(36)47(69)62(46(33)68)37-21-22-41(65)58-45(37)67/h3,11-16,19-20,27-29,37H,1,4-10,17-18,21-26H2,2H3,(H,54,63)(H,56,64)(H,58,65,67)(H2,53,55,57,59)",JZUFFCADCUCQSB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5601,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,967.019,966.399993316,70,7,5,13,C49H53F3N10O8,"InChI=1S/C49H53F3N10O8/c1-3-39(63)54-30-13-11-14-31(27-30)55-44-34(49(50,51)52)29-53-48(59-44)57-35-20-19-32(28-38(35)70-2)60-23-25-61(26-24-60)42(66)18-10-8-6-4-5-7-9-17-40(64)56-36-16-12-15-33-43(36)47(69)62(46(33)68)37-21-22-41(65)58-45(37)67/h3,11-16,19-20,27-29,37H,1,4-10,17-18,21-26H2,2H3,(H,54,63)(H,56,64)(H,58,65,67)(H2,53,55,57,59)",JZUFFCADCUCQSB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5601,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,967.019,966.399993316,70,7,5,13,C49H53F3N10O8,"InChI=1S/C49H53F3N10O8/c1-3-39(63)54-30-13-11-14-31(27-30)55-44-34(49(50,51)52)29-53-48(59-44)57-35-20-19-32(28-38(35)70-2)60-23-25-61(26-24-60)42(66)18-10-8-6-4-5-7-9-17-40(64)56-36-16-12-15-33-43(36)47(69)62(46(33)68)37-21-22-41(65)58-45(37)67/h3,11-16,19-20,27-29,37H,1,4-10,17-18,21-26H2,2H3,(H,54,63)(H,56,64)(H,58,65,67)(H2,53,55,57,59)",JZUFFCADCUCQSB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5466,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,907.089,906.454079576,67,7,4,12,C51H58N10O6,"InChI=1S/C51H58N10O6/c1-6-26-60(27-15-11-9-8-10-12-21-47(63)53-38-19-16-18-35-37(38)33-61(50(35)66)43-22-23-48(64)57-49(43)65)29-28-58(3)44-31-45(67-5)41(30-40(44)54-46(62)7-2)56-51-52-25-24-39(55-51)36-32-59(4)42-20-14-13-17-34(36)42/h1,7,13-14,16-20,24-25,30-32,43H,2,8-12,15,21-23,26-29,33H2,3-5H3,(H,53,63)(H,54,62)(H,52,55,56)(H,57,64,65)",CCUICSXOBZZNLW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5508,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,759.195,758.237951392,54,7,3,12,C37H36ClFN8O7,"InChI=1S/C37H36ClFN8O7/c1-53-30-18-28-25(34(42-20-41-28)43-22-4-6-27(39)26(38)16-22)17-31(30)54-14-2-9-45-10-12-46(13-11-45)33(49)19-40-21-3-5-23-24(15-21)37(52)47(36(23)51)29-7-8-32(48)44-35(29)50/h3-6,15-18,20,29,40H,2,7-14,19H2,1H3,(H,41,42,43)(H,44,48,50)",RPZBAXUTGSETGB-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5605,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,926.914,926.34354106,67,7,7,15,C44H45F3N12O8,"InChI=1S/C44H45F3N12O8/c1-3-34(60)52-25-6-4-7-26(20-25)53-39-29(44(45,46)47)22-51-43(56-39)54-30-11-10-27(21-33(30)67-2)58-18-16-57(17-19-58)24-37(63)49-15-14-48-36(62)23-50-31-9-5-8-28-38(31)42(66)59(41(28)65)32-12-13-35(61)55-40(32)64/h3-11,20-22,32,50H,1,12-19,23-24H2,2H3,(H,48,62)(H,49,63)(H,52,60)(H,55,61,64)(H2,51,53,54,56)",QGOXHILUCXTQLL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5605,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,926.914,926.34354106,67,7,7,15,C44H45F3N12O8,"InChI=1S/C44H45F3N12O8/c1-3-34(60)52-25-6-4-7-26(20-25)53-39-29(44(45,46)47)22-51-43(56-39)54-30-11-10-27(21-33(30)67-2)58-18-16-57(17-19-58)24-37(63)49-15-14-48-36(62)23-50-31-9-5-8-28-38(31)42(66)59(41(28)65)32-12-13-35(61)55-40(32)64/h3-11,20-22,32,50H,1,12-19,23-24H2,2H3,(H,48,62)(H,49,63)(H,52,60)(H,55,61,64)(H2,51,53,54,56)",QGOXHILUCXTQLL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5605,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,926.914,926.34354106,67,7,7,15,C44H45F3N12O8,"InChI=1S/C44H45F3N12O8/c1-3-34(60)52-25-6-4-7-26(20-25)53-39-29(44(45,46)47)22-51-43(56-39)54-30-11-10-27(21-33(30)67-2)58-18-16-57(17-19-58)24-37(63)49-15-14-48-36(62)23-50-31-9-5-8-28-38(31)42(66)59(41(28)65)32-12-13-35(61)55-40(32)64/h3-11,20-22,32,50H,1,12-19,23-24H2,2H3,(H,48,62)(H,49,63)(H,52,60)(H,55,61,64)(H2,51,53,54,56)",QGOXHILUCXTQLL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5606,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,940.941,940.359191124,68,7,7,15,C45H47F3N12O8,"InChI=1S/C45H47F3N12O8/c1-3-35(61)53-26-7-4-8-27(21-26)54-40-30(45(46,47)48)23-52-44(57-40)55-31-12-11-28(22-34(31)68-2)59-19-17-58(18-20-59)25-38(64)50-16-6-15-49-37(63)24-51-32-10-5-9-29-39(32)43(67)60(42(29)66)33-13-14-36(62)56-41(33)65/h3-5,7-12,21-23,33,51H,1,6,13-20,24-25H2,2H3,(H,49,63)(H,50,64)(H,53,61)(H,56,62,65)(H2,52,54,55,57)",OOPUCXGRCZJBPY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5606,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,940.941,940.359191124,68,7,7,15,C45H47F3N12O8,"InChI=1S/C45H47F3N12O8/c1-3-35(61)53-26-7-4-8-27(21-26)54-40-30(45(46,47)48)23-52-44(57-40)55-31-12-11-28(22-34(31)68-2)59-19-17-58(18-20-59)25-38(64)50-16-6-15-49-37(63)24-51-32-10-5-9-29-39(32)43(67)60(42(29)66)33-13-14-36(62)56-41(33)65/h3-5,7-12,21-23,33,51H,1,6,13-20,24-25H2,2H3,(H,49,63)(H,50,64)(H,53,61)(H,56,62,65)(H2,52,54,55,57)",OOPUCXGRCZJBPY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5606,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,940.941,940.359191124,68,7,7,15,C45H47F3N12O8,"InChI=1S/C45H47F3N12O8/c1-3-35(61)53-26-7-4-8-27(21-26)54-40-30(45(46,47)48)23-52-44(57-40)55-31-12-11-28(22-34(31)68-2)59-19-17-58(18-20-59)25-38(64)50-16-6-15-49-37(63)24-51-32-10-5-9-29-39(32)43(67)60(42(29)66)33-13-14-36(62)56-41(33)65/h3-5,7-12,21-23,33,51H,1,6,13-20,24-25H2,2H3,(H,49,63)(H,50,64)(H,53,61)(H,56,62,65)(H2,52,54,55,57)",OOPUCXGRCZJBPY-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5607,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,954.968,954.374841188,69,7,7,15,C46H49F3N12O8,"InChI=1S/C46H49F3N12O8/c1-3-36(62)54-27-8-6-9-28(22-27)55-41-31(46(47,48)49)24-53-45(58-41)56-32-13-12-29(23-35(32)69-2)60-20-18-59(19-21-60)26-39(65)51-17-5-4-16-50-38(64)25-52-33-11-7-10-30-40(33)44(68)61(43(30)67)34-14-15-37(63)57-42(34)66/h3,6-13,22-24,34,52H,1,4-5,14-21,25-26H2,2H3,(H,50,64)(H,51,65)(H,54,62)(H,57,63,66)(H2,53,55,56,58)",ODSWBKRWMXTEAF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5607,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,954.968,954.374841188,69,7,7,15,C46H49F3N12O8,"InChI=1S/C46H49F3N12O8/c1-3-36(62)54-27-8-6-9-28(22-27)55-41-31(46(47,48)49)24-53-45(58-41)56-32-13-12-29(23-35(32)69-2)60-20-18-59(19-21-60)26-39(65)51-17-5-4-16-50-38(64)25-52-33-11-7-10-30-40(33)44(68)61(43(30)67)34-14-15-37(63)57-42(34)66/h3,6-13,22-24,34,52H,1,4-5,14-21,25-26H2,2H3,(H,50,64)(H,51,65)(H,54,62)(H,57,63,66)(H2,53,55,56,58)",ODSWBKRWMXTEAF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5607,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,954.968,954.374841188,69,7,7,15,C46H49F3N12O8,"InChI=1S/C46H49F3N12O8/c1-3-36(62)54-27-8-6-9-28(22-27)55-41-31(46(47,48)49)24-53-45(58-41)56-32-13-12-29(23-35(32)69-2)60-20-18-59(19-21-60)26-39(65)51-17-5-4-16-50-38(64)25-52-33-11-7-10-30-40(33)44(68)61(43(30)67)34-14-15-37(63)57-42(34)66/h3,6-13,22-24,34,52H,1,4-5,14-21,25-26H2,2H3,(H,50,64)(H,51,65)(H,54,62)(H,57,63,66)(H2,53,55,56,58)",ODSWBKRWMXTEAF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5609,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,983.022,982.406141316,71,7,7,15,C48H53F3N12O8,"InChI=1S/C48H53F3N12O8/c1-3-38(64)56-29-10-8-11-30(24-29)57-43-33(48(49,50)51)26-55-47(60-43)58-34-15-14-31(25-37(34)71-2)62-22-20-61(21-23-62)28-41(67)53-19-7-5-4-6-18-52-40(66)27-54-35-13-9-12-32-42(35)46(70)63(45(32)69)36-16-17-39(65)59-44(36)68/h3,8-15,24-26,36,54H,1,4-7,16-23,27-28H2,2H3,(H,52,66)(H,53,67)(H,56,64)(H,59,65,68)(H2,55,57,58,60)",VAYZYSLFDFSAJT-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5609,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,983.022,982.406141316,71,7,7,15,C48H53F3N12O8,"InChI=1S/C48H53F3N12O8/c1-3-38(64)56-29-10-8-11-30(24-29)57-43-33(48(49,50)51)26-55-47(60-43)58-34-15-14-31(25-37(34)71-2)62-22-20-61(21-23-62)28-41(67)53-19-7-5-4-6-18-52-40(66)27-54-35-13-9-12-32-42(35)46(70)63(45(32)69)36-16-17-39(65)59-44(36)68/h3,8-15,24-26,36,54H,1,4-7,16-23,27-28H2,2H3,(H,52,66)(H,53,67)(H,56,64)(H,59,65,68)(H2,55,57,58,60)",VAYZYSLFDFSAJT-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5609,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,983.022,982.406141316,71,7,7,15,C48H53F3N12O8,"InChI=1S/C48H53F3N12O8/c1-3-38(64)56-29-10-8-11-30(24-29)57-43-33(48(49,50)51)26-55-47(60-43)58-34-15-14-31(25-37(34)71-2)62-22-20-61(21-23-62)28-41(67)53-19-7-5-4-6-18-52-40(66)27-54-35-13-9-12-32-42(35)46(70)63(45(32)69)36-16-17-39(65)59-44(36)68/h3,8-15,24-26,36,54H,1,4-7,16-23,27-28H2,2H3,(H,52,66)(H,53,67)(H,56,64)(H,59,65,68)(H2,55,57,58,60)",VAYZYSLFDFSAJT-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5515,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,817.275,816.279816204,58,7,3,13,C40H42ClFN8O8,"InChI=1S/C40H42ClFN8O8/c1-56-33-22-31-28(37(45-23-44-31)46-25-4-6-30(42)29(41)20-25)21-34(33)58-16-2-11-48-12-14-49(15-13-48)36(52)9-17-57-18-10-43-24-3-5-26-27(19-24)40(55)50(39(26)54)32-7-8-35(51)47-38(32)53/h3-6,19-23,32,43H,2,7-18H2,1H3,(H,44,45,46)(H,47,51,53)",NJDFBNDDZVUHJW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5517,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,905.381,904.3322457,64,7,3,15,C44H50ClFN8O10,"InChI=1S/C44H50ClFN8O10/c1-60-37-26-35-32(41(49-27-48-35)50-29-4-6-34(46)33(45)24-29)25-38(37)64-16-2-11-52-12-14-53(15-13-52)40(56)9-17-61-19-21-63-22-20-62-18-10-47-28-3-5-30-31(23-28)44(59)54(43(30)58)36-7-8-39(55)51-42(36)57/h3-6,23-27,36,47H,2,7-22H2,1H3,(H,48,49,50)(H,51,55,57)",QWQPTNDZYZDTLQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5516,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,861.328,860.306030952,61,7,3,14,C42H46ClFN8O9,"InChI=1S/C42H46ClFN8O9/c1-58-35-24-33-30(39(47-25-46-33)48-27-4-6-32(44)31(43)22-27)23-36(35)61-16-2-11-50-12-14-51(15-13-50)38(54)9-17-59-19-20-60-18-10-45-26-3-5-28-29(21-26)42(57)52(41(28)56)34-7-8-37(53)49-40(34)55/h3-6,21-25,34,45H,2,7-20H2,1H3,(H,46,47,48)(H,49,53,55)",QEZLBSWVQQGURV-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5616,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-34(57)49-25-5-4-6-26(19-25)50-37-30(42(43,44)45)22-48-41(53-37)51-31-10-8-27(21-33(31)63-2)55-17-15-54(16-18-55)23-36(59)47-14-13-46-24-7-9-28-29(20-24)40(62)56(39(28)61)32-11-12-35(58)52-38(32)60/h3-10,19-22,32,46H,1,11-18,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",CDTQXWDBHCWCFC-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5616,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-34(57)49-25-5-4-6-26(19-25)50-37-30(42(43,44)45)22-48-41(53-37)51-31-10-8-27(21-33(31)63-2)55-17-15-54(16-18-55)23-36(59)47-14-13-46-24-7-9-28-29(20-24)40(62)56(39(28)61)32-11-12-35(58)52-38(32)60/h3-10,19-22,32,46H,1,11-18,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",CDTQXWDBHCWCFC-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5616,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-34(57)49-25-5-4-6-26(19-25)50-37-30(42(43,44)45)22-48-41(53-37)51-31-10-8-27(21-33(31)63-2)55-17-15-54(16-18-55)23-36(59)47-14-13-46-24-7-9-28-29(20-24)40(62)56(39(28)61)32-11-12-35(58)52-38(32)60/h3-10,19-22,32,46H,1,11-18,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",CDTQXWDBHCWCFC-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4228,P00533,EGFR e19d,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(OCCOCCOCCOCCC(=O)NC4=CC5=C(NC6=CC=C(F)C(Cl)=C6)N=CN=C5C=C4O[C@H]4CCOC4)=C3C2=O)C(=O)N1,,,835.242,834.242762,59,7,3,14,C40H40ClFN6O11,"InChI=1S/C40H40ClFN6O11/c41-27-18-23(4-5-28(27)42)45-37-26-19-30(33(20-29(26)43-22-44-37)59-24-8-10-57-21-24)46-35(50)9-11-54-12-13-55-14-15-56-16-17-58-32-3-1-2-25-36(32)40(53)48(39(25)52)31-6-7-34(49)47-38(31)51/h1-5,18-20,22,24,31H,6-17,21H2,(H,46,50)(H,43,44,45)(H,47,49,51)/t24-,31?/m0/s1",GOYMQUKZVXEGIY-ACXKHFGCSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5510,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,787.249,786.26925152,56,7,3,12,C39H40ClFN8O7,"InChI=1S/C39H40ClFN8O7/c1-55-32-21-30-27(36(44-22-43-30)45-24-6-8-29(41)28(40)19-24)20-33(32)56-17-3-12-47-13-15-48(16-14-47)35(51)4-2-11-42-23-5-7-25-26(18-23)39(54)49(38(25)53)31-9-10-34(50)46-37(31)52/h5-8,18-22,31,42H,2-4,9-17H2,1H3,(H,43,44,45)(H,46,50,52)",ACYJANXDHHGXIO-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4279,P00533,EGFR,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1110.345,1109.52558984,79,7,5,17,C57H75N9O12S,"InChI=1S/C57H75N9O12S/c1-38-52(79-37-62-38)41-13-11-39(12-14-41)32-59-55(71)46-29-43(67)33-66(46)56(72)53(57(2,3)4)64-50(69)35-77-28-27-76-24-19-58-49(68)17-22-74-25-26-75-23-18-51(70)65-20-15-40(16-21-65)34-78-48-31-45-44(30-47(48)73-5)54(61-36-60-45)63-42-9-7-6-8-10-42/h6-14,30-31,36-37,40,43,46,53,67H,15-29,32-35H2,1-5H3,(H,58,68)(H,59,71)(H,64,69)(H,60,61,63)/t43-,46+,53-/m1/s1",DOKFKKPHHAPTKI-BSDSDUADSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4279,P00533,EGFR L858R,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1110.345,1109.52558984,79,7,5,17,C57H75N9O12S,"InChI=1S/C57H75N9O12S/c1-38-52(79-37-62-38)41-13-11-39(12-14-41)32-59-55(71)46-29-43(67)33-66(46)56(72)53(57(2,3)4)64-50(69)35-77-28-27-76-24-19-58-49(68)17-22-74-25-26-75-23-18-51(70)65-20-15-40(16-21-65)34-78-48-31-45-44(30-47(48)73-5)54(61-36-60-45)63-42-9-7-6-8-10-42/h6-14,30-31,36-37,40,43,46,53,67H,15-29,32-35H2,1-5H3,(H,58,68)(H,59,71)(H,64,69)(H,60,61,63)/t43-,46+,53-/m1/s1",DOKFKKPHHAPTKI-BSDSDUADSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4279,P00533,EGFR e19d,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1110.345,1109.52558984,79,7,5,17,C57H75N9O12S,"InChI=1S/C57H75N9O12S/c1-38-52(79-37-62-38)41-13-11-39(12-14-41)32-59-55(71)46-29-43(67)33-66(46)56(72)53(57(2,3)4)64-50(69)35-77-28-27-76-24-19-58-49(68)17-22-74-25-26-75-23-18-51(70)65-20-15-40(16-21-65)34-78-48-31-45-44(30-47(48)73-5)54(61-36-60-45)63-42-9-7-6-8-10-42/h6-14,30-31,36-37,40,43,46,53,67H,15-29,32-35H2,1-5H3,(H,58,68)(H,59,71)(H,64,69)(H,60,61,63)/t43-,46+,53-/m1/s1",DOKFKKPHHAPTKI-BSDSDUADSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4280,P00533,EGFR,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)NCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1116.484,1115.62418168,80,7,5,13,C62H85N9O8S,"InChI=1S/C62H85N9O8S/c1-43-57(80-42-67-43)46-28-26-44(27-29-46)38-64-60(76)51-35-48(72)39-71(51)61(77)58(62(2,3)4)69-55(74)24-18-14-20-32-63-54(73)23-17-11-9-7-6-8-10-12-19-25-56(75)70-33-30-45(31-34-70)40-79-53-37-50-49(36-52(53)78-5)59(66-41-65-50)68-47-21-15-13-16-22-47/h13,15-16,21-22,26-29,36-37,41-42,45,48,51,58,72H,6-12,14,17-20,23-25,30-35,38-40H2,1-5H3,(H,63,73)(H,64,76)(H,69,74)(H,65,66,68)/t48-,51+,58-/m1/s1",XPPVTROCTSYANZ-MLLYKJHQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4280,P00533,EGFR L858R,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)NCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1116.484,1115.62418168,80,7,5,13,C62H85N9O8S,"InChI=1S/C62H85N9O8S/c1-43-57(80-42-67-43)46-28-26-44(27-29-46)38-64-60(76)51-35-48(72)39-71(51)61(77)58(62(2,3)4)69-55(74)24-18-14-20-32-63-54(73)23-17-11-9-7-6-8-10-12-19-25-56(75)70-33-30-45(31-34-70)40-79-53-37-50-49(36-52(53)78-5)59(66-41-65-50)68-47-21-15-13-16-22-47/h13,15-16,21-22,26-29,36-37,41-42,45,48,51,58,72H,6-12,14,17-20,23-25,30-35,38-40H2,1-5H3,(H,63,73)(H,64,76)(H,69,74)(H,65,66,68)/t48-,51+,58-/m1/s1",XPPVTROCTSYANZ-MLLYKJHQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,4280,P00533,EGFR e19d,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)NCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1116.484,1115.62418168,80,7,5,13,C62H85N9O8S,"InChI=1S/C62H85N9O8S/c1-43-57(80-42-67-43)46-28-26-44(27-29-46)38-64-60(76)51-35-48(72)39-71(51)61(77)58(62(2,3)4)69-55(74)24-18-14-20-32-63-54(73)23-17-11-9-7-6-8-10-12-19-25-56(75)70-33-30-45(31-34-70)40-79-53-37-50-49(36-52(53)78-5)59(66-41-65-50)68-47-21-15-13-16-22-47/h13,15-16,21-22,26-29,36-37,41-42,45,48,51,58,72H,6-12,14,17-20,23-25,30-35,38-40H2,1-5H3,(H,63,73)(H,64,76)(H,69,74)(H,65,66,68)/t48-,51+,58-/m1/s1",XPPVTROCTSYANZ-MLLYKJHQSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5479,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)C2CCN(C3CCN(C(=O)C[C@H](NC(=O)[C@@H]4C[C@@H](O)CN4C(=O)[C@@H](C4=CC(C)=NO4)C(C)C)C4=CC=C(C5=C(C)N=CS5)C=C4)CC3)CC2)CC1,,,1162.831,1161.5036852,82,10,3,16,C60H73ClFN11O8S,"InChI=1S/C60H73ClFN11O8S/c1-36(2)55(53-27-37(3)68-81-53)60(78)73-33-44(74)29-50(73)58(76)67-48(39-7-9-40(10-8-39)56-38(4)65-35-82-56)32-54(75)71-20-15-43(16-21-71)70-18-13-41(14-19-70)59(77)72-24-22-69(23-25-72)17-6-26-80-52-30-45-49(31-51(52)79-5)63-34-64-57(45)66-42-11-12-47(62)46(61)28-42/h7-12,27-28,30-31,34-36,41,43-44,48,50,55,74H,6,13-26,29,32-33H2,1-5H3,(H,67,76)(H,63,64,66)/t44-,48+,50+,55-/m1/s1",UJNSVDWEUKQKFH-CEEPQZMUSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5491,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)C2CCN(C3CCN(C(=O)C[C@H](NC(=O)[C@@H]4C[C@@H](O)CN4C(=O)[C@@H](NC(=O)C4(F)CC4)C(C)(C)C)C4=CC=C(C5=C(C)N=CS5)C=C4)CC3)CC2)CC1,,,1196.864,1195.52556351,84,10,4,15,C61H76ClF2N11O8S,"InChI=1S/C61H76ClF2N11O8S/c1-37-53(84-36-67-37)39-9-7-38(8-10-39)47(69-56(78)49-30-43(76)34-75(49)58(80)54(60(2,3)4)70-59(81)61(64)17-18-61)33-52(77)73-22-15-42(16-23-73)72-20-13-40(14-21-72)57(79)74-26-24-71(25-27-74)19-6-28-83-51-31-44-48(32-50(51)82-5)65-35-66-55(44)68-41-11-12-46(63)45(62)29-41/h7-12,29,31-32,35-36,40,42-43,47,49,54,76H,6,13-28,30,33-34H2,1-5H3,(H,69,78)(H,70,81)(H,65,66,68)/t43-,47+,49+,54-/m1/s1",BNSYXHHDTDWBJT-SVOJDZOVSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5519,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,82,,993.487,992.384675196,70,7,3,17,C48H58ClFN8O12,"InChI=1S/C48H58ClFN8O12/c1-64-41-30-39-36(45(53-31-52-39)54-33-4-6-38(50)37(49)28-33)29-42(41)70-16-2-11-56-12-14-57(15-13-56)44(60)9-17-65-19-21-67-23-25-69-26-24-68-22-20-66-18-10-51-32-3-5-34-35(27-32)48(63)58(47(34)62)40-7-8-43(59)55-46(40)61/h3-6,27-31,40,51H,2,7-26H2,1H3,(H,52,53,54)(H,55,59,61)",DJJBJKUHJYCNMD-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5520,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,816.291,815.295800616,58,7,4,13,C40H43ClFN9O7,"InChI=1S/C40H43ClFN9O7/c1-57-33-22-31-28(37(46-23-45-31)47-25-4-6-30(42)29(41)20-25)21-34(33)58-18-2-12-49-14-16-50(17-15-49)13-9-35(52)44-11-10-43-24-3-5-26-27(19-24)40(56)51(39(26)55)32-7-8-36(53)48-38(32)54/h3-6,19-23,32,43H,2,7-18H2,1H3,(H,44,52)(H,45,46,47)(H,48,53,54)",POGOXECKYDOXCQ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5521,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,830.318,829.31145068,59,7,4,13,C41H45ClFN9O7,"InChI=1S/C41H45ClFN9O7/c1-58-34-23-32-29(38(47-24-46-32)48-26-5-7-31(43)30(42)21-26)22-35(34)59-19-3-13-50-15-17-51(18-16-50)14-10-36(53)45-12-2-11-44-25-4-6-27-28(20-25)41(57)52(40(27)56)33-8-9-37(54)49-39(33)55/h4-7,20-24,33,44H,2-3,8-19H2,1H3,(H,45,53)(H,46,47,48)(H,49,54,55)",UIBOZTWGZNBUTI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5522,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,844.345,843.327100744,60,7,4,13,C42H47ClFN9O7,"InChI=1S/C42H47ClFN9O7/c1-59-35-24-33-30(39(48-25-47-33)49-27-6-8-32(44)31(43)22-27)23-36(35)60-20-4-14-51-16-18-52(19-17-51)15-11-37(54)46-13-3-2-12-45-26-5-7-28-29(21-26)42(58)53(41(28)57)34-9-10-38(55)50-40(34)56/h5-8,21-25,34,45H,2-4,9-20H2,1H3,(H,46,54)(H,47,48,49)(H,50,55,56)",ISMILGGVLKEGJZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5523,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,858.372,857.342750808,61,7,4,13,C43H49ClFN9O7,"InChI=1S/C43H49ClFN9O7/c1-60-36-25-34-31(40(49-26-48-34)50-28-7-9-33(45)32(44)23-28)24-37(36)61-21-5-15-52-17-19-53(20-18-52)16-12-38(55)47-14-4-2-3-13-46-27-6-8-29-30(22-27)43(59)54(42(29)58)35-10-11-39(56)51-41(35)57/h6-9,22-26,35,46H,2-5,10-21H2,1H3,(H,47,55)(H,48,49,50)(H,51,56,57)",PIJJSPQFXYLIHL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5524,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,872.399,871.358400872,62,7,4,13,C44H51ClFN9O7,"InChI=1S/C44H51ClFN9O7/c1-61-37-26-35-32(41(50-27-49-35)51-29-8-10-34(46)33(45)24-29)25-38(37)62-22-6-16-53-18-20-54(21-19-53)17-13-39(56)48-15-5-3-2-4-14-47-28-7-9-30-31(23-28)44(60)55(43(30)59)36-11-12-40(57)52-42(36)58/h7-10,23-27,36,47H,2-6,11-22H2,1H3,(H,48,56)(H,49,50,51)(H,52,57,58)",HPYIBAWLHRPWRF-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5525,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,886.426,885.374050936,63,7,4,13,C45H53ClFN9O7,"InChI=1S/C45H53ClFN9O7/c1-62-38-27-36-33(42(51-28-50-36)52-30-9-11-35(47)34(46)25-30)26-39(38)63-23-7-17-54-19-21-55(22-20-54)18-14-40(57)49-16-6-4-2-3-5-15-48-29-8-10-31-32(24-29)45(61)56(44(31)60)37-12-13-41(58)53-43(37)59/h8-11,24-28,37,48H,2-7,12-23H2,1H3,(H,49,57)(H,50,51,52)(H,53,58,59)",MMINECLGVAIGGU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5526,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,900.453,899.389701,64,7,4,13,C46H55ClFN9O7,"InChI=1S/C46H55ClFN9O7/c1-63-39-28-37-34(43(52-29-51-37)53-31-10-12-36(48)35(47)26-31)27-40(39)64-24-8-18-55-20-22-56(23-21-55)19-15-41(58)50-17-7-5-3-2-4-6-16-49-30-9-11-32-33(25-30)46(62)57(45(32)61)38-13-14-42(59)54-44(38)60/h9-12,25-29,38,49H,2-8,13-24H2,1H3,(H,50,58)(H,51,52,53)(H,54,59,60)",UCLWPMAGPRUQED-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5527,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,860.344,859.322015364,61,7,4,14,C42H47ClFN9O8,"InChI=1S/C42H47ClFN9O8/c1-59-35-24-33-30(39(48-25-47-33)49-27-4-6-32(44)31(43)22-27)23-36(35)61-18-2-12-51-14-16-52(17-15-51)13-9-37(54)46-11-20-60-19-10-45-26-3-5-28-29(21-26)42(58)53(41(28)57)34-7-8-38(55)50-40(34)56/h3-6,21-25,34,45H,2,7-20H2,1H3,(H,46,54)(H,47,48,49)(H,50,55,56)",SKWRCBVELUBGQL-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5528,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,904.397,903.348230112,64,7,4,15,C44H51ClFN9O9,"InChI=1S/C44H51ClFN9O9/c1-61-37-26-35-32(41(50-27-49-35)51-29-4-6-34(46)33(45)24-29)25-38(37)64-18-2-12-53-14-16-54(17-15-53)13-9-39(56)48-11-20-63-22-21-62-19-10-47-28-3-5-30-31(23-28)44(60)55(43(30)59)36-7-8-40(57)52-42(36)58/h3-6,23-27,36,47H,2,7-22H2,1H3,(H,48,56)(H,49,50,51)(H,52,57,58)",OLVDBJKGILNHNM-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5529,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,948.45,947.37444486,67,7,4,16,C46H55ClFN9O10,"InChI=1S/C46H55ClFN9O10/c1-63-39-28-37-34(43(52-29-51-37)53-31-4-6-36(48)35(47)26-31)27-40(39)67-18-2-12-55-14-16-56(17-15-55)13-9-41(58)50-11-20-65-22-24-66-23-21-64-19-10-49-30-3-5-32-33(25-30)46(62)57(45(32)61)38-7-8-42(59)54-44(38)60/h3-6,25-29,38,49H,2,7-24H2,1H3,(H,50,58)(H,51,52,53)(H,54,59,60)",QJNHORRXWQBCMZ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5530,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,992.503,991.400659608,70,7,4,17,C48H59ClFN9O11,"InChI=1S/C48H59ClFN9O11/c1-65-41-30-39-36(45(54-31-53-39)55-33-4-6-38(50)37(49)28-33)29-42(41)70-18-2-12-57-14-16-58(17-15-57)13-9-43(60)52-11-20-67-22-24-69-26-25-68-23-21-66-19-10-51-32-3-5-34-35(27-32)48(64)59(47(34)63)40-7-8-44(61)56-46(40)62/h3-6,27-31,40,51H,2,7-26H2,1H3,(H,52,60)(H,53,54,55)(H,56,61,62)",KQJFVIBHSOMATC-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5531,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,1036.556,1035.42687436,73,7,4,18,C50H63ClFN9O12,"InChI=1S/C50H63ClFN9O12/c1-67-43-32-41-38(47(56-33-55-41)57-35-4-6-40(52)39(51)30-35)31-44(43)73-18-2-12-59-14-16-60(17-15-59)13-9-45(62)54-11-20-69-22-24-71-26-28-72-27-25-70-23-21-68-19-10-53-34-3-5-36-37(29-34)50(66)61(49(36)65)42-7-8-46(63)58-48(42)64/h3-6,29-33,42,53H,2,7-28H2,1H3,(H,54,62)(H,55,56,57)(H,58,63,64)",JCHKTBMRARJZJU-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5596,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,896.884,896.321742996,65,7,5,13,C44H43F3N10O8,"InChI=1S/C44H43F3N10O8/c1-3-34(58)49-25-8-6-9-26(22-25)50-39-29(44(45,46)47)24-48-43(54-39)52-30-15-14-27(23-33(30)65-2)55-18-20-56(21-19-55)37(61)13-5-4-12-35(59)51-31-11-7-10-28-38(31)42(64)57(41(28)63)32-16-17-36(60)53-40(32)62/h3,6-11,14-15,22-24,32H,1,4-5,12-13,16-21H2,2H3,(H,49,58)(H,51,59)(H,53,60,62)(H2,48,50,52,54)",QIIMOISWZUBKMI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5596,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,896.884,896.321742996,65,7,5,13,C44H43F3N10O8,"InChI=1S/C44H43F3N10O8/c1-3-34(58)49-25-8-6-9-26(22-25)50-39-29(44(45,46)47)24-48-43(54-39)52-30-15-14-27(23-33(30)65-2)55-18-20-56(21-19-55)37(61)13-5-4-12-35(59)51-31-11-7-10-28-38(31)42(64)57(41(28)63)32-16-17-36(60)53-40(32)62/h3,6-11,14-15,22-24,32H,1,4-5,12-13,16-21H2,2H3,(H,49,58)(H,51,59)(H,53,60,62)(H2,48,50,52,54)",QIIMOISWZUBKMI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5596,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,896.884,896.321742996,65,7,5,13,C44H43F3N10O8,"InChI=1S/C44H43F3N10O8/c1-3-34(58)49-25-8-6-9-26(22-25)50-39-29(44(45,46)47)24-48-43(54-39)52-30-15-14-27(23-33(30)65-2)55-18-20-56(21-19-55)37(61)13-5-4-12-35(59)51-31-11-7-10-28-38(31)42(64)57(41(28)63)32-16-17-36(60)53-40(32)62/h3,6-11,14-15,22-24,32H,1,4-5,12-13,16-21H2,2H3,(H,49,58)(H,51,59)(H,53,60,62)(H2,48,50,52,54)",QIIMOISWZUBKMI-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5600,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,952.992,952.384343252,69,7,5,13,C48H51F3N10O8,"InChI=1S/C48H51F3N10O8/c1-3-38(62)53-29-12-10-13-30(26-29)54-43-33(48(49,50)51)28-52-47(58-43)56-34-19-18-31(27-37(34)69-2)59-22-24-60(25-23-59)41(65)17-9-7-5-4-6-8-16-39(63)55-35-15-11-14-32-42(35)46(68)61(45(32)67)36-20-21-40(64)57-44(36)66/h3,10-15,18-19,26-28,36H,1,4-9,16-17,20-25H2,2H3,(H,53,62)(H,55,63)(H,57,64,66)(H2,52,54,56,58)",ABNBPPYKXTVRDW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5600,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,952.992,952.384343252,69,7,5,13,C48H51F3N10O8,"InChI=1S/C48H51F3N10O8/c1-3-38(62)53-29-12-10-13-30(26-29)54-43-33(48(49,50)51)28-52-47(58-43)56-34-19-18-31(27-37(34)69-2)59-22-24-60(25-23-59)41(65)17-9-7-5-4-6-8-16-39(63)55-35-15-11-14-32-42(35)46(68)61(45(32)67)36-20-21-40(64)57-44(36)66/h3,10-15,18-19,26-28,36H,1,4-9,16-17,20-25H2,2H3,(H,53,62)(H,55,63)(H,57,64,66)(H2,52,54,56,58)",ABNBPPYKXTVRDW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5600,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,952.992,952.384343252,69,7,5,13,C48H51F3N10O8,"InChI=1S/C48H51F3N10O8/c1-3-38(62)53-29-12-10-13-30(26-29)54-43-33(48(49,50)51)28-52-47(58-43)56-34-19-18-31(27-37(34)69-2)59-22-24-60(25-23-59)41(65)17-9-7-5-4-6-8-16-39(63)55-35-15-11-14-32-42(35)46(68)61(45(32)67)36-20-21-40(64)57-44(36)66/h3,10-15,18-19,26-28,36H,1,4-9,16-17,20-25H2,2H3,(H,53,62)(H,55,63)(H,57,64,66)(H2,52,54,56,58)",ABNBPPYKXTVRDW-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5603,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,995.073,994.431293444,72,7,5,13,C51H57F3N10O8,"InChI=1S/C51H57F3N10O8/c1-3-41(65)56-32-15-13-16-33(29-32)57-46-36(51(52,53)54)31-55-50(61-46)59-37-22-21-34(30-40(37)72-2)62-25-27-63(28-26-62)44(68)20-12-10-8-6-4-5-7-9-11-19-42(66)58-38-18-14-17-35-45(38)49(71)64(48(35)70)39-23-24-43(67)60-47(39)69/h3,13-18,21-22,29-31,39H,1,4-12,19-20,23-28H2,2H3,(H,56,65)(H,58,66)(H,60,67,69)(H2,55,57,59,61)",MBCGKBGJUJSJBE-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5603,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,995.073,994.431293444,72,7,5,13,C51H57F3N10O8,"InChI=1S/C51H57F3N10O8/c1-3-41(65)56-32-15-13-16-33(29-32)57-46-36(51(52,53)54)31-55-50(61-46)59-37-22-21-34(30-40(37)72-2)62-25-27-63(28-26-62)44(68)20-12-10-8-6-4-5-7-9-11-19-42(66)58-38-18-14-17-35-45(38)49(71)64(48(35)70)39-23-24-43(67)60-47(39)69/h3,13-18,21-22,29-31,39H,1,4-12,19-20,23-28H2,2H3,(H,56,65)(H,58,66)(H,60,67,69)(H2,55,57,59,61)",MBCGKBGJUJSJBE-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5603,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,995.073,994.431293444,72,7,5,13,C51H57F3N10O8,"InChI=1S/C51H57F3N10O8/c1-3-41(65)56-32-15-13-16-33(29-32)57-46-36(51(52,53)54)31-55-50(61-46)59-37-22-21-34(30-40(37)72-2)62-25-27-63(28-26-62)44(68)20-12-10-8-6-4-5-7-9-11-19-42(66)58-38-18-14-17-35-45(38)49(71)64(48(35)70)39-23-24-43(67)60-47(39)69/h3,13-18,21-22,29-31,39H,1,4-12,19-20,23-28H2,2H3,(H,56,65)(H,58,66)(H,60,67,69)(H2,55,57,59,61)",MBCGKBGJUJSJBE-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5604,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,1009.1,1008.44694351,73,7,5,13,C52H59F3N10O8,"InChI=1S/C52H59F3N10O8/c1-3-42(66)57-33-16-14-17-34(30-33)58-47-37(52(53,54)55)32-56-51(62-47)60-38-23-22-35(31-41(38)73-2)63-26-28-64(29-27-63)45(69)21-13-11-9-7-5-4-6-8-10-12-20-43(67)59-39-19-15-18-36-46(39)50(72)65(49(36)71)40-24-25-44(68)61-48(40)70/h3,14-19,22-23,30-32,40H,1,4-13,20-21,24-29H2,2H3,(H,57,66)(H,59,67)(H,61,68,70)(H2,56,58,60,62)",GZDWQVDOWOTXBJ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5604,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,1009.1,1008.44694351,73,7,5,13,C52H59F3N10O8,"InChI=1S/C52H59F3N10O8/c1-3-42(66)57-33-16-14-17-34(30-33)58-47-37(52(53,54)55)32-56-51(62-47)60-38-23-22-35(31-41(38)73-2)63-26-28-64(29-27-63)45(69)21-13-11-9-7-5-4-6-8-10-12-20-43(67)59-39-19-15-18-36-46(39)50(72)65(49(36)71)40-24-25-44(68)61-48(40)70/h3,14-19,22-23,30-32,40H,1,4-13,20-21,24-29H2,2H3,(H,57,66)(H,59,67)(H,61,68,70)(H2,56,58,60,62)",GZDWQVDOWOTXBJ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5604,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,1009.1,1008.44694351,73,7,5,13,C52H59F3N10O8,"InChI=1S/C52H59F3N10O8/c1-3-42(66)57-33-16-14-17-34(30-33)58-47-37(52(53,54)55)32-56-51(62-47)60-38-23-22-35(31-41(38)73-2)63-26-28-64(29-27-63)45(69)21-13-11-9-7-5-4-6-8-10-12-20-43(67)59-39-19-15-18-36-46(39)50(72)65(49(36)71)40-24-25-44(68)61-48(40)70/h3,14-19,22-23,30-32,40H,1,4-13,20-21,24-29H2,2H3,(H,57,66)(H,59,67)(H,61,68,70)(H2,56,58,60,62)",GZDWQVDOWOTXBJ-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5608,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,968.995,968.390491252,70,7,7,15,C47H51F3N12O8,"InChI=1S/C47H51F3N12O8/c1-3-37(63)55-28-9-7-10-29(23-28)56-42-32(47(48,49)50)25-54-46(59-42)57-33-14-13-30(24-36(33)70-2)61-21-19-60(20-22-61)27-40(66)52-18-6-4-5-17-51-39(65)26-53-34-12-8-11-31-41(34)45(69)62(44(31)68)35-15-16-38(64)58-43(35)67/h3,7-14,23-25,35,53H,1,4-6,15-22,26-27H2,2H3,(H,51,65)(H,52,66)(H,55,63)(H,58,64,67)(H2,54,56,57,59)",WYJXGCHJOGRWLX-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5608,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,968.995,968.390491252,70,7,7,15,C47H51F3N12O8,"InChI=1S/C47H51F3N12O8/c1-3-37(63)55-28-9-7-10-29(23-28)56-42-32(47(48,49)50)25-54-46(59-42)57-33-14-13-30(24-36(33)70-2)61-21-19-60(20-22-61)27-40(66)52-18-6-4-5-17-51-39(65)26-53-34-12-8-11-31-41(34)45(69)62(44(31)68)35-15-16-38(64)58-43(35)67/h3,7-14,23-25,35,53H,1,4-6,15-22,26-27H2,2H3,(H,51,65)(H,52,66)(H,55,63)(H,58,64,67)(H2,54,56,57,59)",WYJXGCHJOGRWLX-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5608,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC(=O)CNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,968.995,968.390491252,70,7,7,15,C47H51F3N12O8,"InChI=1S/C47H51F3N12O8/c1-3-37(63)55-28-9-7-10-29(23-28)56-42-32(47(48,49)50)25-54-46(59-42)57-33-14-13-30(24-36(33)70-2)61-21-19-60(20-22-61)27-40(66)52-18-6-4-5-17-51-39(65)26-53-34-12-8-11-31-41(34)45(69)62(44(31)68)35-15-16-38(64)58-43(35)67/h3,7-14,23-25,35,53H,1,4-6,15-22,26-27H2,2H3,(H,51,65)(H,52,66)(H,55,63)(H,58,64,67)(H2,54,56,57,59)",WYJXGCHJOGRWLX-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5617,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCOC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,870.846,870.306092932,63,7,5,14,C42H41F3N10O8,"InChI=1S/C42H41F3N10O8/c1-3-33(56)48-24-6-4-7-25(20-24)49-37-28(42(43,44)45)22-47-41(52-37)50-29-11-10-26(21-32(29)62-2)54-17-15-53(16-18-54)23-35(58)46-14-19-63-31-9-5-8-27-36(31)40(61)55(39(27)60)30-12-13-34(57)51-38(30)59/h3-11,20-22,30H,1,12-19,23H2,2H3,(H,46,58)(H,48,56)(H,51,57,59)(H2,47,49,50,52)",CKQLLRWGNMJKRO-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5617,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCOC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,870.846,870.306092932,63,7,5,14,C42H41F3N10O8,"InChI=1S/C42H41F3N10O8/c1-3-33(56)48-24-6-4-7-25(20-24)49-37-28(42(43,44)45)22-47-41(52-37)50-29-11-10-26(21-32(29)62-2)54-17-15-53(16-18-54)23-35(58)46-14-19-63-31-9-5-8-27-36(31)40(61)55(39(27)60)30-12-13-34(57)51-38(30)59/h3-11,20-22,30H,1,12-19,23H2,2H3,(H,46,58)(H,48,56)(H,51,57,59)(H2,47,49,50,52)",CKQLLRWGNMJKRO-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5617,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCOC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,870.846,870.306092932,63,7,5,14,C42H41F3N10O8,"InChI=1S/C42H41F3N10O8/c1-3-33(56)48-24-6-4-7-25(20-24)49-37-28(42(43,44)45)22-47-41(52-37)50-29-11-10-26(21-32(29)62-2)54-17-15-53(16-18-54)23-35(58)46-14-19-63-31-9-5-8-27-36(31)40(61)55(39(27)60)30-12-13-34(57)51-38(30)59/h3-11,20-22,30H,1,12-19,23H2,2H3,(H,46,58)(H,48,56)(H,51,57,59)(H2,47,49,50,52)",CKQLLRWGNMJKRO-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5635,P00533,EGFR del19/T790M/C797S,CRBN,COC1=CC(N2CCC(N3CCN(CCC#CC4=CC=CC5=C4CN(C4CCC(=O)NC4=O)C5=O)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,864.388,863.343930042,61,8,3,12,C45H51ClN9O5P,"InChI=1S/C45H51ClN9O5P/c1-60-39-27-32(14-15-36(39)49-45-47-28-35(46)42(51-45)48-37-12-4-5-13-40(37)61(2,3)59)53-21-18-31(19-22-53)54-25-23-52(24-26-54)20-7-6-9-30-10-8-11-33-34(30)29-55(44(33)58)38-16-17-41(56)50-43(38)57/h4-5,8,10-15,27-28,31,38H,7,16-26,29H2,1-3H3,(H,50,56,57)(H2,47,48,49,51)",WTUTUUAYVNLJQA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5635,P00533,EGFR L858R/T790M/C797S,CRBN,COC1=CC(N2CCC(N3CCN(CCC#CC4=CC=CC5=C4CN(C4CCC(=O)NC4=O)C5=O)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,864.388,863.343930042,61,8,3,12,C45H51ClN9O5P,"InChI=1S/C45H51ClN9O5P/c1-60-39-27-32(14-15-36(39)49-45-47-28-35(46)42(51-45)48-37-12-4-5-13-40(37)61(2,3)59)53-21-18-31(19-22-53)54-25-23-52(24-26-54)20-7-6-9-30-10-8-11-33-34(30)29-55(44(33)58)38-16-17-41(56)50-43(38)57/h4-5,8,10-15,27-28,31,38H,7,16-26,29H2,1-3H3,(H,50,56,57)(H2,47,48,49,51)",WTUTUUAYVNLJQA-UHFFFAOYSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5468,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,968.553,967.361772,68,8,3,14,C49H55ClFN9O7S,"InChI=1S/C49H55ClFN9O7S/c1-28(2)45(43-19-29(3)57-67-43)49(64)60-25-34(61)21-40(60)48(63)56-38(31-7-9-32(10-8-31)46-30(4)54-27-68-46)24-44(62)59-16-14-58(15-17-59)13-6-18-66-42-22-35-39(23-41(42)65-5)52-26-53-47(35)55-33-11-12-37(51)36(50)20-33/h7-12,19-20,22-23,26-28,34,38,40,45,61H,6,13-18,21,24-25H2,1-5H3,(H,56,63)(H,52,53,55)/t34-,38+,40+,45-/m1/s1",GJGCQFCLQPCWIB-BDQJMDTOSA-N
DB00002,Cetuximab,BiotechDrug,Epidermal growth factor receptor,5480,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1002.586,1001.38365032,70,8,4,13,C50H58ClF2N9O7S,"InChI=1S/C50H58ClF2N9O7S/c1-29-43(70-28-56-29)31-9-7-30(8-10-31)37(58-46(65)39-22-33(63)26-62(39)47(66)44(49(2,3)4)59-48(67)50(53)13-14-50)25-42(64)61-18-16-60(17-19-61)15-6-20-69-41-23-34-38(24-40(41)68-5)54-27-55-45(34)57-32-11-12-36(52)35(51)21-32/h7-12,21,23-24,27-28,33,37,39,44,63H,6,13-20,22,25-26H2,1-5H3,(H,58,65)(H,59,67)(H,54,55,57)/t33-,37+,39+,44-/m1/s1",FHCRUFFURRLEFH-CGGYIAGXSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1347,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,716.755,716.270695492,53,7,4,13,C38H36N8O7,"InChI=1S/C38H36N8O7/c47-33-13-12-31(35(48)45-33)46-36(49)28-5-3-7-30(34(28)37(46)50)39-16-17-51-18-19-52-20-21-53-27-10-8-25(9-11-27)43-38-40-15-14-32(44-38)42-26-22-24-4-1-2-6-29(24)41-23-26/h1-11,14-15,22-23,31,39H,12-13,16-21H2,(H,45,47,48)(H2,40,42,43,44)",VQLXJBPQVMWNGC-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1346,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,672.702,672.244480744,50,7,4,12,C36H32N8O6,"InChI=1S/C36H32N8O6/c45-31-13-12-29(33(46)43-31)44-34(47)26-5-3-7-28(32(26)35(44)48)37-16-17-49-18-19-50-25-10-8-23(9-11-25)41-36-38-15-14-30(42-36)40-24-20-22-4-1-2-6-27(22)39-21-24/h1-11,14-15,20-21,29,37H,12-13,16-19H2,(H,43,45,46)(H2,38,40,41,42)",BLGABOHGKRXYSB-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1348,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,760.808,760.29691024,56,7,4,14,C40H40N8O8,"InChI=1S/C40H40N8O8/c49-35-13-12-33(37(50)47-35)48-38(51)30-5-3-7-32(36(30)39(48)52)41-16-17-53-18-19-54-20-21-55-22-23-56-29-10-8-27(9-11-29)45-40-42-15-14-34(46-40)44-28-24-26-4-1-2-6-31(26)43-25-28/h1-11,14-15,24-25,33,41H,12-13,16-23H2,(H,47,49,50)(H2,42,44,45,46)",NNFLJXWHNNZGBH-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1349,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,625.646,625.239729712,46,6,5,12,C31H31N9O6,"InChI=1S/C31H31N9O6/c1-18-17-25(39-38-18)35-24-11-12-33-31(36-24)34-19-5-7-20(8-6-19)46-16-15-45-14-13-32-22-4-2-3-21-27(22)30(44)40(29(21)43)23-9-10-26(41)37-28(23)42/h2-8,11-12,17,23,32H,9-10,13-16H2,1H3,(H,37,41,42)(H3,33,34,35,36,38,39)",YEBGDZYCAZJQHH-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1351,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,660.091,659.20075736,47,6,5,12,C31H30ClN9O6,"InChI=1S/C31H30ClN9O6/c1-17-15-24(40-39-17)36-27-21(32)16-34-31(38-27)35-18-5-7-19(8-6-18)47-14-13-46-12-11-33-22-4-2-3-20-26(22)30(45)41(29(20)44)23-9-10-25(42)37-28(23)43/h2-8,15-16,23,33H,9-14H2,1H3,(H,37,42,43)(H3,34,35,36,38,39,40)",IOHSXHAPQQQUGP-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1350,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,669.699,669.26594446,49,6,5,13,C33H35N9O7,"InChI=1S/C33H35N9O7/c1-20-19-27(41-40-20)37-26-11-12-35-33(38-26)36-21-5-7-22(8-6-21)49-18-17-48-16-15-47-14-13-34-24-4-2-3-23-29(24)32(46)42(31(23)45)25-9-10-28(43)39-30(25)44/h2-8,11-12,19,25,34H,9-10,13-18H2,1H3,(H,39,43,44)(H3,35,36,37,38,40,41)",KSJXWXGDPRCSIV-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1352,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,704.144,703.226972108,50,6,5,13,C33H34ClN9O7,"InChI=1S/C33H34ClN9O7/c1-19-17-26(42-41-19)38-29-23(34)18-36-33(40-29)37-20-5-7-21(8-6-20)50-16-15-49-14-13-48-12-11-35-24-4-2-3-22-28(24)32(47)43(31(22)46)25-9-10-27(44)39-30(25)45/h2-8,17-18,25,35H,9-16H2,1H3,(H,39,44,45)(H3,36,37,38,40,41,42)",UYDSYJMBAOFSTK-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1353,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,738.205,737.247707552,53,7,4,13,C37H36ClN9O6,"InChI=1S/C37H36ClN9O6/c38-23-7-5-22(6-8-23)32-31-33(39)42-21-43-34(31)46(45-32)17-2-15-40-24-9-11-25(12-10-24)53-20-19-52-18-16-41-27-4-1-3-26-30(27)37(51)47(36(26)50)28-13-14-29(48)44-35(28)49/h1,3-12,21,28,40-41H,2,13-20H2,(H2,39,42,43)(H,44,48,49)",XWGDNKJJVPSPJY-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1354,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,782.258,781.2739223,56,7,4,14,C39H40ClN9O7,"InChI=1S/C39H40ClN9O7/c40-25-7-5-24(6-8-25)34-33-35(41)44-23-45-36(33)48(47-34)17-2-15-42-26-9-11-27(12-10-26)56-22-21-55-20-19-54-18-16-43-29-4-1-3-28-32(29)39(53)49(38(28)52)30-13-14-31(50)46-37(30)51/h1,3-12,23,30,42-43H,2,13-22H2,(H2,41,44,45)(H,46,50,51)",ZOQUWFJXKUZLHH-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1355,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,819.283,818.280404648,59,8,4,16,C40H39ClN12O6,"InChI=1S/C40H39ClN12O6/c41-25-7-5-24(6-8-25)35-34-36(42)45-23-46-37(34)52(49-35)17-2-16-51-22-27(48-50-51)21-44-26-9-11-28(12-10-26)59-20-19-58-18-15-43-30-4-1-3-29-33(30)40(57)53(39(29)56)31-13-14-32(54)47-38(31)55/h1,3-12,22-23,31,43-44H,2,13-21H2,(H2,42,45,46)(H,47,54,55)",YEBIAPTXRZULTM-UHFFFAOYSA-N
DB00030,Insulin Human,BiotechDrug,Insulin-like growth factor 1 receptor,1356,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,863.336,862.306619396,62,8,4,17,C42H43ClN12O7,"InChI=1S/C42H43ClN12O7/c43-27-7-5-26(6-8-27)37-36-38(44)47-25-48-39(36)54(51-37)17-2-16-53-24-29(50-52-53)23-46-28-9-11-30(12-10-28)62-22-21-61-20-19-60-18-15-45-32-4-1-3-31-35(32)42(59)55(41(31)58)33-13-14-34(56)49-40(33)57/h1,3-12,24-25,33,45-46H,2,13-23H2,(H2,44,47,48)(H,49,56,57)",UPKHTGRZRRRAME-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2881,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CCCCCC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,,,1073.162,1071.43226984,74,7,5,14,C53H67Cl2N11O7S,"InChI=1S/C53H67Cl2N11O7S/c1-32(34-13-15-35(16-14-34)48-33(2)58-31-74-48)59-50(69)39-26-38(67)29-66(39)51(70)49(53(3,4)5)61-44(68)12-10-9-11-21-64-22-24-65(25-23-64)37-19-17-36(18-20-37)60-42-28-43(57-30-56-42)63(6)52(71)62-47-45(54)40(72-7)27-41(73-8)46(47)55/h13-20,27-28,30-32,38-39,49,67H,9-12,21-26,29H2,1-8H3,(H,59,69)(H,61,68)(H,62,71)(H,56,57,60)/t32-,38+,39-,49+/m0/s1",NQDPHUVGEBTZGP-WYAMOQRKSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2879,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CCC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,,,1031.081,1029.38531965,71,7,5,14,C50H61Cl2N11O7S,"InChI=1S/C50H61Cl2N11O7S/c1-29(31-9-11-32(12-10-31)45-30(2)55-28-71-45)56-47(66)36-23-35(64)26-63(36)48(67)46(50(3,4)5)58-41(65)17-18-61-19-21-62(22-20-61)34-15-13-33(14-16-34)57-39-25-40(54-27-53-39)60(6)49(68)59-44-42(51)37(69-7)24-38(70-8)43(44)52/h9-16,24-25,27-29,35-36,46,64H,17-23,26H2,1-8H3,(H,56,66)(H,58,65)(H,59,68)(H,53,54,57)/t29-,35+,36-,46+/m0/s1",ZNPJWQLRJHZTJD-BOWIIDCISA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2880,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CCCC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,,,1045.108,1043.40096972,72,7,5,14,C51H63Cl2N11O7S,"InChI=1S/C51H63Cl2N11O7S/c1-30(32-11-13-33(14-12-32)46-31(2)56-29-72-46)57-48(67)37-24-36(65)27-64(37)49(68)47(51(3,4)5)59-42(66)10-9-19-62-20-22-63(23-21-62)35-17-15-34(16-18-35)58-40-26-41(55-28-54-40)61(6)50(69)60-45-43(52)38(70-7)25-39(71-8)44(45)53/h11-18,25-26,28-30,36-37,47,65H,9-10,19-24,27H2,1-8H3,(H,57,67)(H,59,66)(H,60,69)(H,54,55,58)/t30-,36+,37-,47+/m0/s1",RXLNCCJOUYWTSY-XRVDDDQASA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2882,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,,,1088.133,1086.40678337,75,7,6,15,C52H64Cl2N12O8S,"InChI=1S/C52H64Cl2N12O8S/c1-30(32-9-11-33(12-10-32)47-31(2)58-29-75-47)59-49(70)37-23-36(67)26-66(37)50(71)48(52(3,4)5)61-42(68)17-18-55-43(69)27-64-19-21-65(22-20-64)35-15-13-34(14-16-35)60-40-25-41(57-28-56-40)63(6)51(72)62-46-44(53)38(73-7)24-39(74-8)45(46)54/h9-16,24-25,28-30,36-37,48,67H,17-23,26-27H2,1-8H3,(H,55,69)(H,59,70)(H,61,68)(H,62,72)(H,56,57,60)/t30-,36+,37-,48+/m0/s1",JTSBMXASQWEDHX-PRWMCYMISA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2884,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCCCOC5=CC(C6=C(C)N=CS6)=CC=C5[C@H](C)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@@H](NC(C)=O)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,,,1160.24,1158.46429824,80,7,6,16,C56H72Cl2N12O9S,"InChI=1S/C56H72Cl2N12O9S/c1-33(63-53(74)41-26-39(72)29-70(41)54(75)52(56(4,5)6)64-35(3)71)40-18-13-36(51-34(2)62-32-80-51)25-42(40)79-24-12-10-11-19-59-47(73)30-68-20-22-69(23-21-68)38-16-14-37(15-17-38)65-45-28-46(61-31-60-45)67(7)55(76)66-50-48(57)43(77-8)27-44(78-9)49(50)58/h13-18,25,27-28,31-33,39,41,52,72H,10-12,19-24,26,29-30H2,1-9H3,(H,59,73)(H,63,74)(H,64,71)(H,66,76)(H,60,61,65)/t33-,39+,41-,52+/m0/s1",MRMAJCGYNDXOKM-NYCPUKLJSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2885,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCCCSC(C)(C)[C@@H](NC(C)=O)C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)CC4)C=C3)=NC=N2)=C1Cl,,,1162.281,1160.42580456,79,7,6,16,C55H70Cl2N12O8S2,"InChI=1S/C55H70Cl2N12O8S2/c1-33(36-12-14-37(15-13-36)50-34(2)61-32-78-50)62-52(73)41-26-40(71)29-69(41)53(74)51(63-35(3)70)55(4,5)79-25-11-9-10-20-58-46(72)30-67-21-23-68(24-22-67)39-18-16-38(17-19-39)64-44-28-45(60-31-59-44)66(6)54(75)65-49-47(56)42(76-7)27-43(77-8)48(49)57/h12-19,27-28,31-33,40-41,51,71H,9-11,20-26,29-30H2,1-8H3,(H,58,72)(H,62,73)(H,63,70)(H,65,75)(H,59,60,64)/t33-,40+,41-,51-/m0/s1",YDWFJDWUHDYBPB-RBDVPONJSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2874,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCOCCOCCOC5=CC6=C7C(=CC=CC7=C5)C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,1071.973,1070.34562259,75,8,4,17,C51H56Cl2N10O12,"InChI=1S/C51H56Cl2N10O12/c1-60(51(69)59-47-45(52)38(70-2)27-39(71-3)46(47)53)41-28-40(55-30-56-41)57-32-7-9-33(10-8-32)62-16-14-61(15-17-62)29-43(65)54-13-18-72-19-20-73-21-22-74-23-24-75-34-25-31-5-4-6-35-44(31)36(26-34)50(68)63(49(35)67)37-11-12-42(64)58-48(37)66/h4-10,25-28,30,37H,11-24,29H2,1-3H3,(H,54,65)(H,59,69)(H,55,56,57)(H,58,64,66)",JFSWWOCDWFNCIB-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3884,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,985.971,984.381614176,69,7,4,13,C49H58Cl2N10O8,"InChI=1S/C49H58Cl2N10O8/c1-58(49(67)57-45-43(50)36(68-2)28-37(69-3)44(45)51)39-29-38(53-30-54-39)55-31-17-19-32(20-18-31)59-24-26-60(27-25-59)41(63)16-11-9-7-5-4-6-8-10-12-23-52-34-15-13-14-33-42(34)48(66)61(47(33)65)35-21-22-40(62)56-46(35)64/h13-15,17-20,28-30,35,52H,4-12,16,21-27H2,1-3H3,(H,57,67)(H,53,54,55)(H,56,62,64)",ZYVXZKHJIKUZFD-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3882,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)CCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,929.863,928.31901392,65,7,4,13,C45H50Cl2N10O8,"InChI=1S/C45H50Cl2N10O8/c1-54(45(63)53-41-39(46)32(64-2)24-33(65-3)40(41)47)35-25-34(49-26-50-35)51-27-13-15-28(16-14-27)55-20-22-56(23-21-55)37(59)12-7-5-4-6-8-19-48-30-11-9-10-29-38(30)44(62)57(43(29)61)31-17-18-36(58)52-42(31)60/h9-11,13-16,24-26,31,48H,4-8,12,17-23H2,1-3H3,(H,53,63)(H,49,50,51)(H,52,58,60)",UHKKYMIGCPAFDW-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3880,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)CCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,901.809,900.287713792,63,7,4,13,C43H46Cl2N10O8,"InChI=1S/C43H46Cl2N10O8/c1-52(43(61)51-39-37(44)30(62-2)22-31(63-3)38(39)45)33-23-32(47-24-48-33)49-25-11-13-26(14-12-25)53-18-20-54(21-19-53)35(57)10-5-4-6-17-46-28-9-7-8-27-36(28)42(60)55(41(27)59)29-15-16-34(56)50-40(29)58/h7-9,11-14,22-24,29,46H,4-6,10,15-21H2,1-3H3,(H,51,61)(H,47,48,49)(H,50,56,58)",SQDJXBHTPRYFOS-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2878,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,70,74,1017.054,1015.36966959,70,7,5,14,C49H59Cl2N11O7S,"InChI=1S/C49H59Cl2N11O7S/c1-28(30-9-11-31(12-10-30)44-29(2)54-27-70-44)55-46(65)35-21-34(63)24-62(35)47(66)45(49(3,4)5)57-40(64)25-60-17-19-61(20-18-60)33-15-13-32(14-16-33)56-38-23-39(53-26-52-38)59(6)48(67)58-43-41(50)36(68-7)22-37(69-8)42(43)51/h9-16,22-23,26-28,34-35,45,63H,17-21,24-25H2,1-8H3,(H,55,65)(H,57,64)(H,58,67)(H,52,53,56)/t28-,34+,35-,45+/m0/s1",WDBUEMWHXKHQNB-AURZXHAXSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2872,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCOC5=CC6=C7C(=CC=CC7=C5)C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,995.922,994.329578604,70,8,4,14,C49H52Cl2N10O9,"InChI=1S/C49H52Cl2N10O9/c1-58(49(67)57-45-43(50)36(68-2)25-37(69-3)44(45)51)39-26-38(53-28-54-39)55-30-11-13-31(14-12-30)60-20-18-59(19-21-60)27-41(63)52-17-6-4-5-7-22-70-32-23-29-9-8-10-33-42(29)34(24-32)48(66)61(47(33)65)35-15-16-40(62)56-46(35)64/h8-14,23-26,28,35H,4-7,15-22,27H2,1-3H3,(H,52,63)(H,57,67)(H,53,54,55)(H,56,62,64)",SDHHYHZXQFOIAW-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2186,P21802,FGFR2,CRBN,O=C(CCCCCCNC(=O)COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCOC1=CC=C(NC2=NC=C3C=CC(=O)N(C4CC5CCC4C5)C3=N2)C=C1,,,832.915,832.354425116,61,8,4,13,C44H48N8O9,"InChI=1S/C44H48N8O9/c53-35(8-3-1-2-4-19-45-37(55)25-61-34-7-5-6-31-39(34)43(59)52(42(31)58)32-16-17-36(54)49-41(32)57)46-20-21-60-30-14-12-29(13-15-30)48-44-47-24-28-11-18-38(56)51(40(28)50-44)33-23-26-9-10-27(33)22-26/h5-7,11-15,18,24,26-27,32-33H,1-4,8-10,16-17,19-23,25H2,(H,45,55)(H,46,53)(H,47,48,50)(H,49,54,57)",BWXWVWXEEUERBK-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2883,P21802,FGFR2,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)NCCOCCC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,,,1118.159,1116.41734805,77,7,6,15,C53H66Cl2N12O9S,"InChI=1S/C53H66Cl2N12O9S/c1-31(33-9-11-34(12-10-33)47-32(2)59-30-77-47)60-49(70)38-25-37(68)28-67(38)50(71)48(53(3,4)5)62-43(69)17-23-76-24-18-56-51(72)66-21-19-65(20-22-66)36-15-13-35(14-16-36)61-41-27-42(58-29-57-41)64(6)52(73)63-46-44(54)39(74-7)26-40(75-8)45(46)55/h9-16,26-27,29-31,37-38,48,68H,17-25,28H2,1-8H3,(H,56,72)(H,60,70)(H,62,69)(H,63,73)(H,57,58,61)/t31-,37+,38-,48+/m0/s1",IBBCKHDOUXMNDD-ATOBMBAHSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2870,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCOC5=CC6=C7C(=CC=CC7=C5)C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,953.841,952.282628412,67,8,4,14,C46H46Cl2N10O9,"InChI=1S/C46H46Cl2N10O9/c1-55(46(64)54-42-40(47)33(65-2)22-34(66-3)41(42)48)36-23-35(50-25-51-36)52-27-8-10-28(11-9-27)57-17-15-56(16-18-57)24-38(60)49-14-5-19-67-29-20-26-6-4-7-30-39(26)31(21-29)45(63)58(44(30)62)32-12-13-37(59)53-43(32)61/h4,6-11,20-23,25,32H,5,12-19,24H2,1-3H3,(H,49,60)(H,54,64)(H,50,51,52)(H,53,59,61)",BSESSTWXMHAUJO-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2875,P21802,FGFR2,CRBN,CCC(=O)NC1=CC=C(CN2C(=O)N(C3=CC(OC)=CC(OC)=C3)CC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCOC6=CC7=C8C(=CC=CC8=C6)C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4)N=C32)C=C1,,,1044.139,1043.42898702,77,10,4,15,C56H57N11O10,"InChI=1S/C56H57N11O10/c1-4-47(68)59-37-11-9-34(10-12-37)31-66-51-36(32-65(56(66)74)40-26-41(75-2)28-42(27-40)76-3)30-58-55(62-51)60-38-13-15-39(16-14-38)64-22-20-63(21-23-64)33-49(70)57-19-6-24-77-43-25-35-7-5-8-44-50(35)45(29-43)54(73)67(53(44)72)46-17-18-48(69)61-52(46)71/h5,7-16,25-30,46H,4,6,17-24,31-33H2,1-3H3,(H,57,70)(H,59,68)(H,58,60,62)(H,61,69,71)",PAANDANLMSMAMR-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2871,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCCCOC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,931.835,930.298278476,65,7,4,14,C44H48Cl2N10O9,"InChI=1S/C44H48Cl2N10O9/c1-53(44(62)52-40-38(45)31(63-2)22-32(64-3)39(40)46)34-23-33(48-25-49-34)50-26-10-12-27(13-11-26)55-19-17-54(18-20-55)24-36(58)47-16-5-4-6-21-65-30-9-7-8-28-37(30)43(61)56(42(28)60)29-14-15-35(57)51-41(29)59/h7-13,22-23,25,29H,4-6,14-21,24H2,1-3H3,(H,47,58)(H,52,62)(H,48,49,50)(H,51,57,59)",FPOHQFPZOFIGNG-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2876,P21802,FGFR2,CRBN,CCC(=O)NC1=CC=C(CN2C(=O)N(C3=CC(OC)=CC(OC)=C3)CC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCOC6=CC7=C8C(=CC=CC8=C6)C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4)N=C32)C=C1,,,1072.193,1071.46028715,79,10,4,15,C58H61N11O10,"InChI=1S/C58H61N11O10/c1-4-49(70)61-39-13-11-36(12-14-39)33-68-53-38(34-67(58(68)76)42-28-43(77-2)30-44(29-42)78-3)32-60-57(64-53)62-40-15-17-41(18-16-40)66-24-22-65(23-25-66)35-51(72)59-21-6-5-7-26-79-45-27-37-9-8-10-46-52(37)47(31-45)56(75)69(55(46)74)48-19-20-50(71)63-54(48)73/h8-18,27-32,48H,4-7,19-26,33-35H2,1-3H3,(H,59,72)(H,61,70)(H,60,62,64)(H,63,71,73)",BKEHRFBIGKYCNA-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2873,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCOCCOC5=CC6=C7C(=CC=CC7=C5)C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,1027.92,1026.31940784,72,8,4,16,C49H52Cl2N10O11,"InChI=1S/C49H52Cl2N10O11/c1-58(49(67)57-45-43(50)36(68-2)25-37(69-3)44(45)51)39-26-38(53-28-54-39)55-30-7-9-31(10-8-30)60-16-14-59(15-17-60)27-41(63)52-13-18-70-19-20-71-21-22-72-32-23-29-5-4-6-33-42(29)34(24-32)48(66)61(47(33)65)35-11-12-40(62)56-46(35)64/h4-10,23-26,28,35H,11-22,27H2,1-3H3,(H,52,63)(H,57,67)(H,53,54,55)(H,56,62,64)",HHJFZKQQXBSGNM-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,2877,P21802,FGFR2,CRBN,CCC(=O)NC1=CC=C(CN2C(=O)N(C3=CC(OC)=CC(OC)=C3)CC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCOCCOCCOC6=CC7=C8C(=CC=CC8=C6)C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4)N=C32)C=C1,,,1118.218,1117.46576646,82,10,4,17,C59H63N11O12,"InChI=1S/C59H63N11O12/c1-4-50(71)62-40-10-8-37(9-11-40)34-69-54-39(35-68(59(69)77)43-29-44(78-2)31-45(30-43)79-3)33-61-58(65-54)63-41-12-14-42(15-13-41)67-21-19-66(20-22-67)36-52(73)60-18-23-80-24-25-81-26-27-82-46-28-38-6-5-7-47-53(38)48(32-46)57(76)70(56(47)75)49-16-17-51(72)64-55(49)74/h5-15,28-33,49H,4,16-27,34-36H2,1-3H3,(H,60,73)(H,62,71)(H,61,63,65)(H,64,72,74)",KKGUTKZKISBKGJ-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3889,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)C5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)=NC=N2)=C1Cl,11.8,80,899.793,898.272063728,63,8,3,13,C43H44Cl2N10O8,"InChI=1S/C43H44Cl2N10O8/c1-51(43(61)50-38-36(44)31(62-2)21-32(63-3)37(38)45)34-22-33(46-23-47-34)48-25-4-6-26(7-5-25)53-16-18-54(19-17-53)40(58)24-12-14-52(15-13-24)27-8-9-28-29(20-27)42(60)55(41(28)59)30-10-11-35(56)49-39(30)57/h4-9,20-24,30H,10-19H2,1-3H3,(H,50,61)(H,46,47,48)(H,49,56,57)",BUEXWHUMUYQITQ-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3885,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,932.823,931.293527444,65,7,5,15,C43H47Cl2N11O9,"InChI=1S/C43H47Cl2N11O9/c1-53(43(62)52-39-37(44)30(63-2)21-31(64-3)38(39)45)33-22-32(48-24-49-33)50-25-7-9-26(10-8-25)55-17-15-54(16-18-55)23-35(58)47-14-20-65-19-13-46-28-6-4-5-27-36(28)42(61)56(41(27)60)29-11-12-34(57)51-40(29)59/h4-10,21-22,24,29,46H,11-20,23H2,1-3H3,(H,47,58)(H,52,62)(H,48,49,50)(H,51,57,59)",GCQGSNAFUMUMCO-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3886,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,976.876,975.319742192,68,7,5,16,C45H51Cl2N11O10,"InChI=1S/C45H51Cl2N11O10/c1-55(45(64)54-41-39(46)32(65-2)23-33(66-3)40(41)47)35-24-34(50-26-51-35)52-27-7-9-28(10-8-27)57-17-15-56(16-18-57)25-37(60)49-14-20-68-22-21-67-19-13-48-30-6-4-5-29-38(30)44(63)58(43(29)62)31-11-12-36(59)53-42(31)61/h4-10,23-24,26,31,48H,11-22,25H2,1-3H3,(H,49,60)(H,54,64)(H,50,51,52)(H,53,59,61)",LZQHTYUPXVENBV-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3887,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,1020.929,1019.34595694,71,7,5,17,C47H55Cl2N11O11,"InChI=1S/C47H55Cl2N11O11/c1-57(47(66)56-43-41(48)34(67-2)25-35(68-3)42(43)49)37-26-36(52-28-53-37)54-29-7-9-30(10-8-29)59-17-15-58(16-18-59)27-39(62)51-14-20-70-22-24-71-23-21-69-19-13-50-32-6-4-5-31-40(32)46(65)60(45(31)64)33-11-12-38(61)55-44(33)63/h4-10,25-26,28,33,50H,11-24,27H2,1-3H3,(H,51,62)(H,56,66)(H,52,53,54)(H,55,61,63)",FKDSZJNNHRNJBD-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3887,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,1020.929,1019.34595694,71,7,5,17,C47H55Cl2N11O11,"InChI=1S/C47H55Cl2N11O11/c1-57(47(66)56-43-41(48)34(67-2)25-35(68-3)42(43)49)37-26-36(52-28-53-37)54-29-7-9-30(10-8-29)59-17-15-58(16-18-59)27-39(62)51-14-20-70-22-24-71-23-21-69-19-13-50-32-6-4-5-31-40(32)46(65)60(45(31)64)33-11-12-38(61)55-44(33)63/h4-10,25-26,28,33,50H,11-24,27H2,1-3H3,(H,51,62)(H,56,66)(H,52,53,54)(H,55,61,63)",FKDSZJNNHRNJBD-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3879,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,888.77,887.267312696,62,7,5,14,C41H43Cl2N11O8,"InChI=1S/C41H43Cl2N11O8/c1-51(41(60)50-37-35(42)28(61-2)19-29(62-3)36(37)43)31-20-30(46-22-47-31)48-23-7-9-24(10-8-23)53-17-15-52(16-18-53)21-33(56)45-14-13-44-26-6-4-5-25-34(26)40(59)54(39(25)58)27-11-12-32(55)49-38(27)57/h4-10,19-20,22,27,44H,11-18,21H2,1-3H3,(H,45,56)(H,50,60)(H,46,47,48)(H,49,55,57)",RDLAONCJPYTFIH-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3881,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,41.5,,930.851,929.314262888,65,7,5,14,C44H49Cl2N11O8,"InChI=1S/C44H49Cl2N11O8/c1-54(44(63)53-40-38(45)31(64-2)22-32(65-3)39(40)46)34-23-33(49-25-50-34)51-26-10-12-27(13-11-26)56-20-18-55(19-21-56)24-36(59)48-17-6-4-5-16-47-29-9-7-8-28-37(29)43(62)57(42(28)61)30-14-15-35(58)52-41(30)60/h7-13,22-23,25,30,47H,4-6,14-21,24H2,1-3H3,(H,48,59)(H,53,63)(H,49,50,51)(H,52,58,60)",LDDCFXPRZCUBQQ-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3883,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3)=NC=N2)=C1Cl,,,972.932,971.36121308,68,7,5,14,C47H55Cl2N11O8,"InChI=1S/C47H55Cl2N11O8/c1-57(47(66)56-43-41(48)34(67-2)25-35(68-3)42(43)49)37-26-36(52-28-53-37)54-29-13-15-30(16-14-29)59-23-21-58(22-24-59)27-39(62)51-20-9-7-5-4-6-8-19-50-32-12-10-11-31-40(32)46(65)60(45(31)64)33-17-18-38(61)55-44(33)63/h10-16,25-26,28,33,50H,4-9,17-24,27H2,1-3H3,(H,51,62)(H,56,66)(H,52,53,54)(H,55,61,63)",HJEDSMLVVBWURN-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3888,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)CCOCC#CC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)=NC=N2)=C1Cl,,,898.761,897.240429252,63,7,3,13,C43H41Cl2N9O9,"InChI=1S/C43H41Cl2N9O9/c1-51(43(60)50-39-37(44)31(61-2)22-32(62-3)38(39)45)34-23-33(46-24-47-34)48-26-7-9-27(10-8-26)52-15-17-53(18-16-52)36(56)14-20-63-19-4-5-25-6-11-28-29(21-25)42(59)54(41(28)58)30-12-13-35(55)49-40(30)57/h6-11,21-24,30H,12-20H2,1-3H3,(H,50,60)(H,46,47,48)(H,49,55,57)",VDRSPVIYVODUBN-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3890,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)CCOCCOCCOC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)=NC=N2)=C1Cl,,,948.818,947.277208684,66,7,3,15,C44H47Cl2N9O11,"InChI=1S/C44H47Cl2N9O11/c1-52(44(61)51-40-38(45)32(62-2)23-33(63-3)39(40)46)35-24-34(47-25-48-35)49-26-4-6-27(7-5-26)53-13-15-54(16-14-53)37(57)12-17-64-18-19-65-20-21-66-28-8-9-29-30(22-28)43(60)55(42(29)59)31-10-11-36(56)50-41(31)58/h4-9,22-25,31H,10-21H2,1-3H3,(H,51,61)(H,47,48,49)(H,50,56,58)",WOWYFVZPUHPBBL-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3891,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)CCOCCOCCOCCOC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)=NC=N2)=C1Cl,,,992.871,991.303423432,69,7,3,16,C46H51Cl2N9O12,"InChI=1S/C46H51Cl2N9O12/c1-54(46(63)53-42-40(47)34(64-2)25-35(65-3)41(42)48)37-26-36(49-27-50-37)51-28-4-6-29(7-5-28)55-13-15-56(16-14-55)39(59)12-17-66-18-19-67-20-21-68-22-23-69-30-8-9-31-32(24-30)45(62)57(44(31)61)33-10-11-38(58)52-43(33)60/h4-9,24-27,33H,10-23H2,1-3H3,(H,53,63)(H,49,50,51)(H,52,58,60)",IZGHMVOJNFVPLV-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 2,3892,P21802,FGFR2,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)NCCOCCOCCNC(=O)C5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)=NC=N2)=C1Cl,,,1088.02,1086.3881561,76,8,5,17,C51H60Cl2N12O11,"InChI=1S/C51H60Cl2N12O11/c1-61(51(72)60-46-44(52)38(73-2)27-39(74-3)45(46)53)41-28-40(56-30-57-41)58-32-4-6-33(7-5-32)64-20-18-62(19-21-64)29-43(67)54-14-22-75-24-25-76-23-15-55-47(68)31-12-16-63(17-13-31)34-8-9-35-36(26-34)50(71)65(49(35)70)37-10-11-42(66)59-48(37)69/h4-9,26-28,30-31,37H,10-25,29H2,1-3H3,(H,54,67)(H,55,68)(H,60,72)(H,56,57,58)(H,59,66,69)",SQQYGJLFYLOYQE-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,2161,P11362,FGFR1,VHL,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCN3CCN(C4=CC=C(NC5=NC=C(Cl)C(NC6=CC=CC=C6S(=O)(=O)C(C)C)=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1073.784,1072.44297885,74,7,5,16,C53H69ClN10O8S2,"InChI=1S/C53H69ClN10O8S2/c1-34(2)74(69,70)45-11-9-8-10-43(45)59-49-42(54)31-55-52(61-49)58-39-16-18-40(19-17-39)63-23-21-62(22-24-63)25-27-72-29-28-71-26-20-46(66)60-48(53(5,6)7)51(68)64-32-41(65)30-44(64)50(67)57-35(3)37-12-14-38(15-13-37)47-36(4)56-33-73-47/h8-19,31,33-35,41,44,48,65H,20-30,32H2,1-7H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t35-,41+,44-,48+/m0/s1",KRCGDZOGRHISNJ-NQGAHEFWSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,2878,P11362,FGFR1,VHL,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,4.35,85,1017.054,1015.36966959,70,7,5,14,C49H59Cl2N11O7S,"InChI=1S/C49H59Cl2N11O7S/c1-28(30-9-11-31(12-10-30)44-29(2)54-27-70-44)55-46(65)35-21-34(63)24-62(35)47(66)45(49(3,4)5)57-40(64)25-60-17-19-61(20-18-60)33-15-13-32(14-16-33)56-38-23-39(53-26-52-38)59(6)48(67)58-43-41(50)36(68-7)22-37(69-8)42(43)51/h9-16,22-23,26-28,34-35,45,63H,17-21,24-25H2,1-8H3,(H,55,65)(H,57,64)(H,58,67)(H,52,53,56)/t28-,34+,35-,45+/m0/s1",WDBUEMWHXKHQNB-AURZXHAXSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5151,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,948.204,947.47276642,68,7,5,12,C51H65N9O7S,"InChI=1S/C51H65N9O7S/c1-30-25-58(39-18-15-37(16-19-39)48(63)54-44-22-38(56-57-44)17-10-34-20-41(66-8)24-42(21-34)67-9)26-31(2)59(30)28-45(62)55-47(51(5,6)7)50(65)60-27-40(61)23-43(60)49(64)53-32(3)35-11-13-36(14-12-35)46-33(4)52-29-68-46/h11-16,18-22,24,29-32,40,43,47,61H,10,17,23,25-28H2,1-9H3,(H,53,64)(H,55,62)(H2,54,56,57,63)/t30-,31+,32-,40+,43-,47+/m0/s1",NXZXTJAYMUMROO-DMPDXKOMSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,3889,P11362,FGFR1,CRBN,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)C5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)=NC=N2)=C1Cl,,,899.793,898.272063728,63,8,3,13,C43H44Cl2N10O8,"InChI=1S/C43H44Cl2N10O8/c1-51(43(61)50-38-36(44)31(62-2)21-32(63-3)37(38)45)34-22-33(46-23-47-34)48-25-4-6-26(7-5-25)53-16-18-54(19-17-53)40(58)24-12-14-52(15-13-24)27-8-9-28-29(20-27)42(60)55(41(28)59)30-10-11-35(56)49-39(30)57/h4-9,20-24,30H,10-19H2,1-3H3,(H,50,61)(H,46,47,48)(H,49,56,57)",BUEXWHUMUYQITQ-UHFFFAOYSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5127,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1124.379,1123.53134392,81,8,6,15,C60H73N11O9S,"InChI=1S/C60H73N11O9S/c1-36-30-69(46-20-17-44(18-21-46)57(75)64-52-26-45(66-67-52)19-10-41-24-49(78-8)28-50(25-41)79-9)31-37(2)70(36)33-53(73)68-62-29-40-11-22-48(23-12-40)80-34-54(74)65-56(60(5,6)7)59(77)71-32-47(72)27-51(71)58(76)63-38(3)42-13-15-43(16-14-42)55-39(4)61-35-81-55/h11-18,20-26,28-29,35-38,47,51,56,72H,10,19,27,30-34H2,1-9H3,(H,63,76)(H,65,74)(H,68,73)(H2,64,66,67,75)/b62-29-/t36-,37+,38-,47+,51-,56+/m0/s1",AXGKLFFXLXIINS-KMTVTLQXSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5128,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1152.433,1151.56264404,83,8,6,15,C62H77N11O9S,"InChI=1S/C62H77N11O9S/c1-38-33-71(48-22-19-46(20-23-48)59(77)66-54-29-47(68-69-54)21-12-43-27-51(80-8)31-52(28-43)81-9)34-39(2)72(38)36-56(76)70-64-32-42-13-24-50(25-14-42)82-26-10-11-55(75)67-58(62(5,6)7)61(79)73-35-49(74)30-53(73)60(78)65-40(3)44-15-17-45(18-16-44)57-41(4)63-37-83-57/h13-20,22-25,27-29,31-32,37-40,49,53,58,74H,10-12,21,26,30,33-36H2,1-9H3,(H,65,78)(H,67,75)(H,70,76)(H2,66,68,69,77)/b64-32-/t38-,39+,40-,49+,53-,58+/m0/s1",QPYYVQHSVGBPFW-LYGCWZTGSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5129,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1166.46,1165.57829411,84,8,6,15,C63H79N11O9S,"InChI=1S/C63H79N11O9S/c1-39-34-72(49-23-20-47(21-24-49)60(78)67-55-30-48(69-70-55)22-13-44-28-52(81-8)32-53(29-44)82-9)35-40(2)73(39)37-57(77)71-65-33-43-14-25-51(26-15-43)83-27-11-10-12-56(76)68-59(63(5,6)7)62(80)74-36-50(75)31-54(74)61(79)66-41(3)45-16-18-46(19-17-45)58-42(4)64-38-84-58/h14-21,23-26,28-30,32-33,38-41,50,54,59,75H,10-13,22,27,31,34-37H2,1-9H3,(H,66,79)(H,68,76)(H,71,77)(H2,67,69,70,78)/b65-33-/t39-,40+,41-,50+,54-,59+/m0/s1",JSACESHBYOQWEJ-MIKSQFANSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5130,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1180.487,1179.59394417,85,8,6,15,C64H81N11O9S,"InChI=1S/C64H81N11O9S/c1-40-35-73(50-24-21-48(22-25-50)61(79)68-56-31-49(70-71-56)23-14-45-29-53(82-8)33-54(30-45)83-9)36-41(2)74(40)38-58(78)72-66-34-44-15-26-52(27-16-44)84-28-12-10-11-13-57(77)69-60(64(5,6)7)63(81)75-37-51(76)32-55(75)62(80)67-42(3)46-17-19-47(20-18-46)59-43(4)65-39-85-59/h15-22,24-27,29-31,33-34,39-42,51,55,60,76H,10-14,23,28,32,35-38H2,1-9H3,(H,67,80)(H,69,77)(H,72,78)(H2,68,70,71,79)/b66-34-/t40-,41+,42-,51+,55-,60+/m0/s1",BWUOOYAKIUDJFS-RJSHNRFRSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5131,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1194.514,1193.60959424,86,8,6,15,C65H83N11O9S,"InChI=1S/C65H83N11O9S/c1-41-36-74(51-25-22-49(23-26-51)62(80)69-57-32-50(71-72-57)24-15-46-30-54(83-8)34-55(31-46)84-9)37-42(2)75(41)39-59(79)73-67-35-45-16-27-53(28-17-45)85-29-13-11-10-12-14-58(78)70-61(65(5,6)7)64(82)76-38-52(77)33-56(76)63(81)68-43(3)47-18-20-48(21-19-47)60-44(4)66-40-86-60/h16-23,25-28,30-32,34-35,40-43,52,56,61,77H,10-15,24,29,33,36-39H2,1-9H3,(H,68,81)(H,70,78)(H,73,79)(H2,69,71,72,80)/b67-35-/t41-,42+,43-,52+,56-,61+/m0/s1",YWBMGQICDIUGJO-XQZXAJIUSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5132,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1208.541,1207.6252443,87,8,6,15,C66H85N11O9S,"InChI=1S/C66H85N11O9S/c1-42-37-75(52-26-23-50(24-27-52)63(81)70-58-33-51(72-73-58)25-16-47-31-55(84-8)35-56(32-47)85-9)38-43(2)76(42)40-60(80)74-68-36-46-17-28-54(29-18-46)86-30-14-12-10-11-13-15-59(79)71-62(66(5,6)7)65(83)77-39-53(78)34-57(77)64(82)69-44(3)48-19-21-49(22-20-48)61-45(4)67-41-87-61/h17-24,26-29,31-33,35-36,41-44,53,57,62,78H,10-16,25,30,34,37-40H2,1-9H3,(H,69,82)(H,71,79)(H,74,80)(H2,70,72,73,81)/b68-36-/t42-,43+,44-,53+,57-,62+/m0/s1",HKZOPZOTOHWXMQ-YHZSVWMESA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5133,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1168.432,1167.55755866,84,8,6,16,C62H77N11O10S,"InChI=1S/C62H77N11O10S/c1-38-32-71(48-20-17-46(18-21-48)59(77)66-54-28-47(68-69-54)19-10-43-26-51(80-8)30-52(27-43)81-9)33-39(2)72(38)35-55(75)70-64-31-42-11-22-50(23-12-42)83-25-24-82-36-56(76)67-58(62(5,6)7)61(79)73-34-49(74)29-53(73)60(78)65-40(3)44-13-15-45(16-14-44)57-41(4)63-37-84-57/h11-18,20-23,26-28,30-31,37-40,49,53,58,74H,10,19,24-25,29,32-36H2,1-9H3,(H,65,78)(H,67,76)(H,70,75)(H2,66,68,69,77)/b64-31-/t38-,39+,40-,49+,53-,58+/m0/s1",HVDCEXBRKPJPET-PIDVBWMTSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5134,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1212.485,1211.58377341,87,8,6,17,C64H81N11O11S,"InChI=1S/C64H81N11O11S/c1-40-34-73(50-20-17-48(18-21-50)61(79)68-56-30-49(70-71-56)19-10-45-28-53(82-8)32-54(29-45)83-9)35-41(2)74(40)37-57(77)72-66-33-44-11-22-52(23-12-44)86-27-26-84-24-25-85-38-58(78)69-60(64(5,6)7)63(81)75-36-51(76)31-55(75)62(80)67-42(3)46-13-15-47(16-14-46)59-43(4)65-39-87-59/h11-18,20-23,28-30,32-33,39-42,51,55,60,76H,10,19,24-27,31,34-38H2,1-9H3,(H,67,80)(H,69,78)(H,72,77)(H2,68,70,71,79)/b66-33-/t40-,41+,42-,51+,55-,60+/m0/s1",HMVBEYNDBBAUIG-GXTROXEUSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5135,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCOCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1256.538,1255.60998816,90,8,6,18,C66H85N11O12S,"InChI=1S/C66H85N11O12S/c1-42-36-75(52-20-17-50(18-21-52)63(81)70-58-32-51(72-73-58)19-10-47-30-55(84-8)34-56(31-47)85-9)37-43(2)76(42)39-59(79)74-68-35-46-11-22-54(23-12-46)89-29-28-87-25-24-86-26-27-88-40-60(80)71-62(66(5,6)7)65(83)77-38-53(78)33-57(77)64(82)69-44(3)48-13-15-49(16-14-48)61-45(4)67-41-90-61/h11-18,20-23,30-32,34-35,41-44,53,57,62,78H,10,19,24-29,33,36-40H2,1-9H3,(H,69,82)(H,71,80)(H,74,79)(H2,70,72,73,81)/b68-35-/t42-,43+,44-,53+,57-,62+/m0/s1",WWMGOBCRJJJMFG-IPYPQHNZSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5136,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1300.591,1299.63620291,93,8,6,19,C68H89N11O13S,"InChI=1S/C68H89N11O13S/c1-44-38-77(54-20-17-52(18-21-54)65(83)72-60-34-53(74-75-60)19-10-49-32-57(86-8)36-58(33-49)87-9)39-45(2)78(44)41-61(81)76-70-37-48-11-22-56(23-12-48)92-31-30-90-27-26-88-24-25-89-28-29-91-42-62(82)73-64(68(5,6)7)67(85)79-40-55(80)35-59(79)66(84)71-46(3)50-13-15-51(16-14-50)63-47(4)69-43-93-63/h11-18,20-23,32-34,36-37,43-46,55,59,64,80H,10,19,24-31,35,38-42H2,1-9H3,(H,71,84)(H,73,82)(H,76,81)(H2,72,74,75,83)/b70-37-/t44-,45+,46-,55+,59-,64+/m0/s1",CXHXJHCIVSXXMN-PUECKKCRSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5137,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCOCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1344.644,1343.66241766,96,8,6,20,C70H93N11O14S,"InChI=1S/C70H93N11O14S/c1-46-40-79(56-20-17-54(18-21-56)67(85)74-62-36-55(76-77-62)19-10-51-34-59(88-8)38-60(35-51)89-9)41-47(2)80(46)43-63(83)78-72-39-50-11-22-58(23-12-50)95-33-32-93-29-28-91-25-24-90-26-27-92-30-31-94-44-64(84)75-66(70(5,6)7)69(87)81-42-57(82)37-61(81)68(86)73-48(3)52-13-15-53(16-14-52)65-49(4)71-45-96-65/h11-18,20-23,34-36,38-39,45-48,57,61,66,82H,10,19,24-33,37,40-44H2,1-9H3,(H,73,86)(H,75,84)(H,78,83)(H2,74,76,77,85)/b72-39-/t46-,47+,48-,57+,61-,66+/m0/s1",GSEFNZXZUMOIGR-VSYIEZNLSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5138,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C\C5=CC=C(OCCOCCOCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1388.697,1387.6886324,99,8,6,21,C72H97N11O15S,"InChI=1S/C72H97N11O15S/c1-48-42-81(58-20-17-56(18-21-58)69(87)76-64-38-57(78-79-64)19-10-53-36-61(90-8)40-62(37-53)91-9)43-49(2)82(48)45-65(85)80-74-41-52-11-22-60(23-12-52)98-35-34-96-31-30-94-27-26-92-24-25-93-28-29-95-32-33-97-46-66(86)77-68(72(5,6)7)71(89)83-44-59(84)39-63(83)70(88)75-50(3)54-13-15-55(16-14-54)67-51(4)73-47-99-67/h11-18,20-23,36-38,40-41,47-50,59,63,68,84H,10,19,24-35,39,42-46H2,1-9H3,(H,75,88)(H,77,86)(H,80,85)(H2,76,78,79,87)/b74-41-/t48-,49+,50-,59+,63-,68+/m0/s1",NBGVHQIMRUMNOH-HQNUFBMJSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5139,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1021.145,1020.44938812,75,8,5,14,C55H60N10O10,"InChI=1S/C55H60N10O10/c1-35-30-63(42-16-13-40(14-17-42)53(69)58-49-27-41(60-61-49)15-10-38-25-44(72-3)28-45(26-38)73-4)31-36(2)64(35)33-51(67)62-57-29-37-11-18-43(19-12-37)75-24-23-74-34-52(68)56-22-6-8-39-7-5-9-46-47(39)32-65(55(46)71)48-20-21-50(66)59-54(48)70/h5,7,9,11-14,16-19,25-29,35-36,48H,10,15,20-24,30-34H2,1-4H3,(H,56,68)(H,62,67)(H,59,66,70)(H2,58,60,61,69)/b57-29+/t35-,36+,48?",AXAOTIVSXYEOIV-KYSLNZHNSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5140,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCCOCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1065.198,1064.47560287,78,8,5,15,C57H64N10O11,"InChI=1S/C57H64N10O11/c1-37-32-65(44-16-13-42(14-17-44)55(71)60-51-29-43(62-63-51)15-10-40-27-46(74-3)30-47(28-40)75-4)33-38(2)66(37)35-53(69)64-59-31-39-11-18-45(19-12-39)78-26-25-76-23-24-77-36-54(70)58-22-6-8-41-7-5-9-48-49(41)34-67(57(48)73)50-20-21-52(68)61-56(50)72/h5,7,9,11-14,16-19,27-31,37-38,50H,10,15,20-26,32-36H2,1-4H3,(H,58,70)(H,64,69)(H,61,68,72)(H2,60,62,63,71)/b59-31+/t37-,38+,50?",XQBGSGHIQQLIFB-TWWMJXPJSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5141,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCCOCCOCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1109.251,1108.50181762,81,8,5,16,C59H68N10O12,"InChI=1S/C59H68N10O12/c1-39-34-67(46-16-13-44(14-17-46)57(73)62-53-31-45(64-65-53)15-10-42-29-48(76-3)32-49(30-42)77-4)35-40(2)68(39)37-55(71)66-61-33-41-11-18-47(19-12-41)81-28-27-79-24-23-78-25-26-80-38-56(72)60-22-6-8-43-7-5-9-50-51(43)36-69(59(50)75)52-20-21-54(70)63-58(52)74/h5,7,9,11-14,16-19,29-33,39-40,52H,10,15,20-28,34-38H2,1-4H3,(H,60,72)(H,66,71)(H,63,70,74)(H2,62,64,65,73)/b61-33+/t39-,40+,52?",KMAFXIYXYAOFFN-JIFLKELTSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5142,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCCOCCOCCOCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1153.304,1152.52803236,84,8,5,17,C61H72N10O13,"InChI=1S/C61H72N10O13/c1-41-36-69(48-16-13-46(14-17-48)59(75)64-55-33-47(66-67-55)15-10-44-31-50(78-3)34-51(32-44)79-4)37-42(2)70(41)39-57(73)68-63-35-43-11-18-49(19-12-43)84-30-29-82-26-25-80-23-24-81-27-28-83-40-58(74)62-22-6-8-45-7-5-9-52-53(45)38-71(61(52)77)54-20-21-56(72)65-60(54)76/h5,7,9,11-14,16-19,31-35,41-42,54H,10,15,20-30,36-40H2,1-4H3,(H,62,74)(H,68,73)(H,65,72,76)(H2,64,66,67,75)/b63-35+/t41-,42+,54?",MFSDQUHZONGBKN-OHHMYBMGSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5143,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCCOCCOCCOCCOCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1197.357,1196.55424711,87,8,5,18,C63H76N10O14,"InChI=1S/C63H76N10O14/c1-43-38-71(50-16-13-48(14-17-50)61(77)66-57-35-49(68-69-57)15-10-46-33-52(80-3)36-53(34-46)81-4)39-44(2)72(43)41-59(75)70-65-37-45-11-18-51(19-12-45)87-32-31-85-28-27-83-24-23-82-25-26-84-29-30-86-42-60(76)64-22-6-8-47-7-5-9-54-55(47)40-73(63(54)79)56-20-21-58(74)67-62(56)78/h5,7,9,11-14,16-19,33-37,43-44,56H,10,15,20-32,38-42H2,1-4H3,(H,64,76)(H,70,75)(H,67,74,78)(H2,66,68,69,77)/b65-37+/t43-,44+,56?",UWZISXFYDWXMAK-ZNYNUWIESA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5144,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCCOCCOCCOCCOCCOCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1241.41,1240.58046186,90,8,5,19,C65H80N10O15,"InChI=1S/C65H80N10O15/c1-45-40-73(52-16-13-50(14-17-52)63(79)68-59-37-51(70-71-59)15-10-48-35-54(82-3)38-55(36-48)83-4)41-46(2)74(45)43-61(77)72-67-39-47-11-18-53(19-12-47)90-34-33-88-30-29-86-26-25-84-23-24-85-27-28-87-31-32-89-44-62(78)66-22-6-8-49-7-5-9-56-57(49)42-75(65(56)81)58-20-21-60(76)69-64(58)80/h5,7,9,11-14,16-19,35-39,45-46,58H,10,15,20-34,40-44H2,1-4H3,(H,66,78)(H,72,77)(H,69,76,80)(H2,68,70,71,79)/b67-39+/t45-,46+,58?",PUVASRCPHKJTRD-YKSKIPPASA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5145,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,977.092,976.423173372,72,8,5,13,C53H56N10O9,"InChI=1S/C53H56N10O9/c1-33-28-61(40-16-13-38(14-17-40)51(67)56-47-25-39(58-59-47)15-10-36-23-42(70-3)26-43(24-36)71-4)29-34(2)62(33)31-49(65)60-55-27-35-11-18-41(19-12-35)72-32-50(66)54-22-6-8-37-7-5-9-44-45(37)30-63(53(44)69)46-20-21-48(64)57-52(46)68/h5,7,9,11-14,16-19,23-27,33-34,46H,10,15,20-22,28-32H2,1-4H3,(H,54,66)(H,60,65)(H,57,64,68)(H2,56,58,59,67)/b55-27+/t33-,34+,46?",QQPUZQMZECLXEW-XUKOKOCCSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5146,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCC(=O)NCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1005.146,1004.4544735,74,8,5,13,C55H60N10O9,"InChI=1S/C55H60N10O9/c1-35-30-63(42-18-15-40(16-19-42)53(69)58-49-27-41(60-61-49)17-12-38-25-44(72-3)28-45(26-38)73-4)31-36(2)64(35)33-51(67)62-57-29-37-13-20-43(21-14-37)74-34-52(68)56-24-7-5-6-9-39-10-8-11-46-47(39)32-65(55(46)71)48-22-23-50(66)59-54(48)70/h8,10-11,13-16,18-21,25-29,35-36,48H,5,7,12,17,22-24,30-34H2,1-4H3,(H,56,68)(H,62,67)(H,59,66,70)(H2,58,60,61,69)/b57-29+/t35-,36+,48?",QIGUXSWRTUGGCG-KYSLNZHNSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5147,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCC(=O)NCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1019.173,1018.47012356,75,8,5,13,C56H62N10O9,"InChI=1S/C56H62N10O9/c1-36-31-64(43-19-16-41(17-20-43)54(70)59-50-28-42(61-62-50)18-13-39-26-45(73-3)29-46(27-39)74-4)32-37(2)65(36)34-52(68)63-58-30-38-14-21-44(22-15-38)75-35-53(69)57-25-8-6-5-7-10-40-11-9-12-47-48(40)33-66(56(47)72)49-23-24-51(67)60-55(49)71/h9,11-12,14-17,19-22,26-30,36-37,49H,5-6,8,13,18,23-25,31-35H2,1-4H3,(H,57,69)(H,63,68)(H,60,67,71)(H2,59,61,62,70)/b58-30+/t36-,37+,49?",PGZQYTPXNVHPNG-SZRNHCHFSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5148,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCC(=O)NCCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1033.2,1032.48577363,76,8,5,13,C57H64N10O9,"InChI=1S/C57H64N10O9/c1-37-32-65(44-20-17-42(18-21-44)55(71)60-51-29-43(62-63-51)19-14-40-27-46(74-3)30-47(28-40)75-4)33-38(2)66(37)35-53(69)64-59-31-39-15-22-45(23-16-39)76-36-54(70)58-26-9-7-5-6-8-11-41-12-10-13-48-49(41)34-67(57(48)73)50-24-25-52(68)61-56(50)72/h10,12-13,15-18,20-23,27-31,37-38,50H,5-7,9,14,19,24-26,32-36H2,1-4H3,(H,58,70)(H,64,69)(H,61,68,72)(H2,60,62,63,71)/b59-31+/t37-,38+,50?",RTMIZGZPPAQDRK-TWWMJXPJSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5149,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCC(=O)NCCCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1047.227,1046.50142369,77,8,5,13,C58H66N10O9,"InChI=1S/C58H66N10O9/c1-38-33-66(45-21-18-43(19-22-45)56(72)61-52-30-44(63-64-52)20-15-41-28-47(75-3)31-48(29-41)76-4)34-39(2)67(38)36-54(70)65-60-32-40-16-23-46(24-17-40)77-37-55(71)59-27-10-8-6-5-7-9-12-42-13-11-14-49-50(42)35-68(58(49)74)51-25-26-53(69)62-57(51)73/h11,13-14,16-19,21-24,28-32,38-39,51H,5-8,10,15,20,25-27,33-37H2,1-4H3,(H,59,71)(H,65,70)(H,62,69,73)(H2,61,63,64,72)/b60-32+/t38-,39+,51?",ULZAHKQFVQVHEJ-YQWQRLRPSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5150,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)N/N=C/C5=CC=C(OCC(=O)NCCCCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1061.254,1060.51707376,78,8,5,13,C59H68N10O9,"InChI=1S/C59H68N10O9/c1-39-34-67(46-22-19-44(20-23-46)57(73)62-53-31-45(64-65-53)21-16-42-29-48(76-3)32-49(30-42)77-4)35-40(2)68(39)37-55(71)66-61-33-41-17-24-47(25-18-41)78-38-56(72)60-28-11-9-7-5-6-8-10-13-43-14-12-15-50-51(43)36-69(59(50)75)52-26-27-54(70)63-58(52)74/h12,14-15,17-20,22-25,29-33,39-40,52H,5-9,11,16,21,26-28,34-38H2,1-4H3,(H,60,72)(H,66,71)(H,63,70,74)(H2,62,64,65,73)/b61-33+/t39-,40+,52?",YOTKEBRPQREQAL-JIFLKELTSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5152,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)NCCC5=CC=C(OCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1125.407,1124.55174501,81,8,6,14,C61H76N10O9S,"InChI=1S/C61H76N10O9S/c1-37-31-69(47-20-17-45(18-21-47)58(75)65-53-28-46(67-68-53)19-10-42-26-50(78-8)30-51(27-42)79-9)32-38(2)70(37)34-54(73)62-25-24-41-11-22-49(23-12-41)80-35-55(74)66-57(61(5,6)7)60(77)71-33-48(72)29-52(71)59(76)64-39(3)43-13-15-44(16-14-43)56-40(4)63-36-81-56/h11-18,20-23,26-28,30,36-39,48,52,57,72H,10,19,24-25,29,31-35H2,1-9H3,(H,62,73)(H,64,76)(H,66,74)(H2,65,67,68,75)/t37-,38+,39-,48+,52-,57+/m0/s1",YTTVAAVPYIYNRH-HHNAXFNBSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5153,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)NCCC5=CC=C(OCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1139.434,1138.56739508,82,8,6,14,C62H78N10O9S,"InChI=1S/C62H78N10O9S/c1-38-33-70(48-20-17-46(18-21-48)59(76)66-54-30-47(68-69-54)19-10-43-28-51(79-8)32-52(29-43)80-9)34-39(2)71(38)36-56(75)63-26-24-42-11-22-50(23-12-42)81-27-25-55(74)67-58(62(5,6)7)61(78)72-35-49(73)31-53(72)60(77)65-40(3)44-13-15-45(16-14-44)57-41(4)64-37-82-57/h11-18,20-23,28-30,32,37-40,49,53,58,73H,10,19,24-27,31,33-36H2,1-9H3,(H,63,75)(H,65,77)(H,67,74)(H2,66,68,69,76)/t38-,39+,40-,49+,53-,58+/m0/s1",TWIDFPNUXSYEMC-QRHRBQEQSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5154,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)NCCC5=CC=C(OCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1153.461,1152.58304514,83,8,6,14,C63H80N10O9S,"InChI=1S/C63H80N10O9S/c1-39-34-71(49-22-19-47(20-23-49)60(77)67-55-31-48(69-70-55)21-12-44-29-52(80-8)33-53(30-44)81-9)35-40(2)72(39)37-57(76)64-27-26-43-13-24-51(25-14-43)82-28-10-11-56(75)68-59(63(5,6)7)62(79)73-36-50(74)32-54(73)61(78)66-41(3)45-15-17-46(18-16-45)58-42(4)65-38-83-58/h13-20,22-25,29-31,33,38-41,50,54,59,74H,10-12,21,26-28,32,34-37H2,1-9H3,(H,64,76)(H,66,78)(H,68,75)(H2,67,69,70,77)/t39-,40+,41-,50+,54-,59+/m0/s1",HQAXFZULDALGFX-SOGGWDSGSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5155,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)NCCC5=CC=C(OCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1167.488,1166.5986952,84,8,6,14,C64H82N10O9S,"InChI=1S/C64H82N10O9S/c1-40-35-72(50-23-20-48(21-24-50)61(78)68-56-32-49(70-71-56)22-13-45-30-53(81-8)34-54(31-45)82-9)36-41(2)73(40)38-58(77)65-28-27-44-14-25-52(26-15-44)83-29-11-10-12-57(76)69-60(64(5,6)7)63(80)74-37-51(75)33-55(74)62(79)67-42(3)46-16-18-47(19-17-46)59-43(4)66-39-84-59/h14-21,23-26,30-32,34,39-42,51,55,60,75H,10-13,22,27-29,33,35-38H2,1-9H3,(H,65,77)(H,67,79)(H,69,76)(H2,68,70,71,78)/t40-,41+,42-,51+,55-,60+/m0/s1",RXHHYMYOACWMHR-UYJUHQRNSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5156,P11362,FGFR1,VHL,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)NCCC5=CC=C(OCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1181.515,1180.61434527,85,8,6,14,C65H84N10O9S,"InChI=1S/C65H84N10O9S/c1-41-36-73(51-24-21-49(22-25-51)62(79)69-57-33-50(71-72-57)23-14-46-31-54(82-8)35-55(32-46)83-9)37-42(2)74(41)39-59(78)66-29-28-45-15-26-53(27-16-45)84-30-12-10-11-13-58(77)70-61(65(5,6)7)64(81)75-38-52(76)34-56(75)63(80)68-43(3)47-17-19-48(20-18-47)60-44(4)67-40-85-60/h15-22,24-27,31-33,35,40-43,52,56,61,76H,10-14,23,28-30,34,36-39H2,1-9H3,(H,66,78)(H,68,80)(H,70,77)(H2,69,71,72,79)/t41-,42+,43-,52+,56-,61+/m0/s1",KGFPFMCABAUHDI-BFTACKNWSA-N
DB00039,Palifermin,BiotechDrug,Fibroblast growth factor receptor 1,5157,P11362,FGFR1,CRBN,COC1=CC(CCC2=CC(NC(=O)C3=CC=C(N4C[C@H](C)N(CC(=O)NCCC5=CC=C(OCCOCCOCC(=O)NCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)C=C5)[C@H](C)C4)C=C3)=N[NH]2)=CC(OC)=C1,,,1066.226,1065.49600396,78,8,5,14,C58H67N9O11,"InChI=1S/C58H67N9O11/c1-38-33-65(45-16-13-43(14-17-45)56(71)61-52-31-44(63-64-52)15-10-41-29-47(74-3)32-48(30-41)75-4)34-39(2)66(38)36-54(69)60-24-22-40-11-18-46(19-12-40)78-28-27-76-25-26-77-37-55(70)59-23-6-8-42-7-5-9-49-50(42)35-67(58(49)73)51-20-21-53(68)62-57(51)72/h5,7,9,11-14,16-19,29-32,38-39,51H,10,15,20-28,33-37H2,1-4H3,(H,59,70)(H,60,69)(H,62,68,72)(H2,61,63,64,71)/t38-,39+,51?",BEINRJCYNPMXHE-TUZYQDNCSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1347,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,716.755,716.270695492,53,7,4,13,C38H36N8O7,"InChI=1S/C38H36N8O7/c47-33-13-12-31(35(48)45-33)46-36(49)28-5-3-7-30(34(28)37(46)50)39-16-17-51-18-19-52-20-21-53-27-10-8-25(9-11-27)43-38-40-15-14-32(44-38)42-26-22-24-4-1-2-6-29(24)41-23-26/h1-11,14-15,22-23,31,39H,12-13,16-21H2,(H,45,47,48)(H2,40,42,43,44)",VQLXJBPQVMWNGC-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1346,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,672.702,672.244480744,50,7,4,12,C36H32N8O6,"InChI=1S/C36H32N8O6/c45-31-13-12-29(33(46)43-31)44-34(47)26-5-3-7-28(32(26)35(44)48)37-16-17-49-18-19-50-25-10-8-23(9-11-25)41-36-38-15-14-30(42-36)40-24-20-22-4-1-2-6-27(22)39-21-24/h1-11,14-15,20-21,29,37H,12-13,16-19H2,(H,43,45,46)(H2,38,40,41,42)",BLGABOHGKRXYSB-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1348,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,760.808,760.29691024,56,7,4,14,C40H40N8O8,"InChI=1S/C40H40N8O8/c49-35-13-12-33(37(50)47-35)48-38(51)30-5-3-7-32(36(30)39(48)52)41-16-17-53-18-19-54-20-21-55-22-23-56-29-10-8-27(9-11-29)45-40-42-15-14-34(46-40)44-28-24-26-4-1-2-6-31(26)43-25-28/h1-11,14-15,24-25,33,41H,12-13,16-23H2,(H,47,49,50)(H2,42,44,45,46)",NNFLJXWHNNZGBH-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1349,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,625.646,625.239729712,46,6,5,12,C31H31N9O6,"InChI=1S/C31H31N9O6/c1-18-17-25(39-38-18)35-24-11-12-33-31(36-24)34-19-5-7-20(8-6-19)46-16-15-45-14-13-32-22-4-2-3-21-27(22)30(44)40(29(21)43)23-9-10-26(41)37-28(23)42/h2-8,11-12,17,23,32H,9-10,13-16H2,1H3,(H,37,41,42)(H3,33,34,35,36,38,39)",YEBGDZYCAZJQHH-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1351,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,660.091,659.20075736,47,6,5,12,C31H30ClN9O6,"InChI=1S/C31H30ClN9O6/c1-17-15-24(40-39-17)36-27-21(32)16-34-31(38-27)35-18-5-7-19(8-6-18)47-14-13-46-12-11-33-22-4-2-3-20-26(22)30(45)41(29(20)44)23-9-10-25(42)37-28(23)43/h2-8,15-16,23,33H,9-14H2,1H3,(H,37,42,43)(H3,34,35,36,38,39,40)",IOHSXHAPQQQUGP-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1350,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,669.699,669.26594446,49,6,5,13,C33H35N9O7,"InChI=1S/C33H35N9O7/c1-20-19-27(41-40-20)37-26-11-12-35-33(38-26)36-21-5-7-22(8-6-21)49-18-17-48-16-15-47-14-13-34-24-4-2-3-23-29(24)32(46)42(31(23)45)25-9-10-28(43)39-30(25)44/h2-8,11-12,19,25,34H,9-10,13-18H2,1H3,(H,39,43,44)(H3,35,36,37,38,40,41)",KSJXWXGDPRCSIV-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1352,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,704.144,703.226972108,50,6,5,13,C33H34ClN9O7,"InChI=1S/C33H34ClN9O7/c1-19-17-26(42-41-19)38-29-23(34)18-36-33(40-29)37-20-5-7-21(8-6-20)50-16-15-49-14-13-48-12-11-35-24-4-2-3-22-28(24)32(47)43(31(22)46)25-9-10-27(44)39-30(25)45/h2-8,17-18,25,35H,9-16H2,1H3,(H,39,44,45)(H3,36,37,38,40,41,42)",UYDSYJMBAOFSTK-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1353,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,738.205,737.247707552,53,7,4,13,C37H36ClN9O6,"InChI=1S/C37H36ClN9O6/c38-23-7-5-22(6-8-23)32-31-33(39)42-21-43-34(31)46(45-32)17-2-15-40-24-9-11-25(12-10-24)53-20-19-52-18-16-41-27-4-1-3-26-30(27)37(51)47(36(26)50)28-13-14-29(48)44-35(28)49/h1,3-12,21,28,40-41H,2,13-20H2,(H2,39,42,43)(H,44,48,49)",XWGDNKJJVPSPJY-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1354,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,782.258,781.2739223,56,7,4,14,C39H40ClN9O7,"InChI=1S/C39H40ClN9O7/c40-25-7-5-24(6-8-25)34-33-35(41)44-23-45-36(33)48(47-34)17-2-15-42-26-9-11-27(12-10-26)56-22-21-55-20-19-54-18-16-43-29-4-1-3-28-32(29)39(53)49(38(28)52)30-13-14-31(50)46-37(30)51/h1,3-12,23,30,42-43H,2,13-22H2,(H2,41,44,45)(H,46,50,51)",ZOQUWFJXKUZLHH-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1355,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,819.283,818.280404648,59,8,4,16,C40H39ClN12O6,"InChI=1S/C40H39ClN12O6/c41-25-7-5-24(6-8-25)35-34-36(42)45-23-46-37(34)52(49-35)17-2-16-51-22-27(48-50-51)21-44-26-9-11-28(12-10-26)59-20-19-58-18-15-43-30-4-1-3-29-33(30)40(57)53(39(29)56)31-13-14-32(54)47-38(31)55/h1,3-12,22-23,31,43-44H,2,13-21H2,(H2,42,45,46)(H,47,54,55)",YEBIAPTXRZULTM-UHFFFAOYSA-N
DB00046,Insulin Lispro,BiotechDrug,Insulin-like growth factor 1 receptor,1356,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,863.336,862.306619396,62,8,4,17,C42H43ClN12O7,"InChI=1S/C42H43ClN12O7/c43-27-7-5-26(6-8-27)37-36-38(44)47-25-48-39(36)54(51-37)17-2-16-53-24-29(50-52-53)23-46-28-9-11-30(12-10-28)62-22-21-61-20-19-60-18-15-45-32-4-1-3-31-35(32)42(59)55(41(31)58)33-13-14-34(56)49-40(33)57/h1,3-12,24-25,33,45-46H,2,13-23H2,(H2,44,47,48)(H,49,56,57)",UPKHTGRZRRRAME-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1347,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,716.755,716.270695492,53,7,4,13,C38H36N8O7,"InChI=1S/C38H36N8O7/c47-33-13-12-31(35(48)45-33)46-36(49)28-5-3-7-30(34(28)37(46)50)39-16-17-51-18-19-52-20-21-53-27-10-8-25(9-11-27)43-38-40-15-14-32(44-38)42-26-22-24-4-1-2-6-29(24)41-23-26/h1-11,14-15,22-23,31,39H,12-13,16-21H2,(H,45,47,48)(H2,40,42,43,44)",VQLXJBPQVMWNGC-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1346,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,672.702,672.244480744,50,7,4,12,C36H32N8O6,"InChI=1S/C36H32N8O6/c45-31-13-12-29(33(46)43-31)44-34(47)26-5-3-7-28(32(26)35(44)48)37-16-17-49-18-19-50-25-10-8-23(9-11-25)41-36-38-15-14-30(42-36)40-24-20-22-4-1-2-6-27(22)39-21-24/h1-11,14-15,20-21,29,37H,12-13,16-19H2,(H,43,45,46)(H2,38,40,41,42)",BLGABOHGKRXYSB-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1348,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,760.808,760.29691024,56,7,4,14,C40H40N8O8,"InChI=1S/C40H40N8O8/c49-35-13-12-33(37(50)47-35)48-38(51)30-5-3-7-32(36(30)39(48)52)41-16-17-53-18-19-54-20-21-55-22-23-56-29-10-8-27(9-11-29)45-40-42-15-14-34(46-40)44-28-24-26-4-1-2-6-31(26)43-25-28/h1-11,14-15,24-25,33,41H,12-13,16-23H2,(H,47,49,50)(H2,42,44,45,46)",NNFLJXWHNNZGBH-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1349,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,625.646,625.239729712,46,6,5,12,C31H31N9O6,"InChI=1S/C31H31N9O6/c1-18-17-25(39-38-18)35-24-11-12-33-31(36-24)34-19-5-7-20(8-6-19)46-16-15-45-14-13-32-22-4-2-3-21-27(22)30(44)40(29(21)43)23-9-10-26(41)37-28(23)42/h2-8,11-12,17,23,32H,9-10,13-16H2,1H3,(H,37,41,42)(H3,33,34,35,36,38,39)",YEBGDZYCAZJQHH-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1351,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,660.091,659.20075736,47,6,5,12,C31H30ClN9O6,"InChI=1S/C31H30ClN9O6/c1-17-15-24(40-39-17)36-27-21(32)16-34-31(38-27)35-18-5-7-19(8-6-18)47-14-13-46-12-11-33-22-4-2-3-20-26(22)30(45)41(29(20)44)23-9-10-25(42)37-28(23)43/h2-8,15-16,23,33H,9-14H2,1H3,(H,37,42,43)(H3,34,35,36,38,39,40)",IOHSXHAPQQQUGP-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1350,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,669.699,669.26594446,49,6,5,13,C33H35N9O7,"InChI=1S/C33H35N9O7/c1-20-19-27(41-40-20)37-26-11-12-35-33(38-26)36-21-5-7-22(8-6-21)49-18-17-48-16-15-47-14-13-34-24-4-2-3-23-29(24)32(46)42(31(23)45)25-9-10-28(43)39-30(25)44/h2-8,11-12,19,25,34H,9-10,13-18H2,1H3,(H,39,43,44)(H3,35,36,37,38,40,41)",KSJXWXGDPRCSIV-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1352,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,704.144,703.226972108,50,6,5,13,C33H34ClN9O7,"InChI=1S/C33H34ClN9O7/c1-19-17-26(42-41-19)38-29-23(34)18-36-33(40-29)37-20-5-7-21(8-6-20)50-16-15-49-14-13-48-12-11-35-24-4-2-3-22-28(24)32(47)43(31(22)46)25-9-10-27(44)39-30(25)45/h2-8,17-18,25,35H,9-16H2,1H3,(H,39,44,45)(H3,36,37,38,40,41,42)",UYDSYJMBAOFSTK-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1353,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,738.205,737.247707552,53,7,4,13,C37H36ClN9O6,"InChI=1S/C37H36ClN9O6/c38-23-7-5-22(6-8-23)32-31-33(39)42-21-43-34(31)46(45-32)17-2-15-40-24-9-11-25(12-10-24)53-20-19-52-18-16-41-27-4-1-3-26-30(27)37(51)47(36(26)50)28-13-14-29(48)44-35(28)49/h1,3-12,21,28,40-41H,2,13-20H2,(H2,39,42,43)(H,44,48,49)",XWGDNKJJVPSPJY-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1354,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,782.258,781.2739223,56,7,4,14,C39H40ClN9O7,"InChI=1S/C39H40ClN9O7/c40-25-7-5-24(6-8-25)34-33-35(41)44-23-45-36(33)48(47-34)17-2-15-42-26-9-11-27(12-10-26)56-22-21-55-20-19-54-18-16-43-29-4-1-3-28-32(29)39(53)49(38(28)52)30-13-14-31(50)46-37(30)51/h1,3-12,23,30,42-43H,2,13-22H2,(H2,41,44,45)(H,46,50,51)",ZOQUWFJXKUZLHH-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1355,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,819.283,818.280404648,59,8,4,16,C40H39ClN12O6,"InChI=1S/C40H39ClN12O6/c41-25-7-5-24(6-8-25)35-34-36(42)45-23-46-37(34)52(49-35)17-2-16-51-22-27(48-50-51)21-44-26-9-11-28(12-10-26)59-20-19-58-18-15-43-30-4-1-3-29-33(30)40(57)53(39(29)56)31-13-14-32(54)47-38(31)55/h1,3-12,22-23,31,43-44H,2,13-21H2,(H2,42,45,46)(H,47,54,55)",YEBIAPTXRZULTM-UHFFFAOYSA-N
DB00047,Insulin Glargine,BiotechDrug,Insulin-like growth factor 1 receptor,1356,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,863.336,862.306619396,62,8,4,17,C42H43ClN12O7,"InChI=1S/C42H43ClN12O7/c43-27-7-5-26(6-8-27)37-36-38(44)47-25-48-39(36)54(51-37)17-2-16-53-24-29(50-52-53)23-46-28-9-11-30(12-10-28)62-22-21-61-20-19-60-18-15-45-32-4-1-3-31-35(32)42(59)55(41(31)58)33-13-14-34(56)49-40(33)57/h1,3-12,24-25,33,45-46H,2,13-23H2,(H2,44,47,48)(H,49,56,57)",UPKHTGRZRRRAME-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1347,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,716.755,716.270695492,53,7,4,13,C38H36N8O7,"InChI=1S/C38H36N8O7/c47-33-13-12-31(35(48)45-33)46-36(49)28-5-3-7-30(34(28)37(46)50)39-16-17-51-18-19-52-20-21-53-27-10-8-25(9-11-27)43-38-40-15-14-32(44-38)42-26-22-24-4-1-2-6-29(24)41-23-26/h1-11,14-15,22-23,31,39H,12-13,16-21H2,(H,45,47,48)(H2,40,42,43,44)",VQLXJBPQVMWNGC-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1346,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,672.702,672.244480744,50,7,4,12,C36H32N8O6,"InChI=1S/C36H32N8O6/c45-31-13-12-29(33(46)43-31)44-34(47)26-5-3-7-28(32(26)35(44)48)37-16-17-49-18-19-50-25-10-8-23(9-11-25)41-36-38-15-14-30(42-36)40-24-20-22-4-1-2-6-27(22)39-21-24/h1-11,14-15,20-21,29,37H,12-13,16-19H2,(H,43,45,46)(H2,38,40,41,42)",BLGABOHGKRXYSB-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1348,P08069,IGF-1R,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOC4=CC=C(NC5=NC=CC(NC6=CN=C7C=CC=CC7=C6)=N5)C=C4)=C3C2=O)C(=O)N1,,,760.808,760.29691024,56,7,4,14,C40H40N8O8,"InChI=1S/C40H40N8O8/c49-35-13-12-33(37(50)47-35)48-38(51)30-5-3-7-32(36(30)39(48)52)41-16-17-53-18-19-54-20-21-55-22-23-56-29-10-8-27(9-11-29)45-40-42-15-14-34(46-40)44-28-24-26-4-1-2-6-31(26)43-25-28/h1-11,14-15,24-25,33,41H,12-13,16-23H2,(H,47,49,50)(H2,42,44,45,46)",NNFLJXWHNNZGBH-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1349,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,625.646,625.239729712,46,6,5,12,C31H31N9O6,"InChI=1S/C31H31N9O6/c1-18-17-25(39-38-18)35-24-11-12-33-31(36-24)34-19-5-7-20(8-6-19)46-16-15-45-14-13-32-22-4-2-3-21-27(22)30(44)40(29(21)43)23-9-10-26(41)37-28(23)42/h2-8,11-12,17,23,32H,9-10,13-16H2,1H3,(H,37,41,42)(H3,33,34,35,36,38,39)",YEBGDZYCAZJQHH-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1351,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,660.091,659.20075736,47,6,5,12,C31H30ClN9O6,"InChI=1S/C31H30ClN9O6/c1-17-15-24(40-39-17)36-27-21(32)16-34-31(38-27)35-18-5-7-19(8-6-18)47-14-13-46-12-11-33-22-4-2-3-20-26(22)30(45)41(29(20)44)23-9-10-25(42)37-28(23)43/h2-8,15-16,23,33H,9-14H2,1H3,(H,37,42,43)(H3,34,35,36,38,39,40)",IOHSXHAPQQQUGP-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1350,P08069,IGF-1R,CRBN,CC1=CC(NC2=CC=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=N2)=N[NH]1,,,669.699,669.26594446,49,6,5,13,C33H35N9O7,"InChI=1S/C33H35N9O7/c1-20-19-27(41-40-20)37-26-11-12-35-33(38-26)36-21-5-7-22(8-6-21)49-18-17-48-16-15-47-14-13-34-24-4-2-3-23-29(24)32(46)42(31(23)45)25-9-10-28(43)39-30(25)44/h2-8,11-12,19,25,34H,9-10,13-18H2,1H3,(H,39,43,44)(H3,35,36,37,38,40,41)",KSJXWXGDPRCSIV-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1352,P08069,IGF-1R,CRBN,CC1=CC(NC2=NC(NC3=CC=C(OCCOCCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2Cl)=N[NH]1,,,704.144,703.226972108,50,6,5,13,C33H34ClN9O7,"InChI=1S/C33H34ClN9O7/c1-19-17-26(42-41-19)38-29-23(34)18-36-33(40-29)37-20-5-7-21(8-6-20)50-16-15-49-14-13-48-12-11-35-24-4-2-3-22-28(24)32(47)43(31(22)46)25-9-10-27(44)39-30(25)45/h2-8,17-18,25,35H,9-16H2,1H3,(H,39,44,45)(H3,36,37,38,40,41,42)",UYDSYJMBAOFSTK-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1353,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,738.205,737.247707552,53,7,4,13,C37H36ClN9O6,"InChI=1S/C37H36ClN9O6/c38-23-7-5-22(6-8-23)32-31-33(39)42-21-43-34(31)46(45-32)17-2-15-40-24-9-11-25(12-10-24)53-20-19-52-18-16-41-27-4-1-3-26-30(27)37(51)47(36(26)50)28-13-14-29(48)44-35(28)49/h1,3-12,21,28,40-41H,2,13-20H2,(H2,39,42,43)(H,44,48,49)",XWGDNKJJVPSPJY-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1354,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCNC1=CC=C(OCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,,782.258,781.2739223,56,7,4,14,C39H40ClN9O7,"InChI=1S/C39H40ClN9O7/c40-25-7-5-24(6-8-25)34-33-35(41)44-23-45-36(33)48(47-34)17-2-15-42-26-9-11-27(12-10-26)56-22-21-55-20-19-54-18-16-43-29-4-1-3-28-32(29)39(53)49(38(28)52)30-13-14-31(50)46-37(30)51/h1,3-12,23,30,42-43H,2,13-22H2,(H2,41,44,45)(H,46,50,51)",ZOQUWFJXKUZLHH-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1355,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,819.283,818.280404648,59,8,4,16,C40H39ClN12O6,"InChI=1S/C40H39ClN12O6/c41-25-7-5-24(6-8-25)35-34-36(42)45-23-46-37(34)52(49-35)17-2-16-51-22-27(48-50-51)21-44-26-9-11-28(12-10-26)59-20-19-58-18-15-43-30-4-1-3-29-33(30)40(57)53(39(29)56)31-13-14-32(54)47-38(31)55/h1,3-12,22-23,31,43-44H,2,13-21H2,(H2,42,45,46)(H,47,54,55)",YEBIAPTXRZULTM-UHFFFAOYSA-N
DB00071,Insulin Pork,BiotechDrug,Insulin-like growth factor 1 receptor,1356,P08069,IGF-1R,CRBN,NC1=NC=NC2=C1C(C1=CC=C(Cl)C=C1)=NN2CCCN1C=C(CNC2=CC=C(OCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)N=N1,,,863.336,862.306619396,62,8,4,17,C42H43ClN12O7,"InChI=1S/C42H43ClN12O7/c43-27-7-5-26(6-8-27)37-36-38(44)47-25-48-39(36)54(51-37)17-2-16-53-24-29(50-52-53)23-46-28-9-11-30(12-10-28)62-22-21-61-20-19-60-18-15-45-32-4-1-3-31-35(32)42(59)55(41(31)58)33-13-14-34(56)49-40(33)57/h1,3-12,24-25,33,45-46H,2,13-23H2,(H2,44,47,48)(H,49,56,57)",UPKHTGRZRRRAME-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Receptor tyrosine-protein kinase erbB-2,275,P04626,HER2,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,39.2/736.2,97.6/68.8,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR L858R,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,275,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1030.62,1029.36618868,73,8,4,13,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1218,P00533,EGFR,CRBN,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,872.984,872.396958624,64,7,4,14,C46H52N10O8,"InChI=1S/C46H52N10O8/c1-6-41(57)49-35-24-36(51-46-47-17-16-34(50-46)31-26-55(4)37-13-8-7-10-29(31)37)40(62-5)25-39(35)54(3)19-18-53(2)20-21-63-22-23-64-28-43(59)48-33-12-9-11-30-32(33)27-56(45(30)61)38-14-15-42(58)52-44(38)60/h6-13,16-17,24-26,38H,1,14-15,18-23,27-28H2,2-5H3,(H,48,59)(H,49,57)(H,47,50,51)(H,52,58,60)",WOALWHLORCCRQM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5655,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCN4N=C5[NH]C6=CC=CC=C6N=C5C4=O)=C3C2=O)C(=O)N1,43.4,,587.549,587.17646076,43,6,3,11,C28H25N7O8,"InChI=1S/C28H25N7O8/c36-20-9-8-19(25(38)32-20)35-26(39)15-4-3-7-18(22(15)27(35)40)29-21(37)14-43-13-12-42-11-10-34-28(41)23-24(33-34)31-17-6-2-1-5-16(17)30-23/h1-7,19H,8-14H2,(H,29,37)(H,31,33)(H,32,36,38)",OXSXZSPEDPGYSH-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5655,P00533,EGFR T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCN4N=C5[NH]C6=CC=CC=C6N=C5C4=O)=C3C2=O)C(=O)N1,,,587.549,587.17646076,43,6,3,11,C28H25N7O8,"InChI=1S/C28H25N7O8/c36-20-9-8-19(25(38)32-20)35-26(39)15-4-3-7-18(22(15)27(35)40)29-21(37)14-43-13-12-42-11-10-34-28(41)23-24(33-34)31-17-6-2-1-5-16(17)30-23/h1-7,19H,8-14H2,(H,29,37)(H,31,33)(H,32,36,38)",OXSXZSPEDPGYSH-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5656,P00533,EGFR,CRBN,CN1C(=O)C(C(=O)NNCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=NC2=CC=CC=C21,32.9,,619.591,619.202675508,45,5,4,12,C29H29N7O9,"InChI=1S/C29H29N7O9/c1-35-19-8-3-2-6-17(19)32-24(29(35)43)26(40)34-30-11-12-44-13-14-45-15-22(38)31-18-7-4-5-16-23(18)28(42)36(27(16)41)20-9-10-21(37)33-25(20)39/h2-8,20,30H,9-15H2,1H3,(H,31,38)(H,34,40)(H,33,37,39)",MGPULBDTVXSSAA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5656,P00533,EGFR T790M,CRBN,CN1C(=O)C(C(=O)NNCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=NC2=CC=CC=C21,,,619.591,619.202675508,45,5,4,12,C29H29N7O9,"InChI=1S/C29H29N7O9/c1-35-19-8-3-2-6-17(19)32-24(29(35)43)26(40)34-30-11-12-44-13-14-45-15-22(38)31-18-7-4-5-16-23(18)28(42)36(27(16)41)20-9-10-21(37)33-25(20)39/h2-8,20,30H,9-15H2,1H3,(H,31,38)(H,34,40)(H,33,37,39)",MGPULBDTVXSSAA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5657,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCOCCNC(=O)C4=NC5=CC=CC=C5[NH]C4=O)=C3C2=O)C(=O)N1,,,634.602,634.20234116,46,5,4,11,C30H30N6O10,"InChI=1S/C30H30N6O10/c37-22-9-8-21(26(39)35-22)36-29(42)17-4-3-7-20(24(17)30(36)43)32-23(38)16-46-15-14-45-13-12-44-11-10-31-27(40)25-28(41)34-19-6-2-1-5-18(19)33-25/h1-7,21H,8-16H2,(H,31,40)(H,32,38)(H,34,41)(H,35,37,39)",OZPRDNWEPCURPP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5657,P00533,EGFR T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCOCCNC(=O)C4=NC5=CC=CC=C5[NH]C4=O)=C3C2=O)C(=O)N1,,,634.602,634.20234116,46,5,4,11,C30H30N6O10,"InChI=1S/C30H30N6O10/c37-22-9-8-21(26(39)35-22)36-29(42)17-4-3-7-20(24(17)30(36)43)32-23(38)16-46-15-14-45-13-12-44-11-10-31-27(40)25-28(41)34-19-6-2-1-5-18(19)33-25/h1-7,21H,8-16H2,(H,31,40)(H,32,38)(H,34,41)(H,35,37,39)",OZPRDNWEPCURPP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5658,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCNNC(=O)C4=CC=C(/N=C5\C(=O)NC6=CC=CC=C56)C=C4)=C3C2=O)C(=O)N1,,,681.662,681.218325572,50,6,5,11,C34H31N7O9,"InChI=1S/C34H31N7O9/c42-26-13-12-25(31(45)39-26)41-33(47)22-5-3-7-24(28(22)34(41)48)37-27(43)18-50-17-16-49-15-14-35-40-30(44)19-8-10-20(11-9-19)36-29-21-4-1-2-6-23(21)38-32(29)46/h1-11,25,35H,12-18H2,(H,37,43)(H,40,44)(H,36,38,46)(H,39,42,45)",UUISUTLLNFRLKV-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5658,P00533,EGFR T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COCCOCCNNC(=O)C4=CC=C(/N=C5\C(=O)NC6=CC=CC=C56)C=C4)=C3C2=O)C(=O)N1,,,681.662,681.218325572,50,6,5,11,C34H31N7O9,"InChI=1S/C34H31N7O9/c42-26-13-12-25(31(45)39-26)41-33(47)22-5-3-7-24(28(22)34(41)48)37-27(43)18-50-17-16-49-15-14-35-40-30(44)19-8-10-20(11-9-19)36-29-21-4-1-2-6-23(21)38-32(29)46/h1-11,25,35H,12-18H2,(H,37,43)(H,40,44)(H,36,38,46)(H,39,42,45)",UUISUTLLNFRLKV-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5659,P00533,EGFR,CRBN,CN1C(=O)/C(=N\C2=CC=C(C(=O)NNCCOCCOCC(=O)NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)C2=CC=CC=C21,,,695.689,695.233975636,51,6,4,11,C35H33N7O9,"InChI=1S/C35H33N7O9/c1-41-25-8-3-2-5-22(25)30(35(41)49)37-21-11-9-20(10-12-21)31(45)40-36-15-16-50-17-18-51-19-28(44)38-24-7-4-6-23-29(24)34(48)42(33(23)47)26-13-14-27(43)39-32(26)46/h2-12,26,36H,13-19H2,1H3,(H,38,44)(H,40,45)(H,39,43,46)/b37-30-",KLLIEGYJHUITHF-ONQIKCEGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5659,P00533,EGFR T790M,CRBN,CN1C(=O)/C(=N\C2=CC=C(C(=O)NNCCOCCOCC(=O)NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2)C2=CC=CC=C21,,,695.689,695.233975636,51,6,4,11,C35H33N7O9,"InChI=1S/C35H33N7O9/c1-41-25-8-3-2-5-22(25)30(35(41)49)37-21-11-9-20(10-12-21)31(45)40-36-15-16-50-17-18-51-19-28(44)38-24-7-4-6-23-29(24)34(48)42(33(23)47)26-13-14-27(43)39-32(26)46/h2-12,26,36H,13-19H2,1H3,(H,38,44)(H,40,45)(H,39,43,46)/b37-30-",KLLIEGYJHUITHF-ONQIKCEGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5660,P00533,EGFR,CRBN,O=C(CSC1=NC2=CC=CC=C2O1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,624.632,624.163847476,44,5,4,12,C28H28N6O9S,"InChI=1S/C28H28N6O9S/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-44-28-31-17-5-1-2-7-20(17)43-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",CWWRWDWAERVKAB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5660,P00533,EGFR T790M,CRBN,O=C(CSC1=NC2=CC=CC=C2O1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,624.632,624.163847476,44,5,4,12,C28H28N6O9S,"InChI=1S/C28H28N6O9S/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-44-28-31-17-5-1-2-7-20(17)43-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",CWWRWDWAERVKAB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5661,P00533,EGFR,CRBN,O=C(CSC1=NC2=CC=CC=C2S1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,640.7,640.141003856,44,5,4,12,C28H28N6O8S2,"InChI=1S/C28H28N6O8S2/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-43-28-31-17-5-1-2-7-20(17)44-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",ZYHGWXRBVVVZAU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5661,P00533,EGFR T790M,CRBN,O=C(CSC1=NC2=CC=CC=C2S1)NNCCOCCOCC(=O)NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,640.7,640.141003856,44,5,4,12,C28H28N6O8S2,"InChI=1S/C28H28N6O8S2/c35-21-9-8-19(25(38)32-21)34-26(39)16-4-3-6-18(24(16)27(34)40)30-22(36)14-42-13-12-41-11-10-29-33-23(37)15-43-28-31-17-5-1-2-7-20(17)44-28/h1-7,19,29H,8-15H2,(H,30,36)(H,33,37)(H,32,35,38)",ZYHGWXRBVVVZAU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1220,P00533,EGFR,CRBN,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCOCCOCCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,161,68,961.09,960.44938812,70,7,4,16,C50H60N10O10,"InChI=1S/C50H60N10O10/c1-6-45(61)53-39-28-40(55-50-51-17-16-38(54-50)35-30-59(4)41-13-8-7-10-33(35)41)44(66-5)29-43(39)58(3)19-18-57(2)20-21-67-22-23-68-24-25-69-26-27-70-32-47(63)52-37-12-9-11-34-36(37)31-60(49(34)65)42-14-15-46(62)56-48(42)64/h6-13,16-17,28-30,42H,1,14-15,18-27,31-32H2,2-5H3,(H,52,63)(H,53,61)(H,51,54,55)(H,56,62,64)",MVXHKLZUALKPTB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR L858R,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,278,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,,,1074.673,1073.39240343,76,8,4,14,C57H61ClFN7O9S,"InChI=1S/C57H61ClFN7O9S/c1-36-52(76-35-63-36)40-10-8-37(9-11-40)30-60-55(69)49-29-44(67)31-66(49)56(70)53(57(2,3)4)65-51(68)33-73-23-22-71-20-21-72-24-25-74-45-16-12-39(13-17-45)41-14-18-48-46(27-41)54(62-34-61-48)64-43-15-19-50(47(58)28-43)75-32-38-6-5-7-42(59)26-38/h5-19,26-28,34-35,44,49,53,67H,20-25,29-33H2,1-4H3,(H,60,69)(H,65,68)(H,61,62,64)/t44-,49+,53-/m1/s1",XZNORRXEBCTXPB-KHBXAZQSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,570,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1074.342,1073.54332624,77,9,6,18,C56H72FN13O6S,"InChI=1S/C56H72FN13O6S/c1-37-50(77-36-62-37)40-7-5-38(6-8-40)31-61-53(73)47-29-44(72)34-70(47)54(74)51(56(2,3)4)58-17-25-75-27-28-76-26-24-67-20-22-68(23-21-67)43-13-14-48(59-32-43)65-49-30-45-46(33-60-49)64-55(63-42-11-9-41(57)10-12-42)66-52(45)69-18-15-39(35-71)16-19-69/h5-14,30,32-33,36,39,44,47,51,58,71-72H,15-29,31,34-35H2,1-4H3,(H,61,73)(H,59,60,65)(H,63,64,66)/t44-,47+,51-/m1/s1",CQUCWGCCDVGZNK-SRLHMHSXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1549,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,897.027,896.331581496,65,9,3,13,C48H48N8O8S,"InChI=1S/C48H48N8O8S/c57-40-16-15-39(43(58)51-40)56-46(61)36-7-4-8-38(41(36)47(56)62)49-17-24-63-26-27-64-25-23-53-19-21-54(22-20-53)35-13-11-31(12-14-35)33-9-10-34-30-55(45(60)37(34)29-33)42(32-5-2-1-3-6-32)44(59)52-48-50-18-28-65-48/h1-14,18,28-29,39,42,49H,15-17,19-27,30H2,(H,50,52,59)(H,51,57,58)",LCRBAPSWBSEBAG-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1551,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=C(NCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)C=C3C2=O)C(=O)N1,,,898.015,897.326830464,65,9,3,14,C47H47N9O8S,"InChI=1S/C47H47N9O8S/c57-40-13-11-38(42(58)51-40)56-45(61)35-10-9-34(27-37(35)46(56)62)48-14-21-63-23-24-64-22-20-53-16-18-54(19-17-53)39-12-8-32(28-50-39)31-6-7-33-29-55(44(60)36(33)26-31)41(30-4-2-1-3-5-30)43(59)52-47-49-15-25-65-47/h1-10,12,15,25-28,38,41,48H,11,13-14,16-24,29H2,(H,49,52,59)(H,51,57,58)",QHQDVRLNEVZTFS-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1554,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCN3CCN(C4=CC=C(C5=CC=C6CN(C(C(=O)NC7=NC=CS7)C7=CC=CC=C7)C(=O)C6=C5)C=N4)CC3)C(C)(C)C)C=C2)SC=N1,,,1083.351,1082.45065107,77,9,4,15,C57H66N10O8S2,"InChI=1S/C57H66N10O8S2/c1-37-50(77-36-61-37)40-12-10-38(11-13-40)32-60-52(70)46-31-44(68)35-66(46)55(73)51(57(2,3)4)62-48(69)18-25-74-27-28-75-26-24-64-20-22-65(23-21-64)47-17-16-42(33-59-47)41-14-15-43-34-67(54(72)45(43)30-41)49(39-8-6-5-7-9-39)53(71)63-56-58-19-29-76-56/h5-17,19,29-30,33,36,44,46,49,51,68H,18,20-28,31-32,34-35H2,1-4H3,(H,60,70)(H,62,69)(H,58,63,71)/t44-,46+,49?,51-/m1/s1",BJESFCSPXPZXNP-ZSIHQRNSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2000,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,999.3,998.53128434,72,9,5,16,C54H70N12O5S,"InChI=1S/C54H70N12O5S/c1-37-47(72-36-58-37)39-16-14-38(15-17-39)33-56-50(68)46-32-44(67)35-65(46)51(69)48(54(2,3)4)55-22-28-70-30-31-71-29-27-63-23-25-64(26-24-63)42-20-18-41(19-21-42)59-52-57-34-45-49(62-52)66(43-12-8-9-13-43)53(61-45)60-40-10-6-5-7-11-40/h5-7,10-11,14-21,34,36,43-44,46,48,55,67H,8-9,12-13,22-33,35H2,1-4H3,(H,56,68)(H,60,61)(H,57,59,62)/t44-,46+,48-/m1/s1",VKKCYHNIIBYIGZ-IVTDSOLVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2000,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,999.3,998.53128434,72,9,5,16,C54H70N12O5S,"InChI=1S/C54H70N12O5S/c1-37-47(72-36-58-37)39-16-14-38(15-17-39)33-56-50(68)46-32-44(67)35-65(46)51(69)48(54(2,3)4)55-22-28-70-30-31-71-29-27-63-23-25-64(26-24-63)42-20-18-41(19-21-42)59-52-57-34-45-49(62-52)66(43-12-8-9-13-43)53(61-45)60-40-10-6-5-7-11-40/h5-7,10-11,14-21,34,36,43-44,46,48,55,67H,8-9,12-13,22-33,35H2,1-4H3,(H,56,68)(H,60,61)(H,57,59,62)/t44-,46+,48-/m1/s1",VKKCYHNIIBYIGZ-IVTDSOLVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2000,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,999.3,998.53128434,72,9,5,16,C54H70N12O5S,"InChI=1S/C54H70N12O5S/c1-37-47(72-36-58-37)39-16-14-38(15-17-39)33-56-50(68)46-32-44(67)35-65(46)51(69)48(54(2,3)4)55-22-28-70-30-31-71-29-27-63-23-25-64(26-24-63)42-20-18-41(19-21-42)59-52-57-34-45-49(62-52)66(43-12-8-9-13-43)53(61-45)60-40-10-6-5-7-11-40/h5-7,10-11,14-21,34,36,43-44,46,48,55,67H,8-9,12-13,22-33,35H2,1-4H3,(H,56,68)(H,60,61)(H,57,59,62)/t44-,46+,48-/m1/s1",VKKCYHNIIBYIGZ-IVTDSOLVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,4278,P00533,EGFR,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,965.187,964.451696628,69,7,4,14,C51H64N8O9S,"InChI=1S/C51H64N8O9S/c1-33-46(69-32-55-33)36-13-11-34(12-14-36)28-52-49(63)41-25-38(60)29-59(41)50(64)47(51(2,3)4)57-44(61)17-21-66-23-24-67-22-18-45(62)58-19-15-35(16-20-58)30-68-43-27-40-39(26-42(43)65-5)48(54-31-53-40)56-37-9-7-6-8-10-37/h6-14,26-27,31-32,35,38,41,47,60H,15-25,28-30H2,1-5H3,(H,52,63)(H,57,61)(H,53,54,56)/t38-,41+,47-/m1/s1",NRZFMGQSOZOFHN-HSKQCWAZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,4278,P00533,EGFR L858R,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,965.187,964.451696628,69,7,4,14,C51H64N8O9S,"InChI=1S/C51H64N8O9S/c1-33-46(69-32-55-33)36-13-11-34(12-14-36)28-52-49(63)41-25-38(60)29-59(41)50(64)47(51(2,3)4)57-44(61)17-21-66-23-24-67-22-18-45(62)58-19-15-35(16-20-58)30-68-43-27-40-39(26-42(43)65-5)48(54-31-53-40)56-37-9-7-6-8-10-37/h6-14,26-27,31-32,35,38,41,47,60H,15-25,28-30H2,1-5H3,(H,52,63)(H,57,61)(H,53,54,56)/t38-,41+,47-/m1/s1",NRZFMGQSOZOFHN-HSKQCWAZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,4278,P00533,EGFR e19d,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,965.187,964.451696628,69,7,4,14,C51H64N8O9S,"InChI=1S/C51H64N8O9S/c1-33-46(69-32-55-33)36-13-11-34(12-14-36)28-52-49(63)41-25-38(60)29-59(41)50(64)47(51(2,3)4)57-44(61)17-21-66-23-24-67-22-18-45(62)58-19-15-35(16-20-58)30-68-43-27-40-39(26-42(43)65-5)48(54-31-53-40)56-37-9-7-6-8-10-37/h6-14,26-27,31-32,35,38,41,47,60H,15-25,28-30H2,1-5H3,(H,52,63)(H,57,61)(H,53,54,56)/t38-,41+,47-/m1/s1",NRZFMGQSOZOFHN-HSKQCWAZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1475,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,985.133,984.384010992,71,9,3,15,C52H56N8O10S,"InChI=1S/C52H56N8O10S/c61-44-16-15-43(47(62)55-44)60-50(65)40-7-4-8-42(45(40)51(60)66)53-17-24-67-26-28-69-30-31-70-29-27-68-25-23-57-19-21-58(22-20-57)39-13-11-35(12-14-39)37-9-10-38-34-59(49(64)41(38)33-37)46(36-5-2-1-3-6-36)48(63)56-52-54-18-32-71-52/h1-14,18,32-33,43,46,53H,15-17,19-31,34H2,(H,54,56,63)(H,55,61,62)",LWCGWAABACSQFJ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2002,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1087.406,1086.58371384,78,9,5,18,C58H78N12O7S,"InChI=1S/C58H78N12O7S/c1-41-51(78-40-62-41)43-16-14-42(15-17-43)37-60-54(72)50-36-48(71)39-69(50)55(73)52(58(2,3)4)59-22-28-74-30-32-76-34-35-77-33-31-75-29-27-67-23-25-68(26-24-67)46-20-18-45(19-21-46)63-56-61-38-49-53(66-56)70(47-12-8-9-13-47)57(65-49)64-44-10-6-5-7-11-44/h5-7,10-11,14-21,38,40,47-48,50,52,59,71H,8-9,12-13,22-37,39H2,1-4H3,(H,60,72)(H,64,65)(H,61,63,66)/t48-,50+,52-/m1/s1",BPHMNBCRTHSRFO-KPYPFJKESA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2002,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1087.406,1086.58371384,78,9,5,18,C58H78N12O7S,"InChI=1S/C58H78N12O7S/c1-41-51(78-40-62-41)43-16-14-42(15-17-43)37-60-54(72)50-36-48(71)39-69(50)55(73)52(58(2,3)4)59-22-28-74-30-32-76-34-35-77-33-31-75-29-27-67-23-25-68(26-24-67)46-20-18-45(19-21-46)63-56-61-38-49-53(66-56)70(47-12-8-9-13-47)57(65-49)64-44-10-6-5-7-11-44/h5-7,10-11,14-21,38,40,47-48,50,52,59,71H,8-9,12-13,22-37,39H2,1-4H3,(H,60,72)(H,64,65)(H,61,63,66)/t48-,50+,52-/m1/s1",BPHMNBCRTHSRFO-KPYPFJKESA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2002,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1087.406,1086.58371384,78,9,5,18,C58H78N12O7S,"InChI=1S/C58H78N12O7S/c1-41-51(78-40-62-41)43-16-14-42(15-17-43)37-60-54(72)50-36-48(71)39-69(50)55(73)52(58(2,3)4)59-22-28-74-30-32-76-34-35-77-33-31-75-29-27-67-23-25-68(26-24-67)46-20-18-45(19-21-46)63-56-61-38-49-53(66-56)70(47-12-8-9-13-47)57(65-49)64-44-10-6-5-7-11-44/h5-7,10-11,14-21,38,40,47-48,50,52,59,71H,8-9,12-13,22-37,39H2,1-4H3,(H,60,72)(H,64,65)(H,61,63,66)/t48-,50+,52-/m1/s1",BPHMNBCRTHSRFO-KPYPFJKESA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5610,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,856.863,856.326828376,62,7,5,14,C42H43F3N10O7,"InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)",IRLRGBUCUIJYPP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5610,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,856.863,856.326828376,62,7,5,14,C42H43F3N10O7,"InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)",IRLRGBUCUIJYPP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5610,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,856.863,856.326828376,62,7,5,14,C42H43F3N10O7,"InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)",IRLRGBUCUIJYPP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,569,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1118.395,1117.56954099,80,9,6,19,C58H76FN13O7S,"InChI=1S/C58H76FN13O7S/c1-39-52(80-38-64-39)42-7-5-40(6-8-42)33-63-55(75)49-31-46(74)36-72(49)56(76)53(58(2,3)4)60-17-25-77-27-29-79-30-28-78-26-24-69-20-22-70(23-21-69)45-13-14-50(61-34-45)67-51-32-47-48(35-62-51)66-57(65-44-11-9-43(59)10-12-44)68-54(47)71-18-15-41(37-73)16-19-71/h5-14,32,34-35,38,41,46,49,53,60,73-74H,15-31,33,36-37H2,1-4H3,(H,63,75)(H,61,62,67)(H,65,66,68)/t46-,49+,53-/m1/s1",FFHRIJQREBDIFV-XYNMIOBWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1474,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,941.08,940.357796244,68,9,3,14,C50H52N8O9S,"InChI=1S/C50H52N8O9S/c59-42-16-15-41(45(60)53-42)58-48(63)38-7-4-8-40(43(38)49(58)64)51-17-24-65-26-28-67-29-27-66-25-23-55-19-21-56(22-20-55)37-13-11-33(12-14-37)35-9-10-36-32-57(47(62)39(36)31-35)44(34-5-2-1-3-6-34)46(61)54-50-52-18-30-68-50/h1-14,18,30-31,41,44,51H,15-17,19-29,32H2,(H,52,54,61)(H,53,59,60)",DXDCJEWJBVJABL-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1476,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-41-14-12-39(44(60)53-41)58-47(63)36-7-4-8-38(42(36)48(58)64)50-15-22-65-24-26-67-27-25-66-23-21-55-17-19-56(20-18-55)40-13-11-34(30-52-40)33-9-10-35-31-57(46(62)37(35)29-33)43(32-5-2-1-3-6-32)45(61)54-49-51-16-28-68-49/h1-11,13,16,28-30,39,43,50H,12,14-15,17-27,31H2,(H,51,54,61)(H,53,59,60)",QVOJDGYNXIRHHU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1476,P00533,EGFR L858R/T790M/C797S,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-41-14-12-39(44(60)53-41)58-47(63)36-7-4-8-38(42(36)48(58)64)50-15-22-65-24-26-67-27-25-66-23-21-55-17-19-56(20-18-55)40-13-11-34(30-52-40)33-9-10-35-31-57(46(62)37(35)29-33)43(32-5-2-1-3-6-32)45(61)54-49-51-16-28-68-49/h1-11,13,16,28-30,39,43,50H,12,14-15,17-27,31H2,(H,51,54,61)(H,53,59,60)",QVOJDGYNXIRHHU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1476,P00533,EGFR L858R/T790M/L718Q,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-41-14-12-39(44(60)53-41)58-47(63)36-7-4-8-38(42(36)48(58)64)50-15-22-65-24-26-67-27-25-66-23-21-55-17-19-56(20-18-55)40-13-11-34(30-52-40)33-9-10-35-31-57(46(62)37(35)29-33)43(32-5-2-1-3-6-32)45(61)54-49-51-16-28-68-49/h1-11,13,16,28-30,39,43,50H,12,14-15,17-27,31H2,(H,51,54,61)(H,53,59,60)",QVOJDGYNXIRHHU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1538,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC(F)=CC=C8O)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,975.069,974.343289052,70,9,4,15,C50H51FN8O10S,"InChI=1S/C50H51FN8O10S/c51-34-8-12-41(60)38(29-34)44(46(63)55-50-53-15-27-70-50)58-30-33-5-4-32(28-37(33)47(58)64)31-6-9-35(10-7-31)57-18-16-56(17-19-57)20-22-68-24-26-69-25-23-67-21-14-52-39-3-1-2-36-43(39)49(66)59(48(36)65)40-11-13-42(61)54-45(40)62/h1-10,12,15,27-29,40,44,52,60H,11,13-14,16-26,30H2,(H,53,55,63)(H,54,61,62)",YJHQLBPJGVDMDW-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1540,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC(F)=CC=C8F)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,977.06,976.33895262,70,9,3,14,C50H50F2N8O9S,"InChI=1S/C50H50F2N8O9S/c51-34-8-11-39(52)38(29-34)44(46(63)56-50-54-15-27-70-50)59-30-33-5-4-32(28-37(33)47(59)64)31-6-9-35(10-7-31)58-18-16-57(17-19-58)20-22-68-24-26-69-25-23-67-21-14-53-40-3-1-2-36-43(40)49(66)60(48(36)65)41-12-13-42(61)55-45(41)62/h1-11,15,27-29,41,44,53H,12-14,16-26,30H2,(H,54,56,63)(H,55,61,62)",WHLIZTUDKDTXIF-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1550,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8O)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,958.067,957.347959832,69,9,4,16,C49H51N9O10S,"InChI=1S/C49H51N9O10S/c59-39-7-2-1-4-34(39)43(45(62)54-49-51-15-27-69-49)57-30-33-9-8-31(28-36(33)46(57)63)32-10-12-40(52-29-32)56-18-16-55(17-19-56)20-22-67-24-26-68-25-23-66-21-14-50-37-6-3-5-35-42(37)48(65)58(47(35)64)38-11-13-41(60)53-44(38)61/h1-10,12,15,27-29,38,43,50,59H,11,13-14,16-26,30H2,(H,51,54,62)(H,53,60,61)",JTOYENRLVILXMD-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1552,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=C(NCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)C=C3C2=O)C(=O)N1,,,942.068,941.353045212,68,9,3,15,C49H51N9O9S,"InChI=1S/C49H51N9O9S/c59-42-13-11-40(44(60)53-42)58-47(63)37-10-9-36(29-39(37)48(58)64)50-14-21-65-23-25-67-26-24-66-22-20-55-16-18-56(19-17-55)41-12-8-34(30-52-41)33-6-7-35-31-57(46(62)38(35)28-33)43(32-4-2-1-3-5-32)45(61)54-49-51-15-27-68-49/h1-10,12,15,27-30,40,43,50H,11,13-14,16-26,31H2,(H,51,54,61)(H,53,59,60)",SSCWZTSBNMMURN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1555,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOCCN3CCN(C4=CC=C(C5=CC=C6CN(C(C(=O)NC7=NC=CS7)C7=CC=CC=C7)C(=O)C6=C5)C=N4)CC3)C(C)(C)C)C=C2)SC=N1,,,1127.404,1126.47686582,80,9,4,16,C59H70N10O9S2,"InChI=1S/C59H70N10O9S2/c1-39-52(80-38-63-39)42-12-10-40(11-13-42)34-62-54(72)48-33-46(70)37-68(48)57(75)53(59(2,3)4)64-50(71)18-25-76-27-29-78-30-28-77-26-24-66-20-22-67(23-21-66)49-17-16-44(35-61-49)43-14-15-45-36-69(56(74)47(45)32-43)51(41-8-6-5-7-9-41)55(73)65-58-60-19-31-79-58/h5-17,19,31-32,35,38,46,48,51,53,70H,18,20-30,33-34,36-37H2,1-4H3,(H,62,72)(H,64,71)(H,60,65,73)/t46-,48+,51?,53-/m1/s1",KPMNKWKMJWXUGN-RLMRRVSWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2001,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1043.353,1042.55749909,75,9,5,17,C56H74N12O6S,"InChI=1S/C56H74N12O6S/c1-39-49(75-38-60-39)41-16-14-40(15-17-41)35-58-52(70)48-34-46(69)37-67(48)53(71)50(56(2,3)4)57-22-28-72-30-32-74-33-31-73-29-27-65-23-25-66(26-24-65)44-20-18-43(19-21-44)61-54-59-36-47-51(64-54)68(45-12-8-9-13-45)55(63-47)62-42-10-6-5-7-11-42/h5-7,10-11,14-21,36,38,45-46,48,50,57,69H,8-9,12-13,22-35,37H2,1-4H3,(H,58,70)(H,62,63)(H,59,61,64)/t46-,48+,50-/m1/s1",HUPCKZOCINPJII-AJKYVBNFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2001,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1043.353,1042.55749909,75,9,5,17,C56H74N12O6S,"InChI=1S/C56H74N12O6S/c1-39-49(75-38-60-39)41-16-14-40(15-17-41)35-58-52(70)48-34-46(69)37-67(48)53(71)50(56(2,3)4)57-22-28-72-30-32-74-33-31-73-29-27-65-23-25-66(26-24-65)44-20-18-43(19-21-44)61-54-59-36-47-51(64-54)68(45-12-8-9-13-45)55(63-47)62-42-10-6-5-7-11-42/h5-7,10-11,14-21,36,38,45-46,48,50,57,69H,8-9,12-13,22-35,37H2,1-4H3,(H,58,70)(H,62,63)(H,59,61,64)/t46-,48+,50-/m1/s1",HUPCKZOCINPJII-AJKYVBNFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2001,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1043.353,1042.55749909,75,9,5,17,C56H74N12O6S,"InChI=1S/C56H74N12O6S/c1-39-49(75-38-60-39)41-16-14-40(15-17-41)35-58-52(70)48-34-46(69)37-67(48)53(71)50(56(2,3)4)57-22-28-72-30-32-74-33-31-73-29-27-65-23-25-66(26-24-65)44-20-18-43(19-21-44)61-54-59-36-47-51(64-54)68(45-12-8-9-13-45)55(63-47)62-42-10-6-5-7-11-42/h5-7,10-11,14-21,36,38,45-46,48,50,57,69H,8-9,12-13,22-35,37H2,1-4H3,(H,58,70)(H,62,63)(H,59,61,64)/t46-,48+,50-/m1/s1",HUPCKZOCINPJII-AJKYVBNFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,586,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,5.9,,1038.289,1037.49456448,75,8,5,15,C56H67N11O7S,"InChI=1S/C56H67N11O7S/c1-8-47(69)60-39-13-12-14-41(28-39)67-49(71)27-35(2)43-32-58-55(63-52(43)67)61-44-21-20-40(29-46(44)74-7)65-25-23-64(24-26-65)22-11-9-10-15-48(70)62-51(56(4,5)6)54(73)66-33-42(68)30-45(66)53(72)57-31-37-16-18-38(19-17-37)50-36(3)59-34-75-50/h8,12-14,16-21,27-29,32,34,42,45,51,68H,1,9-11,15,22-26,30-31,33H2,2-7H3,(H,57,72)(H,60,69)(H,62,70)(H,58,61,63)/t42-,45+,51-/m1/s1",CBWIPIZLLNOTMZ-PDMHGPQCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,586,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1038.289,1037.49456448,75,8,5,15,C56H67N11O7S,"InChI=1S/C56H67N11O7S/c1-8-47(69)60-39-13-12-14-41(28-39)67-49(71)27-35(2)43-32-58-55(63-52(43)67)61-44-21-20-40(29-46(44)74-7)65-25-23-64(24-26-65)22-11-9-10-15-48(70)62-51(56(4,5)6)54(73)66-33-42(68)30-45(66)53(72)57-31-37-16-18-38(19-17-37)50-36(3)59-34-75-50/h8,12-14,16-21,27-29,32,34,42,45,51,68H,1,9-11,15,22-26,30-31,33H2,2-7H3,(H,57,72)(H,60,69)(H,62,70)(H,58,61,63)/t42-,45+,51-/m1/s1",CBWIPIZLLNOTMZ-PDMHGPQCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2860,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(C2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2NS(C)(=O)=O)=N1,,,1043.758,1042.43241416,72,7,6,14,C52H67ClN10O7S2,"InChI=1S/C52H67ClN10O7S2/c1-32(34-16-18-36(19-17-34)46-33(2)55-31-71-46)56-49(66)43-28-38(64)30-63(43)50(67)47(52(3,4)5)59-45(65)15-9-8-12-24-62-25-22-35(23-26-62)37-20-21-42(44(27-37)70-6)58-51-54-29-39(53)48(60-51)57-40-13-10-11-14-41(40)61-72(7,68)69/h10-11,13-14,16-21,27,29,31-32,35,38,43,47,61,64H,8-9,12,15,22-26,28,30H2,1-7H3,(H,56,66)(H,59,65)(H2,54,57,58,60)/t32-,38+,43-,47+/m0/s1",LWCAXNBXZPQKSD-LOLWDDHHSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2861,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(C2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2N(C)S(C)(=O)=O)=N1,,,1057.785,1056.44806423,73,7,5,14,C53H69ClN10O7S2,"InChI=1S/C53H69ClN10O7S2/c1-33(35-17-19-37(20-18-35)47-34(2)56-32-72-47)57-50(67)44-29-39(65)31-64(44)51(68)48(53(3,4)5)60-46(66)16-10-9-13-25-63-26-23-36(24-27-63)38-21-22-42(45(28-38)71-7)59-52-55-30-40(54)49(61-52)58-41-14-11-12-15-43(41)62(6)73(8,69)70/h11-12,14-15,17-22,28,30,32-33,36,39,44,48,65H,9-10,13,16,23-27,29,31H2,1-8H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t33-,39+,44-,48+/m0/s1",JLWGCLJIWXUANI-WQWWALRQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2862,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1027.674,1026.44701521,71,7,5,14,C52H68ClN10O6PS,"InChI=1S/C52H68ClN10O6PS/c1-33(35-17-19-36(20-18-35)46-34(2)55-32-71-46)56-49(66)42-29-38(64)31-63(42)50(67)47(52(3,4)5)59-45(65)16-10-9-13-23-61-24-26-62(27-25-61)37-21-22-40(43(28-37)69-6)58-51-54-30-39(53)48(60-51)57-41-14-11-12-15-44(41)70(7,8)68/h11-12,14-15,17-22,28,30,32-33,38,42,47,64H,9-10,13,16,23-27,29,31H2,1-8H3,(H,56,66)(H,59,65)(H2,54,57,58,60)/t33-,38+,42-,47+/m0/s1",PGNBEPVWKCSKAS-RZQFPGPRSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2863,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,1057.785,1056.44806423,73,7,5,15,C53H69ClN10O7S2,"InChI=1S/C53H69ClN10O7S2/c1-33(2)73(69,70)45-15-12-11-14-42(45)58-49-40(54)30-55-52(61-49)59-41-22-21-38(28-44(41)71-8)63-26-24-62(25-27-63)23-13-9-10-16-46(66)60-48(53(5,6)7)51(68)64-31-39(65)29-43(64)50(67)57-34(3)36-17-19-37(20-18-36)47-35(4)56-32-72-47/h11-12,14-15,17-22,28,30,32-34,39,43,48,65H,9-10,13,16,23-27,29,31H2,1-8H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t34-,39+,43-,48+/m0/s1",JGZVZHAUKMEBKN-OESUUHGFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5492,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1069.658,1068.40945046,75,8,4,16,C53H62ClFN10O9S,"InChI=1S/C53H62ClFN10O9S/c1-31(2)49(46-21-32(3)62-74-46)53(70)65-27-37(66)23-43(65)52(69)61-41(34-7-9-35(10-8-34)50-33(4)59-30-75-50)26-47(67)56-13-20-72-28-48(68)64-17-15-63(16-18-64)14-6-19-73-45-24-38-42(25-44(45)71-5)57-29-58-51(38)60-36-11-12-40(55)39(54)22-36/h7-12,21-22,24-25,29-31,37,41,43,49,66H,6,13-20,23,26-28H2,1-5H3,(H,56,67)(H,61,69)(H,57,58,60)/t37-,41+,43+,49-/m1/s1",DHBPVPJKBOUIKZ-JYAIWFTJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5500,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1103.691,1102.43132878,77,8,5,15,C54H65ClF2N10O9S,"InChI=1S/C54H65ClF2N10O9S/c1-32-47(77-31-61-32)34-9-7-33(8-10-34)40(63-50(71)42-24-36(68)28-67(42)51(72)48(53(2,3)4)64-52(73)54(57)13-14-54)27-45(69)58-15-22-75-29-46(70)66-19-17-65(18-20-66)16-6-21-76-44-25-37-41(26-43(44)74-5)59-30-60-49(37)62-35-11-12-39(56)38(55)23-35/h7-12,23,25-26,30-31,36,40,42,48,68H,6,13-22,24,27-29H2,1-5H3,(H,58,69)(H,63,71)(H,64,73)(H,59,60,62)/t36-,40+,42+,48-/m1/s1",GLMYWROCCPQEMY-OQQYKNMXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5494,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1113.711,1112.43566521,78,8,4,17,C55H66ClFN10O10S,"InChI=1S/C55H66ClFN10O10S/c1-33(2)51(48-23-34(3)64-77-48)55(72)67-29-39(68)25-45(67)54(71)63-43(36-7-9-37(10-8-36)52-35(4)61-32-78-52)28-49(69)58-13-20-74-21-22-75-30-50(70)66-17-15-65(16-18-66)14-6-19-76-47-26-40-44(27-46(47)73-5)59-31-60-53(40)62-38-11-12-42(57)41(56)24-38/h7-12,23-24,26-27,31-33,39,43,45,51,68H,6,13-22,25,28-30H2,1-5H3,(H,58,69)(H,63,71)(H,59,60,62)/t39-,43+,45+,51-/m1/s1",YXOJREVIFBPBTG-NZMHYKQJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5502,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1147.744,1146.45754353,80,8,5,16,C56H69ClF2N10O10S,"InChI=1S/C56H69ClF2N10O10S/c1-34-49(80-33-63-34)36-9-7-35(8-10-36)42(65-52(73)44-26-38(70)30-69(44)53(74)50(55(2,3)4)66-54(75)56(59)13-14-56)29-47(71)60-15-22-77-23-24-78-31-48(72)68-19-17-67(18-20-68)16-6-21-79-46-27-39-43(28-45(46)76-5)61-32-62-51(39)64-37-11-12-41(58)40(57)25-37/h7-12,25,27-28,32-33,38,42,44,50,70H,6,13-24,26,29-31H2,1-5H3,(H,60,71)(H,65,73)(H,66,75)(H,61,62,64)/t38-,42+,44+,50-/m1/s1",IGYCAMNBZAAFRM-VYRQVLTMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5496,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1157.764,1156.46187996,81,8,4,18,C57H70ClFN10O11S,"InChI=1S/C57H70ClFN10O11S/c1-35(2)53(50-25-36(3)66-80-50)57(74)69-31-41(70)27-47(69)56(73)65-45(38-7-9-39(10-8-38)54-37(4)63-34-81-54)30-51(71)60-13-20-76-21-22-77-23-24-78-32-52(72)68-17-15-67(16-18-68)14-6-19-79-49-28-42-46(29-48(49)75-5)61-33-62-55(42)64-40-11-12-44(59)43(58)26-40/h7-12,25-26,28-29,33-35,41,45,47,53,70H,6,13-24,27,30-32H2,1-5H3,(H,60,71)(H,65,73)(H,61,62,64)/t41-,45+,47+,53-/m1/s1",NFWFKMISKOKRAY-UYZZMYMLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5504,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)COCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1191.797,1190.48375828,83,8,5,17,C58H73ClF2N10O11S,"InChI=1S/C58H73ClF2N10O11S/c1-36-51(83-35-65-36)38-9-7-37(8-10-38)44(67-54(75)46-28-40(72)32-71(46)55(76)52(57(2,3)4)68-56(77)58(61)13-14-58)31-49(73)62-15-22-79-23-24-80-25-26-81-33-50(74)70-19-17-69(18-20-70)16-6-21-82-48-29-41-45(30-47(48)78-5)63-34-64-53(41)66-39-11-12-43(60)42(59)27-39/h7-12,27,29-30,34-35,40,44,46,52,72H,6,13-26,28,31-33H2,1-5H3,(H,62,73)(H,67,75)(H,68,77)(H,63,64,66)/t40-,44+,46+,52-/m1/s1",ZXKZWFISZTXLOV-YHXFZPEXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,583,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1052.272,1051.47382904,76,8,5,15,C56H65N11O8S,"InChI=1S/C56H65N11O8S/c1-8-46(69)60-38-12-11-13-40(27-38)67-49(72)26-34(2)42-31-58-55(63-52(42)67)61-43-21-20-39(28-45(43)75-7)64-22-24-65(25-23-64)48(71)15-10-9-14-47(70)62-51(56(4,5)6)54(74)66-32-41(68)29-44(66)53(73)57-30-36-16-18-37(19-17-36)50-35(3)59-33-76-50/h8,11-13,16-21,26-28,31,33,41,44,51,68H,1,9-10,14-15,22-25,29-30,32H2,2-7H3,(H,57,73)(H,60,69)(H,62,70)(H,58,61,63)/t41-,44+,51-/m1/s1",SUWGYDIQBJOKHS-MSYDQUDQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,583,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1052.272,1051.47382904,76,8,5,15,C56H65N11O8S,"InChI=1S/C56H65N11O8S/c1-8-46(69)60-38-12-11-13-40(27-38)67-49(72)26-34(2)42-31-58-55(63-52(42)67)61-43-21-20-39(28-45(43)75-7)64-22-24-65(25-23-64)48(71)15-10-9-14-47(70)62-51(56(4,5)6)54(74)66-32-41(68)29-44(66)53(73)57-30-36-16-18-37(19-17-36)50-35(3)59-33-76-50/h8,11-13,16-21,26-28,31,33,41,44,51,68H,1,9-10,14-15,22-25,29-30,32H2,2-7H3,(H,57,73)(H,60,69)(H,62,70)(H,58,61,63)/t41-,44+,51-/m1/s1",SUWGYDIQBJOKHS-MSYDQUDQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2230,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,840.313,839.295800616,60,7,4,12,C42H43ClFN9O7,"InChI=1S/C42H43ClFN9O7/c1-2-35(54)49-32-22-27-31(46-24-47-39(27)48-25-10-11-29(44)28(43)21-25)23-34(32)60-20-6-15-51-16-18-52(19-17-51)37(56)9-3-4-14-45-30-8-5-7-26-38(30)42(59)53(41(26)58)33-12-13-36(55)50-40(33)57/h2,5,7-8,10-11,21-24,33,45H,1,3-4,6,9,12-20H2,(H,49,54)(H,46,47,48)(H,50,55,57)",DZXXQMUFFJDNFM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2230,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,840.313,839.295800616,60,7,4,12,C42H43ClFN9O7,"InChI=1S/C42H43ClFN9O7/c1-2-35(54)49-32-22-27-31(46-24-47-39(27)48-25-10-11-29(44)28(43)21-25)23-34(32)60-20-6-15-51-16-18-52(19-17-51)37(56)9-3-4-14-45-30-8-5-7-26-38(30)42(59)53(41(26)58)33-12-13-36(55)50-40(33)57/h2,5,7-8,10-11,21-24,33,45H,1,3-4,6,9,12-20H2,(H,49,54)(H,46,47,48)(H,50,55,57)",DZXXQMUFFJDNFM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5472,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1067.686,1066.43018591,75,8,4,15,C54H64ClFN10O8S,"InChI=1S/C54H64ClFN10O8S/c1-32(2)50(47-23-33(3)63-74-47)54(71)66-29-38(67)25-44(66)53(70)62-42(35-10-12-36(13-11-35)51-34(4)60-31-75-51)28-48(68)57-16-7-6-9-49(69)65-20-18-64(19-21-65)17-8-22-73-46-26-39-43(27-45(46)72-5)58-30-59-52(39)61-37-14-15-41(56)40(55)24-37/h10-15,23-24,26-27,30-32,38,42,44,50,67H,6-9,16-22,25,28-29H2,1-5H3,(H,57,68)(H,62,70)(H,58,59,61)/t38-,42+,44+,50-/m1/s1",CLHSOESPINIVIM-VYRQVLTMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5484,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1101.719,1100.45206422,77,8,5,14,C55H67ClF2N10O8S,"InChI=1S/C55H67ClF2N10O8S/c1-33-48(77-32-62-33)35-12-10-34(11-13-35)41(64-51(72)43-26-37(69)30-68(43)52(73)49(54(2,3)4)65-53(74)55(58)16-17-55)29-46(70)59-18-7-6-9-47(71)67-22-20-66(21-23-67)19-8-24-76-45-27-38-42(28-44(45)75-5)60-31-61-50(38)63-36-14-15-40(57)39(56)25-36/h10-15,25,27-28,31-32,37,41,43,49,69H,6-9,16-24,26,29-30H2,1-5H3,(H,59,70)(H,64,72)(H,65,74)(H,60,61,63)/t37-,41+,43+,49-/m1/s1",UHXOCIVWYWWAFP-JYAIWFTJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,568,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1042.3,1041.5171115,75,9,6,16,C55H68FN13O5S,"InChI=1S/C55H68FN13O5S/c1-35-49(75-34-60-35)38-10-8-36(9-11-38)29-59-52(73)45-27-42(71)32-69(45)53(74)50(55(2,3)4)64-48(72)7-5-6-20-66-23-25-67(26-24-66)41-16-17-46(57-30-41)63-47-28-43-44(31-58-47)62-54(61-40-14-12-39(56)13-15-40)65-51(43)68-21-18-37(33-70)19-22-68/h8-17,28,30-31,34,37,42,45,50,70-71H,5-7,18-27,29,32-33H2,1-4H3,(H,59,73)(H,64,72)(H,57,58,63)(H,61,62,65)/t42-,45+,50-/m1/s1",DBOZEYKAOPNYFQ-YPPXMBQWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2865,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1013.647,1012.43136514,70,7,5,14,C51H66ClN10O6PS,"InChI=1S/C51H66ClN10O6PS/c1-32(34-16-18-35(19-17-34)45-33(2)54-31-70-45)55-48(65)41-28-37(63)30-62(41)49(66)46(51(3,4)5)58-44(64)15-11-12-22-60-23-25-61(26-24-60)36-20-21-39(42(27-36)68-6)57-50-53-29-38(52)47(59-50)56-40-13-9-10-14-43(40)69(7,8)67/h9-10,13-14,16-21,27,29,31-32,37,41,46,63H,11-12,15,22-26,28,30H2,1-8H3,(H,55,65)(H,58,64)(H2,53,56,57,59)/t32-,37+,41-,46+/m0/s1",PIVNHCZTKNSYDX-KXGURFEISA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,587,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1010.235,1009.46326436,73,8,5,15,C54H63N11O7S,"InChI=1S/C54H63N11O7S/c1-8-45(67)58-37-11-9-12-39(26-37)65-47(69)25-33(2)41-30-56-53(61-50(41)65)59-42-19-18-38(27-44(42)72-7)63-23-21-62(22-24-63)20-10-13-46(68)60-49(54(4,5)6)52(71)64-31-40(66)28-43(64)51(70)55-29-35-14-16-36(17-15-35)48-34(3)57-32-73-48/h8-9,11-12,14-19,25-27,30,32,40,43,49,66H,1,10,13,20-24,28-29,31H2,2-7H3,(H,55,70)(H,58,67)(H,60,68)(H,56,59,61)/t40-,43+,49-/m1/s1",GHHZCEDRWNWCTG-PCGSYBQZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,587,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1010.235,1009.46326436,73,8,5,15,C54H63N11O7S,"InChI=1S/C54H63N11O7S/c1-8-45(67)58-37-11-9-12-39(26-37)65-47(69)25-33(2)41-30-56-53(61-50(41)65)59-42-19-18-38(27-44(42)72-7)63-23-21-62(22-24-63)20-10-13-46(68)60-49(54(4,5)6)52(71)64-31-40(66)28-43(64)51(70)55-29-35-14-16-36(17-15-35)48-34(3)57-32-73-48/h8-9,11-12,14-19,25-27,30,32,40,43,49,66H,1,10,13,20-24,28-29,31H2,2-7H3,(H,55,70)(H,58,67)(H,60,68)(H,56,59,61)/t40-,43+,49-/m1/s1",GHHZCEDRWNWCTG-PCGSYBQZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2864,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,999.62,998.415715078,69,7,5,14,C50H64ClN10O6PS,"InChI=1S/C50H64ClN10O6PS/c1-31(33-15-17-34(18-16-33)44-32(2)53-30-69-44)54-47(64)40-27-36(62)29-61(40)48(65)45(50(3,4)5)57-43(63)14-11-21-59-22-24-60(25-23-59)35-19-20-38(41(26-35)67-6)56-49-52-28-37(51)46(58-49)55-39-12-9-10-13-42(39)68(7,8)66/h9-10,12-13,15-20,26,28,30-31,36,40,45,62H,11,14,21-25,27,29H2,1-8H3,(H,54,64)(H,57,63)(H2,52,55,56,58)/t31-,36+,40-,45+/m0/s1",CQYHZVXZWVBOLV-DKGDNKRPSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,567,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,34.8,98,1070.354,1069.54841162,77,9,6,16,C57H72FN13O5S,"InChI=1S/C57H72FN13O5S/c1-37-51(77-36-62-37)40-12-10-38(11-13-40)31-61-54(75)47-29-44(73)34-71(47)55(76)52(57(2,3)4)66-50(74)9-7-5-6-8-22-68-25-27-69(28-26-68)43-18-19-48(59-32-43)65-49-30-45-46(33-60-49)64-56(63-42-16-14-41(58)15-17-42)67-53(45)70-23-20-39(35-72)21-24-70/h10-19,30,32-33,36,39,44,47,52,72-73H,5-9,20-29,31,34-35H2,1-4H3,(H,61,75)(H,66,74)(H,59,60,65)(H,63,64,67)/t44-,47+,52-/m1/s1",LCTCXOPSLJEXKE-FEDPBZRBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1543,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCCCCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,865.029,864.341752256,63,9,3,11,C48H48N8O6S,"InChI=1S/C48H48N8O6S/c57-40-20-19-39(43(58)51-40)56-46(61)36-11-8-12-38(41(36)47(56)62)49-21-6-1-2-7-23-53-24-26-54(27-25-53)35-17-15-31(16-18-35)33-13-14-34-30-55(45(60)37(34)29-33)42(32-9-4-3-5-10-32)44(59)52-48-50-22-28-63-48/h3-5,8-18,22,28-29,39,42,49H,1-2,6-7,19-21,23-27,30H2,(H,50,52,59)(H,51,57,58)",PILAFINNPPGQBT-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1995,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,N.D.,995.312,994.53636972,72,9,5,14,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1995,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,126.2,90.3,995.312,994.53636972,72,9,5,14,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1995,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,0.51,80.4,995.312,994.53636972,72,9,5,14,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2610,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1026.322,1025.53094999,74,7,5,14,C56H71N11O6S,"InChI=1S/C56H71N11O6S/c1-10-49(69)60-43-30-44(62-55-57-25-24-42(61-55)41-34-65(8)45-18-15-14-17-40(41)45)48(73-9)31-46(43)66(28-27-64(6)7)26-16-12-11-13-19-50(70)63-52(56(3,4)5)54(72)67-33-39(68)29-47(67)53(71)58-32-37-20-22-38(23-21-37)51-36(2)59-35-74-51/h10,14-15,17-18,20-25,30-31,34-35,39,47,52,68H,1,11-13,16,19,26-29,32-33H2,2-9H3,(H,58,71)(H,60,69)(H,63,70)(H,57,61,62)/t39-,47+,52-/m1/s1",RLLCZBYYTSDTJQ-VHKLOALXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2610,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1026.322,1025.53094999,74,7,5,14,C56H71N11O6S,"InChI=1S/C56H71N11O6S/c1-10-49(69)60-43-30-44(62-55-57-25-24-42(61-55)41-34-65(8)45-18-15-14-17-40(41)45)48(73-9)31-46(43)66(28-27-64(6)7)26-16-12-11-13-19-50(70)63-52(56(3,4)5)54(72)67-33-39(68)29-47(67)53(71)58-32-37-20-22-38(23-21-37)51-36(2)59-35-74-51/h10,14-15,17-18,20-25,30-31,34-35,39,47,52,68H,1,11-13,16,19,26-29,32-33H2,2-9H3,(H,58,71)(H,60,69)(H,63,70)(H,57,61,62)/t39-,47+,52-/m1/s1",RLLCZBYYTSDTJQ-VHKLOALXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2619,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1050.348,1049.54218337,76,9,5,15,C57H71N13O5S,"InChI=1S/C57H71N13O5S/c1-6-49(73)68-27-25-44(35-68)70-52-46(63-56(70)62-41-14-10-9-11-15-41)34-59-55(65-52)61-42-21-23-43(24-22-42)67-30-28-66(29-31-67)26-13-8-7-12-16-48(72)64-51(57(3,4)5)54(75)69-36-45(71)32-47(69)53(74)58-33-39-17-19-40(20-18-39)50-38(2)60-37-76-50/h6,9-11,14-15,17-24,34,37,44-45,47,51,71H,1,7-8,12-13,16,25-33,35-36H2,2-5H3,(H,58,74)(H,62,63)(H,64,72)(H,59,61,65)/t44-,45+,47-,51+/m0/s1",FXWJQZDZCXGXTI-XSCJKQSPSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2619,P00533,EGFR e19d,VHL,C=CC(=O)N1CC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1050.348,1049.54218337,76,9,5,15,C57H71N13O5S,"InChI=1S/C57H71N13O5S/c1-6-49(73)68-27-25-44(35-68)70-52-46(63-56(70)62-41-14-10-9-11-15-41)34-59-55(65-52)61-42-21-23-43(24-22-42)67-30-28-66(29-31-67)26-13-8-7-12-16-48(72)64-51(57(3,4)5)54(75)69-36-45(71)32-47(69)53(74)58-33-39-17-19-40(20-18-39)50-38(2)60-37-76-50/h6,9-11,14-15,17-24,34,37,44-45,47,51,71H,1,7-8,12-13,16,25-33,35-36H2,2-5H3,(H,58,74)(H,62,63)(H,64,72)(H,59,61,65)/t44-,45+,47-,51+/m0/s1",FXWJQZDZCXGXTI-XSCJKQSPSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2620,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1064.375,1063.55783344,77,9,5,15,C58H73N13O5S,"InChI=1S/C58H73N13O5S/c1-6-50(74)69-28-14-17-45(36-69)71-53-47(64-57(71)63-42-15-10-9-11-16-42)35-60-56(66-53)62-43-23-25-44(26-24-43)68-31-29-67(30-32-68)27-13-8-7-12-18-49(73)65-52(58(3,4)5)55(76)70-37-46(72)33-48(70)54(75)59-34-40-19-21-41(22-20-40)51-39(2)61-38-77-51/h6,9-11,15-16,19-26,35,38,45-46,48,52,72H,1,7-8,12-14,17-18,27-34,36-37H2,2-5H3,(H,59,75)(H,63,64)(H,65,73)(H,60,62,66)/t45-,46+,48-,52+/m0/s1",CSQRGDCIFDELOJ-XBQJXWJCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2620,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1064.375,1063.55783344,77,9,5,15,C58H73N13O5S,"InChI=1S/C58H73N13O5S/c1-6-50(74)69-28-14-17-45(36-69)71-53-47(64-57(71)63-42-15-10-9-11-16-42)35-60-56(66-53)62-43-23-25-44(26-24-43)68-31-29-67(30-32-68)27-13-8-7-12-18-49(73)65-52(58(3,4)5)55(76)70-37-46(72)33-48(70)54(75)59-34-40-19-21-41(22-20-40)51-39(2)61-38-77-51/h6,9-11,15-16,19-26,35,38,45-46,48,52,72H,1,7-8,12-14,17-18,27-34,36-37H2,2-5H3,(H,59,75)(H,63,64)(H,65,73)(H,60,62,66)/t45-,46+,48-,52+/m0/s1",CSQRGDCIFDELOJ-XBQJXWJCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2866,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1041.701,1040.46266527,72,7,5,14,C53H70ClN10O6PS,"InChI=1S/C53H70ClN10O6PS/c1-34(36-18-20-37(21-19-36)47-35(2)56-33-72-47)57-50(67)43-30-39(65)32-64(43)51(68)48(53(3,4)5)60-46(66)17-11-9-10-14-24-62-25-27-63(28-26-62)38-22-23-41(44(29-38)70-6)59-52-55-31-40(54)49(61-52)58-42-15-12-13-16-45(42)71(7,8)69/h12-13,15-16,18-23,29,31,33-34,39,43,48,65H,9-11,14,17,24-28,30,32H2,1-8H3,(H,57,67)(H,60,66)(H2,55,58,59,61)/t34-,39+,43-,48+/m0/s1",VTNGOAUXHNQCSE-OESUUHGFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,585,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,466,,1066.343,1065.52586461,77,8,5,15,C58H71N11O7S,"InChI=1S/C58H71N11O7S/c1-8-49(71)62-41-15-14-16-43(30-41)69-51(73)29-37(2)45-34-60-57(65-54(45)69)63-46-23-22-42(31-48(46)76-7)67-27-25-66(26-28-67)24-13-11-9-10-12-17-50(72)64-53(58(4,5)6)56(75)68-35-44(70)32-47(68)55(74)59-33-39-18-20-40(21-19-39)52-38(3)61-36-77-52/h8,14-16,18-23,29-31,34,36,44,47,53,70H,1,9-13,17,24-28,32-33,35H2,2-7H3,(H,59,74)(H,62,71)(H,64,72)(H,60,63,65)/t44-,47+,53-/m1/s1",UKICTJWYEJNYHR-JSYKSQSDSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,585,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1066.343,1065.52586461,77,8,5,15,C58H71N11O7S,"InChI=1S/C58H71N11O7S/c1-8-49(71)62-41-15-14-16-43(30-41)69-51(73)29-37(2)45-34-60-57(65-54(45)69)63-46-23-22-42(31-48(46)76-7)67-27-25-66(26-28-67)24-13-11-9-10-12-17-50(72)64-53(58(4,5)6)56(75)68-35-44(70)32-47(68)55(74)59-33-39-18-20-40(21-19-39)52-38(3)61-36-77-52/h8,14-16,18-23,29-31,34,36,44,47,53,70H,1,9-13,17,24-28,32-33,35H2,2-7H3,(H,59,74)(H,62,71)(H,64,72)(H,60,63,65)/t44-,47+,53-/m1/s1",UKICTJWYEJNYHR-JSYKSQSDSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1996,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,,,1009.339,1008.55201978,73,9,5,14,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1996,P00533,EGFR L858R/T790M,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,151.2,80.3,1009.339,1008.55201978,73,9,5,14,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1996,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,3.54,74.8,1009.339,1008.55201978,73,9,5,14,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2613,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1040.349,1039.54660006,75,7,5,14,C57H73N11O6S,"InChI=1S/C57H73N11O6S/c1-10-50(70)61-44-31-45(63-56-58-26-25-43(62-56)42-35-67(8)46-19-16-15-18-41(42)46)49(74-9)32-47(44)66(7)29-28-65(6)27-17-13-11-12-14-20-51(71)64-53(57(3,4)5)55(73)68-34-40(69)30-48(68)54(72)59-33-38-21-23-39(24-22-38)52-37(2)60-36-75-52/h10,15-16,18-19,21-26,31-32,35-36,40,48,53,69H,1,11-14,17,20,27-30,33-34H2,2-9H3,(H,59,72)(H,61,70)(H,64,71)(H,58,62,63)/t40-,48+,53-/m1/s1",ZSAWNDDMNMQIIJ-KEQUNFJLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2613,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1040.349,1039.54660006,75,7,5,14,C57H73N11O6S,"InChI=1S/C57H73N11O6S/c1-10-50(70)61-44-31-45(63-56-58-26-25-43(62-56)42-35-67(8)46-19-16-15-18-41(42)46)49(74-9)32-47(44)66(7)29-28-65(6)27-17-13-11-12-14-20-51(71)64-53(57(3,4)5)55(73)68-34-40(69)30-48(68)54(72)59-33-38-21-23-39(24-22-38)52-37(2)60-36-75-52/h10,15-16,18-19,21-26,31-32,35-36,40,48,53,69H,1,11-14,17,20,27-30,33-34H2,2-9H3,(H,59,72)(H,61,70)(H,64,71)(H,58,62,63)/t40-,48+,53-/m1/s1",ZSAWNDDMNMQIIJ-KEQUNFJLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2621,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1078.402,1077.5734835,78,9,5,15,C59H75N13O5S,"InChI=1S/C59H75N13O5S/c1-6-51(75)70-29-15-18-46(37-70)72-54-48(65-58(72)64-43-16-11-10-12-17-43)36-61-57(67-54)63-44-24-26-45(27-25-44)69-32-30-68(31-33-69)28-14-9-7-8-13-19-50(74)66-53(59(3,4)5)56(77)71-38-47(73)34-49(71)55(76)60-35-41-20-22-42(23-21-41)52-40(2)62-39-78-52/h6,10-12,16-17,20-27,36,39,46-47,49,53,73H,1,7-9,13-15,18-19,28-35,37-38H2,2-5H3,(H,60,76)(H,64,65)(H,66,74)(H,61,63,67)/t46-,47+,49-,53+/m0/s1",WSSNDQVXHFXMID-APOZONLHSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2621,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1078.402,1077.5734835,78,9,5,15,C59H75N13O5S,"InChI=1S/C59H75N13O5S/c1-6-51(75)70-29-15-18-46(37-70)72-54-48(65-58(72)64-43-16-11-10-12-17-43)36-61-57(67-54)63-44-24-26-45(27-25-44)69-32-30-68(31-33-69)28-14-9-7-8-13-19-50(74)66-53(59(3,4)5)56(77)71-38-47(73)34-49(71)55(76)60-35-41-20-22-42(23-21-41)52-40(2)62-39-78-52/h6,10-12,16-17,20-27,36,39,46-47,49,53,73H,1,7-9,13-15,18-19,28-35,37-38H2,2-5H3,(H,60,76)(H,64,65)(H,66,74)(H,61,63,67)/t46-,47+,49-,53+/m0/s1",WSSNDQVXHFXMID-APOZONLHSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2625,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,1.56,86,1092.429,1091.58913356,79,9,5,15,C60H77N13O5S,"InChI=1S/C60H77N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h7,11-13,17-18,21-28,36,39-40,47-48,50,54,74H,1,8-10,14-16,19-20,29-35,37-38H2,2-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",RYXQXEGTLNBKEC-DKQRTKIFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2625,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,0.49,82,1092.429,1091.58913356,79,9,5,15,C60H77N13O5S,"InChI=1S/C60H77N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h7,11-13,17-18,21-28,36,39-40,47-48,50,54,74H,1,8-10,14-16,19-20,29-35,37-38H2,2-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",RYXQXEGTLNBKEC-DKQRTKIFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2626,P00533,EGFR L858R/T790M,VHL,CCC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1094.445,1093.60478363,79,9,5,15,C60H79N13O5S,"InChI=1S/C60H79N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h11-13,17-18,21-28,36,39-40,47-48,50,54,74H,7-10,14-16,19-20,29-35,37-38H2,1-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",NEBQLCJXQCQWAT-DKQRTKIFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2626,P00533,EGFR e19d,VHL,CCC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1094.445,1093.60478363,79,9,5,15,C60H79N13O5S,"InChI=1S/C60H79N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h11-13,17-18,21-28,36,39-40,47-48,50,54,74H,7-10,14-16,19-20,29-35,37-38H2,1-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",NEBQLCJXQCQWAT-DKQRTKIFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2867,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,8,,1055.728,1054.47831533,73,7,5,14,C54H72ClN10O6PS,"InChI=1S/C54H72ClN10O6PS/c1-35(37-19-21-38(22-20-37)48-36(2)57-34-73-48)58-51(68)44-31-40(66)33-65(44)52(69)49(54(3,4)5)61-47(67)18-12-10-9-11-15-25-63-26-28-64(29-27-63)39-23-24-42(45(30-39)71-6)60-53-56-32-41(55)50(62-53)59-43-16-13-14-17-46(43)72(7,8)70/h13-14,16-17,19-24,30,32,34-35,40,44,49,66H,9-12,15,18,25-29,31,33H2,1-8H3,(H,58,68)(H,61,67)(H2,56,59,60,62)/t35-,40+,44-,49+/m0/s1",KSHZFKVXGRVRTM-XJLLBULKSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2867,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(CCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1055.728,1054.47831533,73,7,5,14,C54H72ClN10O6PS,"InChI=1S/C54H72ClN10O6PS/c1-35(37-19-21-38(22-20-37)48-36(2)57-34-73-48)58-51(68)44-31-40(66)33-65(44)52(69)49(54(3,4)5)61-47(67)18-12-10-9-11-15-25-63-26-28-64(29-27-63)39-23-24-42(45(30-39)71-6)60-53-56-32-41(55)50(62-53)59-43-16-13-14-17-46(43)72(7,8)70/h13-14,16-17,19-24,30,32,34-35,40,44,49,66H,9-12,15,18,25-29,31,33H2,1-8H3,(H,58,68)(H,61,67)(H2,56,59,60,62)/t35-,40+,44-,49+/m0/s1",KSHZFKVXGRVRTM-XJLLBULKSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2867,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(CCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1055.728,1054.47831533,73,7,5,14,C54H72ClN10O6PS,"InChI=1S/C54H72ClN10O6PS/c1-35(37-19-21-38(22-20-37)48-36(2)57-34-73-48)58-51(68)44-31-40(66)33-65(44)52(69)49(54(3,4)5)61-47(67)18-12-10-9-11-15-25-63-26-28-64(29-27-63)39-23-24-42(45(30-39)71-6)60-53-56-32-41(55)50(62-53)59-43-16-13-14-17-46(43)72(7,8)70/h13-14,16-17,19-24,30,32,34-35,40,44,49,66H,9-12,15,18,25-29,31,33H2,1-8H3,(H,58,68)(H,61,67)(H2,56,59,60,62)/t35-,40+,44-,49+/m0/s1",KSHZFKVXGRVRTM-XJLLBULKSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1544,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCCCCCCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,893.083,892.373052384,65,9,3,11,C50H52N8O6S,"InChI=1S/C50H52N8O6S/c59-42-22-21-41(45(60)53-42)58-48(63)38-13-10-14-40(43(38)49(58)64)51-23-8-3-1-2-4-9-25-55-26-28-56(29-27-55)37-19-17-33(18-20-37)35-15-16-36-32-57(47(62)39(36)31-35)44(34-11-6-5-7-12-34)46(61)54-50-52-24-30-65-50/h5-7,10-20,24,30-31,41,44,51H,1-4,8-9,21-23,25-29,32H2,(H,52,54,61)(H,53,59,60)",OARWNJPFFUUHMW-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2868,P00533,EGFR del19/T790M/C797S,VHL,COC1=CC(N2CCN(CCCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,,,1069.755,1068.4939654,74,7,5,14,C55H74ClN10O6PS,"InChI=1S/C55H74ClN10O6PS/c1-36(38-20-22-39(23-21-38)49-37(2)58-35-74-49)59-52(69)45-32-41(67)34-66(45)53(70)50(55(3,4)5)62-48(68)19-13-11-9-10-12-16-26-64-27-29-65(30-28-64)40-24-25-43(46(31-40)72-6)61-54-57-33-42(56)51(63-54)60-44-17-14-15-18-47(44)73(7,8)71/h14-15,17-18,20-25,31,33,35-36,41,45,50,67H,9-13,16,19,26-30,32,34H2,1-8H3,(H,59,69)(H,62,68)(H2,57,60,61,63)/t36-,41+,45-,50+/m0/s1",AAANIVVODIZQAG-NYJWCRJYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,584,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,132,,1094.397,1093.55716474,79,8,5,15,C60H75N11O7S,"InChI=1S/C60H75N11O7S/c1-8-51(73)64-43-17-16-18-45(32-43)71-53(75)31-39(2)47-36-62-59(67-56(47)71)65-48-25-24-44(33-50(48)78-7)69-29-27-68(28-30-69)26-15-13-11-9-10-12-14-19-52(74)66-55(60(4,5)6)58(77)70-37-46(72)34-49(70)57(76)61-35-41-20-22-42(23-21-41)54-40(3)63-38-79-54/h8,16-18,20-25,31-33,36,38,46,49,55,72H,1,9-15,19,26-30,34-35,37H2,2-7H3,(H,61,76)(H,64,73)(H,66,74)(H,62,65,67)/t46-,49+,55-/m1/s1",WWVCWKWNVMYOAL-CKCQHBCRSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,584,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1094.397,1093.55716474,79,8,5,15,C60H75N11O7S,"InChI=1S/C60H75N11O7S/c1-8-51(73)64-43-17-16-18-45(32-43)71-53(75)31-39(2)47-36-62-59(67-56(47)71)65-48-25-24-44(33-50(48)78-7)69-29-27-68(28-30-69)26-15-13-11-9-10-12-14-19-52(74)66-55(60(4,5)6)58(77)70-37-46(72)34-49(70)57(76)61-35-41-20-22-42(23-21-41)54-40(3)63-38-79-54/h8,16-18,20-25,31-33,36,38,46,49,55,72H,1,9-15,19,26-30,34-35,37H2,2-7H3,(H,61,76)(H,64,73)(H,66,74)(H,62,65,67)/t46-,49+,55-/m1/s1",WWVCWKWNVMYOAL-CKCQHBCRSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,577,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,25.3,,1122.451,1121.58846487,81,8,5,15,C62H79N11O7S,"InChI=1S/C62H79N11O7S/c1-8-53(75)66-45-19-18-20-47(34-45)73-55(77)33-41(2)49-38-64-61(69-58(49)73)67-50-27-26-46(35-52(50)80-7)71-31-29-70(30-32-71)28-17-15-13-11-9-10-12-14-16-21-54(76)68-57(62(4,5)6)60(79)72-39-48(74)36-51(72)59(78)63-37-43-22-24-44(25-23-43)56-42(3)65-40-81-56/h8,18-20,22-27,33-35,38,40,48,51,57,74H,1,9-17,21,28-32,36-37,39H2,2-7H3,(H,63,78)(H,66,75)(H,68,76)(H,64,67,69)/t48-,51+,57-/m1/s1",HQGHIKHHXKBFOJ-OIQPADLRSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,577,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,50.3,,1122.451,1121.58846487,81,8,5,15,C62H79N11O7S,"InChI=1S/C62H79N11O7S/c1-8-53(75)66-45-19-18-20-47(34-45)73-55(77)33-41(2)49-38-64-61(69-58(49)73)67-50-27-26-46(35-52(50)80-7)71-31-29-70(30-32-71)28-17-15-13-11-9-10-12-14-16-21-54(76)68-57(62(4,5)6)60(79)72-39-48(74)36-51(72)59(78)63-37-43-22-24-44(25-23-43)56-42(3)65-40-81-56/h8,18-20,22-27,33-35,38,40,48,51,57,74H,1,9-17,21,28-32,36-37,39H2,2-7H3,(H,63,78)(H,66,75)(H,68,76)(H,64,67,69)/t48-,51+,57-/m1/s1",HQGHIKHHXKBFOJ-OIQPADLRSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,4281,P00533,EGFR,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1003.324,1002.54011771,72,7,4,12,C56H74N8O7S,"InChI=1S/C56H74N8O7S/c1-38-51(72-37-60-38)41-24-22-39(23-25-41)33-57-54(68)46-30-43(65)34-64(46)55(69)52(56(2,3)4)62-49(66)20-16-11-9-7-6-8-10-12-17-21-50(67)63-28-26-40(27-29-63)35-71-48-32-45-44(31-47(48)70-5)53(59-36-58-45)61-42-18-14-13-15-19-42/h13-15,18-19,22-25,31-32,36-37,40,43,46,52,65H,6-12,16-17,20-21,26-30,33-35H2,1-5H3,(H,57,68)(H,62,66)(H,58,59,61)/t43-,46+,52-/m1/s1",MMPNZJCRKQTTJP-YFNYOHRESA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,4281,P00533,EGFR L858R,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1003.324,1002.54011771,72,7,4,12,C56H74N8O7S,"InChI=1S/C56H74N8O7S/c1-38-51(72-37-60-38)41-24-22-39(23-25-41)33-57-54(68)46-30-43(65)34-64(46)55(69)52(56(2,3)4)62-49(66)20-16-11-9-7-6-8-10-12-17-21-50(67)63-28-26-40(27-29-63)35-71-48-32-45-44(31-47(48)70-5)53(59-36-58-45)61-42-18-14-13-15-19-42/h13-15,18-19,22-25,31-32,36-37,40,43,46,52,65H,6-12,16-17,20-21,26-30,33-35H2,1-5H3,(H,57,68)(H,62,66)(H,58,59,61)/t43-,46+,52-/m1/s1",MMPNZJCRKQTTJP-YFNYOHRESA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,4281,P00533,EGFR e19d,VHL,COC1=CC2=C(NC3=CC=CC=C3)N=CN=C2C=C1OCC1CCN(C(=O)CCCCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1003.324,1002.54011771,72,7,4,12,C56H74N8O7S,"InChI=1S/C56H74N8O7S/c1-38-51(72-37-60-38)41-24-22-39(23-25-41)33-57-54(68)46-30-43(65)34-64(46)55(69)52(56(2,3)4)62-49(66)20-16-11-9-7-6-8-10-12-17-21-50(67)63-28-26-40(27-29-63)35-71-48-32-45-44(31-47(48)70-5)53(59-36-58-45)61-42-18-14-13-15-19-42/h13-15,18-19,22-25,31-32,36-37,40,43,46,52,65H,6-12,16-17,20-21,26-30,33-35H2,1-5H3,(H,57,68)(H,62,66)(H,58,59,61)/t43-,46+,52-/m1/s1",MMPNZJCRKQTTJP-YFNYOHRESA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5613,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,897.916,897.353377472,65,7,6,14,C44H46F3N11O7,"InChI=1S/C44H46F3N11O7/c1-3-35(59)51-26-8-6-9-27(22-26)52-39-30(44(45,46)47)24-50-43(55-39)53-31-13-12-28(23-34(31)65-2)57-20-18-56(19-21-57)25-37(61)49-17-5-4-16-48-32-11-7-10-29-38(32)42(64)58(41(29)63)33-14-15-36(60)54-40(33)62/h3,6-13,22-24,33,48H,1,4-5,14-21,25H2,2H3,(H,49,61)(H,51,59)(H,54,60,62)(H2,50,52,53,55)",DBCOQEBSRVLNQM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5613,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,897.916,897.353377472,65,7,6,14,C44H46F3N11O7,"InChI=1S/C44H46F3N11O7/c1-3-35(59)51-26-8-6-9-27(22-26)52-39-30(44(45,46)47)24-50-43(55-39)53-31-13-12-28(23-34(31)65-2)57-20-18-56(19-21-57)25-37(61)49-17-5-4-16-48-32-11-7-10-29-38(32)42(64)58(41(29)63)33-14-15-36(60)54-40(33)62/h3,6-13,22-24,33,48H,1,4-5,14-21,25H2,2H3,(H,49,61)(H,51,59)(H,54,60,62)(H2,50,52,53,55)",DBCOQEBSRVLNQM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5613,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,897.916,897.353377472,65,7,6,14,C44H46F3N11O7,"InChI=1S/C44H46F3N11O7/c1-3-35(59)51-26-8-6-9-27(22-26)52-39-30(44(45,46)47)24-50-43(55-39)53-31-13-12-28(23-34(31)65-2)57-20-18-56(19-21-57)25-37(61)49-17-5-4-16-48-32-11-7-10-29-38(32)42(64)58(41(29)63)33-14-15-36(60)54-40(33)62/h3,6-13,22-24,33,48H,1,4-5,14-21,25H2,2H3,(H,49,61)(H,51,59)(H,54,60,62)(H2,50,52,53,55)",DBCOQEBSRVLNQM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,561,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,885.018,884.424591016,65,9,5,14,C47H53FN12O5,"InChI=1S/C47H53FN12O5/c48-31-8-10-32(11-9-31)51-47-53-38-27-50-41(25-35(38)44(56-47)59-19-16-30(29-61)17-20-59)54-40-14-12-33(26-49-40)58-23-21-57(22-24-58)18-3-1-2-7-42(62)52-37-6-4-5-34-36(37)28-60(46(34)65)39-13-15-43(63)55-45(39)64/h4-6,8-12,14,25-27,30,39,61H,1-3,7,13,15-24,28-29H2,(H,52,62)(H,49,50,54)(H,51,53,56)(H,55,63,64)",ODJQZPLMAOELRA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5463,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,865.008,864.407129384,64,7,4,12,C48H52N10O6,"InChI=1S/C48H52N10O6/c1-6-23-57(24-12-8-9-18-44(60)50-35-16-13-15-32-34(35)30-58(47(32)63)40-19-20-45(61)54-46(40)62)26-25-55(3)41-28-42(64-5)38(27-37(41)51-43(59)7-2)53-48-49-22-21-36(52-48)33-29-56(4)39-17-11-10-14-31(33)39/h1,7,10-11,13-17,21-22,27-29,40H,2,8-9,12,18-20,23-26,30H2,3-5H3,(H,50,60)(H,51,59)(H,49,52,53)(H,54,61,62)",LZLZXSSMSNOMPK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5611,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-33(57)49-24-6-4-7-25(20-24)50-37-28(42(43,44)45)22-48-41(53-37)51-29-11-10-26(21-32(29)63-2)55-18-16-54(17-19-55)23-35(59)47-15-14-46-30-9-5-8-27-36(30)40(62)56(39(27)61)31-12-13-34(58)52-38(31)60/h3-11,20-22,31,46H,1,12-19,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",FVYDZXSZKLYSRY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5611,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,355.9,83,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-33(57)49-24-6-4-7-25(20-24)50-37-28(42(43,44)45)22-48-41(53-37)51-29-11-10-26(21-32(29)63-2)55-18-16-54(17-19-55)23-35(59)47-15-14-46-30-9-5-8-27-36(30)40(62)56(39(27)61)31-12-13-34(58)52-38(31)60/h3-11,20-22,31,46H,1,12-19,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",FVYDZXSZKLYSRY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5611,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,869.862,869.322077344,63,7,6,14,C42H42F3N11O7,"InChI=1S/C42H42F3N11O7/c1-3-33(57)49-24-6-4-7-25(20-24)50-37-28(42(43,44)45)22-48-41(53-37)51-29-11-10-26(21-32(29)63-2)55-18-16-54(17-19-55)23-35(59)47-15-14-46-30-9-5-8-27-36(30)40(62)56(39(27)61)31-12-13-34(58)52-38(31)60/h3-11,20-22,31,46H,1,12-19,23H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",FVYDZXSZKLYSRY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5618,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,855.879,855.342812788,62,7,6,13,C42H44F3N11O6,"InChI=1S/C42H44F3N11O6/c1-3-35(57)49-25-6-4-7-26(20-25)50-38-30(42(43,44)45)22-48-41(53-38)51-32-11-10-27(21-34(32)62-2)55-18-16-54(17-19-55)24-37(59)47-15-14-46-31-9-5-8-28-29(31)23-56(40(28)61)33-12-13-36(58)52-39(33)60/h3-11,20-22,33,46H,1,12-19,23-24H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",ZZEWLUKGFOHQPN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5618,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,855.879,855.342812788,62,7,6,13,C42H44F3N11O6,"InChI=1S/C42H44F3N11O6/c1-3-35(57)49-25-6-4-7-26(20-25)50-38-30(42(43,44)45)22-48-41(53-38)51-32-11-10-27(21-34(32)62-2)55-18-16-54(17-19-55)24-37(59)47-15-14-46-31-9-5-8-28-29(31)23-56(40(28)61)33-12-13-36(58)52-39(33)60/h3-11,20-22,33,46H,1,12-19,23-24H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",ZZEWLUKGFOHQPN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5618,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCNC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,855.879,855.342812788,62,7,6,13,C42H44F3N11O6,"InChI=1S/C42H44F3N11O6/c1-3-35(57)49-25-6-4-7-26(20-25)50-38-30(42(43,44)45)22-48-41(53-38)51-32-11-10-27(21-34(32)62-2)55-18-16-54(17-19-55)24-37(59)47-15-14-46-31-9-5-8-28-29(31)23-56(40(28)61)33-12-13-36(58)52-39(33)60/h3-11,20-22,33,46H,1,12-19,23-24H2,2H3,(H,47,59)(H,49,57)(H,52,58,60)(H2,48,50,51,53)",ZZEWLUKGFOHQPN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5475,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1109.767,1108.4771361,78,8,4,15,C57H70ClFN10O8S,"InChI=1S/C57H70ClFN10O8S/c1-35(2)53(50-26-36(3)66-77-50)57(74)69-32-41(70)28-47(69)56(73)65-45(38-13-15-39(16-14-38)54-37(4)63-34-78-54)31-51(71)60-19-10-8-6-7-9-12-52(72)68-23-21-67(22-24-68)20-11-25-76-49-29-42-46(30-48(49)75-5)61-33-62-55(42)64-40-17-18-44(59)43(58)27-40/h13-18,26-27,29-30,33-35,41,45,47,53,70H,6-12,19-25,28,31-32H2,1-5H3,(H,60,71)(H,65,73)(H,61,62,64)/t41-,45+,47+,53-/m1/s1",KTBJMRVBXCURAL-UYZZMYMLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5487,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1143.8,1142.49901442,80,8,5,14,C58H73ClF2N10O8S,"InChI=1S/C58H73ClF2N10O8S/c1-36-51(80-35-65-36)38-15-13-37(14-16-38)44(67-54(75)46-29-40(72)33-71(46)55(76)52(57(2,3)4)68-56(77)58(61)19-20-58)32-49(73)62-21-10-8-6-7-9-12-50(74)70-25-23-69(24-26-70)22-11-27-79-48-30-41-45(31-47(48)78-5)63-34-64-53(41)66-39-17-18-43(60)42(59)28-39/h13-18,28,30-31,34-35,40,44,46,52,72H,6-12,19-27,29,32-33H2,1-5H3,(H,62,73)(H,67,75)(H,68,77)(H,63,64,66)/t40-,44+,46+,52-/m1/s1",BDAXJHVAQPPZDC-YHXFZPEXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2229,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,826.286,825.280150552,59,7,4,12,C41H41ClFN9O7,"InChI=1S/C41H41ClFN9O7/c1-2-34(53)48-31-21-26-30(45-23-46-38(26)47-24-9-10-28(43)27(42)20-24)22-33(31)59-19-5-14-50-15-17-51(18-16-50)36(55)8-4-13-44-29-7-3-6-25-37(29)41(58)52(40(25)57)32-11-12-35(54)49-39(32)56/h2-3,6-7,9-10,20-23,32,44H,1,4-5,8,11-19H2,(H,48,53)(H,45,46,47)(H,49,54,56)",PTYUVGHJRRBMOG-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2229,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,826.286,825.280150552,59,7,4,12,C41H41ClFN9O7,"InChI=1S/C41H41ClFN9O7/c1-2-34(53)48-31-21-26-30(45-23-46-38(26)47-24-9-10-28(43)27(42)20-24)22-33(31)59-19-5-14-50-15-17-51(18-16-50)36(55)8-4-13-44-29-7-3-6-25-37(29)41(58)52(40(25)57)32-11-12-35(54)49-39(32)56/h2-3,6-7,9-10,20-23,32,44H,1,4-5,8,11-19H2,(H,48,53)(H,45,46,47)(H,49,54,56)",PTYUVGHJRRBMOG-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5471,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1053.659,1052.41453584,74,8,4,15,C53H62ClFN10O8S,"InChI=1S/C53H62ClFN10O8S/c1-31(2)49(46-22-32(3)62-73-46)53(70)65-28-37(66)24-43(65)52(69)61-41(34-9-11-35(12-10-34)50-33(4)59-30-74-50)27-47(67)56-15-6-8-48(68)64-19-17-63(18-20-64)16-7-21-72-45-25-38-42(26-44(45)71-5)57-29-58-51(38)60-36-13-14-40(55)39(54)23-36/h9-14,22-23,25-26,29-31,37,41,43,49,66H,6-8,15-21,24,27-28H2,1-5H3,(H,56,67)(H,61,69)(H,57,58,60)/t37-,41+,43+,49-/m1/s1",VTEHNUQLGGNRDD-JYAIWFTJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5483,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1087.692,1086.43641416,76,8,5,14,C54H65ClF2N10O8S,"InChI=1S/C54H65ClF2N10O8S/c1-32-47(76-31-61-32)34-11-9-33(10-12-34)40(63-50(71)42-25-36(68)29-67(42)51(72)48(53(2,3)4)64-52(73)54(57)15-16-54)28-45(69)58-17-6-8-46(70)66-21-19-65(20-22-66)18-7-23-75-44-26-37-41(27-43(44)74-5)59-30-60-49(37)62-35-13-14-39(56)38(55)24-35/h9-14,24,26-27,30-31,36,40,42,48,68H,6-8,15-23,25,28-29H2,1-5H3,(H,58,69)(H,63,71)(H,64,73)(H,59,60,62)/t36-,40+,42+,48-/m1/s1",MLPWVFYXPJNYIP-OQQYKNMXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,592,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1000.639,999.424372256,70,7,4,13,C51H63ClFN9O7S,"InChI=1S/C51H63ClFN9O7S/c1-32-46(70-31-57-32)34-14-12-33(13-15-34)28-54-49(66)41-25-36(63)29-62(41)50(67)47(51(2,3)4)59-44(64)10-7-6-8-11-45(65)61-21-19-60(20-22-61)18-9-23-69-43-26-37-40(27-42(43)68-5)55-30-56-48(37)58-35-16-17-39(53)38(52)24-35/h12-17,24,26-27,30-31,36,41,47,63H,6-11,18-23,25,28-29H2,1-5H3,(H,54,66)(H,59,64)(H,55,56,58)/t36-,41+,47-/m1/s1",ISBWTTKCXBFWJM-FGUOTCRGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,592,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1000.639,999.424372256,70,7,4,13,C51H63ClFN9O7S,"InChI=1S/C51H63ClFN9O7S/c1-32-46(70-31-57-32)34-14-12-33(13-15-34)28-54-49(66)41-25-36(63)29-62(41)50(67)47(51(2,3)4)59-44(64)10-7-6-8-11-45(65)61-21-19-60(20-22-61)18-9-23-69-43-26-37-40(27-42(43)68-5)55-30-56-48(37)58-35-16-17-39(53)38(52)24-35/h12-17,24,26-27,30-31,36,41,47,63H,6-11,18-23,25,28-29H2,1-5H3,(H,54,66)(H,59,64)(H,55,56,58)/t36-,41+,47-/m1/s1",ISBWTTKCXBFWJM-FGUOTCRGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2231,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,30-50/100,,854.34,853.31145068,61,7,4,12,C43H45ClFN9O7,"InChI=1S/C43H45ClFN9O7/c1-2-36(55)50-33-23-28-32(47-25-48-40(28)49-26-11-12-30(45)29(44)22-26)24-35(33)61-21-7-16-52-17-19-53(20-18-52)38(57)10-4-3-5-15-46-31-9-6-8-27-39(31)43(60)54(42(27)59)34-13-14-37(56)51-41(34)58/h2,6,8-9,11-12,22-25,34,46H,1,3-5,7,10,13-21H2,(H,50,55)(H,47,48,49)(H,51,56,58)",UFVWZVUFBJDPFK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2231,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,100,40,854.34,853.31145068,61,7,4,12,C43H45ClFN9O7,"InChI=1S/C43H45ClFN9O7/c1-2-36(55)50-33-23-28-32(47-25-48-40(28)49-26-11-12-30(45)29(44)22-26)24-35(33)61-21-7-16-52-17-19-53(20-18-52)38(57)10-4-3-5-15-46-31-9-6-8-27-39(31)43(60)54(42(27)59)34-13-14-37(56)51-41(34)58/h2,6,8-9,11-12,22-25,34,46H,1,3-5,7,10,13-21H2,(H,50,55)(H,47,48,49)(H,51,56,58)",UFVWZVUFBJDPFK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5473,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1081.713,1080.44583597,76,8,4,15,C55H66ClFN10O8S,"InChI=1S/C55H66ClFN10O8S/c1-33(2)51(48-24-34(3)64-75-48)55(72)67-30-39(68)26-45(67)54(71)63-43(36-11-13-37(14-12-36)52-35(4)61-32-76-52)29-49(69)58-17-8-6-7-10-50(70)66-21-19-65(20-22-66)18-9-23-74-47-27-40-44(28-46(47)73-5)59-31-60-53(40)62-38-15-16-42(57)41(56)25-38/h11-16,24-25,27-28,31-33,39,43,45,51,68H,6-10,17-23,26,29-30H2,1-5H3,(H,58,69)(H,63,71)(H,59,60,62)/t39-,43+,45+,51-/m1/s1",GNNZZAAWTZBPGM-NZMHYKQJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5485,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1115.746,1114.46771429,78,8,5,14,C56H69ClF2N10O8S,"InChI=1S/C56H69ClF2N10O8S/c1-34-49(78-33-63-34)36-13-11-35(12-14-36)42(65-52(73)44-27-38(70)31-69(44)53(74)50(55(2,3)4)66-54(75)56(59)17-18-56)30-47(71)60-19-8-6-7-10-48(72)68-23-21-67(22-24-68)20-9-25-77-46-28-39-43(29-45(46)76-5)61-32-62-51(39)64-37-15-16-41(58)40(57)26-37/h11-16,26,28-29,32-33,38,42,44,50,70H,6-10,17-25,27,30-31H2,1-5H3,(H,60,71)(H,65,73)(H,66,75)(H,61,62,64)/t38-,42+,44+,50-/m1/s1",XEFGFUQIJSNZHH-VYRQVLTMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,276,P00533,EGFR,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,11.7/22.3,98.9/96.6,934.532,933.366188684,65,6,4,13,C47H57ClFN7O8S,"InChI=1S/C47H57ClFN7O8S/c1-29-42(65-28-53-29)31-11-9-30(10-12-31)25-50-45(59)38-22-33(57)26-56(38)46(60)43(47(2,3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14,21,23-24,27-28,33,38,43,57H,6-8,15-20,22,25-26H2,1-5H3,(H,50,59)(H,55,58)(H,51,52,54)/t33-,38+,43-/m1/s1",NICKHWYZMNLEPJ-TZSMONEZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,277,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCOCCCCOCCCCOC3=CC4=NC=NC(NC5=CC=C(F)C(Cl)=C5)=C4C=C3NC(=O)/C=C/CN(C)C)C(C)(C)C)C=C2)SC=N1,215.8,79.1,1086.773,1085.4975372,76,6,5,14,C56H73ClFN9O8S,"InChI=1S/C56H73ClFN9O8S/c1-37-51(76-36-62-37)39-19-17-38(18-20-39)33-59-54(71)47-30-41(68)34-67(47)55(72)52(56(2,3)4)65-50(70)15-8-7-9-24-73-25-10-11-26-74-27-12-13-28-75-48-32-45-42(31-46(48)64-49(69)16-14-23-66(5)6)53(61-35-60-45)63-40-21-22-44(58)43(57)29-40/h14,16-22,29,31-32,35-36,41,47,52,68H,7-13,15,23-28,30,33-34H2,1-6H3,(H,59,71)(H,64,69)(H,65,70)(H,60,61,63)/b16-14+/t41-,47+,52-/m1/s1",BXHBYEPLXDQKAT-JYCNGAFSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,560,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,899.045,898.44024108,66,9,5,14,C48H55FN12O5,"InChI=1S/C48H55FN12O5/c49-32-9-11-33(12-10-32)52-48-54-39-28-51-42(26-36(39)45(57-48)60-20-17-31(30-62)18-21-60)55-41-15-13-34(27-50-41)59-24-22-58(23-25-59)19-4-2-1-3-8-43(63)53-38-7-5-6-35-37(38)29-61(47(35)66)40-14-16-44(64)56-46(40)65/h5-7,9-13,15,26-28,31,40,62H,1-4,8,14,16-25,29-30H2,(H,53,63)(H,50,51,55)(H,52,54,57)(H,56,64,65)",FFVKASNNDQLIDU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1993,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,824.003,823.428199176,61,9,4,12,C46H53N11O4,"InChI=1S/C46H53N11O4/c58-40(50-37-16-10-15-35-36(37)30-56(44(35)61)39-22-23-41(59)52-43(39)60)17-6-1-2-9-24-54-25-27-55(28-26-54)33-20-18-32(19-21-33)48-45-47-29-38-42(53-45)57(34-13-7-8-14-34)46(51-38)49-31-11-4-3-5-12-31/h3-5,10-12,15-16,18-21,29,34,39H,1-2,6-9,13-14,17,22-28,30H2,(H,49,51)(H,50,58)(H,47,48,53)(H,52,59,60)",WHKCGHLFWIJUOU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1993,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,824.003,823.428199176,61,9,4,12,C46H53N11O4,"InChI=1S/C46H53N11O4/c58-40(50-37-16-10-15-35-36(37)30-56(44(35)61)39-22-23-41(59)52-43(39)60)17-6-1-2-9-24-54-25-27-55(28-26-54)33-20-18-32(19-21-33)48-45-47-29-38-42(53-45)57(34-13-7-8-14-34)46(51-38)49-31-11-4-3-5-12-31/h3-5,10-12,15-16,18-21,29,34,39H,1-2,6-9,13-14,17,22-28,30H2,(H,49,51)(H,50,58)(H,47,48,53)(H,52,59,60)",WHKCGHLFWIJUOU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1993,P00533,EGFR e19d,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,824.003,823.428199176,61,9,4,12,C46H53N11O4,"InChI=1S/C46H53N11O4/c58-40(50-37-16-10-15-35-36(37)30-56(44(35)61)39-22-23-41(59)52-43(39)60)17-6-1-2-9-24-54-25-27-55(28-26-54)33-20-18-32(19-21-33)48-45-47-29-38-42(53-45)57(34-13-7-8-14-34)46(51-38)49-31-11-4-3-5-12-31/h3-5,10-12,15-16,18-21,29,34,39H,1-2,6-9,13-14,17,22-28,30H2,(H,49,51)(H,50,58)(H,47,48,53)(H,52,59,60)",WHKCGHLFWIJUOU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5464,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,879.035,878.422779448,65,7,4,12,C49H54N10O6,"InChI=1S/C49H54N10O6/c1-6-24-58(25-13-9-8-10-19-45(61)51-36-17-14-16-33-35(36)31-59(48(33)64)41-20-21-46(62)55-47(41)63)27-26-56(3)42-29-43(65-5)39(28-38(42)52-44(60)7-2)54-49-50-23-22-37(53-49)34-30-57(4)40-18-12-11-15-32(34)40/h1,7,11-12,14-18,22-23,28-30,41H,2,8-10,13,19-21,24-27,31H2,3-5H3,(H,51,61)(H,52,60)(H,50,53,54)(H,55,62,63)",ZVJMBUCONGNNOE-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,559,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,45.2,87,913.072,912.455891144,67,9,5,14,C49H57FN12O5,"InChI=1S/C49H57FN12O5/c50-33-10-12-34(13-11-33)53-49-55-40-29-52-43(27-37(40)46(58-49)61-21-18-32(31-63)19-22-61)56-42-16-14-35(28-51-42)60-25-23-59(24-26-60)20-5-3-1-2-4-9-44(64)54-39-8-6-7-36-38(39)30-62(48(36)67)41-15-17-45(65)57-47(41)66/h6-8,10-14,16,27-29,32,41,63H,1-5,9,15,17-26,30-31H2,(H,54,64)(H,51,52,56)(H,53,55,58)(H,57,65,66)",ZWLPWTDAYPOQGR-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,565,P00533,EGFR,CRBN,CN(C)C1CCN(C2=CC=C(NC3=CC4=C(N5CCN(CCCCCCCC(=O)NC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1,,,926.115,925.48752562,68,9,4,14,C50H60FN13O4,"InChI=1S/C50H60FN13O4/c1-60(2)35-20-23-62(24-21-35)36-16-18-43(52-30-36)57-44-29-38-41(31-53-44)56-50(54-34-14-12-33(51)13-15-34)59-47(38)63-27-25-61(26-28-63)22-7-5-3-4-6-11-45(65)55-40-10-8-9-37-39(40)32-64(49(37)68)42-17-19-46(66)58-48(42)67/h8-10,12-16,18,29-31,35,42H,3-7,11,17,19-28,32H2,1-2H3,(H,55,65)(H,52,53,57)(H,54,56,59)(H,58,66,67)",JWIJDEAEELQGIY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1994,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,838.03,837.44384924,62,9,4,12,C47H55N11O4,"InChI=1S/C47H55N11O4/c59-41(51-38-17-11-16-36-37(38)31-57(45(36)62)40-23-24-42(60)53-44(40)61)18-7-2-1-3-10-25-55-26-28-56(29-27-55)34-21-19-33(20-22-34)49-46-48-30-39-43(54-46)58(35-14-8-9-15-35)47(52-39)50-32-12-5-4-6-13-32/h4-6,11-13,16-17,19-22,30,35,40H,1-3,7-10,14-15,18,23-29,31H2,(H,50,52)(H,51,59)(H,48,49,54)(H,53,60,61)",TWTFDTRUNNZWOY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1994,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,838.03,837.44384924,62,9,4,12,C47H55N11O4,"InChI=1S/C47H55N11O4/c59-41(51-38-17-11-16-36-37(38)31-57(45(36)62)40-23-24-42(60)53-44(40)61)18-7-2-1-3-10-25-55-26-28-56(29-27-55)34-21-19-33(20-22-34)49-46-48-30-39-43(54-46)58(35-14-8-9-15-35)47(52-39)50-32-12-5-4-6-13-32/h4-6,11-13,16-17,19-22,30,35,40H,1-3,7-10,14-15,18,23-29,31H2,(H,50,52)(H,51,59)(H,48,49,54)(H,53,60,61)",TWTFDTRUNNZWOY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1994,P00533,EGFR e19d,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4CCN(C5=CC=C(NC6=NC=C7N=C(NC8=CC=CC=C8)N(C8CCCC8)C7=N6)C=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,838.03,837.44384924,62,9,4,12,C47H55N11O4,"InChI=1S/C47H55N11O4/c59-41(51-38-17-11-16-36-37(38)31-57(45(36)62)40-23-24-42(60)53-44(40)61)18-7-2-1-3-10-25-55-26-28-56(29-27-55)34-21-19-33(20-22-34)49-46-48-30-39-43(54-46)58(35-14-8-9-15-35)47(52-39)50-32-12-5-4-6-13-32/h4-6,11-13,16-17,19-22,30,35,40H,1-3,7-10,14-15,18,23-29,31H2,(H,50,52)(H,51,59)(H,48,49,54)(H,53,60,61)",TWTFDTRUNNZWOY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5465,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,893.062,892.438429512,66,7,4,12,C50H56N10O6,"InChI=1S/C50H56N10O6/c1-6-25-59(26-14-10-8-9-11-20-46(62)52-37-18-15-17-34-36(37)32-60(49(34)65)42-21-22-47(63)56-48(42)64)28-27-57(3)43-30-44(66-5)40(29-39(43)53-45(61)7-2)55-50-51-24-23-38(54-50)35-31-58(4)41-19-13-12-16-33(35)41/h1,7,12-13,15-19,23-24,29-31,42H,2,8-11,14,20-22,25-28,32H2,3-5H3,(H,52,62)(H,53,61)(H,51,54,55)(H,56,63,64)",NEPHIFUOEBQFEW-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5467,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCCCCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,921.116,920.46972964,68,7,4,12,C52H60N10O6,"InChI=1S/C52H60N10O6/c1-6-27-61(28-16-12-10-8-9-11-13-22-48(64)54-39-20-17-19-36-38(39)34-62(51(36)67)44-23-24-49(65)58-50(44)66)30-29-59(3)45-32-46(68-5)42(31-41(45)55-47(63)7-2)57-52-53-26-25-40(56-52)37-33-60(4)43-21-15-14-18-35(37)43/h1,7,14-15,17-21,25-26,31-33,44H,2,8-13,16,22-24,27-30,34H2,3-5H3,(H,54,64)(H,55,63)(H,53,56,57)(H,58,65,66)",CHDLLVONGFYTLZ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,563,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCCCCN4C=C(CN5CCN(C6=CC=C(NC7=CC8=C(N9CCC(CO)CC9)N=C(NC9=CC=C(F)C=C9)N=C8C=N7)N=C6)CC5)N=N4)C=CC=C3C2=O)C(=O)N1,,,994.15,993.48858824,73,10,5,17,C52H60FN15O5,"InChI=1S/C52H60FN15O5/c53-35-10-12-36(13-11-35)56-52-58-43-29-55-46(27-40(43)49(61-52)66-21-18-34(33-69)19-22-66)59-45-16-14-38(28-54-45)65-25-23-64(24-26-65)30-37-31-67(63-62-37)20-5-3-1-2-4-9-47(70)57-42-8-6-7-39-41(42)32-68(51(39)73)44-15-17-48(71)60-50(44)72/h6-8,10-14,16,27-29,31,34,44,69H,1-5,9,15,17-26,30,32-33H2,(H,57,70)(H,54,55,59)(H,56,58,61)(H,60,71,72)",YGIUVVAIJWPSDA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2403,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,934.43,933.348898808,67,8,4,14,C47H49ClFN11O7,"InChI=1S/C47H49ClFN11O7/c48-33-23-29(15-16-34(33)49)52-44-32-24-37(54-41(62)14-10-21-58-19-6-4-7-20-58)39(25-36(32)50-28-51-44)67-27-30-26-59(57-56-30)22-8-3-1-2-5-13-40(61)53-35-12-9-11-31-43(35)47(66)60(46(31)65)38-17-18-42(63)55-45(38)64/h9-12,14-16,23-26,28,38H,1-8,13,17-22,27H2,(H,53,61)(H,54,62)(H,50,51,52)(H,55,63,64)/b14-10+",IKDWVMHENZHDMZ-GXDHUFHOSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2405,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,962.484,961.380198936,69,8,4,14,C49H53ClFN11O7,"InChI=1S/C49H53ClFN11O7/c50-35-25-31(17-18-36(35)51)54-46-34-26-39(56-43(64)16-12-23-60-21-8-6-9-22-60)41(27-38(34)52-30-53-46)69-29-32-28-61(59-58-32)24-10-5-3-1-2-4-7-15-42(63)55-37-14-11-13-33-45(37)49(68)62(48(33)67)40-19-20-44(65)57-47(40)66/h11-14,16-18,25-28,30,40H,1-10,15,19-24,29H2,(H,55,63)(H,56,64)(H,52,53,54)(H,57,65,66)/b16-12+",WAIDPWGKISVORF-FOWTUZBSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5612,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,883.889,883.337727408,64,7,6,14,C43H44F3N11O7,"InChI=1S/C43H44F3N11O7/c1-3-34(58)50-25-7-4-8-26(21-25)51-38-29(43(44,45)46)23-49-42(54-38)52-30-12-11-27(22-33(30)64-2)56-19-17-55(18-20-56)24-36(60)48-16-6-15-47-31-10-5-9-28-37(31)41(63)57(40(28)62)32-13-14-35(59)53-39(32)61/h3-5,7-12,21-23,32,47H,1,6,13-20,24H2,2H3,(H,48,60)(H,50,58)(H,53,59,61)(H2,49,51,52,54)",YIUFSCFMBJSOOL-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5612,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,883.889,883.337727408,64,7,6,14,C43H44F3N11O7,"InChI=1S/C43H44F3N11O7/c1-3-34(58)50-25-7-4-8-26(21-25)51-38-29(43(44,45)46)23-49-42(54-38)52-30-12-11-27(22-33(30)64-2)56-19-17-55(18-20-56)24-36(60)48-16-6-15-47-31-10-5-9-28-37(31)41(63)57(40(28)62)32-13-14-35(59)53-39(32)61/h3-5,7-12,21-23,32,47H,1,6,13-20,24H2,2H3,(H,48,60)(H,50,58)(H,53,59,61)(H2,49,51,52,54)",YIUFSCFMBJSOOL-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5612,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,883.889,883.337727408,64,7,6,14,C43H44F3N11O7,"InChI=1S/C43H44F3N11O7/c1-3-34(58)50-25-7-4-8-26(21-25)51-38-29(43(44,45)46)23-49-42(54-38)52-30-12-11-27(22-33(30)64-2)56-19-17-55(18-20-56)24-36(60)48-16-6-15-47-31-10-5-9-28-37(31)41(63)57(40(28)62)32-13-14-35(59)53-39(32)61/h3-5,7-12,21-23,32,47H,1,6,13-20,24H2,2H3,(H,48,60)(H,50,58)(H,53,59,61)(H2,49,51,52,54)",YIUFSCFMBJSOOL-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,571,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NCCOCCOCCN3C=C(CN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1155.42,1154.57602334,83,10,6,21,C59H75FN16O6S,"InChI=1S/C59H75FN16O6S/c1-39-53(83-38-65-39)42-7-5-40(6-8-42)31-64-56(79)50-29-47(78)36-76(50)57(80)54(59(2,3)4)61-17-25-81-27-28-82-26-24-75-35-45(70-71-75)34-72-20-22-73(23-21-72)46-13-14-51(62-32-46)68-52-30-48-49(33-63-52)67-58(66-44-11-9-43(60)10-12-44)69-55(48)74-18-15-41(37-77)16-19-74/h5-14,30,32-33,35,38,41,47,50,54,61,77-78H,15-29,31,34,36-37H2,1-4H3,(H,64,79)(H,62,63,68)(H,66,67,69)/t47-,50+,54-/m1/s1",SCALGKKEKZAYQL-PZUTWEFSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2622,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1107.4,1106.56364709,80,9,6,16,C59H74N14O6S,"InChI=1S/C59H74N14O6S/c1-6-51(77)71-27-13-16-45(35-71)73-54-47(66-58(73)65-42-14-9-7-10-15-42)34-62-57(68-54)64-43-22-24-44(25-23-43)70-30-28-69(29-31-70)37-50(76)60-26-12-8-11-17-49(75)67-53(59(3,4)5)56(79)72-36-46(74)32-48(72)55(78)61-33-40-18-20-41(21-19-40)52-39(2)63-38-80-52/h6-7,9-10,14-15,18-25,34,38,45-46,48,53,74H,1,8,11-13,16-17,26-33,35-37H2,2-5H3,(H,60,76)(H,61,78)(H,65,66)(H,67,75)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",GKMLWAGLQFDOKQ-BCWDIVJWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2622,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1107.4,1106.56364709,80,9,6,16,C59H74N14O6S,"InChI=1S/C59H74N14O6S/c1-6-51(77)71-27-13-16-45(35-71)73-54-47(66-58(73)65-42-14-9-7-10-15-42)34-62-57(68-54)64-43-22-24-44(25-23-43)70-30-28-69(29-31-70)37-50(76)60-26-12-8-11-17-49(75)67-53(59(3,4)5)56(79)72-36-46(74)32-48(72)55(78)61-33-40-18-20-41(21-19-40)52-39(2)63-38-80-52/h6-7,9-10,14-15,18-25,34,38,45-46,48,53,74H,1,8,11-13,16-17,26-33,35-37H2,2-5H3,(H,60,76)(H,61,78)(H,65,66)(H,67,75)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",GKMLWAGLQFDOKQ-BCWDIVJWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5614,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,911.943,911.369027536,66,7,6,14,C45H48F3N11O7,"InChI=1S/C45H48F3N11O7/c1-3-36(60)52-27-9-7-10-28(23-27)53-40-31(45(46,47)48)25-51-44(56-40)54-32-14-13-29(24-35(32)66-2)58-21-19-57(20-22-58)26-38(62)50-18-6-4-5-17-49-33-12-8-11-30-39(33)43(65)59(42(30)64)34-15-16-37(61)55-41(34)63/h3,7-14,23-25,34,49H,1,4-6,15-22,26H2,2H3,(H,50,62)(H,52,60)(H,55,61,63)(H2,51,53,54,56)",XMLUWHZDWMZRLS-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5614,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,911.943,911.369027536,66,7,6,14,C45H48F3N11O7,"InChI=1S/C45H48F3N11O7/c1-3-36(60)52-27-9-7-10-28(23-27)53-40-31(45(46,47)48)25-51-44(56-40)54-32-14-13-29(24-35(32)66-2)58-21-19-57(20-22-58)26-38(62)50-18-6-4-5-17-49-33-12-8-11-30-39(33)43(65)59(42(30)64)34-15-16-37(61)55-41(34)63/h3,7-14,23-25,34,49H,1,4-6,15-22,26H2,2H3,(H,50,62)(H,52,60)(H,55,61,63)(H2,51,53,54,56)",XMLUWHZDWMZRLS-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5614,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,911.943,911.369027536,66,7,6,14,C45H48F3N11O7,"InChI=1S/C45H48F3N11O7/c1-3-36(60)52-27-9-7-10-28(23-27)53-40-31(45(46,47)48)25-51-44(56-40)54-32-14-13-29(24-35(32)66-2)58-21-19-57(20-22-58)26-38(62)50-18-6-4-5-17-49-33-12-8-11-30-39(33)43(65)59(42(30)64)34-15-16-37(61)55-41(34)63/h3,7-14,23-25,34,49H,1,4-6,15-22,26H2,2H3,(H,50,62)(H,52,60)(H,55,61,63)(H2,51,53,54,56)",XMLUWHZDWMZRLS-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,590,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1178.823,1177.5084958,82,7,4,18,C58H77ClFN9O12S,"InChI=1S/C58H77ClFN9O12S/c1-39-53(82-38-64-39)41-9-7-40(8-10-41)35-61-56(73)48-32-43(70)36-69(48)57(74)54(58(2,3)4)66-51(71)13-21-76-23-25-78-27-29-80-30-28-79-26-24-77-22-14-52(72)68-18-16-67(17-19-68)15-6-20-81-50-33-44-47(34-49(50)75-5)62-37-63-55(44)65-42-11-12-46(60)45(59)31-42/h7-12,31,33-34,37-38,43,48,54,70H,6,13-30,32,35-36H2,1-5H3,(H,61,73)(H,66,71)(H,62,63,65)/t43-,48+,54-/m1/s1",PQNOXKXLYLTRFY-WBGXEMRLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,590,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1178.823,1177.5084958,82,7,4,18,C58H77ClFN9O12S,"InChI=1S/C58H77ClFN9O12S/c1-39-53(82-38-64-39)41-9-7-40(8-10-41)35-61-56(73)48-32-43(70)36-69(48)57(74)54(58(2,3)4)66-51(71)13-21-76-23-25-78-27-29-80-30-28-79-26-24-77-22-14-52(72)68-18-16-67(17-19-68)15-6-20-81-50-33-44-47(34-49(50)75-5)62-37-63-55(44)65-42-11-12-46(60)45(59)31-42/h7-12,31,33-34,37-38,43,48,54,70H,6,13-30,32,35-36H2,1-5H3,(H,61,73)(H,66,71)(H,62,63,65)/t43-,48+,54-/m1/s1",PQNOXKXLYLTRFY-WBGXEMRLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1548,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,1057.196,1056.40514036,76,9,3,16,C55H60N8O12S,"InChI=1S/C55H60N8O12S/c64-46-16-15-45(50(66)58-46)63-53(69)42-7-4-8-44(48(42)54(63)70)56-18-25-72-27-29-74-31-33-75-32-30-73-28-26-71-24-17-47(65)61-22-20-60(21-23-61)41-13-11-37(12-14-41)39-9-10-40-36-62(52(68)43(40)35-39)49(38-5-2-1-3-6-38)51(67)59-55-57-19-34-76-55/h1-14,19,34-35,45,49,56H,15-18,20-33,36H2,(H,57,59,67)(H,58,64,66)",NQLZSRAQWCFGSA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5499,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1259.897,1258.52995952,88,8,4,20,C62H80ClFN10O13S,"InChI=1S/C62H80ClFN10O13S/c1-40(2)58(55-31-41(3)71-87-55)62(79)74-37-46(75)33-52(74)61(78)70-50(43-7-9-44(10-8-43)59-42(4)68-39-88-59)36-56(76)65-14-22-82-24-26-84-28-30-85-29-27-83-25-23-81-21-13-57(77)73-18-16-72(17-19-73)15-6-20-86-54-34-47-51(35-53(54)80-5)66-38-67-60(47)69-45-11-12-49(64)48(63)32-45/h7-12,31-32,34-35,38-40,46,50,52,58,75H,6,13-30,33,36-37H2,1-5H3,(H,65,76)(H,70,78)(H,66,67,69)/t46-,50+,52+,58-/m1/s1",PQAZOTYGULGKJL-FAVMTTGLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5507,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1293.93,1292.55183784,90,8,5,19,C63H83ClF2N10O13S,"InChI=1S/C63H83ClF2N10O13S/c1-41-56(90-40-70-41)43-9-7-42(8-10-43)49(72-59(80)51-34-45(77)38-76(51)60(81)57(62(2,3)4)73-61(82)63(66)14-15-63)37-54(78)67-16-24-85-26-28-87-30-32-88-31-29-86-27-25-84-23-13-55(79)75-20-18-74(19-21-75)17-6-22-89-53-35-46-50(36-52(53)83-5)68-39-69-58(46)71-44-11-12-48(65)47(64)33-44/h7-12,33,35-36,39-40,45,49,51,57,77H,6,13-32,34,37-38H2,1-5H3,(H,67,78)(H,72,80)(H,73,82)(H,68,69,71)/t45-,49+,51+,57-/m1/s1",LRJQWBDAUMUYAQ-HCQLXHEYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1547,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,1013.143,1012.37892561,73,9,3,15,C53H56N8O11S,"InChI=1S/C53H56N8O11S/c62-44-16-15-43(48(64)56-44)61-51(67)40-7-4-8-42(46(40)52(61)68)54-18-25-70-27-29-72-31-30-71-28-26-69-24-17-45(63)59-22-20-58(21-23-59)39-13-11-35(12-14-39)37-9-10-38-34-60(50(66)41(38)33-37)47(36-5-2-1-3-6-36)49(65)57-53-55-19-32-73-53/h1-14,19,32-33,43,47,54H,15-18,20-31,34H2,(H,55,57,65)(H,56,62,64)",RQWUUMNUWMTZQD-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5498,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1215.844,1214.50374477,85,8,4,19,C60H76ClFN10O12S,"InChI=1S/C60H76ClFN10O12S/c1-38(2)56(53-29-39(3)69-84-53)60(77)72-35-44(73)31-50(72)59(76)68-48(41-7-9-42(10-8-41)57-40(4)66-37-85-57)34-54(74)63-14-22-80-24-26-82-28-27-81-25-23-79-21-13-55(75)71-18-16-70(17-19-71)15-6-20-83-52-32-45-49(33-51(52)78-5)64-36-65-58(45)67-43-11-12-47(62)46(61)30-43/h7-12,29-30,32-33,36-38,44,48,50,56,73H,6,13-28,31,34-35H2,1-5H3,(H,63,74)(H,68,76)(H,64,65,67)/t44-,48+,50+,56-/m1/s1",WXGPZJDYSLRMDS-HHHFUCLFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5506,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1249.877,1248.52562309,87,8,5,18,C61H79ClF2N10O12S,"InChI=1S/C61H79ClF2N10O12S/c1-39-54(87-38-68-39)41-9-7-40(8-10-41)47(70-57(78)49-32-43(75)36-74(49)58(79)55(60(2,3)4)71-59(80)61(64)14-15-61)35-52(76)65-16-24-83-26-28-85-30-29-84-27-25-82-23-13-53(77)73-20-18-72(19-21-73)17-6-22-86-51-33-44-48(34-50(51)81-5)66-37-67-56(44)69-42-11-12-46(63)45(62)31-42/h7-12,31,33-34,37-38,43,47,49,55,75H,6,13-30,32,35-36H2,1-5H3,(H,65,76)(H,70,78)(H,71,80)(H,66,67,69)/t43-,47+,49+,55-/m1/s1",VOWRMQVEPOIRPR-BUCBQYKQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,589,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1090.717,1089.45606631,76,7,4,16,C54H69ClFN9O10S,"InChI=1S/C54H69ClFN9O10S/c1-35-49(76-34-60-35)37-9-7-36(8-10-37)31-57-52(69)44-28-39(66)32-65(44)53(70)50(54(2,3)4)62-47(67)13-21-72-23-25-74-26-24-73-22-14-48(68)64-18-16-63(17-19-64)15-6-20-75-46-29-40-43(30-45(46)71-5)58-33-59-51(40)61-38-11-12-42(56)41(55)27-38/h7-12,27,29-30,33-34,39,44,50,66H,6,13-26,28,31-32H2,1-5H3,(H,57,69)(H,62,67)(H,58,59,61)/t39-,44+,50-/m1/s1",DUHAIXHBBDGIBP-MLENZQCQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,589,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1090.717,1089.45606631,76,7,4,16,C54H69ClFN9O10S,"InChI=1S/C54H69ClFN9O10S/c1-35-49(76-34-60-35)37-9-7-36(8-10-37)31-57-52(69)44-28-39(66)32-65(44)53(70)50(54(2,3)4)62-47(67)13-21-72-23-25-74-26-24-73-22-14-48(68)64-18-16-63(17-19-64)15-6-20-75-46-29-40-43(30-45(46)71-5)58-33-59-51(40)61-38-11-12-42(56)41(55)27-38/h7-12,27,29-30,33-34,39,44,50,66H,6,13-26,28,31-32H2,1-5H3,(H,57,69)(H,62,67)(H,58,59,61)/t39-,44+,50-/m1/s1",DUHAIXHBBDGIBP-MLENZQCQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1473,P00533,EGFR,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,969.09,968.352710864,70,9,3,14,C51H52N8O10S,"InChI=1S/C51H52N8O10S/c60-42-16-15-41(46(62)54-42)59-49(65)38-7-4-8-40(44(38)50(59)66)52-18-25-68-27-29-69-28-26-67-24-17-43(61)57-22-20-56(21-23-57)37-13-11-33(12-14-37)35-9-10-36-32-58(48(64)39(36)31-35)45(34-5-2-1-3-6-34)47(63)55-51-53-19-30-70-51/h1-14,19,30-31,41,45,52H,15-18,20-29,32H2,(H,53,55,63)(H,54,60,62)",YQIWOKJOFFNGOJ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1473,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,969.09,968.352710864,70,9,3,14,C51H52N8O10S,"InChI=1S/C51H52N8O10S/c60-42-16-15-41(46(62)54-42)59-49(65)38-7-4-8-40(44(38)50(59)66)52-18-25-68-27-29-69-28-26-67-24-17-43(61)57-22-20-56(21-23-57)37-13-11-33(12-14-37)35-9-10-36-32-58(48(64)39(36)31-35)45(34-5-2-1-3-6-34)47(63)55-51-53-19-30-70-51/h1-14,19,30-31,41,45,52H,15-18,20-29,32H2,(H,53,55,63)(H,54,60,62)",YQIWOKJOFFNGOJ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5497,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1171.791,1170.47753002,82,8,4,18,C58H72ClFN10O11S,"InChI=1S/C58H72ClFN10O11S/c1-36(2)54(51-27-37(3)67-81-51)58(75)70-33-42(71)29-48(70)57(74)66-46(39-7-9-40(10-8-39)55-38(4)64-35-82-55)32-52(72)61-14-22-78-24-26-79-25-23-77-21-13-53(73)69-18-16-68(17-19-69)15-6-20-80-50-30-43-47(31-49(50)76-5)62-34-63-56(43)65-41-11-12-45(60)44(59)28-41/h7-12,27-28,30-31,34-36,42,46,48,54,71H,6,13-26,29,32-33H2,1-5H3,(H,61,72)(H,66,74)(H,62,63,65)/t42-,46+,48+,54-/m1/s1",SQUJSQSJQZXAKH-FOCFZSKWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5505,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1205.824,1204.49940834,84,8,5,17,C59H75ClF2N10O11S,"InChI=1S/C59H75ClF2N10O11S/c1-37-52(84-36-66-37)39-9-7-38(8-10-39)45(68-55(76)47-30-41(73)34-72(47)56(77)53(58(2,3)4)69-57(78)59(62)14-15-59)33-50(74)63-16-24-81-26-28-82-27-25-80-23-13-51(75)71-20-18-70(19-21-71)17-6-22-83-49-31-42-46(32-48(49)79-5)64-35-65-54(42)67-40-11-12-44(61)43(60)29-40/h7-12,29,31-32,35-36,41,45,47,53,73H,6,13-28,30,33-34H2,1-5H3,(H,63,74)(H,68,76)(H,69,78)(H,64,65,67)/t41-,45+,47+,53-/m1/s1",OESWSLAPUVIPCV-UYZZMYMLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1546,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,925.037,924.326496116,67,9,3,13,C49H48N8O9S,"InChI=1S/C49H48N8O9S/c58-40-16-15-39(44(60)52-40)57-47(63)36-7-4-8-38(42(36)48(57)64)50-18-25-66-27-26-65-24-17-41(59)55-22-20-54(21-23-55)35-13-11-31(12-14-35)33-9-10-34-30-56(46(62)37(34)29-33)43(32-5-2-1-3-6-32)45(61)53-49-51-19-28-67-49/h1-14,19,28-29,39,43,50H,15-18,20-27,30H2,(H,51,53,61)(H,52,58,60)",BHOFOVKVHRLVFH-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5495,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1127.738,1126.45131528,79,8,4,17,C56H68ClFN10O10S,"InChI=1S/C56H68ClFN10O10S/c1-34(2)52(49-25-35(3)65-78-49)56(73)68-31-40(69)27-46(68)55(72)64-44(37-7-9-38(10-8-37)53-36(4)62-33-79-53)30-50(70)59-14-22-76-24-23-75-21-13-51(71)67-18-16-66(17-19-67)15-6-20-77-48-28-41-45(29-47(48)74-5)60-32-61-54(41)63-39-11-12-43(58)42(57)26-39/h7-12,25-26,28-29,32-34,40,44,46,52,69H,6,13-24,27,30-31H2,1-5H3,(H,59,70)(H,64,72)(H,60,61,63)/t40-,44+,46+,52-/m1/s1",HSYGBRJEVWUWJH-YHXFZPEXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5503,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1161.771,1160.47319359,81,8,5,16,C57H71ClF2N10O10S,"InChI=1S/C57H71ClF2N10O10S/c1-35-50(81-34-64-35)37-9-7-36(8-10-37)43(66-53(74)45-28-39(71)32-70(45)54(75)51(56(2,3)4)67-55(76)57(60)14-15-57)31-48(72)61-16-24-79-26-25-78-23-13-49(73)69-20-18-68(19-21-69)17-6-22-80-47-29-40-44(30-46(47)77-5)62-33-63-52(40)65-38-11-12-42(59)41(58)27-38/h7-12,27,29-30,33-34,39,43,45,51,71H,6,13-26,28,31-32H2,1-5H3,(H,61,72)(H,66,74)(H,67,76)(H,62,63,65)/t39-,43+,45+,51-/m1/s1",HZSHXUUDFTUBHJ-NZMHYKQJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,581,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,69,,1108.38,1107.5364293,80,8,5,15,C60H73N11O8S,"InChI=1S/C60H73N11O8S/c1-8-50(73)64-42-16-15-17-44(31-42)71-53(76)30-38(2)46-35-62-59(67-56(46)71)65-47-25-24-43(32-49(47)79-7)68-26-28-69(29-27-68)52(75)19-14-12-10-9-11-13-18-51(74)66-55(60(4,5)6)58(78)70-36-45(72)33-48(70)57(77)61-34-40-20-22-41(23-21-40)54-39(3)63-37-80-54/h8,15-17,20-25,30-32,35,37,45,48,55,72H,1,9-14,18-19,26-29,33-34,36H2,2-7H3,(H,61,77)(H,64,73)(H,66,74)(H,62,65,67)/t45-,48+,55-/m1/s1",NXHJICMMHCOKPI-ZRJZPVMUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,581,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1108.38,1107.5364293,80,8,5,15,C60H73N11O8S,"InChI=1S/C60H73N11O8S/c1-8-50(73)64-42-16-15-17-44(31-42)71-53(76)30-38(2)46-35-62-59(67-56(46)71)65-47-25-24-43(32-49(47)79-7)68-26-28-69(29-27-68)52(75)19-14-12-10-9-11-13-18-51(74)66-55(60(4,5)6)58(78)70-36-45(72)33-48(70)57(77)61-34-40-20-22-41(23-21-40)54-39(3)63-37-80-54/h8,15-17,20-25,30-32,35,37,45,48,55,72H,1,9-14,18-19,26-29,33-34,36H2,2-7H3,(H,61,77)(H,64,73)(H,66,74)(H,62,65,67)/t45-,48+,55-/m1/s1",NXHJICMMHCOKPI-ZRJZPVMUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5476,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1123.794,1122.49278616,79,8,4,15,C58H72ClFN10O8S,"InChI=1S/C58H72ClFN10O8S/c1-36(2)54(51-27-37(3)67-78-51)58(75)70-33-42(71)29-48(70)57(74)66-46(39-14-16-40(17-15-39)55-38(4)64-35-79-55)32-52(72)61-20-11-9-7-6-8-10-13-53(73)69-24-22-68(23-25-69)21-12-26-77-50-30-43-47(31-49(50)76-5)62-34-63-56(43)65-41-18-19-45(60)44(59)28-41/h14-19,27-28,30-31,34-36,42,46,48,54,71H,6-13,20-26,29,32-33H2,1-5H3,(H,61,72)(H,66,74)(H,62,63,65)/t42-,46+,48+,54-/m1/s1",VZEWWNCXKUBTMG-FOCFZSKWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5488,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1157.827,1156.51466448,81,8,5,14,C59H75ClF2N10O8S,"InChI=1S/C59H75ClF2N10O8S/c1-37-52(81-36-66-37)39-16-14-38(15-17-39)45(68-55(76)47-30-41(73)34-72(47)56(77)53(58(2,3)4)69-57(78)59(62)20-21-59)33-50(74)63-22-11-9-7-6-8-10-13-51(75)71-26-24-70(25-27-71)23-12-28-80-49-31-42-46(32-48(49)79-5)64-35-65-54(42)67-40-18-19-44(61)43(60)29-40/h14-19,29,31-32,35-36,41,45,47,53,73H,6-13,20-28,30,33-34H2,1-5H3,(H,63,74)(H,68,76)(H,69,78)(H,64,65,67)/t41-,45+,47+,53-/m1/s1",FXPAXWXTFWZCFT-UYZZMYMLSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,582,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,235,,1080.326,1079.50512917,78,8,5,15,C58H69N11O8S,"InChI=1S/C58H69N11O8S/c1-8-48(71)62-40-14-13-15-42(29-40)69-51(74)28-36(2)44-33-60-57(65-54(44)69)63-45-23-22-41(30-47(45)77-7)66-24-26-67(27-25-66)50(73)17-12-10-9-11-16-49(72)64-53(58(4,5)6)56(76)68-34-43(70)31-46(68)55(75)59-32-38-18-20-39(21-19-38)52-37(3)61-35-78-52/h8,13-15,18-23,28-30,33,35,43,46,53,70H,1,9-12,16-17,24-27,31-32,34H2,2-7H3,(H,59,75)(H,62,71)(H,64,72)(H,60,63,65)/t43-,46+,53-/m1/s1",HQDMTJMOYXRLMD-BSDSDUADSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,582,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1080.326,1079.50512917,78,8,5,15,C58H69N11O8S,"InChI=1S/C58H69N11O8S/c1-8-48(71)62-40-14-13-15-42(29-40)69-51(74)28-36(2)44-33-60-57(65-54(44)69)63-45-23-22-41(30-47(45)77-7)66-24-26-67(27-25-66)50(73)17-12-10-9-11-16-49(72)64-53(58(4,5)6)56(76)68-34-43(70)31-46(68)55(75)59-32-38-18-20-39(21-19-38)52-37(3)61-35-78-52/h8,13-15,18-23,28-30,33,35,43,46,53,70H,1,9-12,16-17,24-27,31-32,34H2,2-7H3,(H,59,75)(H,62,71)(H,64,72)(H,60,63,65)/t43-,46+,53-/m1/s1",HQDMTJMOYXRLMD-BSDSDUADSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2232,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,<30/100,,868.367,867.327100744,62,7,4,12,C44H47ClFN9O7,"InChI=1S/C44H47ClFN9O7/c1-2-37(56)51-34-24-29-33(48-26-49-41(29)50-27-12-13-31(46)30(45)23-27)25-36(34)62-22-8-17-53-18-20-54(21-19-53)39(58)11-5-3-4-6-16-47-32-10-7-9-28-40(32)44(61)55(43(28)60)35-14-15-38(57)52-42(35)59/h2,7,9-10,12-13,23-26,35,47H,1,3-6,8,11,14-22H2,(H,51,56)(H,48,49,50)(H,52,57,59)",YTNYTUGBAXJPBN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2232,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,30-100,,868.367,867.327100744,62,7,4,12,C44H47ClFN9O7,"InChI=1S/C44H47ClFN9O7/c1-2-37(56)51-34-24-29-33(48-26-49-41(29)50-27-12-13-31(46)30(45)23-27)25-36(34)62-22-8-17-53-18-20-54(21-19-53)39(58)11-5-3-4-6-16-47-32-10-7-9-28-40(32)44(61)55(43(28)60)35-14-15-38(57)52-42(35)59/h2,7,9-10,12-13,23-26,35,47H,1,3-6,8,11,14-22H2,(H,51,56)(H,48,49,50)(H,52,57,59)",YTNYTUGBAXJPBN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5474,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1095.74,1094.46148604,77,8,4,15,C56H68ClFN10O8S,"InChI=1S/C56H68ClFN10O8S/c1-34(2)52(49-25-35(3)65-76-49)56(73)68-31-40(69)27-46(68)55(72)64-44(37-12-14-38(15-13-37)53-36(4)62-33-77-53)30-50(70)59-18-9-7-6-8-11-51(71)67-22-20-66(21-23-67)19-10-24-75-48-28-41-45(29-47(48)74-5)60-32-61-54(41)63-39-16-17-43(58)42(57)26-39/h12-17,25-26,28-29,32-34,40,44,46,52,69H,6-11,18-24,27,30-31H2,1-5H3,(H,59,70)(H,64,72)(H,60,61,63)/t40-,44+,46+,52-/m1/s1",UPGPYGVCAVJCCR-YHXFZPEXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5486,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1129.773,1128.48336435,79,8,5,14,C57H71ClF2N10O8S,"InChI=1S/C57H71ClF2N10O8S/c1-35-50(79-34-64-35)37-14-12-36(13-15-37)43(66-53(74)45-28-39(71)32-70(45)54(75)51(56(2,3)4)67-55(76)57(60)18-19-57)31-48(72)61-20-9-7-6-8-11-49(73)69-24-22-68(23-25-69)21-10-26-78-47-29-40-44(30-46(47)77-5)62-33-63-52(40)65-38-16-17-42(59)41(58)27-38/h12-17,27,29-30,33-34,39,43,45,51,71H,6-11,18-26,28,31-32H2,1-5H3,(H,61,72)(H,66,74)(H,67,76)(H,62,63,65)/t39-,43+,45+,51-/m1/s1",GWVORCNYVKAQRY-NZMHYKQJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,591,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,958.558,957.377422064,67,7,4,13,C48H57ClFN9O7S,"InChI=1S/C48H57ClFN9O7S/c1-29-43(67-28-54-29)31-9-7-30(8-10-31)25-51-46(63)38-22-33(60)26-59(38)47(64)44(48(2,3)4)56-41(61)13-14-42(62)58-18-16-57(17-19-58)15-6-20-66-40-23-34-37(24-39(40)65-5)52-27-53-45(34)55-32-11-12-36(50)35(49)21-32/h7-12,21,23-24,27-28,33,38,44,60H,6,13-20,22,25-26H2,1-5H3,(H,51,63)(H,56,61)(H,52,53,55)/t33-,38+,44-/m1/s1",DUGBSNFGNATMEE-VSPJSQPSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,591,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,958.558,957.377422064,67,7,4,13,C48H57ClFN9O7S,"InChI=1S/C48H57ClFN9O7S/c1-29-43(67-28-54-29)31-9-7-30(8-10-31)25-51-46(63)38-22-33(60)26-59(38)47(64)44(48(2,3)4)56-41(61)13-14-42(62)58-18-16-57(17-19-58)15-6-20-66-40-23-34-37(24-39(40)65-5)52-27-53-45(34)55-32-11-12-36(50)35(49)21-32/h7-12,21,23-24,27-28,33,38,44,60H,6,13-20,22,25-26H2,1-5H3,(H,51,63)(H,56,61)(H,52,53,55)/t33-,38+,44-/m1/s1",DUGBSNFGNATMEE-VSPJSQPSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2228,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,812.259,811.264500488,58,7,4,12,C40H39ClFN9O7,"InChI=1S/C40H39ClFN9O7/c1-2-33(52)47-30-20-25-29(44-22-45-37(25)46-23-7-8-27(42)26(41)19-23)21-32(30)58-18-4-13-49-14-16-50(17-15-49)35(54)11-12-43-28-6-3-5-24-36(28)40(57)51(39(24)56)31-9-10-34(53)48-38(31)55/h2-3,5-8,19-22,31,43H,1,4,9-18H2,(H,47,52)(H,44,45,46)(H,48,53,55)",CYRZHTYQRKEAID-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2228,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,812.259,811.264500488,58,7,4,12,C40H39ClFN9O7,"InChI=1S/C40H39ClFN9O7/c1-2-33(52)47-30-20-25-29(44-22-45-37(25)46-23-7-8-27(42)26(41)19-23)21-32(30)58-18-4-13-49-14-16-50(17-15-49)35(54)11-12-43-28-6-3-5-24-36(28)40(57)51(39(24)56)31-9-10-34(53)48-38(31)55/h2-3,5-8,19-22,31,43H,1,4,9-18H2,(H,47,52)(H,44,45,46)(H,48,53,55)",CYRZHTYQRKEAID-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5470,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1039.632,1038.39888578,73,8,4,15,C52H60ClFN10O8S,"InChI=1S/C52H60ClFN10O8S/c1-30(2)48(45-21-31(3)61-72-45)52(69)64-27-36(65)23-42(64)51(68)60-40(33-7-9-34(10-8-33)49-32(4)58-29-73-49)26-46(66)55-14-13-47(67)63-18-16-62(17-19-63)15-6-20-71-44-24-37-41(25-43(44)70-5)56-28-57-50(37)59-35-11-12-39(54)38(53)22-35/h7-12,21-22,24-25,28-30,36,40,42,48,65H,6,13-20,23,26-27H2,1-5H3,(H,55,66)(H,60,68)(H,56,57,59)/t36-,40+,42+,48-/m1/s1",CJLNAUKEMYLBRN-OQQYKNMXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5482,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1073.665,1072.4207641,75,8,5,14,C53H63ClF2N10O8S,"InChI=1S/C53H63ClF2N10O8S/c1-31-46(75-30-60-31)33-9-7-32(8-10-33)39(62-49(70)41-24-35(67)28-66(41)50(71)47(52(2,3)4)63-51(72)53(56)14-15-53)27-44(68)57-16-13-45(69)65-20-18-64(19-21-65)17-6-22-74-43-25-36-40(26-42(43)73-5)58-29-59-48(36)61-34-11-12-38(55)37(54)23-34/h7-12,23,25-26,29-30,35,39,41,47,67H,6,13-22,24,27-28H2,1-5H3,(H,57,68)(H,62,70)(H,63,72)(H,58,59,61)/t35-,39+,41+,47-/m1/s1",WMQKYBZMAJVTOD-GVXQOCCOSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,593,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,3.3,,1056.747,1055.48697251,74,7,4,13,C55H71ClFN9O7S,"InChI=1S/C55H71ClFN9O7S/c1-36-50(74-35-61-36)38-18-16-37(17-19-38)32-58-53(70)45-29-40(67)33-66(45)54(71)51(55(2,3)4)63-48(68)14-11-9-7-6-8-10-12-15-49(69)65-25-23-64(24-26-65)22-13-27-73-47-30-41-44(31-46(47)72-5)59-34-60-52(41)62-39-20-21-43(57)42(56)28-39/h16-21,28,30-31,34-35,40,45,51,67H,6-15,22-27,29,32-33H2,1-5H3,(H,58,70)(H,63,68)(H,59,60,62)/t40-,45+,51-/m1/s1",HLFLODKZIGYHNR-LTEFSYCBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,593,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,5,,1056.747,1055.48697251,74,7,4,13,C55H71ClFN9O7S,"InChI=1S/C55H71ClFN9O7S/c1-36-50(74-35-61-36)38-18-16-37(17-19-38)32-58-53(70)45-29-40(67)33-66(45)54(71)51(55(2,3)4)63-48(68)14-11-9-7-6-8-10-12-15-49(69)65-25-23-64(24-26-65)22-13-27-73-47-30-41-44(31-46(47)72-5)59-34-60-52(41)62-39-20-21-43(57)42(56)28-39/h16-21,28,30-31,34-35,40,45,51,67H,6-15,22-27,29,32-33H2,1-5H3,(H,58,70)(H,63,68)(H,59,60,62)/t40-,45+,51-/m1/s1",HLFLODKZIGYHNR-LTEFSYCBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5477,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1137.821,1136.50843623,80,8,4,15,C59H74ClFN10O8S,"InChI=1S/C59H74ClFN10O8S/c1-37(2)55(52-28-38(3)68-79-52)59(76)71-34-43(72)30-49(71)58(75)67-47(40-15-17-41(18-16-40)56-39(4)65-36-80-56)33-53(73)62-21-12-10-8-6-7-9-11-14-54(74)70-25-23-69(24-26-70)22-13-27-78-51-31-44-48(32-50(51)77-5)63-35-64-57(44)66-42-19-20-46(61)45(60)29-42/h15-20,28-29,31-32,35-37,43,47,49,55,72H,6-14,21-27,30,33-34H2,1-5H3,(H,62,73)(H,67,75)(H,63,64,66)/t43-,47+,49+,55-/m1/s1",VALYMTQFIVLATQ-BUCBQYKQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5489,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1171.854,1170.53031454,82,8,5,14,C60H77ClF2N10O8S,"InChI=1S/C60H77ClF2N10O8S/c1-38-53(82-37-67-38)40-17-15-39(16-18-40)46(69-56(77)48-31-42(74)35-73(48)57(78)54(59(2,3)4)70-58(79)60(63)21-22-60)34-51(75)64-23-12-10-8-6-7-9-11-14-52(76)72-27-25-71(26-28-72)24-13-29-81-50-32-43-47(33-49(50)80-5)65-36-66-55(43)68-41-19-20-45(62)44(61)30-41/h15-20,30,32-33,36-37,42,46,48,54,74H,6-14,21-29,31,34-35H2,1-5H3,(H,64,75)(H,69,77)(H,70,79)(H,65,66,68)/t42-,46+,48+,54-/m1/s1",UNUYMASCZFRMQY-FOCFZSKWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2227,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,798.232,797.248850424,57,7,4,12,C39H37ClFN9O7,"InChI=1S/C39H37ClFN9O7/c1-2-32(51)46-29-18-24-28(43-21-44-36(24)45-22-7-8-26(41)25(40)17-22)19-31(29)57-16-4-11-48-12-14-49(15-13-48)34(53)20-42-27-6-3-5-23-35(27)39(56)50(38(23)55)30-9-10-33(52)47-37(30)54/h2-3,5-8,17-19,21,30,42H,1,4,9-16,20H2,(H,46,51)(H,43,44,45)(H,47,52,54)",CNJATHSQDNDLIM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2227,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCN(C(=O)CNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,798.232,797.248850424,57,7,4,12,C39H37ClFN9O7,"InChI=1S/C39H37ClFN9O7/c1-2-32(51)46-29-18-24-28(43-21-44-36(24)45-22-7-8-26(41)25(40)17-22)19-31(29)57-16-4-11-48-12-14-49(15-13-48)34(53)20-42-27-6-3-5-23-35(27)39(56)50(38(23)55)30-9-10-33(52)47-37(30)54/h2-3,5-8,17-19,21,30,42H,1,4,9-16,20H2,(H,46,51)(H,43,44,45)(H,47,52,54)",CNJATHSQDNDLIM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2396,P00533,EGFR L858R/T790M,CRBN,COC1=CC(N2CCC(N3CCN(C(=O)CNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,<100,,883.347,882.313358186,62,8,4,14,C43H48ClN10O7P,"InChI=1S/C43H48ClN10O7P/c1-61-34-23-27(11-12-30(34)48-43-46-24-29(44)39(50-43)47-31-8-4-5-10-35(31)62(2,3)60)51-17-15-26(16-18-51)52-19-21-53(22-20-52)37(56)25-45-32-9-6-7-28-38(32)42(59)54(41(28)58)33-13-14-36(55)49-40(33)57/h4-12,23-24,26,33,45H,13-22,25H2,1-3H3,(H,49,55,57)(H2,46,47,48,50)",AQGLXXCBEXDRNS-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5469,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1025.605,1024.38323572,72,8,4,15,C51H58ClFN10O8S,"InChI=1S/C51H58ClFN10O8S/c1-29(2)47(44-19-30(3)60-71-44)51(68)63-26-35(64)21-41(63)50(67)59-39(32-7-9-33(10-8-32)48-31(4)57-28-72-48)24-45(65)54-25-46(66)62-16-14-61(15-17-62)13-6-18-70-43-22-36-40(23-42(43)69-5)55-27-56-49(36)58-34-11-12-38(53)37(52)20-34/h7-12,19-20,22-23,27-29,35,39,41,47,64H,6,13-18,21,24-26H2,1-5H3,(H,54,65)(H,59,67)(H,55,56,58)/t35-,39+,41+,47-/m1/s1",FOLVRBMWEYRSAE-GVXQOCCOSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5481,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1059.638,1058.40511403,74,8,5,14,C52H61ClF2N10O8S,"InChI=1S/C52H61ClF2N10O8S/c1-30-45(74-29-59-30)32-9-7-31(8-10-32)38(61-48(69)40-22-34(66)27-65(40)49(70)46(51(2,3)4)62-50(71)52(55)13-14-52)25-43(67)56-26-44(68)64-18-16-63(17-19-64)15-6-20-73-42-23-35-39(24-41(42)72-5)57-28-58-47(35)60-33-11-12-37(54)36(53)21-33/h7-12,21,23-24,28-29,34,38,40,46,66H,6,13-20,22,25-27H2,1-5H3,(H,56,67)(H,61,69)(H,62,71)(H,57,58,60)/t34-,38+,40+,46-/m1/s1",CGOTUNNDPPEANJ-PEFPNBTRSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,562,P00533,EGFR,CRBN,O=C1CCC(N2CC3=C(NC(=O)CCCCN4CCN(C5=CC=C(NC6=CC7=C(N8CCC(CO)CC8)N=C(NC8=CC=C(F)C=C8)N=C7C=N6)N=C5)CC4)C=CC=C3C2=O)C(=O)N1,,,870.991,870.408940952,64,9,5,14,C46H51FN12O5,"InChI=1S/C46H51FN12O5/c47-30-7-9-31(10-8-30)50-46-52-37-26-49-40(24-34(37)43(55-46)58-18-15-29(28-60)16-19-58)53-39-13-11-32(25-48-39)57-22-20-56(21-23-57)17-2-1-6-41(61)51-36-5-3-4-33-35(36)27-59(45(33)64)38-12-14-42(62)54-44(38)63/h3-5,7-11,13,24-26,29,38,60H,1-2,6,12,14-23,27-28H2,(H,51,61)(H,48,49,53)(H,50,52,55)(H,54,62,63)",ZLQKFKXUGYUHGE-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5462,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,,,850.981,850.39147932,63,7,4,12,C47H50N10O6,"InChI=1S/C47H50N10O6/c1-6-22-56(23-11-10-17-43(59)49-34-15-12-14-31-33(34)29-57(46(31)62)39-18-19-44(60)53-45(39)61)25-24-54(3)40-27-41(63-5)37(26-36(40)50-42(58)7-2)52-47-48-21-20-35(51-47)32-28-55(4)38-16-9-8-13-30(32)38/h1,7-9,12-16,20-21,26-28,39H,2,10-11,17-19,22-25,29H2,3-5H3,(H,49,59)(H,50,58)(H,48,51,52)(H,53,60,61)",BFSUALZSNVHREQ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,564,P00533,EGFR,CRBN,O=C(CN1CCN(C2=CC=C(NC3=CC4=C(N5CCC(CO)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1)NCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.989,899.39910454,66,9,6,15,C46H50FN13O6,"InChI=1S/C46H50FN13O6/c47-29-4-6-30(7-5-29)51-46-53-36-24-50-39(22-33(36)43(56-46)59-16-13-28(27-61)14-17-59)54-38-10-8-31(23-49-38)58-20-18-57(19-21-58)26-42(64)48-15-12-41(63)52-35-3-1-2-32-34(35)25-60(45(32)66)37-9-11-40(62)55-44(37)65/h1-8,10,22-24,28,37,61H,9,11-21,25-27H2,(H,48,64)(H,52,63)(H,49,50,54)(H,51,53,56)(H,55,62,65)",BJYUZUZKGOOWHB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,566,P00533,EGFR,CRBN,CN(C)C1CCN(C2=CC=C(NC3=CC4=C(N5CCN(CC(=O)NCCC(=O)NC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1,,,913.032,912.430739016,67,9,5,15,C47H53FN14O5,"InChI=1S/C47H53FN14O5/c1-58(2)31-15-18-60(19-16-31)32-10-12-39(50-25-32)55-40-24-34-37(26-51-40)54-47(52-30-8-6-29(48)7-9-30)57-44(34)61-22-20-59(21-23-61)28-43(65)49-17-14-42(64)53-36-5-3-4-33-35(36)27-62(46(33)67)38-11-13-41(63)56-45(38)66/h3-10,12,24-26,31,38H,11,13-23,27-28H2,1-2H3,(H,49,65)(H,53,64)(H,50,51,55)(H,52,54,57)(H,56,63,66)",GUZCGEKRDGMCQI-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,572,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)NC6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)=C1,>2000,,979.108,978.438823436,72,8,4,14,C53H58N10O9,"InChI=1S/C53H58N10O9/c1-4-43(64)55-34-15-13-16-36(30-34)62-47(68)29-33(2)38-32-54-53(59-49(38)62)57-39-22-21-35(31-42(39)72-3)60-25-27-61(28-26-60)46(67)20-12-10-8-6-5-7-9-11-19-44(65)56-40-18-14-17-37-48(40)52(71)63(51(37)70)41-23-24-45(66)58-50(41)69/h4,13-18,21-22,29-32,41H,1,5-12,19-20,23-28H2,2-3H3,(H,55,64)(H,56,65)(H,54,57,59)(H,58,66,69)",JYBLMIXCGVMISV-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,572,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)NC6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)=C1,>2000,,979.108,978.438823436,72,8,4,14,C53H58N10O9,"InChI=1S/C53H58N10O9/c1-4-43(64)55-34-15-13-16-36(30-34)62-47(68)29-33(2)38-32-54-53(59-49(38)62)57-39-22-21-35(31-42(39)72-3)60-25-27-61(28-26-60)46(67)20-12-10-8-6-5-7-9-11-19-44(65)56-40-18-14-17-37-48(40)52(71)63(51(37)70)41-23-24-45(66)58-50(41)69/h4,13-18,21-22,29-32,41H,1,5-12,19-20,23-28H2,2-3H3,(H,55,64)(H,56,65)(H,54,57,59)(H,58,66,69)",JYBLMIXCGVMISV-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5602,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,981.046,980.41564338,71,7,5,13,C50H55F3N10O8,"InChI=1S/C50H55F3N10O8/c1-3-40(64)55-31-14-12-15-32(28-31)56-45-35(50(51,52)53)30-54-49(60-45)58-36-21-20-33(29-39(36)71-2)61-24-26-62(27-25-61)43(67)19-11-9-7-5-4-6-8-10-18-41(65)57-37-17-13-16-34-44(37)48(70)63(47(34)69)38-22-23-42(66)59-46(38)68/h3,12-17,20-21,28-30,38H,1,4-11,18-19,22-27H2,2H3,(H,55,64)(H,57,65)(H,59,66,68)(H2,54,56,58,60)",CSKMUJOYDMXURU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5602,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,981.046,980.41564338,71,7,5,13,C50H55F3N10O8,"InChI=1S/C50H55F3N10O8/c1-3-40(64)55-31-14-12-15-32(28-31)56-45-35(50(51,52)53)30-54-49(60-45)58-36-21-20-33(29-39(36)71-2)61-24-26-62(27-25-61)43(67)19-11-9-7-5-4-6-8-10-18-41(65)57-37-17-13-16-34-44(37)48(70)63(47(34)69)38-22-23-42(66)59-46(38)68/h3,12-17,20-21,28-30,38H,1,4-11,18-19,22-27H2,2H3,(H,55,64)(H,57,65)(H,59,66,68)(H2,54,56,58,60)",CSKMUJOYDMXURU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5602,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,981.046,980.41564338,71,7,5,13,C50H55F3N10O8,"InChI=1S/C50H55F3N10O8/c1-3-40(64)55-31-14-12-15-32(28-31)56-45-35(50(51,52)53)30-54-49(60-45)58-36-21-20-33(29-39(36)71-2)61-24-26-62(27-25-61)43(67)19-11-9-7-5-4-6-8-10-18-41(65)57-37-17-13-16-34-44(37)48(70)63(47(34)69)38-22-23-42(66)59-46(38)68/h3,12-17,20-21,28-30,38H,1,4-11,18-19,22-27H2,2H3,(H,55,64)(H,57,65)(H,59,66,68)(H2,54,56,58,60)",CSKMUJOYDMXURU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,573,P00533,EGFR L858R/T790M,cIAP1,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)CC6=CC=CC=C6)CC5)C=C4OC)N=C32)=C1,>2000,,999.271,998.574194708,73,6,6,13,C56H74N10O7,"InChI=1S/C56H74N10O7/c1-6-49(67)60-41-22-19-23-43(35-41)66-51(69)33-39(4)44-37-59-56(63-53(44)66)62-46-26-25-42(36-48(46)73-5)64-28-30-65(31-29-64)50(68)24-17-12-10-8-7-9-11-13-18-27-58-54(71)47(32-38(2)3)61-55(72)52(70)45(57)34-40-20-15-14-16-21-40/h6,14-16,19-23,25-26,33,35-38,45,47,52,70H,1,7-13,17-18,24,27-32,34,57H2,2-5H3,(H,58,71)(H,60,67)(H,61,72)(H,59,62,63)/t45-,47+,52+/m1/s1",DOEISPNISSZUOZ-KTBSTWIUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,573,P00533,EGFR,cIAP1,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)CC6=CC=CC=C6)CC5)C=C4OC)N=C32)=C1,>2000,,999.271,998.574194708,73,6,6,13,C56H74N10O7,"InChI=1S/C56H74N10O7/c1-6-49(67)60-41-22-19-23-43(35-41)66-51(69)33-39(4)44-37-59-56(63-53(44)66)62-46-26-25-42(36-48(46)73-5)64-28-30-65(31-29-64)50(68)24-17-12-10-8-7-9-11-13-18-27-58-54(71)47(32-38(2)3)61-55(72)52(70)45(57)34-40-20-15-14-16-21-40/h6,14-16,19-23,25-26,33,35-38,45,47,52,70H,1,7-13,17-18,24,27-32,34,57H2,2-5H3,(H,58,71)(H,60,67)(H,61,72)(H,59,62,63)/t45-,47+,52+/m1/s1",DOEISPNISSZUOZ-KTBSTWIUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,574,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,263.8,,1307.385,1305.55090567,93,9,5,14,C71H79Cl2F2N11O7,"InChI=1S/C71H79Cl2F2N11O7/c1-8-60(87)79-47-20-18-21-49(39-47)86-62(89)36-44(2)51-42-78-69(83-66(51)86)81-56-30-27-48(40-58(56)93-7)84-32-34-85(35-33-84)61(88)24-16-14-12-10-9-11-13-15-17-31-77-67(90)45-25-29-55(57(37-45)92-6)80-68(91)65-63(50-22-19-23-53(73)64(50)75)71(43-76,59(82-65)41-70(3,4)5)52-28-26-46(72)38-54(52)74/h8,18-23,25-30,36-40,42,59,63,65,82H,1,9-17,24,31-35,41H2,2-7H3,(H,77,90)(H,79,87)(H,80,91)(H,78,81,83)/t59-,63-,65+,71-/m0/s1",DCPNWQZQYCVVJX-UYDHSDFFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,574,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1307.385,1305.55090567,93,9,5,14,C71H79Cl2F2N11O7,"InChI=1S/C71H79Cl2F2N11O7/c1-8-60(87)79-47-20-18-21-49(39-47)86-62(89)36-44(2)51-42-78-69(83-66(51)86)81-56-30-27-48(40-58(56)93-7)84-32-34-85(35-33-84)61(88)24-16-14-12-10-9-11-13-15-17-31-77-67(90)45-25-29-55(57(37-45)92-6)80-68(91)65-63(50-22-19-23-53(73)64(50)75)71(43-76,59(82-65)41-70(3,4)5)52-28-26-46(72)38-54(52)74/h8,18-23,25-30,36-40,42,59,63,65,82H,1,9-17,24,31-35,41H2,2-7H3,(H,77,90)(H,79,87)(H,80,91)(H,78,81,83)/t59-,63-,65+,71-/m0/s1",DCPNWQZQYCVVJX-UYDHSDFFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,575,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1293.402,1291.57164111,92,9,5,14,C71H81Cl2F2N11O6,"InChI=1S/C71H81Cl2F2N11O6/c1-8-61(87)79-48-21-19-22-50(40-48)86-62(88)37-45(2)52-43-78-69(83-66(52)86)81-57-30-27-49(41-59(57)92-7)85-35-33-84(34-36-85)32-18-16-14-12-10-9-11-13-15-17-31-77-67(89)46-25-29-56(58(38-46)91-6)80-68(90)65-63(51-23-20-24-54(73)64(51)75)71(44-76,60(82-65)42-70(3,4)5)53-28-26-47(72)39-55(53)74/h8,19-30,37-41,43,60,63,65,82H,1,9-18,31-36,42H2,2-7H3,(H,77,89)(H,79,87)(H,80,90)(H,78,81,83)/t60-,63-,65+,71-/m0/s1",UPZKEHBNYUDGOC-AFJHDGOUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,575,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(CCCCCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1293.402,1291.57164111,92,9,5,14,C71H81Cl2F2N11O6,"InChI=1S/C71H81Cl2F2N11O6/c1-8-61(87)79-48-21-19-22-50(40-48)86-62(88)37-45(2)52-43-78-69(83-66(52)86)81-57-30-27-49(41-59(57)92-7)85-35-33-84(34-36-85)32-18-16-14-12-10-9-11-13-15-17-31-77-67(89)46-25-29-56(58(38-46)91-6)80-68(90)65-63(51-23-20-24-54(73)64(51)75)71(44-76,60(82-65)42-70(3,4)5)53-28-26-47(72)39-55(53)74/h8,19-30,37-41,43,60,63,65,82H,1,9-18,31-36,42H2,2-7H3,(H,77,89)(H,79,87)(H,80,90)(H,78,81,83)/t60-,63-,65+,71-/m0/s1",UPZKEHBNYUDGOC-AFJHDGOUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,576,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,312.9,,1136.434,1135.56772942,82,8,5,15,C62H77N11O8S,"InChI=1S/C62H77N11O8S/c1-8-52(75)66-44-18-17-19-46(33-44)73-55(78)32-40(2)48-37-64-61(69-58(48)73)67-49-27-26-45(34-51(49)81-7)70-28-30-71(31-29-70)54(77)21-16-14-12-10-9-11-13-15-20-53(76)68-57(62(4,5)6)60(80)72-38-47(74)35-50(72)59(79)63-36-42-22-24-43(25-23-42)56-41(3)65-39-82-56/h8,17-19,22-27,32-34,37,39,47,50,57,74H,1,9-16,20-21,28-31,35-36,38H2,2-7H3,(H,63,79)(H,66,75)(H,68,76)(H,64,67,69)/t47-,50+,57-/m1/s1",GSUQPNOGNRJJQO-YTFMVYPUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,576,P00533,EGFR,VHL,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4OC)N=C32)=C1,>2000,,1136.434,1135.56772942,82,8,5,15,C62H77N11O8S,"InChI=1S/C62H77N11O8S/c1-8-52(75)66-44-18-17-19-46(33-44)73-55(78)32-40(2)48-37-64-61(69-58(48)73)67-49-27-26-45(34-51(49)81-7)70-28-30-71(31-29-70)54(77)21-16-14-12-10-9-11-13-15-20-53(76)68-57(62(4,5)6)60(80)72-38-47(74)35-50(72)59(79)63-36-42-22-24-43(25-23-42)56-41(3)65-39-82-56/h8,17-19,22-27,32-34,37,39,47,50,57,74H,1,9-16,20-21,28-31,35-36,38H2,2-7H3,(H,63,79)(H,66,75)(H,68,76)(H,64,67,69)/t47-,50+,57-/m1/s1",GSUQPNOGNRJJQO-YTFMVYPUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5478,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,7.1,,1151.848,1150.52408629,81,8,4,15,C60H76ClFN10O8S,"InChI=1S/C60H76ClFN10O8S/c1-38(2)56(53-29-39(3)69-80-53)60(77)72-35-44(73)31-50(72)59(76)68-48(41-16-18-42(19-17-41)57-40(4)66-37-81-57)34-54(74)63-22-13-11-9-7-6-8-10-12-15-55(75)71-26-24-70(25-27-71)23-14-28-79-52-32-45-49(33-51(52)78-5)64-36-65-58(45)67-43-20-21-47(62)46(61)30-43/h16-21,29-30,32-33,36-38,44,48,50,56,73H,6-15,22-28,31,34-35H2,1-5H3,(H,63,74)(H,68,76)(H,64,65,67)/t44-,48+,50+,56-/m1/s1",VDUPETHSNLCFNB-HHHFUCLFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5490,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCCCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1185.881,1184.54596461,83,8,5,14,C61H79ClF2N10O8S,"InChI=1S/C61H79ClF2N10O8S/c1-39-54(83-38-68-39)41-18-16-40(17-19-41)47(70-57(78)49-32-43(75)36-74(49)58(79)55(60(2,3)4)71-59(80)61(64)22-23-61)35-52(76)65-24-13-11-9-7-6-8-10-12-15-53(77)73-28-26-72(27-29-73)25-14-30-82-51-33-44-48(34-50(51)81-5)66-37-67-56(44)69-42-20-21-46(63)45(62)31-42/h16-21,31,33-34,37-38,43,47,49,55,75H,6-15,22-30,32,35-36H2,1-5H3,(H,65,76)(H,70,78)(H,71,80)(H,66,67,69)/t43-,47+,49+,55-/m1/s1",JGPDJHWVBWWLDS-BUCBQYKQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,578,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,77,,1279.331,1277.51960554,91,9,5,14,C69H75Cl2F2N11O7,"InChI=1S/C69H75Cl2F2N11O7/c1-8-58(85)77-45-18-16-19-47(37-45)84-60(87)34-42(2)49-40-76-67(81-64(49)84)79-54-28-25-46(38-56(54)91-7)82-30-32-83(33-31-82)59(86)22-14-12-10-9-11-13-15-29-75-65(88)43-23-27-53(55(35-43)90-6)78-66(89)63-61(48-20-17-21-51(71)62(48)73)69(41-74,57(80-63)39-68(3,4)5)50-26-24-44(70)36-52(50)72/h8,16-21,23-28,34-38,40,57,61,63,80H,1,9-15,22,29-33,39H2,2-7H3,(H,75,88)(H,77,85)(H,78,89)(H,76,79,81)/t57-,61-,63+,69-/m0/s1",GDBFIWQFEZVSAL-RBRUZKMXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,578,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1279.331,1277.51960554,91,9,5,14,C69H75Cl2F2N11O7,"InChI=1S/C69H75Cl2F2N11O7/c1-8-58(85)77-45-18-16-19-47(37-45)84-60(87)34-42(2)49-40-76-67(81-64(49)84)79-54-28-25-46(38-56(54)91-7)82-30-32-83(33-31-82)59(86)22-14-12-10-9-11-13-15-29-75-65(88)43-23-27-53(55(35-43)90-6)78-66(89)63-61(48-20-17-21-51(71)62(48)73)69(41-74,57(80-63)39-68(3,4)5)50-26-24-44(70)36-52(50)72/h8,16-21,23-28,34-38,40,57,61,63,80H,1,9-15,22,29-33,39H2,2-7H3,(H,75,88)(H,77,85)(H,78,89)(H,76,79,81)/t57-,61-,63+,69-/m0/s1",GDBFIWQFEZVSAL-RBRUZKMXSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,579,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1251.277,1249.48830541,89,9,5,14,C67H71Cl2F2N11O7,"InChI=1S/C67H71Cl2F2N11O7/c1-8-56(83)75-43-16-14-17-45(35-43)82-58(85)32-40(2)47-38-74-65(79-62(47)82)77-52-26-23-44(36-54(52)89-7)80-28-30-81(31-29-80)57(84)20-12-10-9-11-13-27-73-63(86)41-21-25-51(53(33-41)88-6)76-64(87)61-59(46-18-15-19-49(69)60(46)71)67(39-72,55(78-61)37-66(3,4)5)48-24-22-42(68)34-50(48)70/h8,14-19,21-26,32-36,38,55,59,61,78H,1,9-13,20,27-31,37H2,2-7H3,(H,73,86)(H,75,83)(H,76,87)(H,74,77,79)/t55-,59-,61+,67-/m0/s1",GGZIIUYEYTZDCD-ASJDMNHUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,579,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1251.277,1249.48830541,89,9,5,14,C67H71Cl2F2N11O7,"InChI=1S/C67H71Cl2F2N11O7/c1-8-56(83)75-43-16-14-17-45(35-43)82-58(85)32-40(2)47-38-74-65(79-62(47)82)77-52-26-23-44(36-54(52)89-7)80-28-30-81(31-29-80)57(84)20-12-10-9-11-13-27-73-63(86)41-21-25-51(53(33-41)88-6)76-64(87)61-59(46-18-15-19-49(69)60(46)71)67(39-72,55(78-61)37-66(3,4)5)48-24-22-42(68)34-50(48)70/h8,14-19,21-26,32-36,38,55,59,61,78H,1,9-13,20,27-31,37H2,2-7H3,(H,73,86)(H,75,83)(H,76,87)(H,74,77,79)/t55-,59-,61+,67-/m0/s1",GGZIIUYEYTZDCD-ASJDMNHUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5514,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,843.357,842.331851776,60,7,3,12,C43H48ClFN8O7,"InChI=1S/C43H48ClFN8O7/c1-59-36-25-34-31(40(48-26-47-34)49-28-10-12-33(45)32(44)23-28)24-37(36)60-21-7-16-51-17-19-52(20-18-51)39(55)8-5-3-2-4-6-15-46-27-9-11-29-30(22-27)43(58)53(42(29)57)35-13-14-38(54)50-41(35)56/h9-12,22-26,35,46H,2-8,13-21H2,1H3,(H,47,48,49)(H,50,54,56)",SFHMCPHJVQETCU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,580,P00533,EGFR L858R/T790M,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1223.223,1221.45700528,87,9,5,14,C65H67Cl2F2N11O7,"InChI=1S/C65H67Cl2F2N11O7/c1-8-54(81)73-41-14-12-15-43(33-41)80-56(83)30-38(2)45-36-72-63(77-60(45)80)75-50-24-21-42(34-52(50)87-7)78-26-28-79(29-27-78)55(82)18-10-9-11-25-71-61(84)39-19-23-49(51(31-39)86-6)74-62(85)59-57(44-16-13-17-47(67)58(44)69)65(37-70,53(76-59)35-64(3,4)5)46-22-20-40(66)32-48(46)68/h8,12-17,19-24,30-34,36,53,57,59,76H,1,9-11,18,25-29,35H2,2-7H3,(H,71,84)(H,73,81)(H,74,85)(H,72,75,77)/t53-,57-,59+,65-/m0/s1",KFRDCTCOKBRAAL-OIUJZHHCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,580,P00533,EGFR,MDM2,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCNC(=O)C6=CC=C(NC(=O)[C@@H]7N[C@@H](CC(C)(C)C)[C@](C#N)(C8=CC=C(Cl)C=C8F)[C@H]7C7=CC=CC(Cl)=C7F)C(OC)=C6)CC5)C=C4OC)N=C32)=C1,>2000,,1223.223,1221.45700528,87,9,5,14,C65H67Cl2F2N11O7,"InChI=1S/C65H67Cl2F2N11O7/c1-8-54(81)73-41-14-12-15-43(33-41)80-56(83)30-38(2)45-36-72-63(77-60(45)80)75-50-24-21-42(34-52(50)87-7)78-26-28-79(29-27-78)55(82)18-10-9-11-25-71-61(84)39-19-23-49(51(31-39)86-6)74-62(85)59-57(44-16-13-17-47(67)58(44)69)65(37-70,53(76-59)35-64(3,4)5)46-22-20-40(66)32-48(46)68/h8,12-17,19-24,30-34,36,53,57,59,76H,1,9-11,18,25-29,35H2,2-7H3,(H,71,84)(H,73,81)(H,74,85)(H,72,75,77)/t53-,57-,59+,65-/m0/s1",KFRDCTCOKBRAAL-OIUJZHHCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5512,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,815.303,814.300551648,58,7,3,12,C41H44ClFN8O7,"InChI=1S/C41H44ClFN8O7/c1-57-34-23-32-29(38(46-24-45-32)47-26-8-10-31(43)30(42)21-26)22-35(34)58-19-5-14-49-15-17-50(18-16-49)37(53)6-3-2-4-13-44-25-7-9-27-28(20-25)41(56)51(40(27)55)33-11-12-36(52)48-39(33)54/h7-10,20-24,33,44H,2-6,11-19H2,1H3,(H,45,46,47)(H,48,52,54)",VLEREXHCBCVHGO-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,588,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1002.611,1001.40363681,70,7,4,14,C50H61ClFN9O8S,"InChI=1S/C50H61ClFN9O8S/c1-31-45(70-30-56-31)33-9-7-32(8-10-33)27-53-48(65)40-24-35(62)28-61(40)49(66)46(50(2,3)4)58-43(63)13-21-68-22-14-44(64)60-18-16-59(17-19-60)15-6-20-69-42-25-36-39(26-41(42)67-5)54-29-55-47(36)57-34-11-12-38(52)37(51)23-34/h7-12,23,25-26,29-30,35,40,46,62H,6,13-22,24,27-28H2,1-5H3,(H,53,65)(H,58,63)(H,54,55,57)/t35-,40+,46-/m1/s1",HZVDJJAXDIAOHI-QRYWEXOJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,588,P00533,EGFR L858R,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)CC1,,,1002.611,1001.40363681,70,7,4,14,C50H61ClFN9O8S,"InChI=1S/C50H61ClFN9O8S/c1-31-45(70-30-56-31)33-9-7-32(8-10-33)27-53-48(65)40-24-35(62)28-61(40)49(66)46(50(2,3)4)58-43(63)13-21-68-22-14-44(64)60-18-16-59(17-19-60)15-6-20-69-42-25-36-39(26-41(42)67-5)54-29-55-47(36)57-34-11-12-38(52)37(51)23-34/h7-12,23,25-26,29-30,35,40,46,62H,6,13-22,24,27-28H2,1-5H3,(H,53,65)(H,58,63)(H,54,55,57)/t35-,40+,46-/m1/s1",HZVDJJAXDIAOHI-QRYWEXOJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1545,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCC(=O)N4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=C5)CC4)=C3C2=O)C(=O)N1,,,880.984,880.300281368,64,9,3,12,C47H44N8O8S,"InChI=1S/C47H44N8O8S/c56-38-16-15-37(42(58)50-38)55-45(61)34-7-4-8-36(40(34)46(55)62)48-18-25-63-24-17-39(57)53-22-20-52(21-23-53)33-13-11-29(12-14-33)31-9-10-32-28-54(44(60)35(32)27-31)41(30-5-2-1-3-6-30)43(59)51-47-49-19-26-64-47/h1-14,19,26-27,37,41,48H,15-18,20-25,28H2,(H,49,51,59)(H,50,56,58)",MPSFLLYYUBBAEB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5493,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](C2=CC(C)=NO2)C(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1083.685,1082.42510053,76,8,4,16,C54H64ClFN10O9S,"InChI=1S/C54H64ClFN10O9S/c1-32(2)50(47-23-33(3)63-75-47)54(71)66-29-38(67)25-44(66)53(70)62-42(35-7-9-36(10-8-35)51-34(4)60-31-76-51)28-48(68)57-14-22-73-21-13-49(69)65-18-16-64(17-19-65)15-6-20-74-46-26-39-43(27-45(46)72-5)58-30-59-52(39)61-37-11-12-41(56)40(55)24-37/h7-12,23-24,26-27,30-32,38,42,44,50,67H,6,13-22,25,28-29H2,1-5H3,(H,57,68)(H,62,70)(H,58,59,61)/t38-,42+,44+,50-/m1/s1",GBUREHDGQZLEIU-VYRQVLTMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5501,P00533,EGFR e19d,VHL,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCNC(=O)C[C@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)C2=CC=C(C3=C(C)N=CS3)C=C2)CC1,,,1117.718,1116.44697884,78,8,5,15,C55H67ClF2N10O9S,"InChI=1S/C55H67ClF2N10O9S/c1-33-48(78-32-62-33)35-9-7-34(8-10-35)41(64-51(72)43-26-37(69)30-68(43)52(73)49(54(2,3)4)65-53(74)55(58)14-15-55)29-46(70)59-16-24-76-23-13-47(71)67-20-18-66(19-21-67)17-6-22-77-45-27-38-42(28-44(45)75-5)60-31-61-50(38)63-36-11-12-40(57)39(56)25-36/h7-12,25,27-28,31-32,37,41,43,49,69H,6,13-24,26,29-30H2,1-5H3,(H,59,70)(H,64,72)(H,65,74)(H,60,61,63)/t37-,41+,43+,49-/m1/s1",VEWVNHVHVUTJSR-JYAIWFTJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,594,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,860.344,859.322015364,61,7,4,14,C42H47ClFN9O8,"InChI=1S/C42H47ClFN9O8/c1-59-34-24-32-28(39(48-25-47-32)49-26-6-7-30(44)29(43)22-26)23-35(34)61-19-3-13-51-15-17-52(18-16-51)14-10-36(54)46-12-21-60-20-11-45-31-5-2-4-27-38(31)42(58)53(41(27)57)33-8-9-37(55)50-40(33)56/h2,4-7,22-25,33,45H,3,8-21H2,1H3,(H,46,54)(H,47,48,49)(H,50,55,56)",PDCRYPGMVLBRTP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,594,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,860.344,859.322015364,61,7,4,14,C42H47ClFN9O8,"InChI=1S/C42H47ClFN9O8/c1-59-34-24-32-28(39(48-25-47-32)49-26-6-7-30(44)29(43)22-26)23-35(34)61-19-3-13-51-15-17-52(18-16-51)14-10-36(54)46-12-21-60-20-11-45-31-5-2-4-27-38(31)42(58)53(41(27)57)33-8-9-37(55)50-40(33)56/h2,4-7,22-25,33,45H,3,8-21H2,1H3,(H,46,54)(H,47,48,49)(H,50,55,56)",PDCRYPGMVLBRTP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,595,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,1036.556,1035.42687436,73,7,4,18,C50H63ClFN9O12,"InChI=1S/C50H63ClFN9O12/c1-67-42-32-40-36(47(56-33-55-40)57-34-6-7-38(52)37(51)30-34)31-43(42)73-19-3-13-59-15-17-60(18-16-59)14-10-44(62)54-12-21-69-23-25-71-27-29-72-28-26-70-24-22-68-20-11-53-39-5-2-4-35-46(39)50(66)61(49(35)65)41-8-9-45(63)58-48(41)64/h2,4-7,30-33,41,53H,3,8-29H2,1H3,(H,54,62)(H,55,56,57)(H,58,63,64)",NKTVFYFQSABEHM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,595,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCOCCOCCOCCOCCOCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,1036.556,1035.42687436,73,7,4,18,C50H63ClFN9O12,"InChI=1S/C50H63ClFN9O12/c1-67-42-32-40-36(47(56-33-55-40)57-34-6-7-38(52)37(51)30-34)31-43(42)73-19-3-13-59-15-17-60(18-16-59)14-10-44(62)54-12-21-69-23-25-71-27-29-72-28-26-70-24-22-68-20-11-53-39-5-2-4-35-46(39)50(66)61(49(35)65)41-8-9-45(63)58-48(41)64/h2,4-7,30-33,41,53H,3,8-29H2,1H3,(H,54,62)(H,55,56,57)(H,58,63,64)",NKTVFYFQSABEHM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,596,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,872.399,871.358400872,62,7,4,13,C44H51ClFN9O7,"InChI=1S/C44H51ClFN9O7/c1-61-36-26-34-30(41(50-27-49-34)51-28-10-11-32(46)31(45)24-28)25-37(36)62-23-7-17-53-19-21-54(22-20-53)18-14-38(56)48-16-5-3-2-4-15-47-33-9-6-8-29-40(33)44(60)55(43(29)59)35-12-13-39(57)52-42(35)58/h6,8-11,24-27,35,47H,2-5,7,12-23H2,1H3,(H,48,56)(H,49,50,51)(H,52,57,58)",MPXZGDAUSAQINZ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,596,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCNC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,,,872.399,871.358400872,62,7,4,13,C44H51ClFN9O7,"InChI=1S/C44H51ClFN9O7/c1-61-36-26-34-30(41(50-27-49-34)51-28-10-11-32(46)31(45)24-28)25-37(36)62-23-7-17-53-19-21-54(22-20-53)18-14-38(56)48-16-5-3-2-4-15-47-33-9-6-8-29-40(33)44(60)55(43(29)59)35-12-13-39(57)52-42(35)58/h6,8-11,24-27,35,47H,2-5,7,12-23H2,1H3,(H,48,56)(H,49,50,51)(H,52,57,58)",MPXZGDAUSAQINZ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,597,P00533,EGFR L858R,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,25,,901.437,900.373716588,64,7,3,13,C46H54ClFN8O8,"InChI=1S/C46H54ClFN8O8/c1-62-38-28-35-32(43(51-29-50-35)52-30-12-13-34(48)33(47)26-30)27-39(38)64-25-9-18-54-20-22-55(23-21-54)19-16-40(57)49-17-6-4-2-3-5-7-24-63-37-11-8-10-31-42(37)46(61)56(45(31)60)36-14-15-41(58)53-44(36)59/h8,10-13,26-29,36H,2-7,9,14-25H2,1H3,(H,49,57)(H,50,51,52)(H,53,58,59)",ALKKWBPMCDDKKA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,597,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(CCC(=O)NCCCCCCCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,11,,901.437,900.373716588,64,7,3,13,C46H54ClFN8O8,"InChI=1S/C46H54ClFN8O8/c1-62-38-28-35-32(43(51-29-50-35)52-30-12-13-34(48)33(47)26-30)27-39(38)64-25-9-18-54-20-22-55(23-21-54)19-16-40(57)49-17-6-4-2-3-5-7-24-63-37-11-8-10-31-42(37)46(61)56(45(31)60)36-14-15-41(58)53-44(36)59/h8,10-13,26-29,36H,2-7,9,14-25H2,1H3,(H,49,57)(H,50,51,52)(H,53,58,59)",ALKKWBPMCDDKKA-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2615,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2CC2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1146.433,1145.56331274,83,9,6,16,C62H75N13O7S,"InChI=1S/C62H75N13O7S/c1-39-56(83-38-67-39)42-20-18-41(19-21-42)34-66-59(80)52-30-44(76)35-75(52)60(81)57(62(2,3)4)71-54(77)15-9-7-8-12-23-64-55(78)37-73-25-27-74(28-26-73)51-32-53(82-6)49(31-48(51)68-58(79)43(33-63)29-40-16-17-40)70-61-65-24-22-47(69-61)46-36-72(5)50-14-11-10-13-45(46)50/h10-11,13-14,18-22,24,29,31-32,36,38,40,44,52,57,76H,7-9,12,15-17,23,25-28,30,34-35,37H2,1-6H3,(H,64,78)(H,66,80)(H,68,79)(H,71,77)(H,65,69,70)/b43-29+/t44-,52+,57-/m1/s1",IYEGDDXKUGKHBL-YIBIMTPWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2615,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2CC2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1146.433,1145.56331274,83,9,6,16,C62H75N13O7S,"InChI=1S/C62H75N13O7S/c1-39-56(83-38-67-39)42-20-18-41(19-21-42)34-66-59(80)52-30-44(76)35-75(52)60(81)57(62(2,3)4)71-54(77)15-9-7-8-12-23-64-55(78)37-73-25-27-74(28-26-73)51-32-53(82-6)49(31-48(51)68-58(79)43(33-63)29-40-16-17-40)70-61-65-24-22-47(69-61)46-36-72(5)50-14-11-10-13-45(46)50/h10-11,13-14,18-22,24,29,31-32,36,38,40,44,52,57,76H,7-9,12,15-17,23,25-28,30,34-35,37H2,1-6H3,(H,64,78)(H,66,80)(H,68,79)(H,71,77)(H,65,69,70)/b43-29+/t44-,52+,57-/m1/s1",IYEGDDXKUGKHBL-YIBIMTPWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2616,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2=CC=NC=C2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1183.454,1182.55856171,86,9,6,17,C64H74N14O7S,"InChI=1S/C64H74N14O7S/c1-41-58(86-40-70-41)44-18-16-43(17-19-44)36-69-61(83)54-32-46(79)37-78(54)62(84)59(64(2,3)4)74-56(80)15-9-7-8-12-23-67-57(81)39-76-27-29-77(30-28-76)53-34-55(85-6)51(33-50(53)71-60(82)45(35-65)31-42-20-24-66-25-21-42)73-63-68-26-22-49(72-63)48-38-75(5)52-14-11-10-13-47(48)52/h10-11,13-14,16-22,24-26,31,33-34,38,40,46,54,59,79H,7-9,12,15,23,27-30,32,36-37,39H2,1-6H3,(H,67,81)(H,69,83)(H,71,82)(H,74,80)(H,68,72,73)/b45-31+/t46-,54+,59-/m1/s1",NIJQPCPIFFRGOF-XYOSPYPGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2616,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=C(NC(=O)/C(C#N)=C/C2=CC=NC=C2)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1183.454,1182.55856171,86,9,6,17,C64H74N14O7S,"InChI=1S/C64H74N14O7S/c1-41-58(86-40-70-41)44-18-16-43(17-19-44)36-69-61(83)54-32-46(79)37-78(54)62(84)59(64(2,3)4)74-56(80)15-9-7-8-12-23-67-57(81)39-76-27-29-77(30-28-76)53-34-55(85-6)51(33-50(53)71-60(82)45(35-65)31-42-20-24-66-25-21-42)73-63-68-26-22-49(72-63)48-38-75(5)52-14-11-10-13-47(48)52/h10-11,13-14,16-22,24-26,31,33-34,38,40,46,54,59,79H,7-9,12,15,23,27-30,32,36-37,39H2,1-6H3,(H,67,81)(H,69,83)(H,71,82)(H,74,80)(H,68,72,73)/b45-31+/t46-,54+,59-/m1/s1",NIJQPCPIFFRGOF-XYOSPYPGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2623,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1121.427,1120.57929715,81,9,6,16,C60H76N14O6S,"InChI=1S/C60H76N14O6S/c1-6-52(78)72-28-14-17-46(36-72)74-55-48(67-59(74)66-43-15-10-9-11-16-43)35-63-58(69-55)65-44-23-25-45(26-24-44)71-31-29-70(30-32-71)38-51(77)61-27-13-8-7-12-18-50(76)68-54(60(3,4)5)57(80)73-37-47(75)33-49(73)56(79)62-34-41-19-21-42(22-20-41)53-40(2)64-39-81-53/h6,9-11,15-16,19-26,35,39,46-47,49,54,75H,1,7-8,12-14,17-18,27-34,36-38H2,2-5H3,(H,61,77)(H,62,79)(H,66,67)(H,68,76)(H,63,65,69)/t46-,47+,49-,54+/m0/s1",IROOQIWNFFCZLN-VEJFJKOFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2623,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1121.427,1120.57929715,81,9,6,16,C60H76N14O6S,"InChI=1S/C60H76N14O6S/c1-6-52(78)72-28-14-17-46(36-72)74-55-48(67-59(74)66-43-15-10-9-11-16-43)35-63-58(69-55)65-44-23-25-45(26-24-44)71-31-29-70(30-32-71)38-51(77)61-27-13-8-7-12-18-50(76)68-54(60(3,4)5)57(80)73-37-47(75)33-49(73)56(79)62-34-41-19-21-42(22-20-41)53-40(2)64-39-81-53/h6,9-11,15-16,19-26,35,39,46-47,49,54,75H,1,7-8,12-14,17-18,27-34,36-38H2,2-5H3,(H,61,77)(H,62,79)(H,66,67)(H,68,76)(H,63,65,69)/t46-,47+,49-,54+/m0/s1",IROOQIWNFFCZLN-VEJFJKOFSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5615,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,925.97,925.3846776,67,7,6,14,C46H50F3N11O7,"InChI=1S/C46H50F3N11O7/c1-3-37(61)53-28-10-8-11-29(24-28)54-41-32(46(47,48)49)26-52-45(57-41)55-33-15-14-30(25-36(33)67-2)59-22-20-58(21-23-59)27-39(63)51-19-7-5-4-6-18-50-34-13-9-12-31-40(34)44(66)60(43(31)65)35-16-17-38(62)56-42(35)64/h3,8-15,24-26,35,50H,1,4-7,16-23,27H2,2H3,(H,51,63)(H,53,61)(H,56,62,64)(H2,52,54,55,57)",HLDZFDOEIBZQRP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5615,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,925.97,925.3846776,67,7,6,14,C46H50F3N11O7,"InChI=1S/C46H50F3N11O7/c1-3-37(61)53-28-10-8-11-29(24-28)54-41-32(46(47,48)49)26-52-45(57-41)55-33-15-14-30(25-36(33)67-2)59-22-20-58(21-23-59)27-39(63)51-19-7-5-4-6-18-50-34-13-9-12-31-40(34)44(66)60(43(31)65)35-16-17-38(62)56-42(35)64/h3,8-15,24-26,35,50H,1,4-7,16-23,27H2,2H3,(H,51,63)(H,53,61)(H,56,62,64)(H2,52,54,55,57)",HLDZFDOEIBZQRP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5615,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(CC(=O)NCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,925.97,925.3846776,67,7,6,14,C46H50F3N11O7,"InChI=1S/C46H50F3N11O7/c1-3-37(61)53-28-10-8-11-29(24-28)54-41-32(46(47,48)49)26-52-45(57-41)55-33-15-14-30(25-36(33)67-2)59-22-20-58(21-23-59)27-39(63)51-19-7-5-4-6-18-50-34-13-9-12-31-40(34)44(66)60(43(31)65)35-16-17-38(62)56-42(35)64/h3,8-15,24-26,35,50H,1,4-7,16-23,27H2,2H3,(H,51,63)(H,53,61)(H,56,62,64)(H2,52,54,55,57)",HLDZFDOEIBZQRP-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2402,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,892.349,891.301948616,64,8,4,14,C44H43ClFN11O7,"InChI=1S/C44H43ClFN11O7/c45-30-20-26(12-13-31(30)46)49-41-29-21-34(51-38(59)11-7-18-55-16-3-1-4-17-55)36(22-33(29)47-25-48-41)64-24-27-23-56(54-53-27)19-5-2-10-37(58)50-32-9-6-8-28-40(32)44(63)57(43(28)62)35-14-15-39(60)52-42(35)61/h6-9,11-13,20-23,25,35H,1-5,10,14-19,24H2,(H,50,58)(H,51,59)(H,47,48,49)(H,52,60,61)/b11-7+",NUPNAAWSDJSHQQ-YRNVUSSQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1219,P00533,EGFR,CRBN,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CCOCCOCCOCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,917.037,916.423173372,67,7,4,15,C48H56N10O9,"InChI=1S/C48H56N10O9/c1-6-43(59)51-37-26-38(53-48-49-17-16-36(52-48)33-28-57(4)39-13-8-7-10-31(33)39)42(64-5)27-41(37)56(3)19-18-55(2)20-21-65-22-23-66-24-25-67-30-45(61)50-35-12-9-11-32-34(35)29-58(47(32)63)40-14-15-44(60)54-46(40)62/h6-13,16-17,26-28,40H,1,14-15,18-25,29-30H2,2-5H3,(H,50,61)(H,51,59)(H,49,52,53)(H,54,60,62)",SLRLENALOHTBGF-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5511,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,801.276,800.284901584,57,7,3,12,C40H42ClFN8O7,"InChI=1S/C40H42ClFN8O7/c1-56-33-22-31-28(37(45-23-44-31)46-25-7-9-30(42)29(41)20-25)21-34(33)57-18-4-13-48-14-16-49(17-15-48)36(52)5-2-3-12-43-24-6-8-26-27(19-24)40(55)50(39(26)54)32-10-11-35(51)47-38(32)53/h6-9,19-23,32,43H,2-5,10-18H2,1H3,(H,44,45,46)(H,47,51,53)",LLPZVMLJFWXNSU-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5513,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCCCCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,829.33,828.316201712,59,7,3,12,C42H46ClFN8O7,"InChI=1S/C42H46ClFN8O7/c1-58-35-24-33-30(39(47-25-46-33)48-27-9-11-32(44)31(43)22-27)23-36(35)59-20-6-15-50-16-18-51(19-17-50)38(54)7-4-2-3-5-14-45-26-8-10-28-29(21-26)42(57)52(41(28)56)34-12-13-37(53)49-40(34)55/h8-11,21-25,34,45H,2-7,12-20H2,1H3,(H,46,47,48)(H,49,53,55)",OOOBRWIBWJRNLX-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2407,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,938.374,937.30742792,67,8,4,16,C45H45ClFN11O9,"InChI=1S/C45H45ClFN11O9/c46-31-20-27(9-10-32(31)47)50-42-30-21-35(52-38(59)8-5-15-56-13-2-1-3-14-56)37(22-34(30)48-26-49-42)67-24-28-23-57(55-54-28)16-17-65-18-19-66-25-40(61)51-33-7-4-6-29-41(33)45(64)58(44(29)63)36-11-12-39(60)53-43(36)62/h4-10,20-23,26,36H,1-3,11-19,24-25H2,(H,51,61)(H,52,59)(H,48,49,50)(H,53,60,62)/b8-5+",CZGGKPSGPDNZOD-VMPITWQZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2408,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCOCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,982.427,981.333642668,70,8,4,17,C47H49ClFN11O10,"InChI=1S/C47H49ClFN11O10/c48-33-22-29(9-10-34(33)49)52-44-32-23-37(54-40(61)8-5-15-58-13-2-1-3-14-58)39(24-36(32)50-28-51-44)70-26-30-25-59(57-56-30)16-17-67-18-19-68-20-21-69-27-42(63)53-35-7-4-6-31-43(35)47(66)60(46(31)65)38-11-12-41(62)55-45(38)64/h4-10,22-25,28,38H,1-3,11-21,26-27H2,(H,53,63)(H,54,61)(H,50,51,52)(H,55,62,64)/b8-5+",MDHFKGKNXKSKPN-VMPITWQZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1553,P00533,EGFR L858R/T790M,CRBN,O=C1CCC(N2C(=O)C3=CC=CC(OCCOCCOCCOCCN4CCN(C5=CC=C(C6=CC=C7CN(C(C(=O)NC8=NC=CS8)C8=CC=CC=C8)C(=O)C7=C6)C=N5)CC4)=C3C2=O)C(=O)N1,,,943.052,942.3370608,68,9,2,15,C49H50N8O10S,"InChI=1S/C49H50N8O10S/c58-41-14-12-38(44(59)52-41)57-47(62)36-7-4-8-39(42(36)48(57)63)67-27-26-66-25-24-65-23-22-64-21-20-54-16-18-55(19-17-54)40-13-11-34(30-51-40)33-9-10-35-31-56(46(61)37(35)29-33)43(32-5-2-1-3-6-32)45(60)53-49-50-15-28-68-49/h1-11,13,15,28-30,38,43H,12,14,16-27,31H2,(H,50,53,60)(H,52,58,59)",WWOKCOMOIMLOBV-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5509,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,773.222,772.253601456,55,7,3,12,C38H38ClFN8O7,"InChI=1S/C38H38ClFN8O7/c1-54-31-20-29-26(35(43-21-42-29)44-23-4-6-28(40)27(39)18-23)19-32(31)55-16-2-11-46-12-14-47(15-13-46)34(50)9-10-41-22-3-5-24-25(17-22)38(53)48(37(24)52)30-7-8-33(49)45-36(30)51/h3-6,17-21,30,41H,2,7-16H2,1H3,(H,42,43,44)(H,45,49,51)",UOSCSJYBYLMABE-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1542,P00533,EGFR L858R/T790M,CRBN,O=C(COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCCCNC(=O)CN1CCN(C2=CC=C(C3=CC=C4CN(C(C(=O)NC5=NC=CS5)C5=CC=CC=C5)C(=O)C4=C3)C=C2)CC1,,,952.063,951.337395148,69,9,4,13,C50H49N9O9S,"InChI=1S/C50H49N9O9S/c60-40-18-17-38(45(63)54-40)59-48(66)36-9-6-10-39(43(36)49(59)67)68-30-42(62)52-20-5-4-19-51-41(61)29-56-22-24-57(25-23-56)35-15-13-31(14-16-35)33-11-12-34-28-58(47(65)37(34)27-33)44(32-7-2-1-3-8-32)46(64)55-50-53-21-26-69-50/h1-3,6-16,21,26-27,38,44H,4-5,17-20,22-25,28-30H2,(H,51,61)(H,52,62)(H,53,55,64)(H,54,60,63)",DRFUYHRFDSPHBM-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2614,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1101.345,1100.52659288,79,7,6,17,C57H72N12O9S,"InChI=1S/C57H72N12O9S/c1-10-49(71)62-43-28-44(64-56-59-20-19-42(63-56)41-32-68(8)45-14-12-11-13-40(41)45)48(76-9)29-46(43)67(7)23-22-66(6)33-50(72)58-21-24-77-25-26-78-34-51(73)65-53(57(3,4)5)55(75)69-31-39(70)27-47(69)54(74)60-30-37-15-17-38(18-16-37)52-36(2)61-35-79-52/h10-20,28-29,32,35,39,47,53,70H,1,21-27,30-31,33-34H2,2-9H3,(H,58,72)(H,60,74)(H,62,71)(H,65,73)(H,59,63,64)/t39-,47+,53-/m1/s1",VJOYYKYPRAJJHC-BRBZWKBWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2614,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(C)CCN(C)CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,,,1101.345,1100.52659288,79,7,6,17,C57H72N12O9S,"InChI=1S/C57H72N12O9S/c1-10-49(71)62-43-28-44(64-56-59-20-19-42(63-56)41-32-68(8)45-14-12-11-13-40(41)45)48(76-9)29-46(43)67(7)23-22-66(6)33-50(72)58-21-24-77-25-26-78-34-51(73)65-53(57(3,4)5)55(75)69-31-39(70)27-47(69)54(74)60-30-37-15-17-38(18-16-37)52-36(2)61-35-79-52/h10-20,28-29,32,35,39,47,53,70H,1,21-27,30-31,33-34H2,2-9H3,(H,58,72)(H,60,74)(H,62,71)(H,65,73)(H,59,63,64)/t39-,47+,53-/m1/s1",VJOYYKYPRAJJHC-BRBZWKBWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2624,P00533,EGFR L858R/T790M,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1139.398,1138.55347633,82,9,6,18,C59H74N14O8S,"InChI=1S/C59H74N14O8S/c1-6-51(77)71-23-10-13-45(34-71)73-54-47(66-58(73)65-42-11-8-7-9-12-42)33-62-57(68-54)64-43-18-20-44(21-19-43)70-26-24-69(25-27-70)36-49(75)60-22-28-80-29-30-81-37-50(76)67-53(59(3,4)5)56(79)72-35-46(74)31-48(72)55(78)61-32-40-14-16-41(17-15-40)52-39(2)63-38-82-52/h6-9,11-12,14-21,33,38,45-46,48,53,74H,1,10,13,22-32,34-37H2,2-5H3,(H,60,75)(H,61,78)(H,65,66)(H,67,76)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",HTDTVBXASZKIHM-BCWDIVJWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2624,P00533,EGFR e19d,VHL,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,,,1139.398,1138.55347633,82,9,6,18,C59H74N14O8S,"InChI=1S/C59H74N14O8S/c1-6-51(77)71-23-10-13-45(34-71)73-54-47(66-58(73)65-42-11-8-7-9-12-42)33-62-57(68-54)64-43-18-20-44(21-19-43)70-26-24-69(25-27-70)36-49(75)60-22-28-80-29-30-81-37-50(76)67-53(59(3,4)5)56(79)72-35-46(74)31-48(72)55(78)61-32-40-14-16-41(17-15-40)52-39(2)63-38-82-52/h6-9,11-12,14-21,33,38,45-46,48,53,74H,1,10,13,22-32,34-37H2,2-5H3,(H,60,75)(H,61,78)(H,65,66)(H,67,76)(H,62,64,68)/t45-,46+,48-,53+/m0/s1",HTDTVBXASZKIHM-BCWDIVJWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1541,P00533,EGFR L858R/T790M,CRBN,O=C(COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCOCCOCCOCCNC(=O)CN1CCN(C2=CC=C(C3=CC=C4CN(C(C(=O)NC5=NC=CS5)C5=CC=CC=C5)C(=O)C4=C3)C=C2)CC1,,,1056.168,1055.38473926,76,9,4,16,C54H57N9O12S,"InChI=1S/C54H57N9O12S/c64-44-16-15-42(49(67)58-44)63-52(70)40-7-4-8-43(47(40)53(63)71)75-34-46(66)56-18-25-73-27-29-74-28-26-72-24-17-55-45(65)33-60-20-22-61(23-21-60)39-13-11-35(12-14-39)37-9-10-38-32-62(51(69)41(38)31-37)48(36-5-2-1-3-6-36)50(68)59-54-57-19-30-76-54/h1-14,19,30-31,42,48H,15-18,20-29,32-34H2,(H,55,65)(H,56,66)(H,57,59,68)(H,58,64,67)",SGYWRAOXWISULN-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,3189,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCOCCOCCOCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,765.195,764.237282696,54,6,3,12,C37H38ClFN6O9,"InChI=1S/C37H38ClFN6O9/c1-50-31-19-29-24(35(41-21-40-29)42-22-5-6-27(39)26(38)17-22)18-32(31)54-16-15-53-14-13-52-12-11-51-10-9-34(47)43-28-4-2-3-23-25(28)20-45(37(23)49)30-7-8-33(46)44-36(30)48/h2-6,17-19,21,30H,7-16,20H2,1H3,(H,43,47)(H,40,41,42)(H,44,46,48)",MDAGJVVQTFPEOF-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1997,P00533,EGFR,CRBN,CN(CCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.07,898.460227576,66,9,4,15,C48H58N12O6,"InChI=1S/C48H58N12O6/c1-56(32-43(62)52-39-13-7-12-37-38(39)31-59(46(37)64)41-18-19-42(61)54-45(41)63)24-26-65-28-29-66-27-25-57-20-22-58(23-21-57)35-16-14-34(15-17-35)50-47-49-30-40-44(55-47)60(36-10-5-6-11-36)48(53-40)51-33-8-3-2-4-9-33/h2-4,7-9,12-17,30,36,41H,5-6,10-11,18-29,31-32H2,1H3,(H,51,53)(H,52,62)(H,49,50,55)(H,54,61,63)",WHRASSDAJIPBAF-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1997,P00533,EGFR L858R/T790M,CRBN,CN(CCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.07,898.460227576,66,9,4,15,C48H58N12O6,"InChI=1S/C48H58N12O6/c1-56(32-43(62)52-39-13-7-12-37-38(39)31-59(46(37)64)41-18-19-42(61)54-45(41)63)24-26-65-28-29-66-27-25-57-20-22-58(23-21-57)35-16-14-34(15-17-35)50-47-49-30-40-44(55-47)60(36-10-5-6-11-36)48(53-40)51-33-8-3-2-4-9-33/h2-4,7-9,12-17,30,36,41H,5-6,10-11,18-29,31-32H2,1H3,(H,51,53)(H,52,62)(H,49,50,55)(H,54,61,63)",WHRASSDAJIPBAF-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1997,P00533,EGFR e19d,CRBN,CN(CCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,899.07,898.460227576,66,9,4,15,C48H58N12O6,"InChI=1S/C48H58N12O6/c1-56(32-43(62)52-39-13-7-12-37-38(39)31-59(46(37)64)41-18-19-42(61)54-45(41)63)24-26-65-28-29-66-27-25-57-20-22-58(23-21-57)35-16-14-34(15-17-35)50-47-49-30-40-44(55-47)60(36-10-5-6-11-36)48(53-40)51-33-8-3-2-4-9-33/h2-4,7-9,12-17,30,36,41H,5-6,10-11,18-29,31-32H2,1H3,(H,51,53)(H,52,62)(H,49,50,55)(H,54,61,63)",WHRASSDAJIPBAF-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1998,P00533,EGFR e19d,CRBN,CN(CCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,1.91,82,943.123,942.486442324,69,9,4,16,C50H62N12O7,"InChI=1S/C50H62N12O7/c1-58(34-45(64)54-41-13-7-12-39-40(41)33-61(48(39)66)43-18-19-44(63)56-47(43)65)24-26-67-28-30-69-31-29-68-27-25-59-20-22-60(23-21-59)37-16-14-36(15-17-37)52-49-51-32-42-46(57-49)62(38-10-5-6-11-38)50(55-42)53-35-8-3-2-4-9-35/h2-4,7-9,12-17,32,38,43H,5-6,10-11,18-31,33-34H2,1H3,(H,53,55)(H,54,64)(H,51,52,57)(H,56,63,65)",YTBOHZLAPNSENZ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1998,P00533,EGFR,CRBN,CN(CCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,N.D.,943.123,942.486442324,69,9,4,16,C50H62N12O7,"InChI=1S/C50H62N12O7/c1-58(34-45(64)54-41-13-7-12-39-40(41)33-61(48(39)66)43-18-19-44(63)56-47(43)65)24-26-67-28-30-69-31-29-68-27-25-59-20-22-60(23-21-59)37-16-14-36(15-17-37)52-49-51-32-42-46(57-49)62(38-10-5-6-11-38)50(55-42)53-35-8-3-2-4-9-35/h2-4,7-9,12-17,32,38,43H,5-6,10-11,18-31,33-34H2,1H3,(H,53,55)(H,54,64)(H,51,52,57)(H,56,63,65)",YTBOHZLAPNSENZ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1998,P00533,EGFR L858R/T790M,CRBN,CN(CCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,943.123,942.486442324,69,9,4,16,C50H62N12O7,"InChI=1S/C50H62N12O7/c1-58(34-45(64)54-41-13-7-12-39-40(41)33-61(48(39)66)43-18-19-44(63)56-47(43)65)24-26-67-28-30-69-31-29-68-27-25-59-20-22-60(23-21-59)37-16-14-36(15-17-37)52-49-51-32-42-46(57-49)62(38-10-5-6-11-38)50(55-42)53-35-8-3-2-4-9-35/h2-4,7-9,12-17,32,38,43H,5-6,10-11,18-31,33-34H2,1H3,(H,53,55)(H,54,64)(H,51,52,57)(H,56,63,65)",YTBOHZLAPNSENZ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1999,P00533,EGFR,CRBN,CN(CCOCCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,987.176,986.512657072,72,9,4,17,C52H66N12O8,"InChI=1S/C52H66N12O8/c1-60(36-47(66)56-43-13-7-12-41-42(43)35-63(50(41)68)45-18-19-46(65)58-49(45)67)24-26-69-28-30-71-32-33-72-31-29-70-27-25-61-20-22-62(23-21-61)39-16-14-38(15-17-39)54-51-53-34-44-48(59-51)64(40-10-5-6-11-40)52(57-44)55-37-8-3-2-4-9-37/h2-4,7-9,12-17,34,40,45H,5-6,10-11,18-33,35-36H2,1H3,(H,55,57)(H,56,66)(H,53,54,59)(H,58,65,67)",YHKWJWJTXQMPOK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1999,P00533,EGFR L858R/T790M,CRBN,CN(CCOCCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,987.176,986.512657072,72,9,4,17,C52H66N12O8,"InChI=1S/C52H66N12O8/c1-60(36-47(66)56-43-13-7-12-41-42(43)35-63(50(41)68)45-18-19-46(65)58-49(45)67)24-26-69-28-30-71-32-33-72-31-29-70-27-25-61-20-22-62(23-21-61)39-16-14-38(15-17-39)54-51-53-34-44-48(59-51)64(40-10-5-6-11-40)52(57-44)55-37-8-3-2-4-9-37/h2-4,7-9,12-17,34,40,45H,5-6,10-11,18-33,35-36H2,1H3,(H,55,57)(H,56,66)(H,53,54,59)(H,58,65,67)",YHKWJWJTXQMPOK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,1999,P00533,EGFR e19d,CRBN,CN(CCOCCOCCOCCOCCN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CC=C5)N(C5CCCC5)C4=N3)C=C2)CC1)CC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,987.176,986.512657072,72,9,4,17,C52H66N12O8,"InChI=1S/C52H66N12O8/c1-60(36-47(66)56-43-13-7-12-41-42(43)35-63(50(41)68)45-18-19-46(65)58-49(45)67)24-26-69-28-30-71-32-33-72-31-29-70-27-25-61-20-22-62(23-21-61)39-16-14-38(15-17-39)54-51-53-34-44-48(59-51)64(40-10-5-6-11-40)52(57-44)55-37-8-3-2-4-9-37/h2-4,7-9,12-17,34,40,45H,5-6,10-11,18-33,35-36H2,1H3,(H,55,57)(H,56,66)(H,53,54,59)(H,58,65,67)",YHKWJWJTXQMPOK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5518,P00533,EGFR e19d,CRBN,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCN(C(=O)CCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,,,949.434,948.358460448,67,7,3,16,C46H54ClFN8O11,"InChI=1S/C46H54ClFN8O11/c1-62-39-28-37-34(43(51-29-50-37)52-31-4-6-36(48)35(47)26-31)27-40(39)67-16-2-11-54-12-14-55(15-13-54)42(58)9-17-63-19-21-65-23-24-66-22-20-64-18-10-49-30-3-5-32-33(25-30)46(61)56(45(32)60)38-7-8-41(57)53-44(38)59/h3-6,25-29,38,49H,2,7-24H2,1H3,(H,50,51,52)(H,53,57,59)",ZGONVRUBNDGAQY-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5595,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,882.857,882.306092932,64,7,5,13,C43H41F3N10O8,"InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)",OBHMXNAEXVRWTQ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5595,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,882.857,882.306092932,64,7,5,13,C43H41F3N10O8,"InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)",OBHMXNAEXVRWTQ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5595,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,882.857,882.306092932,64,7,5,13,C43H41F3N10O8,"InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)",OBHMXNAEXVRWTQ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5460,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,35.5,,822.927,822.360179192,61,7,4,12,C45H46N10O6,"InChI=1S/C45H46N10O6/c1-6-20-54(21-18-42(58)47-32-13-10-12-29-31(32)27-55(44(29)60)37-15-16-41(57)51-43(37)59)23-22-52(3)38-25-39(61-5)35(24-34(38)48-40(56)7-2)50-45-46-19-17-33(49-45)30-26-53(4)36-14-9-8-11-28(30)36/h1,7-14,17,19,24-26,37H,2,15-16,18,20-23,27H2,3-5H3,(H,47,58)(H,48,56)(H,46,49,50)(H,51,57,59)",XCZMVDGRCQBGPQ-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5461,P00533,EGFR L858R/T790M,CRBN,C#CCN(CCCC(=O)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)CCN(C)C1=CC(OC)=C(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)C=C1NC(=O)C=C,13.2,,836.954,836.375829256,62,7,4,12,C46H48N10O6,"InChI=1S/C46H48N10O6/c1-6-21-55(22-11-16-42(58)48-33-14-10-13-30-32(33)28-56(45(30)61)38-17-18-43(59)52-44(38)60)24-23-53(3)39-26-40(62-5)36(25-35(39)49-41(57)7-2)51-46-47-20-19-34(50-46)31-27-54(4)37-15-9-8-12-29(31)37/h1,7-10,12-15,19-20,25-27,38H,2,11,16-18,21-24,28H2,3-5H3,(H,48,58)(H,49,57)(H,47,50,51)(H,52,59,60)",MTMBWVDGSVDKJC-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2404,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,948.457,947.364548872,68,8,4,14,C48H51ClFN11O7,"InChI=1S/C48H51ClFN11O7/c49-34-24-30(16-17-35(34)50)53-45-33-25-38(55-42(63)15-11-22-59-20-7-5-8-21-59)40(26-37(33)51-29-52-45)68-28-31-27-60(58-57-31)23-9-4-2-1-3-6-14-41(62)54-36-13-10-12-32-44(36)48(67)61(47(32)66)39-18-19-43(64)56-46(39)65/h10-13,15-17,24-27,29,39H,1-9,14,18-23,28H2,(H,54,62)(H,55,63)(H,51,52,53)(H,56,64,65)/b15-11+",PULWYZNNFMFWCK-RVDMUPIBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2406,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCCCCCCCCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,976.511,975.395849,70,8,4,14,C50H55ClFN11O7,"InChI=1S/C50H55ClFN11O7/c51-36-26-32(18-19-37(36)52)55-47-35-27-40(57-44(65)17-13-24-61-22-9-7-10-23-61)42(28-39(35)53-31-54-47)70-30-33-29-62(60-59-33)25-11-6-4-2-1-3-5-8-16-43(64)56-38-15-12-14-34-46(38)50(69)63(49(34)68)41-20-21-45(66)58-48(41)67/h12-15,17-19,26-29,31,41H,1-11,16,20-25,30H2,(H,56,64)(H,57,65)(H,53,54,55)(H,58,66,67)/b17-13+",QSSBLKJKHHKWHN-GHRIWEEISA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2409,P00533,EGFR e19d,CRBN,O=C(/C=C/CN1CCCCC1)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCC1=CN(CCOCCOCCOCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)N=N1,,,1070.533,1069.38607216,76,8,4,19,C51H57ClFN11O12,"InChI=1S/C51H57ClFN11O12/c52-37-26-33(9-10-38(37)53)56-48-36-27-41(58-44(65)8-5-15-62-13-2-1-3-14-62)43(28-40(36)54-32-55-48)76-30-34-29-63(61-60-34)16-17-71-18-19-72-20-21-73-22-23-74-24-25-75-31-46(67)57-39-7-4-6-35-47(39)51(70)64(50(35)69)42-11-12-45(66)59-49(42)68/h4-10,26-29,32,42H,1-3,11-25,30-31H2,(H,57,67)(H,58,65)(H,54,55,56)(H,59,66,68)/b8-5+",BPDICUFDYMBUFW-VMPITWQZSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2410,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1049.675,1048.4308546,74,8,5,15,C53H62ClFN12O6S,"InChI=1S/C53H62ClFN12O6S/c1-33-48(74-32-59-33)35-15-13-34(14-16-35)27-56-51(71)44-24-38(68)29-67(44)52(72)49(53(2,3)4)62-47(70)11-6-9-22-66-28-37(63-64-66)30-73-45-26-42-39(50(58-31-57-42)60-36-17-18-41(55)40(54)23-36)25-43(45)61-46(69)12-10-21-65-19-7-5-8-20-65/h10,12-18,23,25-26,28,31-32,38,44,49,68H,5-9,11,19-22,24,27,29-30H2,1-4H3,(H,56,71)(H,61,69)(H,62,70)(H,57,58,60)/b12-10+/t38-,44+,49-/m1/s1",GVYSMKFEIYRGRE-QFYOULDSSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2411,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,7.95,98,1091.756,1090.4778048,77,8,5,15,C56H68ClFN12O6S,"InChI=1S/C56H68ClFN12O6S/c1-36-51(77-35-62-36)38-18-16-37(17-19-38)30-59-54(74)47-27-41(71)32-70(47)55(75)52(56(2,3)4)65-50(73)14-9-6-5-7-12-25-69-31-40(66-67-69)33-76-48-29-45-42(53(61-34-60-45)63-39-20-21-44(58)43(57)26-39)28-46(48)64-49(72)15-13-24-68-22-10-8-11-23-68/h13,15-21,26,28-29,31,34-35,41,47,52,71H,5-12,14,22-25,27,30,32-33H2,1-4H3,(H,59,74)(H,64,72)(H,65,73)(H,60,61,63)/b15-13+/t41-,47+,52-/m1/s1",BUDQKNIUFHYJQZ-ABSCMPNGSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2412,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1105.783,1104.49345486,78,8,5,15,C57H70ClFN12O6S,"InChI=1S/C57H70ClFN12O6S/c1-37-52(78-36-63-37)39-19-17-38(18-20-39)31-60-55(75)48-28-42(72)33-71(48)56(76)53(57(2,3)4)66-51(74)15-10-7-5-6-8-13-26-70-32-41(67-68-70)34-77-49-30-46-43(54(62-35-61-46)64-40-21-22-45(59)44(58)27-40)29-47(49)65-50(73)16-14-25-69-23-11-9-12-24-69/h14,16-22,27,29-30,32,35-36,42,48,53,72H,5-13,15,23-26,28,31,33-34H2,1-4H3,(H,60,75)(H,65,73)(H,66,74)(H,61,62,64)/b16-14+/t42-,48+,53-/m1/s1",PFGSMDXDMXYRTC-SBVKIVAMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2413,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1119.81,1118.50910492,79,8,5,15,C58H72ClFN12O6S,"InChI=1S/C58H72ClFN12O6S/c1-38-53(79-37-64-38)40-20-18-39(19-21-40)32-61-56(76)49-29-43(73)34-72(49)57(77)54(58(2,3)4)67-52(75)16-11-8-6-5-7-9-14-27-71-33-42(68-69-71)35-78-50-31-47-44(55(63-36-62-47)65-41-22-23-46(60)45(59)28-41)30-48(50)66-51(74)17-15-26-70-24-12-10-13-25-70/h15,17-23,28,30-31,33,36-37,43,49,54,73H,5-14,16,24-27,29,32,34-35H2,1-4H3,(H,61,76)(H,66,74)(H,67,75)(H,62,63,65)/b17-15+/t43-,49+,54-/m1/s1",CCYWJYVSARIZBI-QRLVMSRCSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2414,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,3.57,91,1133.837,1132.52475499,80,8,5,15,C59H74ClFN12O6S,"InChI=1S/C59H74ClFN12O6S/c1-39-54(80-38-65-39)41-21-19-40(20-22-41)33-62-57(77)50-30-44(74)35-73(50)58(78)55(59(2,3)4)68-53(76)17-12-9-7-5-6-8-10-15-28-72-34-43(69-70-72)36-79-51-32-48-45(56(64-37-63-48)66-42-23-24-47(61)46(60)29-42)31-49(51)67-52(75)18-16-27-71-25-13-11-14-26-71/h16,18-24,29,31-32,34,37-38,44,50,55,74H,5-15,17,25-28,30,33,35-36H2,1-4H3,(H,62,77)(H,67,75)(H,68,76)(H,63,64,66)/b18-16+/t44-,50+,55-/m1/s1",RBUUUIFZYMVDPT-DLMBMICPSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2415,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1095.7,1094.43633391,77,8,5,17,C54H64ClFN12O8S,"InChI=1S/C54H64ClFN12O8S/c1-34-49(77-33-60-34)36-12-10-35(11-13-36)27-57-52(72)45-24-39(69)29-68(45)53(73)50(54(2,3)4)63-48(71)31-75-22-21-74-20-19-67-28-38(64-65-67)30-76-46-26-43-40(51(59-32-58-43)61-37-14-15-42(56)41(55)23-37)25-44(46)62-47(70)9-8-18-66-16-6-5-7-17-66/h8-15,23,25-26,28,32-33,39,45,50,69H,5-7,16-22,24,27,29-31H2,1-4H3,(H,57,72)(H,62,70)(H,63,71)(H,58,59,61)/b9-8+/t39-,45+,50-/m1/s1",ZBDSGNZFIXZXPY-BAKNNEFNSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2416,P00533,EGFR e19d,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,,1227.859,1226.51497815,86,8,5,20,C60H76ClFN12O11S,"InChI=1S/C60H76ClFN12O11S/c1-40-55(86-39-66-40)42-12-10-41(11-13-42)33-63-58(78)51-30-45(75)35-74(51)59(79)56(60(2,3)4)69-54(77)37-84-28-27-83-26-25-82-24-23-81-22-21-80-20-19-73-34-44(70-71-73)36-85-52-32-49-46(57(65-38-64-49)67-43-14-15-48(62)47(61)29-43)31-50(52)68-53(76)9-8-18-72-16-6-5-7-17-72/h8-15,29,31-32,34,38-39,45,51,56,75H,5-7,16-28,30,33,35-37H2,1-4H3,(H,63,78)(H,68,76)(H,69,77)(H,64,65,67)/b9-8+/t45-,51+,56-/m1/s1",XPPPWNIOTVFKQS-ONKWTBNWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2417,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,,N.D.,1139.753,1138.46254866,80,8,5,18,C56H68ClFN12O9S,"InChI=1S/C56H68ClFN12O9S/c1-36-51(80-35-62-36)38-12-10-37(11-13-38)29-59-54(74)47-26-41(71)31-70(47)55(75)52(56(2,3)4)65-50(73)33-78-24-23-77-22-21-76-20-19-69-30-40(66-67-69)32-79-48-28-45-42(53(61-34-60-45)63-39-14-15-44(58)43(57)25-39)27-46(48)64-49(72)9-8-18-68-16-6-5-7-17-68/h8-15,25,27-28,30,34-35,41,47,52,71H,5-7,16-24,26,29,31-33H2,1-4H3,(H,59,74)(H,64,72)(H,65,73)(H,60,61,63)/b9-8+/t41-,47+,52-/m1/s1",VQDITZKUBYFBHD-MUHNYSBJSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2418,P00533,EGFR,VHL,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCN3C=C(CCCCCOC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,36.51,,1151.808,1150.49893416,81,8,5,17,C58H72ClFN12O8S,"InChI=1S/C58H72ClFN12O8S/c1-38-53(81-37-64-38)40-16-14-39(15-17-40)32-61-56(76)49-29-43(73)34-72(49)57(77)54(58(2,3)4)67-52(75)35-79-27-26-78-25-23-71-33-42(68-69-71)12-7-5-10-24-80-50-31-47-44(55(63-36-62-47)65-41-18-19-46(60)45(59)28-41)30-48(50)66-51(74)13-11-22-70-20-8-6-9-21-70/h11,13-19,28,30-31,33,36-37,43,49,54,73H,5-10,12,20-27,29,32,34-35H2,1-4H3,(H,61,76)(H,66,74)(H,67,75)(H,62,63,65)/b13-11+/t43-,49+,54-/m1/s1",PXQHEFZTJMGFAP-QLJGRUAOSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2605,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1126.443,1125.59461287,81,7,5,16,C60H79N13O7S,"InChI=1S/C60H79N13O7S/c1-39-55(81-38-63-39)41-23-21-40(22-24-41)35-62-57(78)50-32-42(74)36-73(50)58(79)56(60(2,3)4)67-53(76)18-14-20-54(77)71(9)31-29-69(7)27-15-19-52(75)64-46-33-47(51(80-11)34-49(46)70(8)30-28-68(5)6)66-59-61-26-25-45(65-59)44-37-72(10)48-17-13-12-16-43(44)48/h12-13,15-17,19,21-26,33-34,37-38,42,50,56,74H,14,18,20,27-32,35-36H2,1-11H3,(H,62,78)(H,64,75)(H,67,76)(H,61,65,66)/b19-15+/t42-,50+,56-/m1/s1",NLHHAISQIXLYLK-GYTYBLAQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2605,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1126.443,1125.59461287,81,7,5,16,C60H79N13O7S,"InChI=1S/C60H79N13O7S/c1-39-55(81-38-63-39)41-23-21-40(22-24-41)35-62-57(78)50-32-42(74)36-73(50)58(79)56(60(2,3)4)67-53(76)18-14-20-54(77)71(9)31-29-69(7)27-15-19-52(75)64-46-33-47(51(80-11)34-49(46)70(8)30-28-68(5)6)66-59-61-26-25-45(65-59)44-37-72(10)48-17-13-12-16-43(44)48/h12-13,15-17,19,21-26,33-34,37-38,42,50,56,74H,14,18,20,27-32,35-36H2,1-11H3,(H,62,78)(H,64,75)(H,67,76)(H,61,65,66)/b19-15+/t42-,50+,56-/m1/s1",NLHHAISQIXLYLK-GYTYBLAQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2606,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1154.497,1153.625913,83,7,5,16,C62H83N13O7S,"InChI=1S/C62H83N13O7S/c1-41-57(83-40-65-41)43-25-23-42(24-26-43)37-64-59(80)52-34-44(76)38-75(52)60(81)58(62(2,3)4)69-55(78)20-13-12-14-22-56(79)73(9)33-31-71(7)29-17-21-54(77)66-48-35-49(53(82-11)36-51(48)72(8)32-30-70(5)6)68-61-63-28-27-47(67-61)46-39-74(10)50-19-16-15-18-45(46)50/h15-19,21,23-28,35-36,39-40,44,52,58,76H,12-14,20,22,29-34,37-38H2,1-11H3,(H,64,80)(H,66,77)(H,69,78)(H,63,67,68)/b21-17+/t44-,52+,58-/m1/s1",AUDHLQVDQXAEMW-FUPPDTOQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2606,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1154.497,1153.625913,83,7,5,16,C62H83N13O7S,"InChI=1S/C62H83N13O7S/c1-41-57(83-40-65-41)43-25-23-42(24-26-43)37-64-59(80)52-34-44(76)38-75(52)60(81)58(62(2,3)4)69-55(78)20-13-12-14-22-56(79)73(9)33-31-71(7)29-17-21-54(77)66-48-35-49(53(82-11)36-51(48)72(8)32-30-70(5)6)68-61-63-28-27-47(67-61)46-39-74(10)50-19-16-15-18-45(46)50/h15-19,21,23-28,35-36,39-40,44,52,58,76H,12-14,20,22,29-34,37-38H2,1-11H3,(H,64,80)(H,66,77)(H,69,78)(H,63,67,68)/b21-17+/t44-,52+,58-/m1/s1",AUDHLQVDQXAEMW-FUPPDTOQSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2607,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1168.524,1167.64156306,84,7,5,16,C63H85N13O7S,"InChI=1S/C63H85N13O7S/c1-42-58(84-41-66-42)44-26-24-43(25-27-44)38-65-60(81)53-35-45(77)39-76(53)61(82)59(63(2,3)4)70-56(79)21-14-12-13-15-23-57(80)74(9)34-32-72(7)30-18-22-55(78)67-49-36-50(54(83-11)37-52(49)73(8)33-31-71(5)6)69-62-64-29-28-48(68-62)47-40-75(10)51-20-17-16-19-46(47)51/h16-20,22,24-29,36-37,40-41,45,53,59,77H,12-15,21,23,30-35,38-39H2,1-11H3,(H,65,81)(H,67,78)(H,70,79)(H,64,68,69)/b22-18+/t45-,53+,59-/m1/s1",BHWDRQOZBAXOIL-YABATYFBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2607,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCN(C)C(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1168.524,1167.64156306,84,7,5,16,C63H85N13O7S,"InChI=1S/C63H85N13O7S/c1-42-58(84-41-66-42)44-26-24-43(25-27-44)38-65-60(81)53-35-45(77)39-76(53)61(82)59(63(2,3)4)70-56(79)21-14-12-13-15-23-57(80)74(9)34-32-72(7)30-18-22-55(78)67-49-36-50(54(83-11)37-52(49)73(8)33-31-71(5)6)69-62-64-29-28-48(68-62)47-40-75(10)51-20-17-16-19-46(47)51/h16-20,22,24-29,36-37,40-41,45,53,59,77H,12-15,21,23,30-35,38-39H2,1-11H3,(H,65,81)(H,67,78)(H,70,79)(H,64,68,69)/b22-18+/t45-,53+,59-/m1/s1",BHWDRQOZBAXOIL-YABATYFBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2608,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1097.445,1096.60444928,79,7,5,15,C60H80N12O6S,"InChI=1S/C60H80N12O6S/c1-40-55(79-39-63-40)42-25-23-41(24-26-42)36-62-57(76)51-33-43(73)37-72(51)58(77)56(60(2,3)4)67-54(75)21-14-12-11-13-17-29-69(7)30-18-22-53(74)64-47-34-48(52(78-10)35-50(47)70(8)32-31-68(5)6)66-59-61-28-27-46(65-59)45-38-71(9)49-20-16-15-19-44(45)49/h15-16,18-20,22-28,34-35,38-39,43,51,56,73H,11-14,17,21,29-33,36-37H2,1-10H3,(H,62,76)(H,64,74)(H,67,75)(H,61,65,66)/b22-18+/t43-,51+,56-/m1/s1",UOILNJUDFXJYIX-NQQHQXCWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2608,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1097.445,1096.60444928,79,7,5,15,C60H80N12O6S,"InChI=1S/C60H80N12O6S/c1-40-55(79-39-63-40)42-25-23-41(24-26-42)36-62-57(76)51-33-43(73)37-72(51)58(77)56(60(2,3)4)67-54(75)21-14-12-11-13-17-29-69(7)30-18-22-53(74)64-47-34-48(52(78-10)35-50(47)70(8)32-31-68(5)6)66-59-61-28-27-46(65-59)45-38-71(9)49-20-16-15-19-44(45)49/h15-16,18-20,22-28,34-35,38-39,43,51,56,73H,11-14,17,21,29-33,36-37H2,1-10H3,(H,62,76)(H,64,74)(H,67,75)(H,61,65,66)/b22-18+/t43-,51+,56-/m1/s1",UOILNJUDFXJYIX-NQQHQXCWSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2609,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1125.499,1124.63574941,81,7,5,15,C62H84N12O6S,"InChI=1S/C62H84N12O6S/c1-42-57(81-41-65-42)44-27-25-43(26-28-44)38-64-59(78)53-35-45(75)39-74(53)60(79)58(62(2,3)4)69-56(77)23-16-14-12-11-13-15-19-31-71(7)32-20-24-55(76)66-49-36-50(54(80-10)37-52(49)72(8)34-33-70(5)6)68-61-63-30-29-48(67-61)47-40-73(9)51-22-18-17-21-46(47)51/h17-18,20-22,24-30,36-37,40-41,45,53,58,75H,11-16,19,23,31-35,38-39H2,1-10H3,(H,64,78)(H,66,76)(H,69,77)(H,63,67,68)/b24-20+/t45-,53+,58-/m1/s1",BDPJWTWTFREFOU-HAZLKTSUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2609,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C=C/CN(C)CCCCCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1125.499,1124.63574941,81,7,5,15,C62H84N12O6S,"InChI=1S/C62H84N12O6S/c1-42-57(81-41-65-42)44-27-25-43(26-28-44)38-64-59(78)53-35-45(75)39-74(53)60(79)58(62(2,3)4)69-56(77)23-16-14-12-11-13-15-19-31-71(7)32-20-24-55(76)66-49-36-50(54(80-10)37-52(49)72(8)34-33-70(5)6)68-61-63-30-29-48(67-61)47-40-73(9)51-22-18-17-21-46(47)51/h17-18,20-22,24-30,36-37,40-41,45,53,58,75H,11-16,19,23,31-35,38-39H2,1-10H3,(H,64,78)(H,66,76)(H,69,77)(H,63,67,68)/b24-20+/t45-,53+,58-/m1/s1",BDPJWTWTFREFOU-HAZLKTSUSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2611,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1171.48,1170.6048432,84,7,6,17,C62H82N12O9S,"InChI=1S/C62H82N12O9S/c1-10-54(76)67-48-34-49(69-61-64-25-24-47(68-61)46-38-72(8)50-18-15-14-17-45(46)50)53(81-9)35-51(48)73(29-28-71(6)7)27-16-12-11-13-19-55(77)63-26-30-82-31-32-83-39-56(78)70-58(62(3,4)5)60(80)74-37-44(75)33-52(74)59(79)65-36-42-20-22-43(23-21-42)57-41(2)66-40-84-57/h10,14-15,17-18,20-25,34-35,38,40,44,52,58,75H,1,11-13,16,19,26-33,36-37,39H2,2-9H3,(H,63,77)(H,65,79)(H,67,76)(H,70,78)(H,64,68,69)/t44-,52+,58-/m1/s1",ALUNGNVSILUROK-WZWSVSESSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2611,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1171.48,1170.6048432,84,7,6,17,C62H82N12O9S,"InChI=1S/C62H82N12O9S/c1-10-54(76)67-48-34-49(69-61-64-25-24-47(68-61)46-38-72(8)50-18-15-14-17-45(46)50)53(81-9)35-51(48)73(29-28-71(6)7)27-16-12-11-13-19-55(77)63-26-30-82-31-32-83-39-56(78)70-58(62(3,4)5)60(80)74-37-44(75)33-52(74)59(79)65-36-42-20-22-43(23-21-42)57-41(2)66-40-84-57/h10,14-15,17-18,20-25,34-35,38,40,44,52,58,75H,1,11-13,16,19,26-33,36-37,39H2,2-9H3,(H,63,77)(H,65,79)(H,67,76)(H,70,78)(H,64,68,69)/t44-,52+,58-/m1/s1",ALUNGNVSILUROK-WZWSVSESSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2612,P00533,EGFR L858R/T790M,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1153.509,1152.63066403,83,7,6,15,C63H84N12O7S,"InChI=1S/C63H84N12O7S/c1-10-55(77)68-49-36-50(70-62-65-31-29-48(69-62)47-40-73(8)51-22-18-17-21-46(47)51)54(82-9)37-52(49)74(34-33-72(6)7)32-20-14-12-15-23-56(78)64-30-19-13-11-16-24-57(79)71-59(63(3,4)5)61(81)75-39-45(76)35-53(75)60(80)66-38-43-25-27-44(28-26-43)58-42(2)67-41-83-58/h10,17-18,21-22,25-29,31,36-37,40-41,45,53,59,76H,1,11-16,19-20,23-24,30,32-35,38-39H2,2-9H3,(H,64,78)(H,66,80)(H,68,77)(H,71,79)(H,65,69,70)/t45-,53+,59-/m1/s1",UWPKPQXGEGLODQ-BDMCWMSBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2612,P00533,EGFR e19d,VHL,C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)=C(OC)C=C1N(CCCCCCC(=O)NCCCCCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCN(C)C,,,1153.509,1152.63066403,83,7,6,15,C63H84N12O7S,"InChI=1S/C63H84N12O7S/c1-10-55(77)68-49-36-50(70-62-65-31-29-48(69-62)47-40-73(8)51-22-18-17-21-46(47)51)54(82-9)37-52(49)74(34-33-72(6)7)32-20-14-12-15-23-56(78)64-30-19-13-11-16-24-57(79)71-59(63(3,4)5)61(81)75-39-45(76)35-53(75)60(80)66-38-43-25-27-44(28-26-43)58-42(2)67-41-83-58/h10,17-18,21-22,25-29,31,36-37,40-41,45,53,59,76H,1,11-16,19-20,23-24,30,32-35,38-39H2,2-9H3,(H,64,78)(H,66,80)(H,68,77)(H,71,79)(H,65,69,70)/t45-,53+,59-/m1/s1",UWPKPQXGEGLODQ-BDMCWMSBSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2617,P00533,EGFR L858R/T790M,VHL,COC1=CC(N2CCN(C)CC2)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1134.422,1133.56331274,82,8,6,16,C61H75N13O7S,"InChI=1S/C61H75N13O7S/c1-38-54(82-37-65-38)40-21-19-39(20-22-40)34-64-57(79)50-29-42(75)35-74(50)58(80)55(60(2,3)4)69-52(76)17-11-10-12-18-53(77)70-61(5,6)32-41(33-62)56(78)66-46-30-47(51(81-9)31-49(46)73-27-25-71(7)26-28-73)68-59-63-24-23-45(67-59)44-36-72(8)48-16-14-13-15-43(44)48/h13-16,19-24,30-32,36-37,42,50,55,75H,10-12,17-18,25-29,34-35H2,1-9H3,(H,64,79)(H,66,78)(H,69,76)(H,70,77)(H,63,67,68)/b41-32+/t42-,50+,55-/m1/s1",QDRZFVWTDVQLLE-SSYYUHPMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2617,P00533,EGFR e19d,VHL,COC1=CC(N2CCN(C)CC2)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1134.422,1133.56331274,82,8,6,16,C61H75N13O7S,"InChI=1S/C61H75N13O7S/c1-38-54(82-37-65-38)40-21-19-39(20-22-40)34-64-57(79)50-29-42(75)35-74(50)58(80)55(60(2,3)4)69-52(76)17-11-10-12-18-53(77)70-61(5,6)32-41(33-62)56(78)66-46-30-47(51(81-9)31-49(46)73-27-25-71(7)26-28-73)68-59-63-24-23-45(67-59)44-36-72(8)48-16-14-13-15-43(44)48/h13-16,19-24,30-32,36-37,42,50,55,75H,10-12,17-18,25-29,34-35H2,1-9H3,(H,64,79)(H,66,78)(H,69,76)(H,70,77)(H,63,67,68)/b41-32+/t42-,50+,55-/m1/s1",QDRZFVWTDVQLLE-SSYYUHPMSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2618,P00533,EGFR L858R/T790M,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1150.465,1149.59461287,83,7,6,16,C62H79N13O7S,"InChI=1S/C62H79N13O7S/c1-39-55(83-38-66-39)41-24-22-40(23-25-41)35-65-58(80)51-30-43(76)36-75(51)59(81)56(61(2,3)4)70-53(77)20-14-12-13-15-21-54(78)71-62(5,6)33-42(34-63)57(79)67-47-31-48(52(82-11)32-50(47)73(9)29-28-72(7)8)69-60-64-27-26-46(68-60)45-37-74(10)49-19-17-16-18-44(45)49/h16-19,22-27,31-33,37-38,43,51,56,76H,12-15,20-21,28-30,35-36H2,1-11H3,(H,65,80)(H,67,79)(H,70,77)(H,71,78)(H,64,68,69)/b42-33+/t43-,51+,56-/m1/s1",PLSIZPKPMOPGBN-MGAZKENVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,2618,P00533,EGFR e19d,VHL,COC1=CC(N(C)CCN(C)C)=C(NC(=O)/C(C#N)=C/C(C)(C)NC(=O)CCCCCCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)C=C1NC1=NC=CC(C2=CN(C)C3=CC=CC=C23)=N1,,,1150.465,1149.59461287,83,7,6,16,C62H79N13O7S,"InChI=1S/C62H79N13O7S/c1-39-55(83-38-66-39)41-24-22-40(23-25-41)35-65-58(80)51-30-43(76)36-75(51)59(81)56(61(2,3)4)70-53(77)20-14-12-13-15-21-54(78)71-62(5,6)33-42(34-63)57(79)67-47-31-48(52(82-11)32-50(47)73(9)29-28-72(7)8)69-60-64-27-26-46(68-60)45-37-74(10)49-19-17-16-18-44(45)49/h16-19,22-27,31-33,37-38,43,51,56,76H,12-15,20-21,28-30,35-36H2,1-11H3,(H,65,80)(H,67,79)(H,70,77)(H,71,78)(H,64,68,69)/b42-33+/t43-,51+,56-/m1/s1",PLSIZPKPMOPGBN-MGAZKENVSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5598,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,924.938,924.353043124,67,7,5,13,C46H47F3N10O8,"InChI=1S/C46H47F3N10O8/c1-3-36(60)51-27-10-8-11-28(24-27)52-41-31(46(47,48)49)26-50-45(56-41)54-32-17-16-29(25-35(32)67-2)57-20-22-58(23-21-57)39(63)15-7-5-4-6-14-37(61)53-33-13-9-12-30-40(33)44(66)59(43(30)65)34-18-19-38(62)55-42(34)64/h3,8-13,16-17,24-26,34H,1,4-7,14-15,18-23H2,2H3,(H,51,60)(H,53,61)(H,55,62,64)(H2,50,52,54,56)",OIMOWCZKWKGTPW-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5598,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,924.938,924.353043124,67,7,5,13,C46H47F3N10O8,"InChI=1S/C46H47F3N10O8/c1-3-36(60)51-27-10-8-11-28(24-27)52-41-31(46(47,48)49)26-50-45(56-41)54-32-17-16-29(25-35(32)67-2)57-20-22-58(23-21-57)39(63)15-7-5-4-6-14-37(61)53-33-13-9-12-30-40(33)44(66)59(43(30)65)34-18-19-38(62)55-42(34)64/h3,8-13,16-17,24-26,34H,1,4-7,14-15,18-23H2,2H3,(H,51,60)(H,53,61)(H,55,62,64)(H2,50,52,54,56)",OIMOWCZKWKGTPW-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5598,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,924.938,924.353043124,67,7,5,13,C46H47F3N10O8,"InChI=1S/C46H47F3N10O8/c1-3-36(60)51-27-10-8-11-28(24-27)52-41-31(46(47,48)49)26-50-45(56-41)54-32-17-16-29(25-35(32)67-2)57-20-22-58(23-21-57)39(63)15-7-5-4-6-14-37(61)53-33-13-9-12-30-40(33)44(66)59(43(30)65)34-18-19-38(62)55-42(34)64/h3,8-13,16-17,24-26,34H,1,4-7,14-15,18-23H2,2H3,(H,51,60)(H,53,61)(H,55,62,64)(H2,50,52,54,56)",OIMOWCZKWKGTPW-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5597,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,910.911,910.33739306,66,7,5,13,C45H45F3N10O8,"InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)",KJJWOVIQRJNQJI-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5597,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,910.911,910.33739306,66,7,5,13,C45H45F3N10O8,"InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)",KJJWOVIQRJNQJI-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5597,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,910.911,910.33739306,66,7,5,13,C45H45F3N10O8,"InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)",KJJWOVIQRJNQJI-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5599,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,938.965,938.368693188,68,7,5,13,C47H49F3N10O8,"InChI=1S/C47H49F3N10O8/c1-3-37(61)52-28-11-9-12-29(25-28)53-42-32(47(48,49)50)27-51-46(57-42)55-33-18-17-30(26-36(33)68-2)58-21-23-59(24-22-58)40(64)16-8-6-4-5-7-15-38(62)54-34-14-10-13-31-41(34)45(67)60(44(31)66)35-19-20-39(63)56-43(35)65/h3,9-14,17-18,25-27,35H,1,4-8,15-16,19-24H2,2H3,(H,52,61)(H,54,62)(H,56,63,65)(H2,51,53,55,57)",XOIIYPQWBHJYDK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5599,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,938.965,938.368693188,68,7,5,13,C47H49F3N10O8,"InChI=1S/C47H49F3N10O8/c1-3-37(61)52-28-11-9-12-29(25-28)53-42-32(47(48,49)50)27-51-46(57-42)55-33-18-17-30(26-36(33)68-2)58-21-23-59(24-22-58)40(64)16-8-6-4-5-7-15-38(62)54-34-14-10-13-31-41(34)45(67)60(44(31)66)35-19-20-39(63)56-43(35)65/h3,9-14,17-18,25-27,35H,1,4-8,15-16,19-24H2,2H3,(H,52,61)(H,54,62)(H,56,63,65)(H2,51,53,55,57)",XOIIYPQWBHJYDK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5599,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,938.965,938.368693188,68,7,5,13,C47H49F3N10O8,"InChI=1S/C47H49F3N10O8/c1-3-37(61)52-28-11-9-12-29(25-28)53-42-32(47(48,49)50)27-51-46(57-42)55-33-18-17-30(26-36(33)68-2)58-21-23-59(24-22-58)40(64)16-8-6-4-5-7-15-38(62)54-34-14-10-13-31-41(34)45(67)60(44(31)66)35-19-20-39(63)56-43(35)65/h3,9-14,17-18,25-27,35H,1,4-8,15-16,19-24H2,2H3,(H,52,61)(H,54,62)(H,56,63,65)(H2,51,53,55,57)",XOIIYPQWBHJYDK-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5601,P00533,EGFR,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,967.019,966.399993316,70,7,5,13,C49H53F3N10O8,"InChI=1S/C49H53F3N10O8/c1-3-39(63)54-30-13-11-14-31(27-30)55-44-34(49(50,51)52)29-53-48(59-44)57-35-20-19-32(28-38(35)70-2)60-23-25-61(26-24-60)42(66)18-10-8-6-4-5-7-9-17-40(64)56-36-16-12-15-33-43(36)47(69)62(46(33)68)37-21-22-41(65)58-45(37)67/h3,11-16,19-20,27-29,37H,1,4-10,17-18,21-26H2,2H3,(H,54,63)(H,56,64)(H,58,65,67)(H2,53,55,57,59)",JZUFFCADCUCQSB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5601,P00533,EGFR L858R/T790M,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,967.019,966.399993316,70,7,5,13,C49H53F3N10O8,"InChI=1S/C49H53F3N10O8/c1-3-39(63)54-30-13-11-14-31(27-30)55-44-34(49(50,51)52)29-53-48(59-44)57-35-20-19-32(28-38(35)70-2)60-23-25-61(26-24-60)42(66)18-10-8-6-4-5-7-9-17-40(64)56-36-16-12-15-33-43(36)47(69)62(46(33)68)37-21-22-41(65)58-45(37)67/h3,11-16,19-20,27-29,37H,1,4-10,17-18,21-26H2,2H3,(H,54,63)(H,56,64)(H,58,65,67)(H2,53,55,57,59)",JZUFFCADCUCQSB-UHFFFAOYSA-N
DB00072,Trastuzumab,BiotechDrug,Epidermal growth factor receptor,5601,P00533,EGFR e19d,CRBN,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(=O)CCCCCCCCCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1,,,967.019,966.399993316,70,7,5,13,C49H53F3N10O8,"InChI=1S/C49H53F3N10O8/c1-3-39(63)54-30-13-11-14-31(27-30)55-44-34(49(50,51)52)29-53-48(59-44)57-35-20-19-32(28-38(35)70-2)60-23-25-61(26-24-60)42(66)18-10-8-6-4-5-7-9-17-40(64)56-36-16-12-15-33-43(36)47(69)62(46(33)68)37-21-22-41(65)58-45(37)67/h3,11-16,19-20,27-29,37H,1,4-10,17-18,21-26H2,2H3,(H,54,63)(H,56,64)(H,58,65,67)(H2,53,55,57,59)",JZUFFCADCUCQSB-UHFFFAOYSA-N
